11-Beta HSD1 Inhibitors
This invention relates to inhibiting 11βHSD1.
This application claims the benefit of U.S. Provisional Application No. 60/771,262, filed on Feb. 7, 2006, which is incorporated herein by reference in its entirety.
TECHNICAL FIELDThis invention relates to inhibiting 11βHSD1.
BACKGROUNDDiabetes is generally characterized by relatively high levels of plasma glucose (hyperglycemia) in the fasting state. Patients having type 2 diabetes (non-insulin dependent diabetes mellitus (NIDDM)) produce insulin (and even exhibit hyperinsulinemia), whilst demonstrating hyperglycemia.
Type 2 diabetics can often develop insulin resistance, in which the effect of insulin in stimulating glucose and lipid metabolism is diminished. Further, patients having insulin resistance, but have not developed type 2 diabetes, are also at risk of developing Syndrome X (metabolic syndrome). Syndrome X is characterized by insulin resistance, along with obesity (e.g., abdominal obesity), hyperinsulinemia, high blood pressure, relatively low HDL and relatively high VLDL.
Glucocorticoids (e.g., cortisol in humans, corticosterone in rodents) are counter regulatory hormones that oppose the action of insulin. It is established that glucocorticoid activity is controlled at the tissue level by intracellular interconversion of active cortisol and inactive cortisone by the 11-beta hydroxysteroid dehydrogenases, 11βHSD1, which activates cortisone and 11βHSD2, which inactivates cortisol. Excess levels of glucocorticoids (e.g., cortisol) can cause metabolic complications. For example, excess cortisol is associated with disorders including NIDDM, obesity, dyslipidemia, insulin resistance, and hypertension.
It is believed that inhibition of 11βHSD1 can reduce the effects of excessive amounts of 11β-hydroxysteroids, e.g., cortisol, and therefore can be useful for the treatment and control of diseases mediated by abnormally high levels of cortisol and other 11β-hydroxysteroids, e.g., NIDDM, obesity, dyslipidemia, and hypertension.
SUMMARYIn one aspect, this invention relates to a compound of formula (I):
in which:
R1 is:
(i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
(ii) C7-C20 aralkyl; C3-C16 cycloalkyl; (C1-C12 alkyl)-(C3-C16 cycloalkyl); heteroaralkyl including 6-20 atoms; arylheterocyclyl including 8-20 atoms; arylcycloalkenyl including 8-20 atoms; arylheterocycloalkenyl including 8-20 atoms (e.g., arylheterocyclyl including 8-20 atoms or arylheterocycloalkenyl including 8-20 atoms); C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb;
R2 is:
(i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Rc; or
(ii) C3-C16 cycloalkyl; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1; or
(iv) C(O)R5, wherein R5 is C1-C20 alkyl or C7-C20 aralkoxy;
X is CO, S(O)n, or S(O)nNR6 wherein n is 1 or 2, and R6 is hydrogen, C1-C12 alkyl, or C3-C16 cycloalkyl;
each of V and Y is, independently, CR7 or N, wherein R7 is hydrogen or C1-C12 alkyl, provided that Y and V cannot both be CR7;
each of W1, Z1, W2, and Z2 is, independently:
(i) hydrogen; or
(ii) oxo; or
(iii) C1-C12 alkyl; or
(iv) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
(ii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb;
Ra at each occurrence is, independently:
(i) halo; NRdRe; nitro; azido; hydroxy; C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; C1-C3 alkylenedioxy; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or
(ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
(iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iv) C2-C20 alkenyl or C2-C20 alkynyl; or
(v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra′;
Ra′ at each occurrence is, independently, C1-C12 alkyl, C1-C12 haloalkyl, C2-C12 alkenyl; C2-C12 alkynyl; C3-C16 cycloalkyl; C3-C16 cycloalkenyl, heterocyclyl including 3-16 atoms, heterocycloalkenyl including 3-16 atoms; C7-C20 aralkyl; C6-C16 aryl; heteroaryl including 5-16 atoms; halo; NRdRe; nitro; azido, hydroxy; C1-C12 alkoxy; C1-C12 thioalkoxy; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy; heteroaryloxy including 5-20 atoms; thioaryloxy including 5-20 atoms; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy; C3-C16 cycloalkenyloxy; heterocyclyloxy including 3-16 atoms; heterocycloalkenyloxy including 3-16 atoms; C7-C20 aralkoxy; heteroaralkoxy including 6-20 atoms; mercapto; cyano; C1-C3 alkylenedioxy; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; or —OC(O)NRdRe;
Rb at each occurrence is, independently:
(i) halo; NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; C1-C3 alkylenedioxy; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or
(ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
(iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iv) C2-C20 alkenyl or C2-C20 alkynyl; or
(v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
Rc at each occurrence is, independently:
(i) halo; nitro; hydroxy; C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; cyano; C1-C3 alkylenedioxy; or SO2Rm; or
(ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
(iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iv) C2-C20 alkenyl or C2-C20 alkynyl; or
(v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
each of Rd, Re, Rg, Rh, and Rk, at each occurrence is, independently:
(i) hydrogen; or
(ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
(iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iv) C2-C20 alkenyl or C2-C20 alkynyl; or
(v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
Rf is NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; C1-C3 alkylenedioxy; —C(O)Rg, —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe;
Ri is Rg; ORg; NRdRe; or heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb;
Rj is NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; C1-C3 alkylenedioxy; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; and
Rm is
(i) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
(ii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iii) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra.
In some embodiments, one, two, three, or four of the following conditions apply:
(a) when V and Y are both N, and R2 is substituted pyridyl or pyrimidinyl, then Rc cannot be C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; or SO2Rm;
(b) when V and Y are both N, X is SO2, and R2 is C3-C16 cycloalkyl, then R1 cannot be a monosubstituted phenyl ring that is substituted at the para-position with either substituted C1-C12 alkyl or substituted C1-C12 haloalkyl;
(c) when V and Y are both N, X is CO, then R1 cannot be unsubstituted or mono, di, or trisubstituted pyrazolo[1,5-a]pyrimidin-2-yl;
(d) when V is N and Y is CH, and X is CO, then R2 cannot be C(O)R5.
In certain embodiments, conditions (a), (b), (c), and (d) apply. In certain embodiments, conditions (b), (c), and (d) apply. In certain embodiments, (a), (b), and (d) apply. In certain embodiments, (b) and (d) apply.
In another aspect, this invention relates to a compound of formula (I), in which:
R2 is:
(i) C6-C18 aryl, optionally substituted with from 1-10 Rc; or heteroaryl including 5-20 atoms, optionally substituted with from 1-10 Rn;
(ii) C3-C16 cycloalkyl; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1 or
(iv) C(O)R5, wherein R5 is C1-C20 alkyl or C7-C20 aralkoxy;
Rn at each occurrence is, independently:
(i) halo; nitro; hydroxy; cyano; or C1-C3 alkylenedioxy (e.g., halo; nitro; hydroxy; cyano); or
(ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
(iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iv) C2-C20 alkenyl or C2-C20 alkynyl; or
(v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
provided:
(b) when V and Y are both N, X is SO2, and R2 is C3-C16 cycloalkyl, then R1 cannot be a monosubstituted phenyl ring that is substituted at the para-position with either substituted C1-C12 alkyl or substituted C1-C12 haloalkyl; and
(c) when V and Y are both N, X is CO, then R1 cannot be unsubstituted or mono, di, or trisubstituted pyrazolo[1,5-a]pyrimidin-2-yl; and
(d) when V is N and Y is CH, and X is CO, then R2 cannot be C(O)R5; and
R1, R3, R4, R5, R6, R7, X, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, and Rm can be as defined anywhere herein.
In a further aspect, this invention relates to a compound of formula (I), in which:
R2 is:
(i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Rc; or
(ii) C6-C16 cycloalkyl; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1; or
(iv) C(O)R5, wherein R5 is C1-C20 alkyl or C7-C20 aralkoxy;
provided:
(a) when V and Y are both N, and R2 is substituted pyridyl or pyrimidinyl, then Rc cannot be C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; or SO2Rm; and
(c) when V and Y are both N, X is CO, then R1 cannot be unsubstituted or mono, di, or trisubstituted pyrazolo[1,5-a]pyrimidin-2-yl; and
(d) when V is N and Y is CH, and X is CO, then R2 cannot be C(O)R5; and
R1, R3, R4, R5, R6, R7, X, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, and Rm can be as defined anywhere herein.
In another aspect, this invention relates to a compound of formula (I), in which:
R2 is:
(i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Rc; or
(ii) C3-C16 cycloalkyl; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1;
provided:
(a) when V and Y are both N, and R2 is substituted pyridyl or pyrimidinyl, then Rc cannot be C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; or SO2Rm; and
(b) when V and Y are both N, X is SO2, and R2 is C3-C16 cycloalkyl, then R1 cannot be a monosubstituted phenyl ring that is substituted at the para-position with either substituted C1-C12 alkyl or substituted C1-C12 haloalkyl; and
(c) when V and Y are both N, X is CO, then R1 cannot be unsubstituted or mono, di, or trisubstituted pyrazolo[1,5-a]pyrimidin-2-yl; and
R1, R3, R4, R5, R6, R7, X, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, and Rm can be as defined anywhere herein.
In a further aspect, this invention relates to a compound of formula (I), in which:
R2 is:
(i) C6-C18 aryl, optionally substituted with from 1-10 Rc; or heteroaryl including 5-20 atoms, optionally substituted with from 1-10 Rn;
(ii) C6-C16 cycloalkyl; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1; or
(iv) C(O)R5, wherein R5 is C1-C20 alkyl or C7-C20 aralkoxy;
provided:
(c) when V and Y are both N, X is CO, then R1 cannot be unsubstituted or mono, di, or trisubstituted pyrazolo[1,5-a]pyrimidin-2-yl; and
(d) when V is N and Y is CH, and X is CO, then R2 cannot be C(O)R5; and
R1, R3, R4, R5, R6, R7, X, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rm, and Rn can be as defined anywhere herein.
In a further aspect, this invention relates to a compound of formula (I), in which:
R2 is:
(i) C6-C18 aryl, optionally substituted with from 1-10 Rc; or heteroaryl including 5-20 atoms, optionally substituted with from 1-10 Rn;
(ii) C3-C16 cycloalkyl; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or provided:
(b) when V and Y are both N, X is SO2, and R2 is C3-C16 cycloalkyl, then R1 cannot be a monosubstituted phenyl ring that is substituted at the para-position with either substituted C1-C12 alkyl or substituted C1-C12 haloalkyl; and
(c) when V and Y are both N, X is CO, then R1 cannot be unsubstituted or mono, di, or trisubstituted pyrazolo[1,5-a]pyrimidin-2-yl; and
R1, R3, R4, R5, R6, R7, X, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, and Rm can be as defined anywhere herein.
In a further aspect, this invention relates to a compound of formula (I), in which:
R2 is:
(i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Rc; or
(ii) C6-C16 cycloalkyl; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1;
provided
(a) when V and Y are both N, and R2 is substituted pyridyl or pyrimidinyl, then Rc cannot be C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; or SO2Rm; and
(c) when V and Y are both N, X is CO, then R1 cannot be unsubstituted or mono, di, or trisubstituted pyrazolo[1,5-a]pyrimidin-2-yl; and
R1, R3, R4, R5, R6, R7, X, V, Y, W1, Z1, W2, Z7, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, and Rm can be as defined anywhere herein.
In a further aspect, this invention relates to a compound of formula (I), in which:
R2 is:
(i) C6-C18 aryl, optionally substituted with from 1-10 Rc; or heteroaryl including 5-20 atoms, optionally substituted with from 1-10 Rn;
(ii) C6-C16 cycloalkyl; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
(iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1;
provided:
(c) when V and Y are both N, X is CO, then R1 cannot be unsubstituted or mono, di, or trisubstituted pyrazolo[1,5-a]pyrimidin-2-yl; and
R1, R3, R4, R5, R6, R7, X, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, and Rm can be as defined anywhere herein.
In a further aspect, this invention relates to a compound of formula (I), in which:
R2 is:
(i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Rc; or
(iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1; or
(iv) C(O)R5, wherein R5 is C1-C20 alkyl or C7-C20 aralkoxy;
provided:
(a) when V and Y are both N, and R2 is substituted pyridyl or pyrimidinyl, then Rc cannot be C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; or SO2Rm; and
(c) when V and Y are both N, X is CO, then R1 cannot be unsubstituted or mono, di, or trisubstituted pyrazolo[1,5-a]pyrimidin-2-yl; and
(d) when V is N and Y is CH, and X is CO, then R2 cannot be C(O)R5; and
R1, R3, R4, R5, R6, R7, X, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, and Rm can be as defined anywhere herein.
In a further aspect, this invention relates to a compound of formula (I), in which:
R2 is:
(i) C6-C18 aryl, optionally substituted with from 1-10 Rc; or heteroaryl including 5-20 atoms, optionally substituted with from 1-10 Rn;
(iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1; or
(iv) C(O)R5, wherein R5 is C1-C20 alkyl or C7-C20 aralkoxy;
provided:
(c) when V and Y are both N, X is CO, then R1 cannot be unsubstituted or mono, di, or trisubstituted pyrazolo[1,5-a]pyrimidin-2-yl; and
(d) when V is N and Y is CH, and X is CO, then R2 cannot be C(O)R5; and
R1, R3, R4, R5, R6, R7, X, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rm, and R1 can be as defined anywhere herein.
In a further aspect, this invention relates to a compound of formula (I), in which:
R2 is:
(i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Rc; or
(iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1;
provided
(a) when V and Y are both N, and R2 is substituted pyridinyl or pyrimidinyl, then Rc cannot be C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; or SO2Rm; and
(c) when V and Y are both N, X is CO, then R1 cannot be unsubstituted or mono, di, or trisubstituted pyrazolo[1,5-a]pyrimidin-2-yl; and
R1, R3, R4, R5, R6, R7, X, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, and Rm can be as defined anywhere herein.
In a further aspect, this invention relates to a compound of formula (I), in which:
R2 is:
(i) C6-C18 aryl, optionally substituted with from 1-10 Rc; or heteroaryl including 5-20 atoms, optionally substituted with from 1-10 Rn;
(iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1;
provided:
(c) when V and Y are both N, X is CO, then R1 cannot be unsubstituted or mono, di, or trisubstituted pyrazolo[1,5-a]pyrimidin-2-yl; and
R1, R3, R4, R5, R6, R7, X, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, and Rm can be as defined anywhere herein.
In one aspect, this invention relates to a compound of formula (I), in which:
R1 is:
(i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
(ii) C7-C20 aralkyl; heteroaralkyl including 6-20 atoms; arylheterocyclyl including 8-20 atoms; arylcycloalkenyl including 8-20 atoms; or arylheterocycloalkenyl including 8-20 atoms; each of which is optionally substituted with from 1-10 Rb;
R2 is C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Rc;
X is S(O)n or S(O)nNR6, wherein n is 1 or 2, and R6 is hydrogen, C1-C12 alkyl, or C3-C16 cycloalkyl;
one, two, three, or four of W1, Z1, W2, and Z2 are each, independently:
(i) C1-C12 alkyl; or
(ii) oxo; or
(iii) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
(iv) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; and the others are hydrogen; and
R6, R7, V, Y, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, and Rm can be as defined anywhere herein.
In some embodiments, one or more of the following conditions apply:
(a) when V and Y are both N, and R2 is substituted pyridyl or pyrimidinyl, then Rc cannot be C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; or SO2Rm;
(e) when V and Y are both N, X is SO2, one of Z1 and W2 is C1-C4 alkyl (e.g., CH3), and R2 is phenyl substituted with from 1-5 Rc, then 1 Rc must be halo; C1-C12 haloalkoxy; cyano; or C1-C12 haloalkyl, optionally substituted with from 1-5 Rj (i.e., if 1 Rc is present, then that Rc substituent must be halo; C1-C12 haloalkoxy; cyano; or C1-C12 haloalkyl, optionally substituted with from 1-5 Rj; if more than 1 Rc is present, then one of the Rc substituents must be one of the four aforementioned substituents);
(f) when V and Y are both N, X is SO2, and R2 is phenyl substituted with from 1-5 R1, then 1 Rc must be halo; C1-C12 haloalkoxy; cyano; or C1-C12 haloalkyl, optionally substituted with from 1-5 Rj;
(g) when V and Y are both N, X is SO2, and one of Z1 and W2 is C1-C4 alkyl (e.g., CH3), then R1 cannot be 4-chlorophenyl;
(h) when V and Y are both N and X is SO2, then R1 cannot be 4-chlorophenyl;
(i) when V and Y are both N, X is SO2, and one of Z1 and W2 is C1-C4 alkyl (e.g., CH3), then R2 cannot be phenyl monosubstituted with C1-C4 alkyl (CH3) or C1-C4 alkoxy (OCH3);
(j) when V and Y are both N and X is SO2, then R2 cannot be phenyl monosubstituted with C1-C4 alkyl (CH3) or C1-C4 alkoxy (OCH3).
In certain embodiments, (a) applies. In certain embodiments, (a) and any one of (e)-(j) apply. In certain embodiments, any one of (e)-(j) applies. In certain embodiments, any two or three of (e)-(j) applies, optionally in combination with (a). For example, (e) or (f) and (g) or (h) and/or (i) and (j), optionally in combination with (a).
In one aspect, this invention relates to a compound of formula (I), in which:
R1 is:
(i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
(ii) C7-C20 aralkyl or heteroaralkyl including 6-20 atoms; each of which is optionally substituted with from 1-10 Rb
R2 is:
(i) C6-C18 aryl substituted with from 1-10 Rc; or heteroaryl including 5-20 atoms, optionally substituted with from 1-10 Rc; or
(iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or
R1;
X is S(O)n or S(O)nNR6, wherein n is 1 or 2, and R6 is hydrogen, C1-C12 alkyl, or C3-C16 cycloalkyl;
each of W1, Z1, W2, and Z2 is hydrogen; and
R3, R4, R6, R7, V, Y, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk and Rm can be as defined anywhere herein.
In some embodiments, one or more of the following conditions apply:
(a) when V and Y are both N, and R2 is substituted pyridyl or pyrimidinyl, then Rc cannot be C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; or SO2Rm;
(k) when V and Y are both N and X is SO2, then R1 cannot be 4-chlorophenyl;
(l) when V and Y are both N and X is SO2, then R1 cannot be 1-chlorophenyl when R2 is: phenyl monosubstituted with hydroxyl, C1-C6 alkoxy, chloro, or nitro; unsubstituted pyridyl; pyridyl monosubstituted with hydroxyl, chloro, or nitro; unsubstituted thiazolyl; thiazolyl monosubstituted with nitro or hydroxymethyl; unsubstituted indolyl; or unsubstituted indazolyl;
(m) when V and Y are both N and X is SO2, then R1 cannot be naphthyl when R2 is: unsubstituted pyridyl; unsubstituted pyrimidinyl; phenyl monosubstituted with hydroxyl or C1-C6 alkoxy; unsubstituted thiazolyl; or 5-chloro-2-methylphenyl;
(n) when Y is N and V is CH and X is SO2, then R1 cannot be 1-chlorophenyl when R2 is: phenyl monosubstituted with C1-C6 alkoxy or C1-C6 alkyl; or substituted benzo[d]isoxazole;
(o) when Y is N and V is CH and X is SO2, then R1 cannot be naphthyl when R2 is phenyl monosubstituted with hydroxymethyl.
In certain embodiments, (a) applies. In certain embodiments, (a) and/or (k) applies. In certain embodiments, (a), (k) and any one, two, three, or four of (l)-(o) apply.
In one aspect, this invention relates to a compound of formula (I), in which:
R1 is C7-C20 aralkyl, C3-C16 cycloalkyl, or (C1-C12 alkyl)-(C3-C16 cycloalkyl), each of which is optionally substituted with from 1-10 Rb;
R2 is:
(i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Rc; or
(ii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1;
X is CO; and
R3, R4, R6, R7, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, and Rm can be as defined anywhere herein.
In one aspect, this invention relates to a compound of formula (I), in which:
R1 is C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra;
R2 is C6-C16 cycloalkyl; C6-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb;
X is S(O)n or S(O)nNR6, wherein n is 1 or 2, and R6 is hydrogen, C1-C12 alkyl, or C3-C16 cycloalkyl; and
R6, R1, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, and Rm can be as defined anywhere herein.
In some embodiments, (p) and/or (q) apply:
(p) when V and Y are both N and X is SO2, then R1 cannot be 1-chlorophenyl when R2 is unsubstituted adamantyl or substituted or unsubstituted cyclohexyl; and
(q) when Y is N, V is CH, and X is SO2, then R1 cannot be 1-chlorophenyl when R2 is unsubstituted piperidyl, piperidyl substituted with oxo, unsubstituted morpholinyl, or unsubstituted pyrrolidinyl; or a pharmaceutically acceptable salt thereof.
In one aspect, this invention relates to a compound of formula (VI-A):
in which:
one or two of Ra2, Ra3, Ra4, and Ra6 are each, independently, halo; NRdRe; hydroxyl; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-2 Rj; C1-C12 alkoxy, optionally substituted with 1-2 Rf; C1-C12 haloalkoxy; cyano; nitro; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; C6-C10 aryloxy or heteroaryloxy including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; heterocyclyl including 3-10 atoms, C3-C10 cycloalkyl, C7-C12 aralkoxy or heteroaralkoxy including 6-12 atoms, each of which is optionally substituted with 1-3 Rb; —C(O)ORg; —C(O)NRdRe; or —NRhC(O)Ri; and the others are hydrogen;
W1 is C1-C4 alkyl; and
one or two of Rc22, Rc23, Rc24, Rc25, and Rc26 are each, independently, halo; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-3 Rj; C1-C12 alkoxy; C1-C12 haloalkoxy; cyano; nitro; or C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra; and the others are hydrogen.
In certain embodiments, one or more of the conditions delineated in the Summary can apply. For example, (a) can apply. In certain embodiments, (a) and any one of (e)-(j) apply. In certain embodiments, any one of (e)-(j) applies. In certain embodiments, any two or three of (e)-(j) applies, optionally in combination with (a). For example, (e) or (f) and (g) or (h) and/or (i) and (j), optionally in combination with (a).
In certain embodiments, (a) applies. In certain embodiments, (a) and/or (k) applies. In certain embodiments, (a), (k) and any one, two, three, or four of (l)-(o) apply.
Embodiments can include one or more of the following features.
The compounds can be in the form of a pharmaceutically acceptable salt. The compounds can be an N-oxide thereof and can also be in the form of a pharmaceutically acceptable salt.
Each of V and Y can both be N. V can be CR7 (e.g., CH), and Y can be N. Y can be CR7 (e.g., CH), and V can be N.
X can be SO2, SO2NH, or C(O).
One or two of W1, Z1, W2, and Z2 (e.g., W1 and Z2, e.g., W1) can each be, independently, other than hydrogen (e.g., C1-C4 alkyl or oxo), and the others can be hydrogen. One or two of W1, Z1, W2, and Z2 (e.g., W1 and Z2, e.g., W1) can each be, independently, C1-C4 alkyl, and the others can be hydrogen. Each of Z1 and W2 can be hydrogen. One or both of W1 and Z2 (e.g., W1) can each be, independently, C1-C4 alkyl; and each of Z1 and W2 can be hydrogen. W1 can be C1-C4 alkyl (e.g., CH3). Each of W1, Z1, W2, and Z2 can be hydrogen.
R1 can be C6-C10 aryl, optionally substituted with 1-4 Ra. In some embodiments, R1 is other than substituted or unsubstituted naphthyl.
Ra at each occurrence can be, independently, halo; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-2 Rj; C1-C12 alkoxy, optionally substituted with 1-2 Rf; C1-C12 haloalkoxy; cyano; nitro; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; C6-C10 aryloxy or heteroaryloxy including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; C3-C10 heterocyclyl, C3-C10 cycloalkyl, C7-C12 aralkoxy or heteroaralkoxy including 6-12 atoms, each of which is optionally substituted with 1-2 Rb; or —NRhC(O)Ri. In some embodiments, Ra is other than halo (e.g., chloro).
Ra at each occurrence is, independently, halo; NRdRe; hydroxyl; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-2 Rj; C1-C12 alkoxy, optionally substituted with from 1-2 Rf; C1-C12 haloalkoxy; cyano; nitro; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra; C6-C10 aryloxy or heteroaryloxy including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; heterocyclyl including 3-10 atoms, C3-C10 cycloalkyl, C7-C12 aralkoxy or heteroaralkoxy including 6-12 atoms, each of which is optionally substituted with 1-2 Rb; —C(O)ORg; —C(O)NRdRe; or —NRhC(O)Ri. In some embodiments, Ra is other than halo (e.g., chloro).
R1 can be 1-naphthyl, 2-naphthyl, or phenyl (i.e., unsubstituted).
R1 can have formula (II):
In certain embodiments, one of Ra2, Ra3, and Ra4 is halo; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with 1-2 Rj; C1-C12 alkoxy, optionally substituted with 1-2 Rf; C1-C12 haloalkoxy; cyano; nitro; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; C6-C10 aryloxy, optionally substituted with from 1-2 Ra′; C3-C10 heterocyclyl, C3-C10 cycloalkyl, or C7-C12 aralkoxy, each of which is optionally substituted with 1-2 Rb; or —NRhC(O)Ri; and the others are hydrogen.
In other embodiments, one of Ra2, Ra3, and Ra4 is halo; NRdRe; hydroxyl; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-2 Rj; C1-C12 alkoxy, optionally substituted with 1-2 Rf; C1-C12 haloalkoxy; cyano; nitro; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; C6-C10 aryloxy or heteroaryloxy including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; heterocyclyl including 3-10 atoms, C3-C10 cycloalkyl, C7-C12 aralkoxy or heteroaralkoxy including 6-12 atoms, each of which is optionally substituted with 1-3 Rb; —C(O)ORg; —C(O)NRdRe; or —NRhC(O)Ri; and the others are hydrogen.
Ra2, Ra3, or Ra4 (e.g., Ra3 or Ra4, e.g., Ra3) can be C1-C12 haloalkyl (e.g., C1-C4 haloalkyl), optionally substituted with 1-2 (e.g., 1) Rj. For example, Ra3 or Ra4 can be 1,1,1-trifluoro-2-hydroxy-2-propyl, in which the stereogenic carbon (i.e., the carbon attached to the hydroxyl group) can have the R or S configuration or some combination thereof (e.g., about 50% R and about 50% S or any other non-racemic combination of configurations). In some embodiments, Ra3 or Ra4 (e.g., Ra3) can be:
In these embodiments, each of the remaining substituents can be hydrogen.
Ra2, Ra3, or Ra4 can be C1-C12 alkyl, optionally substituted with 1 Rj. For example, Ra4 can be CH3 or a C3-C12 branched alkyl, such as tert-butyl. As another example, Ra3 or Ra4 can be C1-C12 alkyl, optionally substituted with 1 Rj (e.g., 2-hydroxy-2-propyl).
Ra3 or Ra4 (e.g., Ra3) can be heterocyclyl including 3-8 atoms, optionally substituted with from 1-3 (e.g., 1) Rb. In embodiments, Ra3 or Ra4 (e.g., Ra3) can be piperazinyl, piperidyl, morpholinyl, or pyrrolidinyl, each of which is optionally substituted with 1-3 (e.g., 1) Rb. For example, Ra3 or Ra4 (e.g., Ra3) can be 3-hydroxypyrrolidin-1-yl or 3-carboxypyrrolidin-1-yl.
In embodiments, Rb at each occurrence can be, independently, halo; NRdRe; hydroxyl; oxo; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-3 Rj; C1-C12 alkoxy, optionally substituted with 1-2 Rf; C1-C12 haloalkoxy; heterocyclyl including 3-10 atoms or C3-C10 cycloalkyl, each of which is optionally substituted with 1-3 Rb; —C(O)Rg; —C(O)ORg; —C(O)NRdRe; —OC(O)Rg; or —NRhC(O)Ri.
Ra3 or R4 (e.g., Ra3) can be heteroaryl including 5 or 6 atoms, optionally substituted with from 1-2 Ra′ (e.g., 1H-1,2,4-triazolyl).
Ra2, Ra3, or Ra4 can be halo (e.g., chloro). Ra3 or Ra4 can be phenyl or phenoxy, each of which is optionally substituted with from 1-2 halo. Ra4 can be C1-C4 alkoxy, optionally substituted with 1 Rf. Ra4 can be —NHC(O)Ri. In embodiments, Ri can be C1-C4 alkyl; or Ri can be NRdRe, in which Rd and Re can each be, independently, hydrogen or C1-C4 alkyl; or Ri can be heterocyclyl including 3-8 atoms. Ra2, Ra3, or Ra4 can be C3-C10 cycloalkyl, optionally substituted with 1 Rb (e.g., 1-hydroxycyclopropyl).
R1 can have formula (II-A):
In certain embodiments, two of Ra2, Ra3, Ra4, and Ra6 can each be, independently, halo; NRdRe; hydroxyl; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with 1-2 Rj; C1-C12 alkoxy, optionally substituted with from 1-2 Rf; C1-C12 haloalkoxy; heterocyclyl including 3-10 atoms, optionally substituted with from 1-3 Rb; heteroaryl including 5-12 atoms, optionally substituted with from 1-2 Ra′; —C(O)ORg; —C(O)NRdRe; or —NRhC(O)Ri; and the others can be hydrogen.
In other embodiments, one or two of Ra2, Ra3, Ra4, and Ra6 can each be, independently, halo; NRdRe; hydroxyl; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-2 Rj; C1-C12 alkoxy, optionally substituted with 1-2 Rf; C1-C12 haloalkoxy; cyano; nitro; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; C6-C10 aryloxy or heteroaryloxy including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; heterocyclyl including 3-10 atoms, C3-C10 cycloalkyl, C7-C12 aralkoxy or heteroaralkoxy including 6-12 atoms, each of which is optionally substituted with 1-3 Rb; —C(O)ORg; —C(O)NRdRe; or —NRhC(O)Ri; and the others can be hydrogen.
Ra2 can be halo (e.g., chloro), and Ra4 can be a substituent other than hydrogen, such as halo; NRdRe; hydroxyl; C1-C12 alkoxy, optionally substituted with from 1-2 Rf; C1-C12 haloalkoxy; heterocyclyl including 3-10 atoms, optionally substituted with from 1-3 Rb; heteroaryl including 5-12 atoms, optionally substituted with from 1-2 Ra′; —C(O)ORg; —C(O)NRdRe; or —NRhC(O)Ri. For example, Ra2 can be halo (e.g., chloro), and Ra4 can be heterocyclyl including 5-8 atoms, optionally substituted with from 1-3 Rb.
R1 can be 3,4-dichlorophenyl, 3-fluoro-4-bromophenyl, 2,6-dichlorophenyl, 2,4-difluorophenyl, 3,4-dimethoxyphenyl, 2-bromo-4-(trifluoromethyl)phenyl, or
R1 can be heteroaryl including 5-14 atoms, optionally substituted with from 1-5 (e.g., 1-2) Ra.
R1 can be a monocyclic heteroaryl including 5-6 atoms, optionally substituted with from 1-2 Ra. In embodiments, R1 can be thienyl, isoxazolyl, or pyridinyl, each of which is optionally substituted with from 1-2 Ra, wherein Ra at each occurrence is, independently, halo, C1-C4 alkyl, or heterocyclyl including 3-8 atoms.
In certain embodiments, R1 can have formula (II-B):
In some embodiments, Ra122 and Ra123 can each be, independently, hydrogen; halo; NRdRe; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-2 Rj; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; heterocyclyl including 3-10 atoms, C3-C10 cycloalkyl, C7-C12 aralkoxy or heteroaralkoxy including 6-12 atoms, each of which is optionally substituted with 1-3 Rb; —C(O)Rg; —C(O)ORg; —C(O)NRdRe; or —NRhC(O)Ri.
Ra222 can be halo; NRdRe; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-2 Rj; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; heterocyclyl including 3-10 atoms, C3-C10 cycloalkyl, C7-C12 aralkoxy or heteroaralkoxy including 6-12 atoms, each of which is optionally substituted with 1-3 Rb; —C(O)Rg; —C(O)ORg; —C(O)NRdRe; or —NRhC(O)Ri; and Ra223 can be hydrogen. For example, Ra222 can be heterocyclyl including 3-8 atoms, optionally substituted with from 1-3 Rb (e.g., piperazinyl, piperidyl, morpholinyl, or pyrrolidinyl, each of which is optionally substituted with 1-3 Rb).
R1 can be a bicyclic or tricyclic heteroaryl including 8-12 atoms, each of which is optionally substituted with from 1-2 Ra. For example, R1 can be quinolyl, benzothienyl, dibenzothienyl, benzofuryl, dibenzofuryl, or benzothiazolyl, each of which is optionally substituted with from 1-2 Ra, wherein Ra at each occurrence is, independently, halo, C1-C4 alkyl, or heterocyclyl including 3-8 atoms.
R1 can be C3-C12 cycloalkyl, optionally substituted with from 1-5 Rb. For example, R1 can be cyclopropyl, cyclopentyl, cyclohexyl, or adamantyl, each of which is optionally substituted with from 1-5 Rb, wherein Rb at each occurrence is, independently, halo or C1-C4 alkyl.
R1 can be (C1-C6 alkyl)-(C3-C12 cycloalkyl), wherein the cycloalkyl ring is optionally substituted with from 1-3 Rb. For example, R1 can be —CH2-(cyclopentyl), —CH2—(cyclohexyl), or —CH2-(bicycloheptyl), wherein the cycloalkyl ring is optionally substituted with from 1-3 C1-C4 alkyl.
R1 can be C7-C12 aralkyl, optionally substituted with from 1-2 Rb (e.g., benzyl, optionally substituted with from 1-2 halo). R1 can be arylheterocyclyl including 9-12 atoms.
R2 can be C6-C10 aryl, optionally substituted with from 1-3 Rc.
R2 can have formula (IV):
In some embodiments, one of Rc22, Rc23, and Rc24 is halo; hydroxyl; C1-C12 alkyl; C1-C12 haloalkyl; C1-C12 alkoxy; C1-C12 haloalkoxy; cyano; nitro; or C6-C10 aryl, optionally substituted with from 1-2 Ra; and the others are hydrogen.
Rc22 or Rc23 (e.g., Rc22) can be C1-C4 haloalkyl (e.g., CF3). Rc22 can be C1-C4 alkyl or C1-C4 alkoxy. Rc22, Rc23, or Rc24 (e.g., Rc23 or Rc24, e.g., Rc24) can be halo (e.g., fluoro). Rc24 can be phenyl substituted with 1 Ra.
R2 can have formula (IV-A):
In certain embodiments, two of Rc22, Rc23, Rc24, Rc25, and Rc26 can each be, independently, halo; C1-C12 alkyl; C1-C12 haloalkyl; cyano, C1-C12 alkoxy; heterocyclyl including 3-10 atoms, optionally substituted with from 1-2 Rb; heteroaryl including from 5-10 atoms, optionally substituted with from 1-2 Ra; or SO2Rm; and the others are hydrogen.
In other embodiments, one or two of Rc22, Rc23, Rc24, Rc25, and Re26 can each be, independently, halo; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-3 Rj; C1-C12 alkoxy; C1-C12 haloalkoxy; cyano; nitro; or C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra; and the others are hydrogen.
Two of Rc22, Rc23, Rc24, Rc25 and Rc26 can each be, independently, halo; C1-C4 haloalkyl, optionally substituted with from 1-3 Rj; cyano; or heteroaryl including 5-6 atoms, optionally substituted with from 1-2 Ra.
Rc22 can be C1-C4 haloalkyl (e.g., CF3), halo (e.g., chloro), C1-C6 alkoxy (e.g., OCH3), cyano, or C1-C6 alkyl (e.g., CH3); and one of Rc23, Rc24, and Rc25 can be: heterocyclyl including 3-8 atoms, optionally substituted with 1 Rb; heteroaryl including 5 or 6 atoms, optionally substituted with 1 Ra; or halo. In embodiments, Rc22 can be CF3, chloro, OCH3, cyano, or CH3; and one of Rc23, Rc24 and Rc25 can be: heterocyclyl including 3-8 atoms, optionally substituted with 1 Rb; heteroaryl including 5 or 6 atoms, optionally substituted with 1 Ra; or halo. In these embodiments, one of Rc23, Rc24, and Rc25 can be piperazinyl, optionally substituted with 1 Rb; morpholinyl, optionally substituted with 1 Rb; 1H-1,2,4-triazolyl; or fluoro.
Two of Rc22, Rc23 Rc24, Rc25 and Rc26 can each be, independently, halo (e.g., fluoro) or C1-C4 haloalkyl (e.g., CF3).
Rc22 can be C1-C4 haloalkyl (e.g., CF3), optionally substituted with from 1-3 Rj; and Rc24 can be halo; C1-C4 haloalkyl, optionally substituted with from 1-3 Rj; cyano; or heteroaryl including 5-6 atoms, optionally substituted with from 1-2 Ra. For example, Rc22 can be CF3. Rc22 can be CF3, and Rc24 can be halo (and the others can be hydrogen).
Rc22 and Rc24 can each be, independently, fluoro or chloro. For example, Rc22 can be chloro, and Rc24 can be fluoro.
R2 can be 4-fluoro-2-(sulfonylmethyl)phenyl; 4-fluoro-2-(trifluoromethyl)phenyl; 2,3-dichlorophenyl; 2,4-difluorophenyl; 2,4-dimethylphenyl; 2,6-dichlorophenyl; 2,6-dimethylphenyl; 3,4-dichlorophenyl; or 3-fluoro-2-(trifluoromethyl)phenyl.
R2 can be heteroaryl including 5-12 atoms, optionally substituted with from 1-3 (e.g., 1-2) Rc.
R2 can have formula (III):
In some embodiments, one or two of Rc3, Rc4, Rc5, and Rc6 can each be, independently, halo; C1-C12 alkyl; C1-C12 haloalkyl, optionally substituted with 1-2 Rj; cyano; or nitro; and the others are hydrogen.
One of Rc3, Rc4, or Rc5 (e.g., Rc3) can be C1-C4 haloalkyl (e.g., CF3). Rc3 or Rc5 can be chloro or fluoro. Rc3 can be C1-C4 alkyl. Rc3 can be CF3, chloro, fluoro, cyano, CH3, or nitro.
Two of Rc3, Rc4, Rc5, and Rc6 are each, independently, halo or C1-C4 haloalkyl. For example, two of Rc3, Rc4, Rc5, and Rc6 are each, independently, fluoro or CF3.
R2 can be 1-quinolyl, 2-quinolyl, 1-isoquinolyl, or 3,5-dichloro-4-pyridyl.
R2 can be OR1, wherein R1 is C6-C10 aryl, or heteroaryl including 5-10 atoms, each of which is optionally substituted with from 1-3 Ra; or C7-C12 aralkyl, optionally substituted with from 1-3 Rb.
R2 can have formula (V):
In some embodiments, one of Rc32, Rc33, and Rc34 can be halo; C1-C12 alkyl; C1-C12 haloalkyl; C1-C12 alkoxy; C1-C12 haloalkoxy; cyano; or nitro; and the others can be hydrogen. Rc32 can be C1-C4 haloalkyl (e.g., CF3) or C1-C4 alkyl. Rc32 or Rc34 can be C1-C4 alkoxy. Rc32 can be halo. For example, R2 can be 2,6-dichlorophenoxy.
R2 can be NR3R4, in which one of R3 and R4 is hydrogen, and the other can be C6-C10 aryl, optionally substituted with from 1-3 Ra. For example, R2 can be 2-chlorophenylamino.
R2 is C3-C12 cycloalkyl, optionally substituted with from 1-5 Rb (e.g., C6-C12 cycloalkyl, optionally substituted with from 1-5 Rb). For example, R2 can be cyclohexyl, bicycloheptyl, cycloheptyl, or adamantyl, each of which is optionally substituted with from 1-2 Rb, in which Rb at each occurrence can be, independently, halo or C1-C4 alkyl.
Each of V and Y is N, and X is SO2, and embodiments can include one or more of the features described anywhere herein.
The compound of formula (I) can be (2R)-1,1,1-trifluoro-2-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propan-2-ol.
In one aspect, this invention features a pharmaceutical composition, which includes a compound of formula (I) or a salt (e.g., a pharmaceutically acceptable salt) or a prodrug thereof (e.g., an effective amount thereof) and a pharmaceutically acceptable adjuvant, carrier or diluent. In some embodiments, the composition can further include an additional therapeutic agent.
In one aspect, this invention relates to a method for treating a disease or condition mediated by excess or uncontrolled amounts of cortisol and/or other corticosteroids, which includes administering to a subject in need thereof an effective amount of a compound of formula (I) or a salt (e.g., a pharmaceutically acceptable salt) or prodrug thereof.
In one aspect of the invention, this invention relates to methods for treating diabetes (e.g., type I diabetes, type 2 diabetes), which includes administering to a subject in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
In another aspect of the invention, this invention relates to methods for treating Syndrome X, which includes administering to a subject in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
In a further aspect of the invention, this invention relates to methods for treating hyperglycemia, diabetes or insulin resistance, which includes administering to a subject in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
In one aspect of the invention, this invention relates to methods for treating obesity, which includes administering to a subject in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
In another aspect of the invention, this invention relates to methods for treating a lipid disorder selected from the group consisting of dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL, which includes administering to a subject in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
In a further aspect of the invention, this invention relates to methods for treating atherosclerosis, which include administering to a subject in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
In one aspect of the invention, this invention relates to methods for treating a cognitive disorder (e.g., Alzheimer's disease), which includes administering to a subject in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
In another aspect of the invention, this invention relates to methods for promoting wound healing, which includes administering to a subject in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
In a further aspect of the invention, this invention relates to methods for treating, controlling, ameliorating, preventing, delaying the onset of, or reducing the risk of developing one or more of diabetes (e.g., type 1 or type 2 diabetes), Syndrome X, hyperglycemia, low glucose tolerance, insulin resistance, obesity, lipid disorders, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, high LDL levels, atherosclerosis and its sequelae, vascular restenosis, pancreatitis, abdominal obesity, neurodegenerative disease, retinopathy, nephropathy, neuropathy, hypertension, coronary heart disease, stroke, peripheral vascular disease, Cushing's syndrome, glaucoma, osteoporosis, hyperinsulinemia, tuberculosis, psoriasis, cognitive disorders and dementia (e.g., impairment associated with aging and of neuronal dysfunction, e.g., Alzheimer's disease), depression, viral diseases, inflammatory disorders, immune disorders); or promoting wound healing, which includes administering to a subject in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
The invention also relates generally to inhibiting 11-beta HSD1 with a compound having formula (I). In some embodiments, the methods can include, e.g., contacting an 11βHSD1 in a sample (e.g., a tissue) with a compound having formula (I). In other embodiments, the methods can include administering a compound having formula (I) to a subject (e.g., a mammal, e.g., a mammal subject to or at risk for diseases mediated by abnormally high levels of cortisol and other 11β-hydroxysteroids, e.g., NIDDM, obesity, dyslipidemia, syndrome X, and hypertension). Accordingly, in yet another aspect, this invention includes methods of screening for compounds that inhibit 11βHSD1.
In some embodiments, the subject can be a subject in need thereof (e.g., a subject identified as being in need of such treatment). Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method). In some embodiments, the subject can be a mammal. In certain embodiments, the subject is a human.
In a further aspect, this invention also relates to methods of making compounds described herein. Alternatively, the method includes taking any one of the intermediate compounds described herein and reacting it with one or more chemical reagents in one or more steps to produce a compound described herein.
In one aspect, this invention relates to any of the compounds described herein.
In one aspect, this invention relates to a packaged product. The packaged product includes a container, one of the aforementioned compounds in the container, and a legend (e.g., a label or an insert) associated with the container and indicating administration of the compound for treatment and control of diseases mediated by abnormally high levels of cortisol and other 11β-hydroxysteroids, e.g., NIDDM and Syndrome X.
The term “mammal” includes organisms, which include mice, rats, cows, sheep, pigs, rabbits, goats, and horses, monkeys, dogs, cats, and preferably humans.
“An effective amount” refers to an amount of a compound that confers a therapeutic effect (e.g., treats, controls, ameliorates, prevents, delays the onset of, or reduces the risk of developing a disease, disorder, or condition or symptoms thereof) on the treated subject. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect). An effective amount of the compound described above may range from about 0.01 mg/Kg to about 1000 mg/Kg, (e.g., from about 0.1 to about 100 mg/Kg, from about 1 to about 100 mg/Kg). Effective doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents.
The term “halo” or “halogen” refers to any radical of fluorine, chlorine, bromine or iodine. The term “carboxy” refers to the —COOH radical.
In general, and unless otherwise indicated, substituent (radical) prefix names are derived from the parent hydride by either (i) replacing the “ane” in the parent hydride with the suffixes “yl,” “diyl,” “triyl,” “tetrayl,” etc.; or (ii) replacing the “e” in the parent hydride with the suffixes “yl,” “diyl,” “triyl,” “tetrayl,” etc. (here the atom(s) with the free valence, when specified, is (are) given numbers as low as is consistent with any established numbering of the parent hydride). Accepted contracted names, e.g., adamantyl, naphthyl, anthryl, phenanthryl, furyl, pyridyl, isoquinolyl, quinolyl, and piperidyl, and trivial names, e.g., vinyl, allyl, phenyl, and thienyl are also used herein throughout. Conventional numbering/lettering systems are also adhered to for substituent numbering and the nomenclature of fused, bicyclic, tricyclic, polycyclic rings.
The term “alkyl” refers to a saturated hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C1-C20 alkyl indicates that the group may have from 1 to 20 (inclusive) carbon atoms in it. Any atom can be substituted. Examples of alkyl groups include without limitation methyl, ethyl, and tert-butyl.
The term “cycloalkyl” refers to saturated monocyclic, bicyclic, tricyclic, or other polycyclic hydrocarbon groups. Any atom can be substituted, e.g., by one or more substituents. A ring carbon serves as the point of attachment of a cycloalkyl group to another moiety. Cycloalkyl groups can contain fused rings. Fused rings are rings that share a common carbon atom. Cycloalkyl moieties can include, e.g., cyclopropyl, cyclohexyl, methylcyclohexyl (provided that the methylcyclohexyl group is attached to another moiety via a cyclohexyl ring carbon and not the methyl group), adamantyl, and norbornyl (bicycle[2.2.1]heptyl).
The term “haloalkyl” refers to an alkyl group, in which at least one hydrogen atom is replaced by halo. In some embodiments, more than one hydrogen atom (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, etc. hydrogen atoms) on a alkyl group can be replaced by more than one halogen (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, etc. halogen atoms). In these embodiments, the hydrogen atoms can each be replaced by the same halogen (e.g., fluoro) or the hydrogen atoms can be replaced by a combination of different halogens (e.g., fluoro and chloro). The term “haloalkyl” also includes alkyl moieties in which all hydrogens have been replaced by halo (e.g., sometimes referred to as perhaloalkyl moieties, such as trifluoromethyl).
The term “aralkyl” refers to an alkyl moiety in which an alkyl hydrogen atom is replaced by an aryl group. One of the carbons of the alkyl moiety serves as the point of attachment of the aralkyl group to another moiety. Aralkyl includes groups in which more than one hydrogen atom on an alkyl moiety has been replaced by an aryl group. Any ring or chain atom can be substituted e.g., by one or more substituents. Examples of “aralkyl” include without limitation benzyl, 2-phenylethyl, 3-phenylpropyl, benzhydryl (diphenylmethyl), and trityl (triphenylmethyl) groups.
The term “heteroaralkyl” refers to an alkyl moiety in which an alkyl hydrogen atom is replaced by a heteroaryl group. One of the carbons of the alkyl moiety serves as the point of attachment of the aralkyl group to another moiety. Heteroaralkyl includes groups in which more than one hydrogen atom on an alkyl moiety has been replaced by a heteroaryl group. Any ring or chain atom can be substituted e.g., by one or more substituents. Heteroaralkyl can include, for example, 2-pyridylethyl.
The term “(alkyl)-(cycloalkyl)” refers to an alkyl moiety in which an alkyl hydrogen atom is replaced by a cycloalkyl group. One of the carbons of the alkyl moiety serves as the point of attachment of the (alkyl)-(cycloalkyl) to another moiety. Any ring or chain atom can be substituted e.g., by one or more substituents. (alkyl)-(cycloalkyl) can include, for example:
The term “alkenyl” refers to a straight or branched hydrocarbon chain containing 2-20 carbon atoms and having one or more double bonds. Any atom can be substituted, e.g., by one or more substituents. Alkenyl groups can include, e.g., allyl, 1-butenyl, 2-hexenyl and 3-octenyl groups. One of the double bond carbons can optionally be the point of attachment of the alkenyl substituent. The term “alkynyl” refers to a straight or branched hydrocarbon chain containing 2-20 carbon atoms and having one or more triple bonds. Any atom can be substituted, e.g., by one or more substituents. Alkynyl groups can include, e.g., ethynyl, propargyl, and 3-hexynyl. One of the triple bond carbons can optionally be the point of attachment of the alkynyl substituent.
The term “alkoxy” refers to an —O-alkyl radical. The term “mercapto” refers to an SH radical. The term “thioalkoxy” refers to an —S-alkyl radical. The terms “aryloxy” and “heteroaryloxy” refer to an —O-aryl radical and —O-heteroaryl radical, respectively. The term “thioaryloxy” refers to an —S-aryl radical. The terms “aralkoxy” and “heteroaralkoxy” refer to an —O-aralkyl radical and —O-heteroaralkyl radical, respectively. The term “cycloalkoxy” refers to an —O-cycloalkyl radical. The terms “cycloalkenyloxy” and “heterocycloalkenyloxy” refer to an —O-cycloalkenyl radical and —O-heterocycloalkenyl radical, respectively. The term “heterocyclyloxy” refers to an —O-heterocyclyl radical. The terms “alkenyloxy” and “alkynyloxy” refer to —O-alkenyl and —O-alkynyl radicals, respectively.
The term “heterocyclyl” refers to a saturated monocyclic, bicyclic, tricyclic or other polycyclic ring system having 1-4 heteroatoms if monocyclic, 1-8 heteroatoms if bicyclic, or 1-10 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-4, 1-8, or 1-10 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively). The heteroatom or ring carbon is the point of attachment of the heterocyclyl substituent to another moiety. Any atom can be substituted, e.g., by one or more substituents. The heterocyclyl groups can contain fused rings. Fused rings are rings that share a common carbon atom. Heterocyclyl groups can include, e.g., tetrahydrofuryl, tetrahydropyranyl, piperidyl (piperidino), piperazinyl, morpholinyl (morpholino), pyrrolinyl, and pyrrolidinyl.
The term “cycloalkenyl” refers to partially unsaturated monocyclic, bicyclic, tricyclic, or other polycyclic hydrocarbon groups. A ring carbon (e.g., saturated or unsaturated) is the point of attachment of the cycloalkenyl substituent. Any atom can be substituted e.g., by one or more substituents. The cycloalkenyl groups can contain fused rings. Fused rings are rings that share a common carbon atom. Cycloalkenyl moieties can include, e.g., cyclohexenyl, cyclohexadienyl, or norbornenyl.
The term “heterocycloalkenyl” refers to partially unsaturated monocyclic, bicyclic, tricyclic, or other polycyclic hydrocarbon groups having 1-4 heteroatoms if monocyclic, 1-8 heteroatoms if bicyclic, or 1-10 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-4, 1-8, or 1-10 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively). A ring carbon (e.g., saturated or unsaturated) or heteroatom is the point of attachment of the heterocycloalkenyl substituent. Any atom can be substituted, e.g., by one or more substituents. The heterocycloalkenyl groups can contain fused rings. Fused rings are rings that share a common carbon atom. Heterocycloalkenyl groups can include, e.g., tetrahydropyridyl, and dihydropyranyl.
The term “aryl” refers to an aromatic monocyclic, bicyclic, or tricyclic hydrocarbon ring system, wherein any ring atom can be substituted, e.g., by one or more substituents. Aryl groups can contain fused rings. Fused rings are rings that share a common carbon atom. Aryl moieties can include, e.g., phenyl, naphthyl, anthracenyl, and pyrenyl.
The term “heteroaryl” refers to an aromatic monocyclic, bicyclic, tricyclic, or other polycyclic hydrocarbon groups having 1-4 heteroatoms if monocyclic, 1-8 heteroatoms if bicyclic, or 1-10 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-4, 1-8, or 1-10 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively). Any atom can be substituted, e.g., by one or more substituents. Heteroaryl groups can contain fused rings. Fused rings are rings that share a common carbon atom. Heteroaryl groups include pyridyl, thienyl, furyl (furanyl), imidazolyl, isoquinolyl, quinolyl and pyrrolyl.
The terms “arylcycloalkenyl,” “arylheterocyclyl,” and “arylheterocycloalkenyl” refer to bicyclic, tricyclic, or other polycyclic ring systems that include an aryl ring fused to a cycloalkenyl, heterocyclyl, and heterocycloalkenyl, respectively. Any atom can be substituted, e.g., by one or more substituents. For example, arylcycloalkenyl can include indenyl; arylheterocyclyl can include 2,3-dihydrobenzofuryl, 1,2,3,4-tetrahydroisoquinolyl, and 2,2-dimethylchromanyl; and arylheterocycloalkenyl can include 1,4-dihydro-1,4-epoxynaphthyl.
The term “oxo” refers to an oxygen atom, which forms a carbonyl (C═O) when attached to carbon or which forms part of a sulfinyl or sulfonyl group when attached to a sulfur atom. The term “thioxo” refers to an oxygen atom, which forms a thiocarbonyl (C═S) when attached to carbon.
The term “substituent” refers to a group “substituted” on, e.g., an alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, heterocyclyl, heterocycloalkenyl, cycloalkenyl, aryl, heteroaryl, arylcycloalkenyl, arylheterocyclyl, or arylheterocycloalkenyl group at any atom of that group. In one aspect, the substituent(s) (e.g., Ra) on a group are independently any one single, or any combination of two or more of the permissible atoms or groups of atoms delineated for that substituent. In another aspect, a substituent may itself be substituted with any one of the above substituents (e.g., substituent Ra can be substituted with Ra′).
In general, when a definition for a particular variable includes both hydrogen and non-hydrogen (halo, alkyl, aryl, etc.) possibilities, the term “substituent(s) other than hydrogen” and the like refers collectively to the non-hydrogen possibilities for that particular variable.
The details of one or more embodiments of the invention are set forth in the description below. Other features and advantages of the invention are in the claims.
DETAILED DESCRIPTIONThis invention relates to 11-beta HSD1 inhibitor compounds, pharmaceutical compositions and related methods.
The 11-beta HSD1 inhibitor compounds have the general formula (I) below:
in which R1, R2, R3, R4, R5, R6, R7, X, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rm, and Rn can be as defined anywhere herein.
For ease of exposition, it is understood that where in this specification (including the claims), a group is defined by “as defined anywhere herein” (or the like), the definitions for that particular group include the first occurring and broadest generic definition as well as any subgeneric and specific definitions delineated anywhere in this specification.
For ease of exposition, it is understood that any recitation of ranges (e.g., C1-C20, 1-3) or subranges of a particular range (e.g., C1-C4, C2-C6, 1-2) for any of R1, R2, R3, R4, R5, R6, R7, X, V, Y, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rm, and Rn expressly includes each of the individual values that fall within the recited range, including the upper and lower limits of the recited range. For example, the range C1-C4 alkyl is understood to mean C1, C2, C3, or C4 alkyl or the range 1-3 Ra is understood to mean 1, 2, or 3 Ra.
In some embodiments, R1 can be:
(A) C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl or heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms, each of which is optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Ra; or
(B) C3-C16 (e.g., C3-C14 or C3-C10) cycloalkyl, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rb; or
(C) (C1-C12 alkyl)-(C3-C16 cycloalkyl) (e.g., (C1-C6 alkyl)-(C3-C12 cycloalkyl) or (CH2)—(C3-C12 cycloalkyl), optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rb; or
(D) C7-C20 (e.g., C7-C16, C7-C12, C7-C10) aralkyl, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rb; or
(E) arylheterocyclyl including 8-20 (e.g., 8-16 or 9-12) atoms, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rb.
In some embodiments, R1 can be C6-C10 aryl, optionally substituted with from 1-3 (e.g., 1-2 or 1) Ra.
In certain embodiments, R1 can be unsubstituted phenyl or unsubstituted napthyl (e.g., 1-naphthyl or 2-naphthyl).
In certain embodiments, R1 can be a monosubstituted (1 Ra), disubstituted (2 Ra), trisubstituted (3 Ra), tetrasubstituted (4 Ra), or pentasubstituted (5 Ra) phenyl group of the general formula P-1:
For purposes of clarification, each of the terms “ortho (o) (or 2- or 6-); meta (m) (or 3- or 5-); or para (p) (or 4-),” when used in conjunction with any substituted phenyl group, indicates the location of the substituent(s) relative to the ring carbon that is attached to the remainder of the molecule (i.e., C1 in formula P-1 above). For example, a monosubstituted phenyl group that is para substituted (or 4-substituted) is one having a substituent attached to C4 in formula P-1 above. As another example, a 2,6- (or ortho, ortho-) disubstituted phenyl group is one having a substituent attached to C2 and to C6, respectively, in formula P-1. As a further example, a 3,5- (or meta, meta) disubstituted phenyl group is one having a substituent attached to C3 and to C5, respectively, in formula P-1.
In certain embodiments, Ra at each occurrence can be, independently, halo; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-2 Rj; C1-C12 alkoxy, optionally substituted with 1-2 Rf; C1-C12 haloalkoxy; cyano; nitro; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; C6-C10 aryloxy or heteroaryloxy including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; C3-C10 heterocyclyl, C3-C10 cycloalkyl, C7-C12 aralkoxy or heteroaralkoxy including 6-12 atoms, each of which is optionally substituted with 1-2 Rb; or —NRhC(O)Ri. In some embodiments, Ra is other than halo (e.g., chloro).
Ra at each occurrence is, independently, halo; NRdRe; hydroxyl; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-2 Rj; C1-C12 alkoxy, optionally substituted with from 1-2 Rf; C1-C12 haloalkoxy; cyano; nitro; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; C6-C10 aryloxy or heteroaryloxy including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; heterocyclyl including 3-10 atoms, C3-C10 cycloalkyl, C7-C12 aralkoxy or heteroaralkoxy including 6-12 atoms, each of which is optionally substituted with 1-2 Rb; —C(O)ORg; —C(O)NRdRe; or —NRhC(O)Ri. In some embodiments, Ra is other than halo (e.g., chloro).
For example, Ra at each occurrence can be, independently, chloro, fluoro, bromo, methyl, tert-butyl, trifluoromethyl, trifluoromethoxy, methoxy, cyano, nitro, phenyl, 4-bromophenyl, 4-fluorophenyl, phenoxy, acetamido, (e.g., R or S) 1,1,1-trifluoro-2-hydroxypropan-2-yl, 2-hydroxypropan-2-yl, 1-hydroxycyclopropan-1-yl, 4-fluorophenoxy, pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, 3-carboxypyrrolidin-1-yl, morpholin-4-yl, 1-piperidyl, 4-piperidyl, 2-cyanopropoxy, piperazin-1-yl, 4-methylpiperazin-1-yl, 1H-1,2,4-triazolyl, or —NHC(O)Ri in which Ri is morpholin-4-yl, N,N-dimethylamino, methylamino, 1-piperidyl, pyrrolidin-1-yl, or azapan-1-yl.
In certain embodiments, R1 can be a monosubstituted phenyl group having formula (II):
in which one of Ra2, Ra3, and Ra4 can be halo; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with 1-2 Rj; C1-C12 alkoxy, optionally substituted with 1-2 Rf; C1-C12 haloalkoxy; cyano; nitro; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; C6-C10 aryloxy, optionally substituted with from 1-2 Ra′; C3-C10 heterocyclyl, C3-C10 cycloalkyl, or C7-C12 aralkoxy, each of which is optionally substituted with 1-2 Rb; or —NRhC(O)Ri; and the others are hydrogen.
In other embodiments, one of Ra2, Ra3, and Ra4 is halo; NRdRe; hydroxyl; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-2 Rj; C1-C12 alkoxy, optionally substituted with 1-2 Rf; C1-C12 haloalkoxy; cyano; nitro; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; C6-C10 aryloxy or heteroaryloxy including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; heterocyclyl including 3-10 atoms, C3-C10 cycloalkyl, C7-C12 aralkoxy or heteroaralkoxy including 6-12 atoms, each of which is optionally substituted with 1-3 Rb; —C(O)ORg; —C(O)NRdRe; or —NRhC(O)Ri; and the others are hydrogen. For example, R1 can be a meta or para monosubstituted phenyl ring.
Ra2, Ra3, or Ra4 can be halo (e.g., chloro, bromo, or fluoro, preferably chloro).
Ra2, Ra3, or Ra4 (e.g., Ra3 or Ra4) can be C1-C12 alkyl, optionally substituted with 1 Rj (e.g., hydroxyl). For example, Ra2, Ra3, or Ra4 (e.g., Ra3 or Ra4, e.g., Ra4) can be CH3 or C3-C12 branched alkyl (e.g., tert-butyl). As another example, Ra2, Ra3, or Ra4 (e.g., Ra3 or Ra4) can be 2-hydroxypropan-2-yl, i.e., (CH3C(OH)(CH3).
Ra2, Ra3, or Ra4 can be C1-C4 haloalkyl, optionally substituted with 1 Rj (e.g., hydroxyl). For example, Ra2, Ra3, or Ra4 (e.g., Ra3 or Ra4, e.g., Ra4) can be CF3. As another example, Ra2, Ra3, or Ra4 (e.g., Ra3 or Ra4) can be (e.g., R or S) 1,1,1-trifluoro-2-hydroxypropan-2-yl, i.e., CF3C(OH)(CH3).
Ra2, Ra3, or Ra4 can be C3-C10 cycloalkyl, optionally substituted with 1 Rb (e.g., hydroxyl). For example, Ra2, Ra3, or Ra4 (e.g., Ra3 or Ra4, e.g., Ra4) can be 1-hydroxycyclopropan-1-yl.
Ra3 or Ra4 can be heterocyclyl including 3-8 atoms, optionally substituted with 1-3 (e.g., 1) Rb (e.g., C1-C4 alkyl (e.g., CH3), OH, C3-C10 cycloalkyl, or COORg (e.g., COOH)). For example, Ra3 or Ra4 can be optionally substituted pyrrolidinyl (e.g., pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, or 3-carboxypyrrolidin-1-yl), morpholinyl (e.g., morpholin-4-yl), piperidyl (e.g., 1-piperidyl or 4-piperidyl) or piperazinyl (e.g., piperazin-1-yl, 4-methylpiperazin-1-yl). For example, Ra3 is optionally substituted pyrrolidin-1-yl (e.g., 3-hydroxypyrrolidin-1-yl).
In these embodiments, Rb at each occurrence can be, independently, halo; NRdRe; hydroxyl; oxo; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-3 Rj; C1-C12 alkoxy, optionally substituted with 1-2 Rf; C1-C12 haloalkoxy; heterocyclyl including 3-10 atoms or C3-C10 cycloalkyl, each of which is optionally substituted with 1-3 Rb; —C(O)Rg; —C(O)ORg; —C(O)NRdRe; —OC(O)Rg; or —NRhC(O)Ri.
Ra3 or Ra4 can be heteroaryl including 5 or 6 atoms (e.g., 1H-1,2,4-triazolyl).
Ra3 or Ra4 can be phenyl or phenoxy, each of which can be optionally substituted with from 1-2 halo (e.g., bromo or fluoro). For example, Ra3 or Ra4 can be phenyl, phenoxy, 4-bromophenyl, 4-fluorophenyl, or 4-fluorophenoxy.
Ra4 can be C1-C4 alkoxy, optionally substituted with 1 Rf (e.g., cyano). For example, Ra4 can be OCH3 or 2-cyanopropoxy.
Ra4 can be —NHC(O)Ri. Ri can be C1-C4 alkyl (e.g., CH3). Ri can be NRdRe, in which Rd and Re can each be, independently, hydrogen or C1-C4 alkyl (e.g., CH3). For example, Ri can be —N(CH3)2 or —NHCH3. Ri can be heterocyclyl including 3-8 atoms (e.g., morpholin-4-yl, 1-piperidyl, pyrrolidin-1-yl, or azapan-1-yl).
Ra4 can be C1-C4 haloalkoxy (e.g., OCF3).
Ra2 can be nitro or cyano.
Ra4 can be C7-C12 aralkoxy, optionally substituted with 1-2 Rb (e.g., chloro). For example, Ra4 can be benzyloxy or 4-chlorobenzyloxy.
In certain embodiments, R1 can be a disubstituted phenyl group having formula (II-A):
In certain embodiments, two of Ra2, Ra3, Ra4, and Ra6 can be, independently, halo; C1-C12 haloalkyl, optionally substituted with 1-2 Rj; C1-C12 alkoxy, optionally substituted with 1-2 Rf; or —NRhC(O)Ri; and the others are hydrogen.
In certain embodiments, two of Ra2, Ra3, Ra4, and Ra6 can each be, independently, halo; NRdRe; hydroxyl; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with 1-2 Rj; C1-C12 alkoxy, optionally substituted with from 1-2 Rf; C1-C12 haloalkoxy; heterocyclyl including 3-10 atoms, optionally substituted with from 1-3 Rb heteroaryl including 5-12 atoms, optionally substituted with from 1-2 Ra′; —C(O)ORg; —C(O)NRdRe; or —NRhC(O)Ri; and the others can be hydrogen.
In other embodiments, two of Ra2, Ra3, Ra4, and Ra6 can each be, independently, halo; NRdRe; hydroxyl; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-2 Rj; C1-C12 alkoxy, optionally substituted with 1-2 Rf; C1-C12 haloalkoxy; cyano; nitro; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; C6-C10 aryloxy or heteroaryloxy including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; heterocyclyl including 3-10 atoms, C3-C10 cycloalkyl, C7-C12 aralkoxy or heteroaralkoxy including 6-12 atoms, each of which is optionally substituted with 1-3 Rb; —C(O)ORg; —C(O)NRdRe; or —NRhC(O)Ri; and the others can be hydrogen.
Ra3 and Ra4 can each be, independently, halo (e.g., chloro, bromo or phenyl) or C1-C4 alkoxy (e.g., OCH3).
Ra2 and Ra4 can each be, independently, halo (e.g., fluoro or bromo), C1-C4 haloalkyl (e.g., CF3), or —NRhC(O)Ri, in which Ri can be heterocyclyl including 3-8 atoms.
Ra2 and Ra6 can each be, independently, halo (e.g., chloro).
For example, R1 can be 3,4-dichlorophenyl, 3-fluoro-4-bromophenyl, 2,6-dichlorophenyl, 2,4-difluorophenyl, 3,4-dimethoxyphenyl, 2-bromo-4-(trifluoromethyl)phenyl, or
In other embodiments, Ra2 can be halo (e.g., chloro), and Ra4 can be a substituent other than hydrogen, such as halo; NRdRe; hydroxyl; C1-C12 alkoxy, optionally substituted with from 1-2 Rf; C1-C12 haloalkoxy; heterocyclyl including 3-10 atoms, optionally substituted with from 1-3 Rb; heteroaryl including 5-12 atoms, optionally substituted with from 1-2 Ra′; —C(O)ORg; —C(O)NRdRe; or —NRhC(O)Ri. For example, Ra2 can be halo (e.g., chloro), and Ra4 can be heterocyclyl including 5-8 atoms, optionally substituted with from 1-3 Rb.
In certain embodiments, R1 can be napthyl substituted with from 1-2 Ra (e.g., chloro). For example, R1 can be 5-chloronaphth-2-yl or 8-chloro-2-naphth-2-yl.
In some embodiments, R1 can be heteroaryl including 5-14 atoms, optionally substituted with from 1-3 (e.g., 1-2 or 1) Ra.
R1 can be a monocyclic heteroaryl including 5-6 atoms, optionally substituted with from 1-2 Ra (e.g., thienyl, isoxazolyl, or pyridyl, each of which is optionally substituted with from 1-2 Ra, in which Ra at each occurrence is, independently, halo, C1-C4 alkyl, or heterocyclyl including 3-8 atoms). For example, R1 can be 2-thienyl, 5-chlorothien-2-yl, 3,5-dimethylisoxazol-4-yl, or 2-morpholinopyridin-5-yl. As another example, R1 can have formula (II-B) as described in the Summary.
R1 can be a bicyclic or tricyclic heteroaryl including 8-12 atoms, each of which is optionally substituted with from 1-2 Ra (e.g., quinolyl, benzothienyl, dibenzothienyl, benzofuryl, dibenzofuryl, or benzothiazolyl, each of which is optionally substituted with from 1-2 Ra, in which Ra at each occurrence is, independently, halo, C1-C4 alkyl, or heterocyclyl including 3-8 atoms). For example, R1 can be 2-quinolyl, 2-benzo[b]thienyl, 3-benzo[b]thienyl, 5-chloro-3-methylbenzo[b]thien-2-yl, dibenzo[b,d]fur-2-yl, dibenzo[b,d]thien-2-yl, dibenzo[b,d]thien-3-yl, dibenzo[b,d]fur-3-yl, 4-chloro-3-methylbenzo[b]thien-2-yl, 1,3-benzothiazol-2-yl, 5-morpholino-3-methylbenzo[b]thien-2-yl, or 5-(piperazin-1-yl)-3-methylbenzo[b]thien-2-yl.
In certain embodiments (e.g., when V and Y are both N, and X is CO), when R1 is a bicyclic heteroaryl, then 1 heteroatom can be present in the bicyclic heteroaryl (e.g., 1 oxygen, 1 nitrogen, or 1 sulfur, e.g., 1 oxygen or 1 sulfur); or 2 heteroatoms can be present (e.g., 2 oxygens, or 2 sulfurs, or 2 nitrogens, or 1 oxygen and 1 sulfur, or 1 oxygen and 1 nitrogen, or 1 sulfur and 1 nitrogen); or 3 heteroatoms can be present (e.g., 1 oxygen and 2 nitrogens; or 1 sulfur and 2 nitrogens; or 3 nitrogens, provided that the bicyclic heterocycle is other than pyrazolo[1,5-a]pyrimidinyl:
(e.g., other than unsubstituted or mono-, di-, or tri-substituted pyrazolo[1,5-a]pyrimidinyl, e.g., other than unsubstituted or mono-, di-, or tri-substituted pyrazolo[1,5-a]pyrimidin-2-yl); or 4 heteroatoms can be present (e.g., 1 oxygen and 3 nitrogens, or 1 sulfur and 3 nitrogens, or 4 nitrogens). In other embodiments, when R1 is a nitrogenous, bicyclic heteroaryl (including those nitrogenous bicyclic heteroaryls in which one or more oxygens and/or sulfur(s) are also present), then R1 has other than 3 nitrogen atoms (e.g., 1 or 2 nitrogen atoms, e.g., more than three nitrogen atoms, e.g., 4-8 nitrogen atoms).
In some embodiments, R1 can be C3-C12 (e.g., C3-C10) cycloalkyl, optionally substituted with from 1-5 (e.g., 1-4, 1-3, 1-2, or 1) Rb (e.g., halo or C1-C4 alkyl). R1 can be monocyclic (e.g., optionally substituted cyclopropyl, cyclopentyl, or cyclohexyl), bicyclic (e.g., optionally substituted bicycloheptyl), or polycyclic (e.g., optionally substituted adamantyl). For example, R1 can be adamant-1-yl, cyclohexyl, 2-methylcyclohexan-1-yl, 3-methylcyclohexan-1-yl, 2,2,3,3-tetramethylcyclopropan-1-yl, 2,2-dichloro-1-methylcyclopropan-1-yl, or 1-methyl-3-isopropyl-cyclopentan-1-yl.
In some embodiments, R1 can be (C1-C6 alkyl)-(C3-C12 cycloalkyl), in which the cycloalkyl ring is optionally substituted with from 1-3 Rb. R1 can be —(CH2)1-6—(C3-C10 cycloalkyl), in which the cycloalkyl ring is optionally substituted with from 1-3 C1-C4 alkyl (e.g., CH3). For example, R1 can be —CH2-(cyclopentyl), —CH2-(cyclohexyl), —CH2-(4-methylcyclohexyl), or —CH2-(bicycloheptyl).
In some embodiments, R1 can be C7-C12 aralkyl, optionally substituted with from 1-2 Rb (e.g., halo). R1 can be —(CH2)1-6—(C6-C10 aryl), in which the aryl ring is optionally substituted with from 1-2 halo (e.g., chloro). For example, R1 can be benzyl, 4-chlorobenzyl; or —(CH2)-(naphthyl), in which the CH2 group is attached to the 1 or 2 position of the naphthalene ring.
In some embodiments, R1 can be arylheterocyclyl including 9-12 atoms, optionally substituted with from 1-5 (e.g., 1-4, 1-3, 1-2, or 1) Rb (e.g., oxo, halo or C1-C4 alkyl), in which the heterocyclyl portion can include 1 or 2 heteroatoms (e.g., nitrogen or oxygen). For example, R1 can be 2,2-dimethylchromanyl.
In some embodiments, R2 can be:
(A) heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rc or Rn; or C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rc; or
(B) C3-C16 (e.g., C3-C14, C3-C10, C6-C16, C6-C14, C6-C10, C7-C16, C8-C16, C9-C16, C10-C16, C7-C14, C8-C14, C9-C14, C10-C14, C7-C10, C8-C10, or C9-C10) cycloalkyl, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rb; or
(C)OR1; or NR3R4, in which R3 and R4 can each be, independently, hydrogen or R1 (e.g., R1 can be C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl or heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms; each of which is optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Ra); or
(D) heterocyclyl including 3-16 (e.g., 3-12, 3-10, 5-12, or 5-6) atoms, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rb; or
(E) C(O)R5, in which R5 is C1-C20 (e.g., C1-C12, C1-C6, or C1-C4) alkyl or C7-C20 (e.g., C7-C12 aralkoxy).
In certain embodiments, R2 can be (A), (B), (C), and/or (D); or (A), (C), (D), and/or (E); or (A), (C), and/or (D); or (A) and/or (C).
In certain embodiments, when R2 is (A), R2 is optionally substituted heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms. In other embodiments, when R2 is (A), R2 is optionally substituted C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl.
In some embodiments, R2 can be heteroaryl including 5-12 atoms, optionally substituted with from 1-3 (e.g., 1-2 or 1) Rc or Rn.
In certain embodiments, R2 can be a monosubstituted pyridyl ring having formula (III):
in which one or two of Rc3, Rc4, Rc5, and Rc6 can each be, independently, halo; C1-C12 alkyl; C1-C12 haloalkyl, optionally substituted with 1-2 Rj; cyano; or nitro; and the others are hydrogen.
One of Rc3, Rc4, or Rc5 can be C1-C4 haloalkyl (e.g., CF3). For example, R2 can be:
One of Rc3, Rc4, Rc5, and Rc6 can be halo (e.g., Rc3 or Rc5 can be chloro or fluoro).
One of Rc3, Rc4, Rc5, and Rc6 can be C1-C4 alkyl (e.g., Rc3 can be C1-C4 alkyl, e.g., CH3).
One of Rc3, Rc4, Rc5, and Rc6 can be cyano or nitro (e.g., Rc3 or Rc5 can be nitro or Rc3 can be cyano).
Two of Rc3, Rc4, Rc5, and Rc6 can each be, independently, halo or C1-C4 haloalkyl. For example, two of Rc3, Rc4, Rc5, and Rc6 can each be, independently, fluoro or CF3.
In certain embodiments, R2 can be a disubstituted (2 Rc or 2 Rn), trisubstituted (3 Rc or 3 Rn), tetrasubstituted (4 Rc or 4 Rn) pyridyl ring. For example, R2 can be 3,5-dichloro-4-pyridyl.
In certain embodiments, R2 can be 1-quinolyl, 2-quinolyl, 1-isoquinolyl, or pyrazinyl (e.g., 2-cyanopyrazin-2-yl).
In some embodiments, R2 can be C6-C10 aryl, optionally substituted with from 1-3 (e.g., 1-2 or 1) Rc.
In certain embodiments, R2 can be a monosubstituted (1 Rc), disubstituted (2 Rc), trisubstituted (3 Rc), tetrasubstituted (4 Rc), or pentasubstituted (5 Rc) phenyl group of the general formula P-1 described elsewhere.
In certain embodiments, R2 can be a monosubstituted phenyl group having formula (IV):
in which one of Rc22, Rc23, and Rc24 can be halo; hydroxyl; C1-C12 alkyl; C1-C12 haloalkyl; C1-C12 alkoxy; C1-C12 haloalkoxy; cyano; nitro; or C6-C10 aryl, optionally substituted with from 1-2 Ra; and the others are hydrogen.
Rc22 or Rc23 can be C1-C4 haloalkyl (e.g., CF3).
Rc22 can be C1-C4 alkyl (e.g., CH3 or CH2CH3); or nitro; or cyano; or hydroxyl; or C1-C4 alkoxy (e.g., OCH3).
Rc22, Rc23, or Rc24 can be halo (e.g., Rc22, Rc23, or Rc24 can be fluoro; or Rc22 can be bromo; or Rc24 can be chloro).
Rc22 or Rc24 can be phenyl optionally substituted with 1 Ra (e.g., C1-C4 alkoxy, e.g., OCH3). For example, Rc22 can be 2-methoxyphenyl.
In certain embodiments, R2 can be a disubstituted phenyl group having formula (IV-A):
In certain embodiments, two of Rc22, Rc23, Rc24, Rc25, and Rc26 can each be, independently, halo; C1-C12 alkyl; C1-C12 haloalkyl; cyano, C1-C12 alkoxy; heterocyclyl including 3-10 atoms, optionally substituted with from 1-2 Rb (e.g., C1-C12 alkyl (e.g., CH3)); heteroaryl including from 5-10 atoms, optionally substituted with from 1-2 Ra; or SO2Rm; and the others are hydrogen.
In other embodiments, two of Rc22, Rc23, Rc24, Rc25, and Rc26 can each be, independently, halo; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-3 Rj; C1-C12 alkoxy; C1-C12 haloalkoxy; cyano; nitro; or C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra; and the others are hydrogen.
Two of Rc22, Rc23, Rc24, Rc25 and Rc26 can each be, independently, halo or C1-C4 haloalkyl (e.g., two of Rc22, Rc23, Rc24, Rc25 and Rc26 can each be, independently, fluoro or CF3). For example, Rc22 can be C1-C4 haloalkyl (e.g., CF3) and Rc23 or Rc24 (e.g., Rc24) can be halo (e.g., fluoro).
Rc22 can be C1-C4 haloalkyl (e.g., CF3), halo (e.g., chloro), C1-C6 alkoxy (e.g., OCH3), cyano, or C1-C6 alkyl (e.g., CH3); and one of Rc23, Rc24, and Rc25 can be heterocyclyl including 3-8 atoms, optionally substituted with 1 Rb (e.g., C1-C12, e.g., C1-C6 alkyl, e.g., CH3); heteroaryl including 5 or 6 atoms, optionally substituted with 1 Ra; or halo (e.g., fluoro).
Rc22 can be CF3, chloro, OCH3, cyano, or CH3; and one of Rc23, Rc24, and Rc25 can be heterocyclyl including 3-8 atoms, optionally substituted with 1 Rb; heteroaryl including 5 or 6 atoms, optionally substituted with 1 Ra; or halo.
In these embodiments, one of Rc23, Rc24, and Rc25 can be optionally substituted piperazinyl (e.g., piperazin-1-yl or 4-(C1-C6 alkyl)piperazin-1-yl); optionally substituted morpholinyl (e.g., morpholin-4-yl); 1H-1,2,4-triazolyl; or fluoro.
Rc22 and Rc24 can each be, independently, halo (e.g., chloro or fluoro); C1-C4 alkyl (e.g., CH3); or SO2Rm (e.g., SO2CH3).
Rc22 and Rc23; or Rc22 and Rc26; or Rc23 and Rc24 can each be, independently, halo (e.g., chloro or fluoro) or C1-C4 alkyl (e.g., CH3).
Rc22 can be C1-C4 haloalkyl (e.g., CF3), optionally substituted with from 1-3 Rj; and Rc24 can be halo; C1-C4 haloalkyl, optionally substituted with from 1-3 Rj; cyano; or heteroaryl including 5-6 atoms, optionally substituted with from 1-2 Ra. For example, Rc22 can be CF3. Rc22 can be CF3, and Rc24 can be halo (and the others can be hydrogen).
Rc22 and Rc24 can each be, independently, fluoro or chloro. For example, Rc22 can be chloro, and Rc24 can be fluoro.
For example, R2 can be 4-fluoro-2-(sulfonylmethyl)phenyl; 4-fluoro-2-(trifluoromethyl)phenyl; 2,3-dichlorophenyl; 2,4-difluorophenyl; 2,4-dimethylphenyl; 2,6-dichlorophenyl; 2,6-dimethylphenyl; 3,4-dichlorophenyl; or 3-fluoro-2-(trifluoromethyl)phenyl.
In some embodiments, R2 can be OR1, in which R1 can be C6-C10 aryl, or heteroaryl including 5-10 atoms, each of which can be optionally substituted with from (e.g., 1-2 or 1) Ra; or R1 can be C7-C12 aralkyl, optionally substituted with from 1-3 Rb.
In certain embodiments, R2 can be unsubstituted phenoxy.
In certain embodiments, R2 can be a monosubstituted phenoxy group having formula (V):
in which one of Rc32, Rc33, and Rc34 can be halo; C1-C12 alkyl; C1-C12 haloalkyl; C1-C12 alkoxy; C1-C12 haloalkoxy; cyano; or nitro; and the others are hydrogen.
Rc32 can be C1-C4 haloalkyl (e.g., CF3).
Rc32 can be C1-C4 alkyl (e.g., CH3, CH2CH3, n-propyl, or iso-propyl).
Rc32 or Rc34 is C1-C4 alkoxy (e.g., OCH3).
Rc32 can be halo (e.g., chloro or bromo); nitro or cyano.
In certain embodiments, R2 can be a disubstituted phenoxy group in which the phenyl ring is substituted, e.g., at the 2- and 6-positions with, e.g., C1-C4 alkyl (e.g., CH3) or halo (e.g., chloro). A preferred disubstituted phenoxy group is 2,6-dichlorophenoxy:
In certain embodiments, R2 can be an unsubstituted, monosubstituted, or disubstituted pyridyloxy group. For example, R2 can be:
in which Ra22 can be, e.g., hydrogen or halo (e.g., chloro).
In certain embodiments, R2 can be an unsubstituted, monosubstituted, or disubstituted aralkoxy group. In certain embodiments, R2 can be benzyloxy or monosubstituted benzyloxy (e.g., 2-methoxybenzyloxy).
In some embodiments, R2 can be NR3R4, in which one of R3 and R4 can be hydrogen, and the other is C6-C10 aryl, optionally substituted with from 1-3 (e.g., 1-2 or 1) Ra. In certain embodiments, one of R3 and R4 can be hydrogen, and the other is phenyl or monosubstituted phenyl (e.g., substituted with halo, e.g., chloro). For example, R2 can be 2-chlorophenylamino:
In some embodiments, R2 can be C3-C12 (e.g., C3-C10) cycloalkyl, optionally substituted with from 1-5 (e.g., 1-4, 1-3, 1-2, or 1) Rb (e.g., halo or C1-C4 alkyl).
In some embodiments, R2 can be C6-C12 (e.g., C6-C10, C7-C12, C8-C12, C9-C12, C10-C12) cycloalkyl, optionally substituted with from 1-5 (e.g., 1-4, 1-3, 1-2, or 1) Rb (e.g., halo or C1-C4 alkyl).
In certain embodiments, R2 can be monocyclic (e.g., optionally substituted cyclohexyl or cycloheptyl), bicyclic (e.g., optionally substituted bicycloheptyl), or polycyclic (e.g., optionally substituted adamantyl). For example, R1 can be 1-adamantyl, 3-methylcyclohexyl, cycloheptyl, or bicycloheptyl.
In some embodiments, R2 can be heterocyclyl including 3-8 atoms, optionally substituted with 1 Rb (e.g., C1-C4 alkyl (e.g., CH3)). For example, R2 can be morpholino or tetrahydropyranyl.
In some embodiments, R2 can be C(O)R5, in which R5 is C1-C20 alkyl or C7-C20 aralkoxy. In certain embodiments, R5 can be C1-C12 alkyl (e.g., C3-C12 branched alkyl, e.g., tert-butyl). In certain embodiments, R5 can be an unsubstituted or monosubstituted aralkoxy group (e.g., benzyloxy).
In some embodiments, X can be S(O)n, (e.g., SO2).
In some embodiments, X can be CO.
In some embodiments, X can be S(O)nNR6, in which n can be 2, and R6 can be hydrogen, C1-C4 alkyl, or C3-C8 cycloalkyl. In certain embodiments, X can be S(O)2NH.
In some embodiments, each of W1, Z1, W2, and Z2 can be hydrogen.
In some embodiments, one or two of W1, Z1, W2, and Z2 can each be, independently, C1-C4 alkyl (e.g., CH3) or oxo, and the others are hydrogen. For example, W1 can be C1-C4 alkyl (e.g., CH3) or oxo; or W2 can be oxo; or W1 and W2 or W1 and Z2 can both be C1-C4 alkyl (e.g., CH3). Each of the carbons bearing W1, Z1, W2, and Z2 can have, independently, the R or the S stereochemical configuration when W1, Z1, W2, or Z2 is other than hydrogen. In certain embodiments, W1 can be C1-C4 alkyl (e.g., CH3), and the carbon bearing W1 can have the R configuration.
One or two of W1, Z1, W2, and Z2 (e.g., W1 and Z2, e.g., W1) can each be, independently, other than hydrogen (e.g., C1-C4 alkyl or oxo), and the others can be hydrogen. One or two of W1, Z1, W2, and Z2 (e.g., W1 and Z2, e.g., W1) can each be, independently, C1-C4 alkyl, and the others can be hydrogen. Each of Z1 and W2 can be hydrogen. One or both of W1 and Z2 (e.g., W1) can each be, independently, C1-C4 alkyl; and each of Z1 and W2 can be hydrogen. W1 can be C1-C4 alkyl (e.g., CH3).
In some embodiments, Y and V can both be nitrogen, and the 11-beta HSD1 inhibitor compounds can have formula (VI):
in which R1, R2, R3, R4, R5, R6, R7, X, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rm, and Rn can be as defined anywhere herein.
In some embodiments, X can be SO2, and the 11-beta HSD1 inhibitor compounds can include one or more of the following features.
R1 can be:
(A) C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl or heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms, each of which is optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Ra; for example, R1 can be C6-C10 aryl, optionally substituted with from 1-3 (e.g., 1-2 or 1) Ra or heteroaryl including 5-14 atoms, optionally substituted with from 1-3 (e.g., 1-2 or 1) Ra as described herein; and/or
(D) C7-C20 (e.g., C7-C16, C7-C12, C7-C10) aralkyl, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rb; for example, R1 can be C7-C12 aralkyl, optionally substituted with from 1-2 Rb (e.g., halo) as described herein; and/or (E) arylheterocyclyl including 8-20 (e.g., 8-16 or 9-12) atoms, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rb; for example, R1 can be arylheterocyclyl including 9-12 atoms, optionally substituted with from 1-5 (e.g., 1-4, 1-3, 1-2, or 1) Rb (e.g., oxo, halo or C1-C4 alkyl), in which the heterocyclyl portion can include 1 or 2 heteroatoms (e.g., nitrogen or oxygen) as described herein.
R2 can be:
(A) heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rc or Rn; or C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rc; for example, R2 can be heteroaryl including 5-12 atoms, optionally substituted with from 1-3 (e.g., 1-2 or 1) Rc or Rn; or R2 can be C6-C10 aryl, optionally substituted with from 1-3 (e.g., 1-2 or 1) Rc as described herein; and/or
(B) C3-C16 (e.g., C3-C14, C3-C10, C6-C16, C6-C14, or C6-C10) cycloalkyl, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rb; for example, R2 can be C3-C12 (e.g., C3-C10) cycloalkyl, optionally substituted with from 1-5 (e.g., 1-4, 1-3, 1-2, or 1) Rb (e.g., halo or C1-C4 alkyl) or C6-C12 (e.g., C6-C10) cycloalkyl, optionally substituted with from 1-5 (e.g., 1-4, 1-3, 1-2, or 1) Rb (e.g., halo or C1-C4 alkyl); as described herein; and/or
(D) heterocyclyl including 3-16 (e.g., 3-12, 3-10, 5-12, or 5-6) atoms, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rb; for example, R2 can be heterocyclyl including 3-8 atoms, optionally substituted with 1 Rb (e.g., C1-C4 alkyl (e.g., CH3)) as described herein; and/or
(E) C(O)R5, in which R5 is C1-C20 (e.g., C1-C12, C1-C6, or C1-C4) alkyl or C7-C20 (e.g., C7-C12 aralkoxy) as described herein.
In certain embodiments, R2 can be (A), (B), (C), and/or (D); or (A), (C), (D), and/or (E); or (A), (C), and/or (D); or (A) and/or (C).
In certain embodiments, when R2 is substituted pyridyl or pyrimidinyl (e.g., 2-, 3-, or 4-pyridyl; or 2- or 3-pyrimidinyl), then Rc cannot be C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; or SO2Rm.
In certain embodiments, when R2 is a substituted heteroaryl including 5-14 atoms (e.g., 5-12 atoms, 5-8 atoms, 5-6 atoms, or 6 atoms), then R2 is substituted with Rn.
In certain embodiments, when R2 is C3-C16 cycloalkyl (e.g., C3-C5 cycloalkyl, e.g., C5 cycloalkyl, e.g., substituted C5 cycloalkyl, e.g., C5 cycloalkyl substituted with hydroxyl or imidazolyl) then R1 cannot be a monosubstituted phenyl ring that is substituted at the para-position with either substituted C1-C12 alkyl or substituted C1-C12 haloalkyl (e.g., a phenyl ring substituted at the para-position with —CR21R22R23, in which R21, R22 and R23 are each independently hydrogen, halo, hydroxyl, cyano, nitro, C1-C6 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, alkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl and at least one of R21, R22 and R23 is other than hydrogen, e.g., a phenyl ring substituted at the para-position with 2-hydroxy-1,1,1-trifluoro-2-propyl, i.e., CF3C(OH)(CH3)).
In certain embodiments, one or more of the other conditions delineated in the Summary can apply. For example, (a) can apply. In certain embodiments, (a) and any one of (e)-(j) apply. In certain embodiments, any one of (e)-(j) applies. In certain embodiments, any two or three of (e)-(j) applies, optionally in combination with (a). For example, (e) or (f) and (g) or (h) and/or (i) and (j), optionally in combination with (a).
In certain embodiments, (a) applies. In certain embodiments, (a) and/or (k) applies. In certain embodiments, (a), (k) and any one, two, three, or four of (l)-(o) apply.
In certain embodiments, R2 can be C6-C16 (e.g., C6-C14, C6-C10, C7-C16, C8-C16, C9-C16, C10-C16, C7-C14, C8-C14, C9-C14, C10-C14, C7-C10, C8-C10, or C9-C10) cycloalkyl, optionally substituted with from 1-5 (e.g., 1-4, 1-3, 1-2, or 1) Rb (e.g., halo or C1-C4 alkyl).
A subset of compounds includes those having formula (VI-A):
in which:
one or two of Ra2, Ra3, Ra4, and Ra6 can each be, independently, halo; C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with from 1-2 Rj; C1-C12 alkoxy, optionally substituted with 1-2 Rf; C1-C12 haloalkoxy; cyano; nitro; C6-C10 aryl or heteroaryl including 5-12 atoms, each of which is optionally substituted with from 1-2 Ra′; C6-C10 aryloxy, optionally substituted with from 1-2 Ra′; C3-C10 heterocyclyl, C3-C10 cycloalkyl, or C7-C12 aralkoxy, each of which is optionally substituted with 1-2 Rb; or —NRhC(O)Ri; and the others are hydrogen;
W1 can be hydrogen or C1-C4 alkyl (e.g., CH3); and
one or two of Rc22, Rc23, Rc24, Rc25, and Rc26 can each be, independently, halo; hydroxyl; C1-C12 alkyl; C1-C12 haloalkyl; C1-C12 alkoxy; C1-C12 haloalkoxy; cyano; nitro; C6-C10 aryl, optionally substituted with from 1-2 Ra′; heterocyclyl including 3-10 atoms, optionally substituted with from 1-2 Rb (e.g., C1-C12 alkyl (e.g., CH3)); heteroaryl including from 5-10 atoms, optionally substituted with from 1-2 Ra′; or SO2Rm; and the others are hydrogen. The variables delineated in formula (VI) above can also be as defined in the Summary and the conditions delineated therein can apply.
In some embodiments, Ra2, Ra3, or Ra4 can be C1-C4 haloalkyl, optionally substituted with 1 Rj (e.g., hydroxyl). For example, Ra2, Ra3, or Ra4 (e.g., Ra3 or Ra4) can be (e.g., R or S) 1,1,1-trifluoro-2-hydroxypropan-2-yl, i.e., CF3C(OH)(CH3), in which the stereogenic carbon (i.e., the carbon attached to the hydroxyl group) can have the R or S configuration or some combination thereof (e.g., about 50% R and about 50% S or any other non-racemic combination of configurations). In some embodiments, Ra3 or Ra4 (e.g., Ra3) can be:
In these embodiments, each of the remaining substituents can be hydrogen.
In some embodiments, Ra2, Ra3, or Ra4 (e.g., Ra3 or Ra4) can be C1-C12 alkyl, optionally substituted with 1 Rj (e.g., hydroxyl). For example, Ra2, Ra3, or Ra4 (e.g., Ra3 or Ra4) can be 2-hydroxy-2-propan-2-yl, i.e., CH3C(OH)(CH3).
In some embodiments, Ra2, Ra3, or Ra4 can be C3-C10 cycloalkyl, optionally substituted with 1 Rb (e.g., hydroxyl). For example, Ra2, Ra3, or Ra4 (e.g., Ra3 or Ra4, e.g., Ra4) can be 1-hydroxycyclopropan-1-yl.
In some embodiments, Ra3 or Ra4 can be heterocyclyl including 3-8 atoms, optionally substituted with 1 Rb (e.g., C1-C4 alkyl (e.g., CH3), OH, C3-C10 cycloalkyl, or COORg (e.g., COOH)). For example, Ra3 or Ra4 can be optionally substituted pyrrolidinyl (e.g., pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, or 3-carboxypyrrolidin-1-yl), morpholinyl (e.g., morpholin-4-yl), piperidyl (e.g., 1-piperidyl or 4-piperidyl) or piperazinyl (e.g., piperazin-1-yl, 4-methylpiperazin-1-yl). In a preferred embodiment, Ra3 is optionally substituted pyrrolidin-1-yl (e.g., 3-hydroxypyrrolidin-1-yl).
In some embodiments, Ra3 or Ra4 can be heteroaryl including 5 or 6 atoms (e.g., 1H-1,2,4-triazolyl).
In some embodiments, W1 can be C1-C4 alkyl (e.g., CH3).
In some embodiments, two of Rc22, Rc23, Rc24, Rc25, and Rc26 can each be, independently, halo or C1-C4 haloalkyl (e.g., two of Rc22, Rc23, Rc24, Rc25, and Rc26 can each be, independently, fluoro or CF3). For example, Rc22 can be C1-C4 haloalkyl (e.g., CF3) and Rc23 or Rc24 (e.g., Rc24) can be halo (e.g., fluoro).
In some embodiments, Rc22 can be C1-C4 haloalkyl (e.g., CF3), halo (e.g., chloro), C1-C6 alkoxy (e.g., OCH3), cyano, or C1-C6 alkyl (e.g., CH3); and one of Rc23, Rc24, and Rc25 can be heterocyclyl including 3-8 atoms, optionally substituted with 1 Rb (e.g., C1-C12, e.g., C1-C6 alkyl, e.g., CH3); heteroaryl including 5 or 6 atoms, optionally substituted with 1 Ra′; or halo (e.g., fluoro). For example, one of Rc23, Rc24, and Rc25 can be optionally substituted piperazinyl (e.g., piperazin-1-yl or 4-(C1-C6 alkyl)piperazin-1-yl); optionally substituted morpholinyl (e.g., morpholin-4-yl); 1H-1,2,4-triazolyl; or fluoro.
In certain embodiments, Ra4 can be 1,1,1-trifluoro-2-hydroxypropan-2-yl; W1 can be CH3; Rc22 can be C1-C4 haloalkyl (e.g., CF3), halo (e.g., chloro), C1-C6 alkoxy (e.g., OCH3), cyano, or C1-C6 alkyl (e.g., CH3); and Rc23, Rc24, or Rc25 can be optionally substituted piperazinyl (e.g., piperazin-1-yl or piperazin-1-yl substituted with C1-C6 alkyl, e.g., 4-(C1-C6 alkyl)piperazin-1-yl).
In certain embodiments, Ra4 can be 1,1,1-trifluoro-2-hydroxypropan-2-yl; W1 can be CH3; Rc22 can be C1-C4 haloalkyl (e.g., CF3), halo (e.g., chloro), C1-C6 alkoxy (e.g., OCH3), cyano, or C1-C6 alkyl (e.g., CH3), and Rc23, Rc24, or Rc25 can be optionally substituted morpholinyl (e.g., morpholin-4-yl or morpholin-4-yl substituted with C1-C6 alkyl).
In certain embodiments, Ra4 can be 1,1,1-trifluoro-2-hydroxypropan-2-yl; W1 can be CH3; Rc22 can be C1-C4 haloalkyl (e.g., CF3), halo (e.g., chloro), C1-C6 alkoxy (e.g., OCH3), cyano, or C1-C6 alkyl (e g, CH3), and Rc23, Rc24, or Rc25 can be optionally substituted 1H-1,2,4-triazolyl.
In certain embodiments, Ra3 can be 1,1,1-trifluoro-2-hydroxypropan-2-yl; W1 can be CH3; Rc22 can be C1-C4 haloalkyl (e.g., CF3), halo (e.g., chloro), C1-C6 alkoxy (e.g., OCH3), cyano, or C1-C6 alkyl (e.g., CH3), and Rc23, Rc24, or Rc25 can be fluoro.
In certain embodiments, Ra3 can be 2-hydroxypropan-2-yl; W1 can be CH3; Rc22 can be C1-C4 haloalkyl (e.g., CF3), halo (e.g., chloro), C1-C6 alkoxy (e.g., OCH3), cyano, or C1-C6 alkyl (e.g., CH3), and Rc23, Rc24 or Rc25 can be fluoro.
In certain embodiments, Ra4 can be 2-hydroxypropan-2-yl; W1 can be CH3; Rc22 can be C1-C4 haloalkyl (e.g., CF3), halo (e.g., chloro), C1-C6 alkoxy (e.g., OCH3), cyano, or C1-C6 alkyl (e.g., CH3), and Rc23, Rc24 or Rc25 can be fluoro.
In certain embodiments, Ra4 can be 1-hydroxycyclopropan-1-yl; W1 can be CH3; Rc22 can be C1-C4 haloalkyl (e.g., CF3), halo (e.g., chloro), C1-C6 alkoxy (e.g., OCH3), cyano, or C1-C6 alkyl (e.g., CH3), and Rc23, Rc24, or Rc25 can be fluoro.
In certain embodiments, Ra3 can be piperazin-1-yl, 4-(C1-C4 alkyl)piperazin-1-yl, or 4-(C3-C10 cycloalkyl)piperazin-1-yl; W1 can be CH3; Rc22 can be C1-C4 haloalkyl (e.g., CF3), halo (e.g., chloro), C1-C6 alkoxy (e.g., OCH3), cyano, or C1-C6 alkyl (e.g., CH3), and Rc23, Rc24, or Rc25 can be fluoro.
In certain embodiments, Ra3 can be 4-piperidyl, 1-(C1-C4 alkyl)-4-piperidyl, or 1-(C3-C10 cycloalkyl)piperidyl; W1 can be CH3; Rc22 can be C1-C4 haloalkyl (e.g., CF3), halo (e.g., chloro), C1-C6 alkoxy (e.g., OCH3), cyano, or C1-C6 alkyl (e.g., CH3), and Rc23, Rc24, or Rc25 can be fluoro.
In certain embodiments, Ra3 can be 1H-1,2,4-triazolyl; W1 can be CH3; Rc22 can be C1-C4 haloalkyl (e.g., CF3), halo (e.g., chloro), C1-C6 alkoxy (e.g., OCH3), cyano, or C1-C6 alkyl (e.g., CH3), and Rc23, Rc24, or Rc25 can be fluoro.
In certain embodiments, Ra3 can be 3-hydroxypyrrolidin-1-yl; W1 can be CH3; Rc22 can be CF3; and Rc23, Rc24, or Rc25 can be fluoro.
In certain embodiments, Ra3 can be 3-carboxypyrrolidin-1-yl; W1 can be CH3; Rc22 can be CF3; and Rc23, Rc24, or Rc25 can be fluoro.
In some embodiments, X can be CO, and the 111-beta HSD1 inhibitor compounds can include one or more of the following features.
R1 can be:
(B) C3-C16 (e.g., C3-C14 or C3-C10) cycloalkyl, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1); Rb as described herein; and/or
(C) (C1-C12 alkyl)-(C3-C16 cycloalkyl) (e.g., (C1-C6 alkyl)-(C3-C12 cycloalkyl) or (CH2)—(C3-C12 cycloalkyl), optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rb as described herein.
R2 can be heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rc or Rn; or C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rc; for example, R2 can be heteroaryl including 5-12 atoms, optionally substituted with from 1-3 (e.g., 1-2 or 1) Rc or Rn or C6-C10 aryl, optionally substituted with from 1-3 (e.g., 1-2 or 1) Rc as described herein. In certain embodiments, R2 can be heteroaryl including 5-12 atoms, optionally substituted with from 1-3 (e.g., 1-2 or 1) Rc or Rn.
In some embodiments, Y can be CR7 (e.g., CH) and V can be nitrogen, and the 11-beta HSD1 inhibitor compounds can have formula (VII):
in which R1, R2, R3, R4, R5, R6, R7, X, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rm, and Rn can be as defined.
In certain embodiments, X can be SO2 or SO2NH, and the 11-beta HSD1 inhibitor compounds can include one or more of the following features.
R1 can be C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl or heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms, each of which is optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Ra; for example, R1 can be C6-C10 aryl, optionally substituted with from 1-3 (e.g., 1-2 or 1) Ra or heteroaryl including 5-14 atoms, optionally substituted with from 1-3 (e.g., 1-2 or 1) Ra as described herein.
R2 can be heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rc or Rn; or C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rc; for example, R2 can be heteroaryl including 5-12 atoms, optionally substituted with from 1-3 (e.g., 1-2 or 1) Rc or Rn or C6-C10 aryl, optionally substituted with from 1-3 (e.g., 1-2 or 1) Rc as described herein. In certain embodiments, R2 can be heteroaryl including 5-12 atoms, optionally substituted with from 1-3 (e.g., 1-2 or 1) Rc or Rn as described herein.
In some embodiments, Y can be nitrogen and V can be CR7 (e.g., CH), and the 11-beta HSD1 inhibitor compounds can have formula (VIII):
in which R1, R2, R3, R4, R5, R6, R7, X, W1, Z1, W2, Z2, Ra, Ra′, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rm, and Rn can be as defined.
In certain embodiments, X can be SO2, and the 11-beta HSD1 inhibitor compounds can include one or more of the following features.
R1 can be C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl or heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms, each of which is optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Ra; for example, R1 can be C6-C10 aryl, optionally substituted with from 1-3 (e.g., 1-2 or 1) Ra or heteroaryl including 5-14 atoms, optionally substituted with from 1-3 (e.g., 1-2 or 1) Ra as described herein.
R2 can be:
(A) heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rc or Rn; or C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rc; for example, R2 can be heteroaryl including 5-12 atoms, optionally substituted with from 1-3 (e.g., 1-2 or 1) Rc or Rn; or R2 can be C6-C10 aryl, optionally substituted with from 1-3 (e.g., 1-2 or 1) Rc as described herein; and/or
(C)OR1; or NR3R4, in which R3 and R4 are each, independently, hydrogen or R1 (e.g., C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl or heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms; each of which is optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Ra); for example, R2 can be OR1, in which R1 can be C6-C10 aryl, or heteroaryl including 5-10 atoms, each of which can be optionally substituted with from (e.g., 1-2 or 1) Ra or R1 can be C7-C12 aralkyl, optionally substituted with from 1-3 Rb; or R2 can be NR3R4, in which one of R3 and R4 can be hydrogen, and the other is C6-C10 aryl, optionally substituted with from 1-3 (e.g., 1-2 or 1) Ra as described herein; and/or
(D) heterocyclyl including 3-16 (e.g., 3-12, 3-10, 5-12, or 5-6) atoms, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rb; for example, R2 can be heterocyclyl including 3-8 atoms, optionally substituted with 1 Rb (e.g., C1-C4 alkyl (e.g., CH3)) as described herein.
In certain embodiments, when R2 is (A), R2 is optionally substituted heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms. In other embodiments, when R2 is (A), R2 is optionally substituted C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl.
In certain embodiments, X can be CO, and the 11-beta HSD1 inhibitor compounds can include one or more of the following features.
R1 can be:
(B) C3-C16 (e.g., C3-C14 or C3-C10) cycloalkyl, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1); Rb as described herein; and/or
(D) C7-C20 (e.g., C7-C16, C7-C12, C7-C10) aralkyl, optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Rb; for example, R1 can be C7-C12 aralkyl, optionally substituted with from 1-2 Rb(e.g., halo) as described herein.
R2 can be OR1; or NR3R4, in which R3 and R4 are each, independently, hydrogen or R1 (e.g., C6-C18 (e.g., C6-C14, C6-C10, or phenyl) aryl or heteroaryl including 5-20 (e.g., 5-16, 5-12, or 5-6) atoms; each of which is optionally substituted with from 1-10 (e.g., 1-5, 1-4, 1-3, 1-2, or 1) Ra); for example, R2 can be OR1, in which R1 can be C6-C10 aryl, or heteroaryl including 5-10 atoms, each of which can be optionally substituted with from (e.g., 1-2 or 1) Ra; or R1 can be C7-C12 aralkyl, optionally substituted with from 1-3 Rb; or R2 can be NR3R4, in which one of R3 and R4 can be hydrogen, and the other is C6-C10 aryl, optionally substituted with from 1-3 (e.g., 1-2 or 1) Ra as described herein. In certain embodiments, R2 can be OR1, in which R1 can be C6-C10 aryl, or heteroaryl including 5-10 atoms, each of which can be optionally substituted with from (e.g., 1-2 or 1) Ra; or R1 can be C7-C12 aralkyl, optionally substituted with from 1-3 Rb.
It is understood that the actual electronic structure of some chemical entities cannot be adequately represented by only one canonical form (i.e. Lewis structure). While not wishing to be bound by theory, the actual structure can instead be some hybrid or weighted average of two or more canonical forms, known collectively as resonance forms or structures. Resonance structures are not discrete chemical entities and exist only on paper. They differ from one another only in the placement or “localization” of the bonding and nonbonding electrons for a particular chemical entity. It can be possible for one resonance structure to contribute to a greater extent to the hybrid than the others. Thus, the written and graphical descriptions of the embodiments of the present invention are made in terms of what the art recognizes as the predominant resonance form for a particular species.
The compounds described herein can be synthesized according to methods described herein and/or conventional, organic chemical synthesis methods from commercially available starting materials and reagents. The compounds described herein can be separated from a reaction mixture and further purified by a method such as column chromatography, high-pressure liquid chromatography, or recrystallization. As can be appreciated by the skilled artisan, further methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.
In some embodiments, the compounds described herein can be prepared according to the general schemes below:
The compounds of this invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention. The compounds of this invention may also contain linkages (e.g., carbon-carbon bonds, carbon-nitrogen bonds such as amide bonds) wherein bond rotation is restricted about that particular linkage, e.g. restriction resulting from the presence of a ring or double bond. Accordingly, all cis/trans and E/Z isomers and rotational isomers are expressly included in the present invention. The compounds of this invention may also be represented in multiple tautomeric forms, in such instances, the invention expressly includes all tautomeric forms of the compounds described herein, even though only a single tautomeric form may be represented (e.g., alkylation of a ring system may result in alkylation at multiple sites, the invention expressly includes all such reaction products). All such isomeric forms of such compounds are expressly included in the present invention. All crystal forms of the compounds described herein are expressly included in the present invention.
The compounds of this invention include the compounds themselves, as well as their salts and their prodrugs, if applicable. A salt, for example, can be formed between an anion and a positively charged substituent (e.g., amino) on a compound described herein. Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, and acetate. Likewise, a salt can also be formed between a cation and a negatively charged substituent (e.g., carboxylate) on a compound described herein. Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion. Examples of prodrugs include esters and other pharmaceutically acceptable derivatives, which, upon administration to a subject, are capable of providing active compounds.
Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl)4+ salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization. Salt forms of the compounds of any of the formulae herein can be amino acid salts of carboxy groups (e.g. L-arginine, -lysine, -histidine salts).
The term “pharmaceutically acceptable carrier or adjuvant” refers to a carrier or adjuvant that may be administered to a subject (e.g., a patient), together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as α-, β-, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.
In general, the compounds described herein can be used for treating, controlling, ameliorating, preventing, delaying the onset of, or reducing the risk of developing one or more diseases, disorders, conditions or symptoms mediated by excess or uncontrolled amounts of cortisol and/or other corticosteroids. While not wishing to be bound by any theory, it is believed that the compounds described herein can reduce the levels of cortisol and other corticosteroids (e.g., 11β-hydroxysteroids) by inhibiting the reductase activity of 11β-HSD1. The diseases, disorders, conditions or symptoms mediated by excess or uncontrolled amounts of cortisol and/or other corticosteroids can include diabetes (e.g., type 1 or type 2 diabetes), Syndrome X, hyperglycemia, low glucose tolerance, insulin resistance, obesity, lipid disorders, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, high LDL levels, atherosclerosis and its sequelae, vascular restenosis, pancreatitis, abdominal obesity, neurodegenerative disease, retinopathy, nephropathy, neuropathy, hypertension, coronary heart disease, stroke, peripheral vascular disease, Cushing's syndrome, glaucoma, osteoporosis, hyperinsulinemia, tuberculosis, psoriasis, cognitive disorders and dementia (e.g., impairment associated with aging and of neuronal dysfunction, e.g., Alzheimer's disease), depression, viral diseases, inflammatory disorders, immune disorders. In some embodiments, the diseases, disorders conditions or symptoms can further include those where insulin resistance is a component. In other embodiments, the compounds described herein can be used for promoting wound healing.
The compounds described herein generally have an inhibition constant IC50 of less than about 10 μM. Examples of such compounds include those described herein in Examples 1A through 1Z; 1AA through 1AZ; 2A, 2B, 2D, 2E, 2F, 2G, 2H, 2I, 2J; 3A through 3D; 5, 6; 7A through 7Z; 7AA through 7AZ; 7BB through 7BD; 9F; 10A through 10X; 11A through 11U; 12A through 12F; 13A; 13A-1 through 13A-7; 13B; 13B-1 through 13B-6; 13C; 14A through 14G; 18A through 18F; 29A through 29AD; 29AF through 29BI; 29BK though 29HN; and 29HP through 29IT. Generally, the IC50 ratio for 11-beta-HSD2 to 11-beta-HSD1 of a compound is at least about 100 or greater.
In some embodiments, the compounds described herein can be coadministered with one or more other therapeutic agents. In certain embodiments, the additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention (e.g., sequentially, e.g., on different overlapping schedules with the administration of one or more compounds of formula (I)). Alternatively, these agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition. In still another embodiment, these agents can be given as a separate dose that is administered at about the same time that one or more compounds of formula (I) are administered (e.g., simultaneously with the administration of one or more compounds of formula (I)). When the compositions of this invention comprise a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.
Other therapeutic agents can include DP-IV inhibitors; insulin sensitizers (e.g., (i) PPAR agonists and (ii) biguanides); insulin and insulin analogues and mimetics; sulfonylureas and other insulin secretagogues; prandial glucose regulators, alpha.-glucosidase inhibitors; glucagon receptor antagonists; GLP-1, GLP-1 mimetics, and GLP-1 receptor agonists; GIP,GIP mimetics, and GIP receptor agonists; PACAP, PACAP mimetics, and PACAP receptor 3 agonists; cholesterol lowering agents (e.g., (i) HMG-CoA reductase inhibitors, (ii) sequestrants, (iii) nicotinyl alcohol, nicotinic acid and salts thereof, (iv) PPAR.alpha. agonists, (v) PPAR.alpha./.gamma. dual agonists, (vi) inhibitors of cholesterol absorption, (vii) acyl CoA:cholesterol acyltransferase inhibitors, and (viii) anti-oxidants; PPAR.delta. agonists); antiobesity compounds (e.g., sibutramine and orlisat); an ileal bile acid transporter inhibitor; anti-inflammatory agents excluding glucocorticoids (e.g., aspirin); protein tyrosine phosphatase-1B (PTP-1B) inhibitors; agents that suppress hepatic glucose output (e.g., metformin); agents designed to reduce the absorption of glucose from the intestine (e.g., acarbose); agents designed to treat the complications of prolonged hyperglycemia (e.g., aldose reductase inhibitors); antidiabetic agents (e.g., glucose phosphatase inhibitors, glucose-6-phosphatase inhibitors, glucagon receptor antagonists, glucose kinase activators, glycogen phosphorylase inhibitors, fructose 1,6 bisphosphatase inhibitors, glutamine:fructose-6-phosphate amidotransferase inhibitors); antihypertensive agents (e.g., β blockers (e.g., atenolol, inderal), ACE inhibitors (e.g., lisinopril), calcium agonists (e.g., nifedipine), angiotensin receptor antagonists (e.g., candesartan), a agonists and diuretic agents (e.g., furosemide, benzthiazide)); and haemostasis modulators (e.g., antithrombotics, activators of fibrinolysis and antiplatelet agents (e.g., clopidogrel, aspirin), thrombin antogonists, factor Xa inhibitors, factor VIIa inhibitors, anticoagulants (e.g., heparin and low molecular weight analogues, hirudin), warfarin).
The compounds and compositions described herein can, for example, be administered orally, parenterally (e.g., subcutaneously, intracutaneously, intravenously, intramuscularly, intraarticularly, intraarterially, intrasynovially, intrasternally, intrathecally, intralesionally and by intracranial injection or infusion techniques), by inhalation spray, topically, rectally, nasally, buccally, vaginally, via an implanted reservoir, by injection, subdermally, intraperitoneally, transmucosally, or in an ophthalmic preparation, with a dosage ranging from about 0.01 mg/Kg to about 1000 mg/Kg, (e.g., from about 0.01 to about 100 mg/kg, from about 0.1 to about 100 mg/Kg, from about 1 to about 100 mg/Kg, from about 1 to about 10 mg/kg) every 4 to 120 hours, or according to the requirements of the particular drug. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., Cancer Chemother. Rep. 50, 219 (1966). Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, N.Y., 537 (1970). In certain embodiments, the compositions are administered by oral administration or administration by injection. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations contain from about 20% to about 80% active compound.
Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.
Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
The compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
The compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
The compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
The compositions of this invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
Topical administration of the compositions of this invention is useful when the desired treatment involves areas or organs readily accessible by topical application. For application topically to the skin, the composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation.
Topically-transdermal patches are also included in this invention. Also within the invention is a patch to deliver active chemotherapeutic combinations herein. A patch includes a material layer (e.g., polymeric, cloth, gauze, bandage) and the compound of the formulae herein as delineated herein. One side of the material layer can have a protective layer adhered to it to resist passage of the compounds or compositions. The patch can additionally include an adhesive to hold the patch in place on a subject. An adhesive is a composition, including those of either natural or synthetic origin, that when contacted with the skin of a subject, temporarily adheres to the skin. It can be water resistant. The adhesive can be placed on the patch to hold it in contact with the skin of the subject for an extended period of time. The adhesive can be made of a tackiness, or adhesive strength, such that it holds the device in place subject to incidental contact, however, upon an affirmative act (e.g., ripping, peeling, or other intentional removal) the adhesive gives way to the external pressure placed on the device or the adhesive itself, and allows for breaking of the adhesion contact. The adhesive can be pressure sensitive, that is, it can allow for positioning of the adhesive (and the device to be adhered to the skin) against the skin by the application of pressure (e.g., pushing, rubbing), on the adhesive or device.
The compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
A composition having the compound of the formulae herein and an additional agent (e.g., a therapeutic agent) can be administered using any of the routes of administration described herein. In some embodiments, a composition having the compound of the formulae herein and an additional agent (e.g., a therapeutic agent) can be administered using an implantable device. Implantable devices and related technology are known in the art and are useful as delivery systems where a continuous, or timed-release delivery of compounds or compositions delineated herein is desired. Additionally, the implantable device delivery system is useful for targeting specific points of compound or composition delivery (e.g., localized sites, organs). Negrin et al., Biomaterials, 22 (6):563 (2001). Timed-release technology involving alternate delivery methods can also be used in this invention. For example, timed-release formulations based on polymer technologies, sustained-release techniques and encapsulation techniques (e.g., polymeric, liposomal) can also be used for delivery of the compounds and compositions delineated herein.
The invention will be further described in the following examples. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
EXAMPLES Example 1Representative sulfonation (Step 1A): To a stirred solution of 1-(3-(trifluoromethyl)phenyl)piperazine (300 mg, 1.3 mmol) and 4-methylbenzene-1-sulfonyl chloride (248 mg, 1.3 mmol) in anhydrous dichloromethane (3 mL) was added diisopropylethylamine (0.27 mL, 1.6 mmol). The mixture was stirred overnight. Reaction was complete as determined by TLC. The reaction mixture was purified with flash column chromatography to yield 1-(4-methylphenylsulfonyl)-4-[3-(trifluoromethyl)phenyl]piperazine in 81% yield (405 mg) as white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 2.41 (s, 3H) 2.85-3.06 (m, 4H) 3.27-3.33 (m, 4H) 7.09 (d, J=7.58 Hz, 1H) 7.13-7.22 (m, 2H) 7.41 (t, J=7.96 Hz, 1H) 7.48 (d, J=8.08 Hz, 2H) 7.62-7.70 (m, 2H); HRMS: calcd for C18H19F3N2O2S+H+, 385.11921; found (ESI-FTMS, [M+H]1+), 385.1198; HPLC Method 1: room temperature, 6.642 min, 97.94%. HPLC Method 2: room temperature, 7.178 min, 97.99%.
Example 1A 1-[(3,4-dichlorophenyl)sulfonyl]-4-(2-fluorophenyl)piperazineStep 1A: Sulfonylation of 1-(2-fluorophenyl)piperazine.HCl (325 mg, 1.5 mmol) with 3,4-dichlorobenzene-1-sulfonyl chloride (368.3 mg, 1.5 mmol) was carried out according to a similar procedure described for step 1A using anhydrous dichloromethane (3 mL) as solvent and diisopropylethylamine (0.575 mL, 3.3 mmol) as base. 1-[(3,4-dichlorophenyl)sulfonyl]-4-(2-fluorophenyl)piperazine was obtained in 85.8% yield (501 mg) as white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 3.02-3.16 (m, 8H) 6.94-7.19 (m, 4H) 7.76 (dd, J=8.46, 2.15 Hz, 1H) 7.96 (d, J=8.34 Hz, 1H) 7.99 (d, J=2.02 Hz, 1H); HRMS: calcd for C16H15C12FN2O2S+H+, 389.02881; found (ESI-FTMS, [M+H]1+), 389.029. HPLC Method 1: room temperature, 6.830 min, 98.81%. HPLC Method 2: room temperature, 7.491 min, 98.91%.
Example 1B 1-[(2-chlorophenyl)sulfonyl]-4-(2-fluorophenyl)piperazineStep 1A: Sulfonylation of 1-(2-fluorophenyl)piperazine.HCl (325 mg, 1.5 mmol) with 2-chlorobenzene-1-sulfonyl chloride (316.6 mg, 1.5 mmol) was carried out according to a similar procedure described for step 1A using anhydrous dichloromethane (3 mL) as solvent and diisopropylethylamine (0.575 mL, 3.3 mmol) as base. 1-[(2-chlorophenyl)sulfonyl]-4-(2-fluorophenyl)piperazine was obtained in 75.5% yield (402 mg) as white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 2.99-3.09 (m, 4H) 3.29-3.37 (m, 4H) 6.95-7.19 (m, 4H) 7.56-7.64 (m, 1H) 7.66-7.78 (m, 2H) 8.02 (dd, J=7.96, 1.64 Hz, 1H); HRS: calcd for C16H16ClFN2O2S+H+, 355.06778; found (ESI-FTMS, [M+H]1+), 355.0686. HPLC Method 1: room temperature, 6.281 min, 99.76%. HPLC Method 2: room temperature, 6.916 min, 99.80%.
Example 1C 1-(2,6-dimethylphenyl)-4-(2-naphthylsulfonyl)piperazineSulfonylation was carried out according to a similar procedure described for step 1A. 1-(2,6-dimethylphenyl)-4-(2-naphthylsulfonyl)piperazine was obtained in 85% yield as white solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.19 (s, 6H) 2.80-3.68 (m, 8H) 6.74-7.06 (m, 3H) 7.52-7.72 (m, 2H) 7.80 (d, J=7.07 Hz, 1H) 7.87-8.24 (m, 3H) 8.39 (s, 1H). HRMS: calcd for C22H24N2O2S+H+, 381.16312; found (ESI-FTMS, [M+H]1+), 381.1619.
Example 1D 1-[(2-chlorophenyl)sulfonyl]-4-(2,3-dichlorophenyl)piperazineSulfonylation was carried out according to a similar procedure described for step 1A. 1-[(2-chlorophenyl)sulfonyl]-4-(2,3-dichlorophenyl)piperazine was obtained in 95% yield as white solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.96-3.18 (m, 4H) 3.33-3.64 (m, 4H) 6.93 (d, J=7.83 Hz, 1H) 7.07-7.22 (m, 3H) 7.43 (t, J=7.45 Hz, 1H) 7.48-7.68 (m, 2H) 8.08 (d, J=8.08 Hz, 1H). HRMS: calcd for C16H15Cl3N2O2S+H+, 404.99925; found (ESI-FTMS, [M+H]1+), 404.9995; HPLC Method 1, room temperature, 6.90 min, 98.56%; HPLC Method 2, room temperature, 7.45 min, 98.84%.
Example 1E 1-(2,3-dichlorophenyl)-4-(2-nalphthylsulfonyl)piperazineSulfonylation was carried out according to a similar procedure described for step 1A. 1-(2,3-dichlorophenyl)-4-(2-naphthylsulfonyl)piperazine was obtained in 90% yield as white solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.12 (t, J=4.67 Hz, 4H) 3.28 (s, 4H) 6.93 (d, J=6.32 Hz, 1H) 7.07-7.23 (m, 2H) 7.53-7.74 (m, 2H) 7.74-7.89 (m, 1H) 7.91-8.00 (m, 1H) 8.02 (dd, J=8.21, 4.17 Hz, 2H) 8.38 (s, 1H). HRMS: calcd for C20H18Cl2N2O2S+H+, 421.05388; found (ESI-FTMS, [M+H]1+), 421.054; HPLC Method 1, room temperature, 6.98 min, 98.97%; HPLC Method 2, room temperature, 7.58 min, 95.34%.
Example 1F 1-(phenylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineStep 1Q: A solution of 1-[3-(trifluoromethyl)-2-pyridyl]piperazine (60 mg, 0.26 mmol), and Benzene sulfonyl chloride (0.043 mL, 0.31 mmol) in DCM (4 mL) and saturated sodium bicarbonate (2 mL) was stirred at room temperature for 12 hours. The mixture was diluted with DCM (5 mL) and water (5 mL). The organic layer was collected and washed two times with water, dried with magnesium sulfate, and concentrated. The product was purified using column chromatography (20% Ethyl Acetate in Hexanes) to produce 1-(phenylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine (81.1 mg, 84%).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.18 (t, 4H) 3.35 (t, 4H) 7.03 (t, 1H) 7.57 (t, J=7.33 Hz, 2H) 7.64 (t, J=7.33 Hz, 1H) 7.80 (d, J=8.59 Hz, 2H) 7.85 (d, J=6.06 Hz, 1H) 8.42 (d, J=4.55 Hz, 1H); HRMS: calcd for C16H16F3N3O2S+H+, 372.09881; found (ESI-FTMS, [M+H]1+), 372.0996.
Example 1G 1-[(2-chlorophenyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineIn an analogous manner to Example 1F, step 1Q 1-[(2-chlorophenyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine was prepared from 2-chlorosulfonyl chloride (44% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.27-3.35 (m, 4 m) 3.42-3.52 (m, 4H) 7.02-7.10 (m, 1H) 7.42 (t, J=7.58 Hz, 1H) 7.48-7.59 (m, 2H) 7.88 (d, J=9.09 Hz, 1H) 8.09 (d, J=9.09 Hz, 1H) 8.44 (d, J=3.79 Hz, 1H); HRMS: calcd for C16H15ClF3N3O2S+H+, 406.05983; found (ESI-FTMS, [M+H]1+), 406.0611.
Example 1H 1-[(3-chlorophenyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineIn an analogous manner to Example 1F, step 1Q 1-[(3-chlorophenyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine was prepared from 3-chlorosulfonyl chloride (37% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.16-3.27 (m, 4H) 3.33-3.42 (m, 4H) 7.01-7.10 (m, 1H) 7.52 (t, J=7.83 Hz, 1H) 7.61 (d, J=8.08 Hz, 1H) 7.68 (d, J=7.58 Hz, 1H) 7.79 (s, 1H) 7.87 (d, J=7.83 Hz, 1H) 8.44 (d, J=4.80 Hz, 1H); HRMS: calcd for C16H15ClF3N3O2S+H+, 406.05983; found (ESI-FTMS, [M+H]1+), 406.0609.
Example 1I 1-(benzylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineIn an analogous manner to Example 1F, step 1Q 1-(benzylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine was prepared from α-toluenesulfonyl chloride (45% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.19-3.24 (m, 4H) 3.24-3.30 (m, 4H) 4.24-4.31 (m, 2H) 7.05 (dd, J=7.71, 4.93 Hz, 1H) 7.35-7.47 (m, 5H) 7.88 (d, 1H) 8.44 (d, J=4.55 Hz, 1H); HRMS: calcd for C17H18F3N3O2S+H+, 386.11446; found (ESI-FTMS, [M+H]1+), 386.1153.
Example 1J 1-[3-chlorobenzyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineIn an analogous manner to Example 1F, step 1Q 1-[(3-chlorobenzyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine was prepared from 3-chlorophenylmethane sulfonyl chloride (26% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.25 (t, 4H) 3.32 (t, 4H) 4.20 (s, 2H) 7.00-7.15 (m, 1H) 7.30-7.42 (m, 3H) 7.45 (s, 1H) 7.89 (d, J=9.60 Hz, 1H) 8.45 (d, J=3.28 Hz, 1H); HRMS: calcd for C17H17ClF3N3O2S+H+, 420.07548; found (ESI-FTMS, [M+H]1+), 420.0769.
Example 1K 1-[(3,4-dichlorobenzyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineIn an analogous manner to Example 1F, step 1Q 1-[(3,4-dichlorobenzyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine was prepared from 3,4-dichlorophenylmethane sulfonyl chloride (29% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.27 (t, 4H) 3.35 (t, 4H) 4.16 (s, 2H) 7.07 (none, 1H) 7.08 (dd, J=5.43 Hz, 1H) 7.29 (d, J=2.27 Hz, 1H) 7.48 (d, J=8.08 Hz, 1H) 7.54 (d, J=2.02 Hz, 1H) 7.90 (d, J=7.83 Hz, 1H) 8.46 (d, J=3.54 Hz, 1H); HRMS: calcd for C17H16Cl2F3N3O2S+H+, 454.03651; found (ESI-FTMS, [M+H]1+), 454.0381.
Example 1L 1-[(2-chlorophenyl)sulfonvyl]-4-(3,5-dichloropyridin-4-yl)piperazineIn an analogous manner to Example 1F, step 1Q 1-[(2-chlorophenyl)sulfonyl]-4-(3,5-dichloropyridin-4-yl)piperazine was prepared from 1-(3,5-dichloro-4-pyridyl)piperazine (0.1 g, 0.43 mmol) and 2-chlorobenzene sulfonyl chloride (59% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.35-3.43 (m, 4H) 3.45-3.50 (m, 4H) 7.39-7.46 (m, 1H) 7.49-7.60 (m, 2H) 8.09 (d, J=7.83 Hz, 1H) 8.36 (s, 2H); HRMS: calcd for C15H14Cl3N3O2S+H+, 405.99450; found (ESI-FTMS, [M+H]1+), 405.9951.
Example 1M 1-[(3-chlorophenyl)sulfonyl]-4-(3,5-dichloropyridin-4-yl)piperazineIn an analogous manner to Example 1F, step 1Q 1-[(3-chlorophenyl)sulfonyl]-4-(3,5-dichloropyridin-4-yl)piperazine was prepared from 1-(3,5-dichloro-4-pyridyl)piperazine (0.1 g, 0.43 mmol) and 3-chlorobenzene sulfonyl chloride (66% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.19-3.27 (m, 4H) 3.41-3.51 (m, 4H) 7.26 (s, 1H) 7.53 (t, J=7.83 Hz, 1H) 7.59-7.72 (m, 2H) 7.79 (s, 1H) 8.37 (s, 2H); HRMS: calcd for C15H14Cl3N3O2S+H+, 405.99450; found (ESI-FTMS, [M+H]1+), 405.9956.
Example 1N 1-[(3,4-dichlorobenzyl)sulfonyl]-4-(3,5-dichloropyridin-4-yl)piperazineIn an analogous manner to Example 1F, step 1Q 1-[(3,4-dichlorobenzyl)sulfonyl]-4-(3,5-dichloropyridin-4-yl)piperazine was prepared from 1-(3,5-dichloro-4-pyridyl)piperazine (0.1 g, 0.43 mmol) and 3,4-dichlorophenylmethyl sulfonyl chloride (61% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.18-3.29 (m, 4H) 3.40-3.48 (m, 4H) 7.26 (s, 1H) 7.59-7.70 (m, 2H) 7.89 (d, J=1.77 Hz, 1H) 8.36 (s, 2H); HRMS: calcd for C16H15Cl4N3O2S+H+, 453.97118; found (ESI-FTMS, [M+H]1+), 453.9733.
Example 1O 1-[(3-chlorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperazineIn an analogous manner to Example 1E, step 1P 1-[(3-chlorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperazine was prepared from 1-(2-trifluoromethylphenyl)piperazine (0.1 g, 0.43 mmol) and 3-chlorobenzyl sulfonyl chloride (71% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.01 (t, J=4.80 Hz, 4H) 3.20 (s, 4H) 7.54 (d, J=8.08 Hz, 1H) 7.55-7.60 (m, 1H) 7.59-7.64 (m, 1H) 7.68 (d, J=6.57 Hz, 1H) 7.73 (d, J=6.82 Hz, 1H) 7.79 (t, J=1.89 Hz, 1H) 7.95 (d, J=8.08 Hz, 1H) 8.04 (t, J=1.89 Hz, 1H); HRMS: calcd for C17H16ClF3N2O2S+H+, 405.06458; found (ESI-FTMS, [M+H]1+), 405.0649.
Example 1P 1-[(4-chlorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperazineIn an analogous manner to Example 1E, step 1P 1-[(4-chlorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperazine was prepared from 1-(2-trifluoromethylphenyl)piperazine (0.1 g, 0.43 mmol) and 4-chlorobenzyl sulfonyl chloride (69% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.01 (t, J=4.80 Hz, 4H) 3.18 (s, 4H) 7.35 (d, J=8.08 Hz, 2H) 7.50-7.65 (m, 3H) 7.73 (d, J=8.59 Hz, 2H) 7.99 (d, J=8.59 Hz, 1H); HRMS: calcd for C17H16ClF3N2O2S+H+, 405.06458; found (ESI-FTMS, [M+H]1+), 405.0649.
Example 1Q 1-[(3,4-dichlorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperazineIn an analogous manner to Example 1E, step 1P 1-[(3,4-dichlorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperazine was prepared from 1-(2-trifluoromethylphenyl)piperazine (0.1 g, 0.43 mmol) and 3,4-dichlorobenzene sulfonyl chloride (82% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.02 (t, J=4.80 Hz, 4H) 3.20 (s, 4H) 7.35 (d, J=8.08 Hz, 1H) 7.59-7.64 (m, 3H) 7.65-7.69 (m, 1H) 7.72 (d, J=8.59 Hz, 1H) 8.14 (d, J=2.27 Hz, 1H); HRMS: calcd for C17H15Cl2F3N2O2S+H+, 439.02561; found (ESI-FTMS, [M+H]1+), 439.0251.
Example 1R 1-[(3,4-dichlorobenzyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperazineIn an analogous manner to Example 1E, step 1P 1-[(3,4-dichlorobenzyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperazine was prepared from 1-(2-trifluoromethylphenyl)piperazine (0.1 g, 0.43 mmol) and 3,4-dichlorophenylmethyl sulfonyl chloride (93% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.60 (s, 2H) 2.92-2.96 (m, 4H) 3.31-3.38 (m, 4H) 7.25-7.35 (m, 4H) 7.48-7.58 (m, 2H) 7.64 (d, J=6.32 Hz, 1H); HRMS: calcd for C18H17Cl2F3N2O2S+H+, 453.04126; found (ESI-FTMS, [M+H]1+), 453.0396.
Example 1S 3-{4-[(4-chlorophenyl)sulfonyl]piperazin-1-yl}pyrazine-2-carbonitrileIn an analogous manner to Example 1E, step 1P 3-{4-[(4-chlorophenyl)sulfonyl]piperazin-1-yl}pyrazine-2-carbonitrile was prepared from (3-piperazine-1-yl)pyperazine-2-carbonitrile (0.1 g, 0.53 mmol) and 4-chlorobenzene sulfonyl chloride (40% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.17-3.23 (m, 4H) 3.82-3.90 (m, 4H) 7.54 (d, J=8.84 Hz, 2H) 7.72 (d, J=8.59 Hz, 2H) 8.08 (d, J=2.27 Hz, 1H) 8.26 (d, J=2.27 Hz, 1H); HRMS: calcd for C15H14ClN5O2S+H+, 364.06295; found (ESI-FTMS, [M+H]1+), 364.0636.
Example 1T 3-{4-[(3,4-dichlorophenyl)sulfonyl]piperazin-1-yl}pyrazine-2-carbonitrileIn an analogous manner to Example 1E, step 1P 3-{4-[(3,4-dichlorophenyl)sulfonyl]piperazin-1-yl}pyrazine-2-carbonitrile was prepared from (3-piperazine-1-yl)pyperazine-2-carbonitrile (0.1 g, 0.53 mmol) and 3,4-dichlorobenzene sulfonyl chloride (75% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.21-3.26 (m, 4H) 3.87 (t, 4H) 7.73 (s, 1H) 7.87 (t, J=2.15 Hz, 1H) 8.10 (d, J=2.27 Hz, 1H) 8.14 (d, J=2.27 Hz, 1H) 8.27 (d, J=2.27 Hz, 1H); HRMS: calcd for C15H13Cl2N5O2S+H+, 398.02397; found (ESI-FTMS, [M+H]1+), 398.0223.
Example 1U 1-[(3,4-dichlorophenyl)sulfonyl]-4-(3′-methoxybiphenyl-2-yl)piperazineIn an analogous manner to Example 1E, step 1P, 1-[(3,4-dichlorophenyl)sulfonyl]-4-(3′-methoxybiphenyl-2-yl)piperazine was prepared from (3-piperazine-1-yl)pyperazine-2-carbonitrile (0.1 g, 0.53 mmol) and 3,4-dichlorphenyl methyl sulfonyl chloride (18% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.92 (s, 8H) 4.60 (d, J=5.56 Hz, 3H) 7.00 (d, J=8.08 Hz, 1H) 7.11 (t, J=6.95 Hz, 1H) 7.22-7.34 (m, 4H) 7.42 (d, J=7.33 Hz, 1H) 7.55 (d, J=8.34 Hz, 2H) 7.65 (d, J=8.59 Hz, 1H) 7.81 (s, 1H); HRMS: calcd for C23H22Cl2N2O3S+H+, 477.08009; found (ESI-FTMS, [M+H]1+), 477.0784.
Example 1V N-[4-({4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)phenyl]acetamideThe desired product was obtained in 98% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.13-2.33 (m, 3H) 3.07-3.23 (m, 4H) 3.26-3.45 (m, 4H) 6.99-7.08 (m, 1H) 7.46 (s, 1H) 7.66-7.80 (m, 4H) 7.85 (dd, J=7.71, 1.89 Hz, 1H) 8.42 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C18H19F3N4O3S+H+, 429.12027; found (ESI-FTMS, [M+H]1+), 429.1207.
Example 1W 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 83% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.09-3.24 (m, 4H) 3.26-3.42 (m, 4H) 3.85-4.09 (m, 6H) 6.99 (d, J=8.59 Hz, 1H) 7.03 (dd, J=7.83, 4.80 Hz, 1H) 7.24 (d, J=2.02 Hz, 1H) 7.41 (dd, J=8.46, 2.15 Hz, 1H). HRMS: calcd for C18H20F3N3O4S+H+, 432.11994; found (ESI-FTMS, [M+H]1+), 432.1212.
Example 1X 1-[(2,4-difluorophenyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 100% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.31-3.39 (m, 4H) 3.39-3.47 (m, 4H) 7.01-7.12 (m, 3H) 7.50-7.60 (m, 1H) 7.88 (dd, J=7.83, 2.02 Hz, 1H) 8.45 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C16H14F5N3O2S+H+, 408.07996; found (ESI-FTMS, [M+H]1+), 408.0811.
Example 1Y 1-(2-naphthylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 92% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.16-3.31 (m, 4H) 3.32-3.50 (m, 4H) 6.97-7.10 (m, 1H) 7.58-7.73 (m, 2H) 7.76-7.87 (m, 2H) 7.95 (d, 1H) 8.01 (d, 2H) 8.35-8.46 (m, 2H). HRMS: calcd for C20H18F3N3O2S+H+, 422.11446; found (ESI-FTMS, [M+H]1+), 422.1145.
Example 1Z 1-(1-benzothien-2-ylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 100% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.23-3.49 (m, 8H) 6.97-7.10 (m, 1H) 7.40-7.59 (m, 2H) 7.75-7.99 (m, 4H) 8.43 (dd, J=4.80, 1.77 Hz, 1H). HRMS: calcd for C18H16F3N3O2S2+H+, 428.07088; found (ESI-FTMS, [M+H]1+), 428.0716.
Example 1AA 1-(1-benzothien-3-ylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 80% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.21-3.41 (m, 8H) 7.02 (dd, J=7.45, 5.18 Hz, 1H) 7.43-7.59 (m, 2H) 7.84 (dd, J=7.58, 1.77 Hz, 1H) 7.92 (dd, J=7.07, 1.01 Hz, 1H) 8.21 (s, 1H) 8.29 (dd, 1H) 8.41 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C18H16F3N3O2S2+H+, 428.07088; found (ESI-FTMS, [M+H]1+), 428.072.
Example 1AB 1-(dibenzo[b,d]furan-3-ylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 61% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.16-3.30 (m, 4H) 3.29-3.46 (m, 4H) 7.01 (dd, J=7.33, 4.29 Hz, 1H) 7.43 (t, 1H) 7.58 (t, 1H) 7.65 (d, 1H) 7.75-7.88 (m, 2H) 8.01-8.07 (m, 2H) 8.12 (d, J=8.08 Hz, 1H) 8.41 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C22H18F3N3O3S+H+, 462.10937; found (ESI-FTMS, [M+H]1+), 462.1102.
Example 1AC 1-[(2,4-difluorophenyl)sulfonyl]-4-(3-methylpyridin-2-yl)piperazineThe desired product was obtained in 100% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.23 (s, 3H) 3.11-3.30 (m, 4H) 3.37-3.57 (m, 4H) 6.88 (dd, J=7.45, 4.93 Hz, 1H) 7.06 (t, J=8.46 Hz, 2H) 7.41 (dd, J=7.45, 1.14 Hz, 1H) 7.48-7.61 (m, 1H) 8.14 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C16H17F2N3O2S+H+, 354.10823; found (ESI-FTMS, [M+H]1+), 354.1084.
Example 1AD 1-[(3,4-dichlorobenzyl)sulfonyl]-4-(3-methylpyridin-2-yl)piperazineThe desired product was obtained in 70% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.25 (s, 3H) 3.07-3.29 (m, 4H) 3.24-3.45 (m, 4H) 6.86-6.94 (m, J=7.33, 4.80 Hz, 1H) 7.27-7.30 (m, J=8.21, 2.15 Hz, 1H) 7.42 (dd, J=7.33, 1.01 Hz, 1H) 7.47 (d, J=8.34 Hz, 1H) 7.54 (d, J=2.27 Hz, 1H) 8.16 (dd, J=4.93, 1.39 Hz, 1H). HRMS: calcd for C17H19Cl2N3O2S+H+, 400.06478; found (ESI-FTMS, [M+H]1+), 400.0653.
Example 1AE 1-(3-methylpyridin-2-yl)-4-(2-naphthylsulfonyl)piperazineThe desired product was obtained in 100% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.10-2.19 (m, 3H) 3.16-3.41 (m, 8H) 6.85 (dd, J=7.33, 4.80 Hz, 1H) 7.36 (dd, J=7.33, 1.01 Hz, 1H) 7.59-7.73 (m, 2H) 7.81 (dd, J=8.72, 1.89 Hz, 1H) 7.95 (d, J=7.83 Hz, 1H) 8.01 (d, J=9.09 Hz, 2H) 8.11 (dd, J=4.80, 1.26 Hz, 1H) 8.39 (d, J=1.01 Hz, 1H). HRMS: calcd for C20H21N3O2S+H+, 368.14272; found (ESI-FTMS, [M+H]1+), 368.1436.
Example 1AF 1-(1-benzothien-2-ylsulfonyl)-4-(3-methylpyridin-2-yl)piperazineThe desired product was obtained in 100% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.13-2.26 (m, 3H) 3.29 (d, 8H) 6.87 (dd, J=7.33, 4.80 Hz, 1H) 7.38 (dd, J=7.33, 1.01 Hz, 1H) 7.45-7.57 (m, 2H) 7.85 (s, 1H) 7.87-7.96 (m, 2H) 8.13 (dd, J=5.18, 1.64 Hz, 1H). HRMS: calcd for C18H19N3O2S2+H+, 374.09914; found (ESI-FTMS, [M+H]1+), 374.0998.
Example 1AG 1-(1-benzothien-3-ylsulfonyl)-4-(3-methylpyridin-2-yl)piperazineThe desired product was obtained in 100% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.11-2.23 (m, 3H) 3.11-3.29 (m, 4H) 3.26-3.44 (m, 4H) 6.86 (t, J=7.33, 4.80 Hz, 1H) 7.37 (dd, J=7.33, 1.26 Hz, 1H) 7.44-7.59 (m, 2H) 7.92 (dd, J=7.07, 1.01 Hz, 1H) 8.22 (s, 1H) 8.31 (dd, 1H). HRMS: calcd for C18H19N3O2S2+H+, 374.09914; found (ESI-FTMS, [M+H]1+), 374.1004.
Example 1AH 1-[(2-chlorophenyl)sulfonyl]-4-(3-methylpyridin-2-yl)piperazineThe desired product was obtained in 73% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.24 (s, 1H) 3.07-3.26 (m, 4H) 3.38-3.56 (m, 4H) 6.88 (dd, J=7.45, 4.93 Hz, 1H) 7.38-7.45 (m, 2H) 7.46-7.61 (m, 2H) 8.09 (dd, J=7.83, 1.77 Hz, 1H) 8.14 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C16H18ClN3O2S+H+, 352.08810; found (ESI-FTMS, [M+H]1+), 352.0883.
Example 1AI 1-(dibenzo[b,d]furan-3-ylsulfonyl)-4-(3-methylpyridin-2-yl)piperazineThe desired product was obtained in 78% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.07-2.19 (m, 3H) 3.17-3.34 (m, 8H) 6.85 (dd, J=7.33, 5.05 Hz, 1H) 7.35 (dd, J=7.33, 1.26 Hz, 1H) 7.44 (t, 1H) 7.58 (t, 1H) 7.65 (dd, 1H) 7.81 (dd, J=8.08, 1.52 Hz, 1H) 8.01-8.06 (m, 2H) 8.08-8.16 (m, 2H). HRMS: calcd for C22H21N3O3S+H+, 408.13764; found (ESI-FTMS, [M+H]1+), 408.1388.
Example 1AJ 1-[(3,4-dichlorophenyl)sulfonyl]-4-(3-methylpyridin-2-yl)piperazineThe desired product was obtained in 94% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.11-2.26 (m, 3H) 3.08-3.35 (m, 8H) 6.75-6.95 (m, J=7.33, 4.80 Hz, 1H) 7.40 (dd, J=7.45, 1.14 Hz, 1H) 7.59-7.68 (m, 2H) 7.89 (d, J=1.77 Hz, 1H) 8.14 (dd, J=4.67, 1.64 Hz, 1H), HRMS: calcd for C16H17Cl2N3O2S+H+, 386.04913; found (ESI-FTMS, [M+H]1+), 386.0484.
Example 1AK 1-(3-methylpyridin-2-yl)-4-{[2-(trifluoromethyl)phenyl]sulfonyl}piperazineThe desired product was obtained in 68% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.23 (s, 3H) 3.13-3.26 (m, 4H) 3.35-3.49 (m, 4H) 6.85-6.93 (m, J=7.20, 4.67 Hz, 1H) 7.40 (dd, J=7.33, 1.01 Hz, 1H) 7.66-7.76 (m, 2H) 7.92 (dd, 1H) 8.11-8.20 (m, 2H). HRMS: calcd for C17H18F3N3O2S+H+, 386.11446; found (ESI-FTMS, [M+H]1+), 386.115.
Example 1AL 1-[(4-chlorophenyl)sulfonyl]-4-(3-methylpyridin-2-yl)piperazineThe desired product was obtained in 63% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.18 (s, 3H) 3.11-3.30 (m, 8H) 6.83-6.92 (m, J=7.20, 4.93 Hz, 1H) 7.40 (d, J=1.01 Hz, 1H) 7.51-7.59 (m, 2H) 7.71-7.78 (m, 2H) 8.13 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C16H18ClN3O2S+H+, 352.08810; found (ESI-FTMS, [M+H]1+), 352.0879.
Example 1AM 1-(dibenzo[b,d]thien-3-ylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 90% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.16-3.29 (m, 4H) 3.30-3.42 (m, 4H) 6.97-7.05 (m, J=7.83, 4.80 Hz, 1H) 7.49-7.62 (m, 2H) 7.79-7.88 (m, 2H) 7.92 (dd, J=6.57, 1.26 Hz, 1H) 8.25 (dd, 1H) 8.28-8.35 (m, 2H) 8.41 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C22H18F3N3O2S2+H+, 478.08653; found (ESI-FTMS, [M+H]1+), 478.0881.
Example 1AN 1-[(3,5-dimethylisoxazol-4-yl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 65% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.43-2.46 (m, 3H) 2.65-2.70 (m, 3H) 3.24-3.31 (m, 4H) 3.31-3.38 (m, 4H) 7.05-7.13 (m, J=7.83, 4.80 Hz, 1H) 7.90 (dd, J=7.83, 2.02 Hz, 1H) 8.46 (dd, J=4.55, 1.52 Hz, 1H). HRMS: calcd for C15H17F3N4O3S+H+, 391.10462; found (ESI-FTMS, [M+H]1+), 391.1061.
Example 1AO 1-(dibenzo[b,d]furan-2-ylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 90% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.17-3.30 (m, 4H) 3.31-3.43 (m, 4H) 6.98-7.08 (m, 1H) 7.44 (t, 1H) 7.56 (t, 1H) 7.64 (d, 1H) 7.74 (d, J=9.35 Hz, 1H) 7.84 (dd, J=7.83, 1.77 Hz, 1H) 7.91 (dd, J=8.72, 1.89 Hz, 1H) 8.04 (d, J=7.83 Hz, 1H) 8.41 (d, J=4.80, 1.26 Hz, 1H) 8.43 (d, J=1.26 Hz, 1H). HRMS: calcd for C22H18F3N3O3S+H+, 462.10937; found (ESI-FTMS, [M+H]1+), 462.1081.
Example AP 1-(biphenyl-4-ylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 92% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.16-3.34 (m, 4H) 3.32-3.47 (m, 4H) 7.01-7.09 (m, J=7.71, 4.93 Hz, 1H) 7.41-7.48 (m, 1H) 7.48-7.56 (m, 1H) 7.66 (d, 2H) 7.79 (d, 2H) 7.88 (d, 3H) 8.45 (dd, J=4.55, 1.52 Hz, 1H). HRMS: calcd for C22H20F3N3O2S+H+, 448.13011; found (ESI-FTMS, [M+H]1+), 448.1279.
Example 1AQ 1-[(2-chlorobenzyl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 58% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.20-3.28 (m, 4H) 3.28-3.36 (m, 4H) 4.44-4.49 (m, 2H) 6.98-7.09 (m, 1H) 7.28-7.34 (m, 2H) 7.39-7.45 (m, 1H) 7.57-7.63 (m, 1H) 7.87 (dd, J=7.71, 1.89 Hz, 1H) 8.42 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C17H17ClF3N3O2S+H+, 420.07548; found (ESI-FTMS, [M+H]1+), 420.0742.
Example 1AR 1-[(4′-fluorobiphenyl-4-yl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 94% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.15-3.29 (m, 4H) 3.32-3.45 (m, 4H) 7.04 (dd, J=7.71, 4.93 Hz, 1H) 7.13-7.22 (m, 2H) 7.55-7.64 (m, 2H) 7.67-7.76 (m, 2H) 7.82-7.91 (m, 3H) 8.43 (dd, J=4.93, 1.39 Hz, 1H). HRMS: calcd for C22H19F4N3O2S+H+, 466.12068; found (ESI-FTMS, [M+H]1+), 466.119.
Example 1AS 1-(dibenzo[b,d]thien-2-ylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 95% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.19-3.29 (m, 4H) 3.37-3.45 (m, 4H) 6.98-7.06 (m, J=6.95, 4.93 Hz, 1H) 7.50-7.61 (m, 2H) 7.80-7.88 (m, 2H) 7.88-7.94 (m, 1H) 8.03 (d, J=9.09 Hz, 1H) 8.41 (dd, J=5.05, 1.26 Hz, 1H) 8.57 (d, J=1.26 Hz, 1H). HRMS: calcd for C22H18F3N3O2S2+H+, 478.08653; found (ESI-FTMS, [M+H]1+), 478.0862.
Example 1AT 1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 98% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.71 (s, 3H) 3.37 (s, 8H) 7.05 (t, 1H) 7.47 (dd, J=8.59, 2.02 Hz, 1H) 7.77 (d, J=8.34 Hz, 1H) 7.81-7.90 (m, 2H) 8.43 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C19H17ClF3N3O2S2+H+, 476.04755; found (ESI-FTMS, [M+H]1+), 476.0475.
Example 1AU 1-[(2-chlorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperazineIn an analogous manner to Example 1E, step 1P 1-[(2-chlorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperazine was prepared from 1-(2-trifluoromethylphenyl)piperazine (0.1 g, 0.43 mmol) and 2-chlorobenzyl sulfonyl chloride (73% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.94-3.01 (m, 4H) 3.45 (d, J=4.29 Hz, 4H) 7.22-7.30 (m, 1H) 7.35 (d, J=7.83 Hz, 1H) 7.42 (t, J=8.08 Hz, 1H) 7.47-7.59 (m, 3H) 7.63 (d, J=8.08 Hz, 1H) 8.08 (d, J=7.83 Hz, 1H); HRMS: calcd for C17H16ClF3N2O2S+H+, 405.06458; found (ESI-FTMS, [M+H]1+), 405.0648.
Example 1AV 2-({4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)-1,3-benzothiazoleThe desired product was obtained in 30% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.23-3.39 (m, 4H) 3.44-3.62 (m, 4H) 6.94-7.01 (m, J=7.83, 4.80 Hz, 1H) 7.44-7.60 (m, 2H) 8.15 (d, J=7.33 Hz, 1H) 8.36 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C17H15F3N4O2S2+H+, 429.06613; found (ESI-FTMS, [M+H]1+), 429.0661.
Example 1AW 1-(dibenzo[b,d]furan-2-ylsulfonyl)-4-(3-methylpyridin-2-yl)piperazineThe desired product was obtained in 91% yield as white solid. HRMS: calcd for C22H21N3O3S+H+, 408.13764; found (ESI-FTMS, [M+H]1+), 408.137. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.07-2.20 (m, 3H) 3.14-3.34 (m, 8H) 6.80-6.89 (m, J=7.33, 4.80 Hz, 3H) 7.35 (dd, J=7.33, 1.26 Hz, 1H) 7.44 (t, 1H) 7.56 (t, 1H) 7.64 (d, 1H) 7.73 (d, J=8.34 Hz, 1H) 7.92 (dd, J=8.72, 1.89 Hz, 1H) 8.03 (d, J=7.07 Hz, 1H) 8.11 (dd, J=4.93, 1.39 Hz, 1H) 8.44 (d, J=1.52 Hz, 1H).
Example 1AX 1-(dibenzo[b,d]thien-2-ylsulfonyl)-4-(3-methylpyridin-2-yl)piperazineThe desired product was obtained in 94% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.07-2.19 (m, 3H) 3.15-3.31 (m, 8H) 6.84 (dd, J=7.33, 4.80 Hz, 1H) 7.35 (dd, J=7.33, 1.01 Hz, 1H) 7.50-7.61 (m, 2H) 7.86 (dd, J=8.59, 1.77 Hz, 1H) 7.89-7.95 (m, 1H) 8.03 (d, J=8.34 Hz, 1H) 8.11 (dd, J=4.93, 1.39 Hz, 1H) 8.24-8.32 (m, 1H) 8.59 (d, J=1.26 Hz, 1H). HRMS: calcd for C22H21N3O2S2+H+, 424.11479; found (ESI-FTMS, [M+H]1+), 424.1152.
Example 1AY 1-(dibenzo[b,d]thien-3-ylsulfonyl)-4-(3-methylpyridin-2-yl)piperazineThe desired product was obtained in 91% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.10-2.17 (m, 8H) 6.82-6.89 (m, J=7.33, 5.05 Hz, 1H) 7.35 (dd, J=7.33, 1.26 Hz, 1H) 7.50-7.63 (m, 2H) 7.87 (dd, J=8.34, 1.52 Hz, 1H) 7.92 (dd, J=7.20, 1.89 Hz, 1H) 8.12 (dd, J=4.55, 1.52 Hz, 1H) 8.22-8.28 (m, 1H) 8.29-8.38 (m, 2H). HRMS: calcd for C22H21N3O2S2+H+, 424.11479; found (ESI-FTMS, [M+H]1+), 424.1137.
Example 1AZ 1-(biphenyl-4-ylsulfonyl)-4-(3-methylpyridin-2-yl)piperazineThe desired product was obtained in 95% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.09-2.23 (m, 3H) 3.16-3.34 (m, 8H) 6.86 (dd, J=7.33, 5.05 Hz, 1H) 7.38 (dd, J=6.95, 1.64 Hz, 1H) 7.39-7.45 (m, 1H) 7.45-7.54 (m, 2H) 7.58-7.67 (m, 2H) 7.72-7.80 (m, 2H) 7.81-7.91 (m, 2H) 8.13 (dd, J=4.93, 1.89 Hz, 1H). HRMS: calcd for C22H23N3O2S+H+, 394.15837; found (ESI-FTMS, [M+H]1+), 394.1594.
Example 2Step 2A: tert-butyl piperazine-1-carboxylate (1.0 g, 5.37 mmol) and 2,3-dichloropyridine (795 mg, 5.37 mmol) charged to a microwave vial was added with diisopropylethylamine (2.34 mL, 13.42 mmol) and DMF (1.0 mL). The reaction mixture was subject to microwave irradiation at 165° C. for 30 minutes. The reaction was repeated six times in order to scale up. Combined reaction mixture was partitioned between EtOAc and water, organic layer washed with brine and dried over MgSO4. The crude product obtained by solvent evaporation was purified via flash column chromatography. tert-butyl 4-(3-chloropyridin-2-yl)piperazine-1-carboxylate was obtained in 20% yield (1.9 g) as yellow oil.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.49 (s, 9H) 3.26-3.34 (m, 4H) 3.53-3.64 (m, 4H) 6.86 (dd, J=7.71, 4.67 Hz, 1H) 7.60 (dd, J=7.83, 1.77 Hz, 1H) 8.18 (dd, J=4.80, 1.77 Hz, 1H). HRS: calcd for C14H20ClN3O2+H+, 298.13168; found (ESI-FTMS, [M+H]1+), 298.1319. HPLC Method 1: room temperature, 6.051 min, 97.69%, HPLC Method 2: room temperature, 7.085 min, 98.91%.
Step 2B: To a clear solution of tert-butyl 4-(3-chloropyridin-2-yl)piperazine-1-carboxylate in anhydrous dichloromethane (25 mL) was added TFA (25 mL) dropwise. The yellow solution was stirred at room temperature for 2.5 hour. Reaction was complete as determined by TLC. TFA was azeotropped with dichloroethane to give 1-(3-chloropyridin-2-yl)piperazine in quantitative yield (1.265 g).
1H NMR (400 MHz, DMSO-D6) δ ppm 3.19-3.32 (m, 4H) 3.39-3.51 (m, 4H) 7.10 (dd, J=7.83, 4.55 Hz, 2H) 7.87 (dd, J=7.83, 1.52 Hz, 2H) 8.27 (dd, J=4.80, 1.52 Hz, 2H) 8.87 (s, 1H).
Step 2C: To a stirred solution of 1-(3-chloropyridin-2-yl)piperazine (316 mg, 1.6 mmol) in anhydrous dichloromethane (5 mL) was added diisopropylethylamine (0.975 mL, 5.6 mmol) then 4-tert-butylbenzene-1-sulfonyl chloride (372.4 mg, 1.6 mmol). The mixture was stirred at room temperature for 1.5 hour. Reaction was complete as determined by TLC. The reaction mixture was purified with flash column chromatography to yield 1-[(4-tert-butylphenyl)sulfonyl]-4-(3-chloropyridin-2-yl)piperazine in 59.3% yield (374 mg) as white solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.36 (s, 9H) 3.17-3.25 (m, 4H) 3.39-3.47 (m, 4H) 6.86 (dd, J=7.71, 4.67 Hz, 1H) 7.52-7.60 (m, 3H) 7.68-7.75 (m, 2H) 8.16 (dd, J=4.80, 1.52 Hz, 1H). HRMS: calcd for C19H24ClN3O2S+H+, 394.13505; found (ESI-FTMS, [M+H]1+), 394.1358. HPLC Method 1: room temperature, 6.924 min, 99.05%, HPLC Method 2: room temperature, 7.499 min, 99.48%.
Example 2B 1-(3-chloropyridin-2-yl)-4-(2-naphthylsulfonyl)piperazineStep 2C: Sulfonylation of 1-(3-chloropyridin-2-yl)piperazine (632 mg, 3.2 mmol) with naphthalene-2-sulfonyl chloride (725 mg, 3.2 mmol) was carried out according to a similar procedure described for example 2A (except that the sulfonyl chloride was added before the diisopropylethylamine) using anhydrous dichloromethane (10 mL) as solvent and diisopropylethylamine (1.4 mL, 8.0 mmol) as base. 1-(3-chloropyridin-2-yl)-4-(2-naphthylsulfonyl)piperazine was obtained in 17.0% yield (210.2 mg) as white solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.21-3.32 (m, 4H) 3.41-3.50 (m, 4H) 6.87 (dd, J=7.83, 4.80 Hz, 1H) 7.51-7.72 (m, 3H) 7.79 (dd, J=8.72, 1.89 Hz, 1H) 7.91-7.98 (m, 1H) 8.01 (d, J=8.34 Hz, 2H) 8.17 (dd, J=4.80, 1.77 Hz, 1H) 8.38 (d, J=1.77 Hz, 1H). HRMS: calcd for C19H18ClN3O2S+H+, 388.08810; found (ESI-FTMS, [M+H]1+), 388.0885. HPLC Method 1: room temperature, 6.432 min, 99.82%, HPLC Method 2: room temperature, 7.178 min, 99.6%.
Example 2C 1-(3-chloropyridin-2-yl)-4-(1-naphthylsulfonyl)piperazineStep 2C: Sulfonylation of 1-(3-chloropyridin-2-yl)piperazine (316 mg, 1.6 mmol) with naphthalene-1-sulfonyl chloride (362.7 mg, 1.6 mmol) was carried out according to a similar procedure described for example 2A (Except sulfonyl chloride was added before diisopropylethylamine) using anhydrous dichloromethane (3 mL) as solvent and diisopropylethylamine (1.4 mL, 8.0 mmol) as base. 1-(3-chloropyridin-2-yl)-4-(1-naphthylsulfonyl)piperazine was obtained in 70.0% yield (434.0 mg) as white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 3.25 (s, 8H) 7.00 (dd, J=7.71, 4.67 Hz, 1H) 7.63-7.82 (m, 4H) 8.08-8.22 (m, 3H) 8.33 (d, J=8.34 Hz, 1H) 8.73 (d, J=7.83 Hz, 1H). HRMS: calcd for C19H18ClN3O2S+H+, 388.08810; found (ESI-FTMS, [M+H]1+), 388.0886. HPLC Method 1: room temperature, 6.476 min, 100%, HPLC Method 2: room temperature, 7.149 min, 100.0%.
Example 2D 1-[(2-chlorophenyl)sulfonyl]-4-(3-chloropyridin-2-yl)piperazinePreparation of 1-[(2-chlorophenyl)sulfonyl]-4-(3-chloropyridin-2-yl)piperazine was carried out according to a similar procedure described for example 2A. Yield 75%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.36-3.44 (m, 4H) 3.44-3.55 (m, 4H) 6.78-6.93 (m, J=7.83, 4.80 Hz, 1H) 7.38-7.46 (m, 1H) 7.47-7.52 (m, 1H) 7.52-7.56 (m, 1H) 7.59 (dd, J=7.71, 1.64 Hz, 1H) 8.09 (d, J=7.83 Hz, 1H) 8.17 (d, J=4.80 Hz, 1H). HRMS: calcd for C15H15Cl2N3O2S+H+, 372.03348; found (ESI-FTMS, [M+H]1+), 372.0355.
Example 2E 1-[(4-chlorophenyl)sulfonyl]-4-(3-chloropyridin-2-yl)piperazinePreparation of 1-[(4-chlorophenyl)sulfonyl]-4-(3-chloropyridin-2-yl)piperazine was carried out according to a similar procedure described for example 2A. Yield 78%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.20 (br s, 4H) 3.43 (br s, 4H) 6.58-7.04 (m, 1H) 7.10-7.40 (m, 1H) 7.41-7.96 (m, 4H) 8.17 (s, 1H). HRMS: calcd for C15H15Cl2N3O2S+H+, 372.03348; found (ESI-FTMS, [M+H]1+), 372.0345. HPLC Method 1, room temperature, 6.00 min, 97.89%; HPLC Method 2, room temperature, 6.99 min, 97.48%.
Example 2F 1-(3-chloropyridin-2-yl)-4-[(4-methylphenyl)sulfonyl]piperazinePreparation of 1-(3-chloropyridin-2-yl)-4-[(4-methylphenyl)sulfonyl]piperazine was carried out according to a similar procedure described for example 2A. Yield 78%.
1H NMR (400 MHz, DMSO-D6) δ ppm 2.42 (s, 3H) 2.88-3.18 (m, 4H) 3.20-3.45 (m, 4H) 6.74-7.21 (m, J=7.58 Hz, 1H) 7.49 (d, J=8.08 Hz, 2H) 7.67 (d, J=8.08 Hz, 2H) 7.79 (d, J=7.58 Hz, 1H) 8.20 (d, J=4.55 Hz, 1H). HRMS: calcd for C16H18ClN3O2S+H+, 352.08810; found (ESI-FTMS, [M+H]1+), 352.0897.
Example 2G 1-(3-chloropyridin-2-yl)-4-[(4-methoxyphenyl)sulfonyl]piperazinePreparation of 1-(3-chloropyridin-2-yl)-4-[(4-methoxyphenyl)sulfonyl]piperazine was carried out according to a similar procedure described for example 2A. Yield 75%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.99-3.28 (m, 4H) 3.36-3.51 (m, 4H) 3.89 (s, 3H) 6.87 (d, J=4.80 Hz, 1H) 6.98-7.07 (m, 2H) 7.56 (d, J=1.77 Hz, 1H) 7.67-7.84 (m, 2H) 8.16 (dd, J=4.67, 1.64 Hz, 1H). HRMS: calcd for C16H18ClN3O3S+H+, 368.08301; found (ESI-FTMS, [M+H]1+), 368.0839.
Example 2H 1-(biphenyl-4-ylsulfonyl)-4-(3-chloropyridin-2-yl)piperazinePreparation of 1-(biphenyl-4-ylsulfonyl)-4-(3-chloropyridin-2-yl)piperazine was carried out according to a similar procedure described for example 2A. Yield 75%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.25 (d, J=8.84 Hz, 4H) 3.38-3.59 (m, J=8.84 Hz, 4H) 6.74-6.97 (m, 1H) 7.33-7.54 (m, 3H) 7.57 (d, J=7.83 Hz, 1H) 7.59-7.68 (m, J=8.08 Hz, 2H) 7.71-7.81 (m, 2H) 7.82-7.99 (m, 2H) 8.16 (d, J=4.80 Hz, 1H). HRMS: calcd for C21H20ClN3O2S+H+, 414.10375; found (ESI-FTMS, [M+H]1+), 414.1042.
Example 2I 1-(benzylsulfonyl)-4-(3-chloropyridin-2-yl)piperazinePreparation of 1-(benzylsulfonyl)-4-(3-chloropyridin-2-yl)piperazine was carried out according to a similar procedure described for example 2A. Yield 75%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.11-3.56 (m, 8H) 4.26 (s, 2H) 6.91 (dd, J=7.83, 4.80 Hz, 1H) 7.32-7.55 (m, 5H) 7.64 (d, J=7.83 Hz, 1H) 8.20 (d, J=4.80 Hz, 1H). HRMS: calcd for C16H18ClN3O2S+H+, 352.08810; found (ESI-FTMS, [M+H]1+), 352.0881.
Example 2J 1-{[2-bromo-4-(trifluoromethyl)phenyl]sulfonyl}-4-(3-chloropyridin-2-yl)piperazinePreparation of 1-{[2-bromo-4-(trifluoromethyl)phenyl]sulfonyl}-4-(3-chloropyridin-2-yl)piperazine was carried out according to a similar procedure described for example 2A. Yield 75%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.38-3.46 (m, J=4.80 Hz, 4H) 3.48-3.58 (m, J=4.80 Hz, 4H) 6.73-7.04 (m, 1H) 7.60 (d, J=7.58 Hz, 1H) 7.73 (d, J=8.08 Hz, 1H) 8.02 (s, 1H) 8.18 (d, J=4.80 Hz, 1H) 8.25 (d, J=8.08 Hz, 1H). HRMS: calcd for C16H14BrClF3N3O2S+H+, 483.97035; found (ESI-FTMS, [M+H]1+), 483.9716.
Example 2K 1-{[4-(benzyloxy)phenyl]sulfonyl}-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineStep 2A: tert-butyl piperazine-1-carboxylate (3.0 g, 16.11 mmol) and 2-chloro-3-trifluoromethylpyridine (2.93 g, 16.11 mmol) charged to a microwave vial was added with diisopropylethylamine (7.05 mL, 40.28 mmol) and DMF (1.0 mL). The reaction mixture was subject to microwave irradiation at 160° C. for 30 minutes. The reaction mixture was partitioned between EtOAc and water, organic layer washed with brine and dried over Na2SO4. The crude product obtained by solvent evaporation was purified via flash column chromatography. 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester was obtained in 33.9% yield (1.81 g) as light yellow oil.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.48 (s, 9H) 3.18-3.27 (m, 4H) 3.53-3.61 (m, 4H) 7.00-7.06 (m, 1H) 7.88 (dd, J=7.83, 1.77 Hz, 1H) 8.44 (dd, J=4.80, 1.26 Hz, 1H).
Step 2B: To a clear solution of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester in anhydrous dichloromethane (15 mL) was added TFA (8 mL) dropwise. The yellow solution was stirred at room temperature for 2.5 hour. Reaction was complete as determined by TLC. TFA was removed under reduced pressure. The residue was redissolved in dichloromethane (50 mL), and washed with sat. K2CO3 solution first, then washed with brine and dried over Na2SO4, filtered and concentrated down to give 1-(3-trifluoromethyl-pyridin-2-yl)-piperazine as a light yellow oil (1.19 g, 96.0% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.60 (s, 1H) 2.93-3.08 (m, 4H) 3.17-3.36 (m, 4H) 6.97 (dd, J=7.20, 4.67 Hz, 1H) 7.85 (dd, J=7.83, 1.77 Hz, 1H) 8.37-8.52 (m, 1H).
Step 2C: To a stirred solution of 1-(3-trifluoromethyl-pyridin-2-yl)-piperazine (100 mg, 0.39 mmol) in anhydrous dichloromethane (2 mL) was added 4-benzyloxy-benzenesulfonyl chloride (110.27 mg, 0.39 mmol) then diisopropylethylamine (0.17 mL, 0.98 mmol). The mixture was stirred at room temperature for 4 hour. Reaction was complete as determined by TLC. The reaction mixture was purified with flash column chromatography to yield 1-{[4-(benzyloxy)phenyl]sulfonyl}-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine in 78.9% yield (147 mg) as white solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.12-3.20 (m, 4H) 3.32-3.39 (m, 4H) 5.14 (s, 2H) 7.00-7.06 (m, 1H) 7.07-7.13 (m, 2H) 7.34-7.47 (m, 5H) 7.70-7.77 (m, 2H) 7.85 (dd, J=7.83, 1.77 Hz, 1H) 8.43 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C23H22F3N3O3S+H+, 478.14067; found (ESI-FTMS, [M+H]1+), 478.1398. HPLC Method 1: room temperature, 6.793 min, 99.02%; HPLC Method 2: room temperature, 7.419 min, 99.60%.
Example 2L N-[4-({4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)phenyl]morpholine-4-carboxamideThe title compound was prepared according to a similar procedure for Example 2A, step 2C. Yield 78.9%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.12-3.19 (m, 4H) 3.31-3.37 (m, 4H) 3.48-3.56 (m, 4H) 3.72-3.81 (m, 4H) 6.55-6.60 (m, 1H) 7.03 (dd, J=7.71, 4.93 Hz, 1H) 7.52-7.59 (m, 2H) 7.68-7.75 (m, 2H) 7.85 (dd, J=7.83, 2.02 Hz, 1H) 8.42 (dd, J=4.80, 1.77 Hz, 1H). HRMS: calcd for C21H24F3N5O4S+H+, 500.15738; found (ESI-FTMS, [M+H]1+), 500.1567. HPLC Method 1: room temperature, 5.217 min, 99.80%, HPLC Method 2: room temperature, 6.178 min, 99.84%.
Example 2M 1-{[4-(4-fluorophenoxy)phenyl]sulfonyl}-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe title compound was prepared according to a similar procedure for Example 2A, step 2C. Yield 89%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.14-3.20 (m, 4H) 3.32-3.38 (m, 4H) 7.00-7.16 (m, 7H) 7.70-7.77 (m, 2H) 7.86 (dd, J=7.83, 1.77 Hz, 1H) 8.44 (dd, J=4.80, 1.77 Hz, 1H). HRMS: calcd for C22H19F4N3O3S+H+, 482.11560; found (ESI-FTMS, [M+H]1+), 482.1148. HPLC Method 1: room temperature, 6.823 min, 99.77%, HPLC Method 2: room temperature, 7.414 min, 97.29%.
Example 2N 3-[4-({4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)phenoxy]propanenitrileThe title compound was prepared according to a similar procedure for Example 2A, step 2C. Yield 55.7%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.90 (t, J=6.32 Hz, 2H) 3.12-3.20 (m, 4H) 3.30-3.38 (m, 4H) 4.28 (t, J=6.32 Hz, 2H) 7.00-7.08 (m, 3H) 7.72-7.80 (m, 2H) 7.85 (dd, J=7.71, 1.89 Hz, 1H) 8.43 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C19H19F3N4O3S+H+, 441.12027; found (ESI-FTMS, [M+H]1+), 441.1197. HPLC Method 1: room temperature, 5.657 min, 99.00%, HPLC Method 2: room temperature, 6.226 min, 99.30%.
Example 2O 1-[(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)sulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe title compound was prepared according to a similar procedure for Example 2A, step 2C. Yield 81.7%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.37 (s, 6H) 1.86 (t, J=6.69 Hz, 2H) 2.84 (t, J=6.69 Hz, 2H) 3.13-3.19 (m, 4H) 3.32-3.39 (m, 4H) 6.88 (d, J=8.59 Hz, 1H) 7.02 (dd, J=7.83, 4.80 Hz, 1H) 7.47-7.54 (m, 2H) 7.85 (dd, J=7.71, 1.89 Hz, 1H) 8.43 (dd, J=4.42, 1.64 Hz, 1H). HRMS: calcd for C21H24F3N3O3S+H+, 456.15632; found (ESI-FTMS, [M+H]1+), 456.156. HPLC Method 1: room temperature, 6.762 min, 95.21%, HPLC Method 2: room temperature, 7.372 min, 95.92%.
Example 2P N,N-dimethyl-N′-[4-({4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)phenyl]ureaThe title compound was prepared according to a similar procedure for Example 2A, step 2C. Yield 63.1%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.06 (s, 6H) 3.11-3.19 (m, 4H) 3.30-3.38 (m, 4H) 6.55 (s, 1H) 6.98-7.05 (m, 1H) 7.54-7.62 (m, 2H) 7.67-7.73 (m, 2H) 7.84 (dd, J=7.83, 1.77 Hz, 1H) 8.39-8.44 (m, 1H). HRMS: calcd for C19H22F3N5O3S+H+, 458.14682; found (ESI-FTMS, [M+H]1+), 458.1464. HPLC Method 1: room temperature, 5.264 min, 99.31%, HPLC Method 2: room temperature, 6.137 min, 99.80%.
Example 2Q N-methyl-N′-[4-({4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)phenyl]ureaThe title compound was prepared according to a similar procedure for Example 2A, step 2C. Yield 85%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.90 (d, J=4.80 Hz, 3H) 3.12-3.19 (m, 4H) 3.30-3.38 (m, 4H) 4.64 (s, 1H), 6.51 (s, 1H) 6.98-7.06 (m, 1H) 7.51-7.57 (m, 2H) 7.70 (d, J=8.59 Hz, 2H) 7.81-7.87 (m, 1H) 8.40-8.45 (m, 1H). HRMS: calcd for C18H20F3N5O3S+H+, 444.13117; found (ESI-FTMS, [M+H]1+), 444.1306. HPLC Method 1: room temperature, 5.042 min, 99.00%, HPLC Method 2: room temperature, 6.003 min, 99.53%.
Example 2R N-[4-({4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)phenyl]piperidine-1-carboxamideThe title compound was prepared according to a similar procedure for Example 2A, step 2C. Yield 88.8%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.63-1.71 (m, 6H) 3.11-3.18 (m, 4H) 3.30-3.37 (m, 4H) 3.43-3.53 (m, 4H) 6.58 (s, 1H) 7.02 (dd, J=7.83, 4.80 Hz, 1H) 7.52-7.59 (m, 2H) 7.67-7.73 (m, 2H) 7.84 (dd, J=7.96, 1.64 Hz, 1H) 8.42 (dd, J=4.93, 1.64 Hz, 1H). HRMS: calcd for C22H26F3N5O3S+H+, 498.17812; found (ESI-FTMS, [M+H]1+), 498.1786. HPLC Method 1: room temperature, 5.883 min, 100%, HPLC Method 2: room temperature, 6.748 min, 100%.
Example 3Step 3A: To a stirred solution of naphthalene-2-sulfonyl chloride (350 mg, 1.54 mmol) and 1-(2,4-difluorophenyl)piperazine (305.0 mg, 1.54 mmol) in anhydrous dichloromethane (5 mL) was added diisopropylethylamine (0.670 mL, 3.85 mmol). The mixture was stirred for 30 minutes. Reaction was complete as determined by TLC. The reaction mixture was purified via flash column chromatography to afford 1-(2,4-difluorophenyl)-4-(2-naphthylsulfonyl)piperazine in 55% yield (327 mg) as white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 3.00-3.07 (m, 4H) 3.07-3.15 (m, 4H) 6.94-7.02 (m, 1H) 7.03-7.12 (m, 1H) 7.12-7.21 (m, 1H) 7.67-7.84 (m, 3H) 8.11 (d, J=8.08 Hz, 1 H) 8.21 (d, J=8.59 Hz, 1H) 8.25 (d, J=8.08 Hz, 1H) 8.49 (d, J=1.77 Hz, 1H). HRMS: calcd for C20H18F2N2O2S+H+, 389.11298; found (ESI-FTMS, [M+H]1+), 389.113. HPLC Method 1: room temperature, 6.658 min, 96.32%, HPLC Method 2: room temperature, 7.312 min, 99.29%.
Example 3B 1-(2,4-dimethylphenyl)-4-(2-naphthylsulfonyl)piperazineStep 3A: Sulfonylation of 1-(2,4-dimethylphenyl)piperazine (293 mg, 1.54 mmol) with naphthalene-2-sulfonyl chloride (350 mg, 1.54 mmol) was carried out according to a similar procedure described for example 3A using anhydrous dichloromethane (5 mL) as solvent and diisopropylethylamine (0.670 mL, 3.85 mmol) as base. 1-(2,4-dimethylphenyl)-4-(2-naphthylsulfonyl)piperazine was obtained in 92% yield (539 mg) as white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 2.03 (s, 3H) 2.18 (s, 3H) 2.86 (t, J=4.80 Hz, 4H) 3.11 (s, 4H) 6.92 (s, 3H) 7.67-7.85 (m, 3H) 8.11 (d, J=8.08 Hz, 1H) 8.22 (d, J=8.84 Hz, 1H) 8.25 (d, J=8.08 Hz, 1H) 8.49 (d, J=1.52 Hz, 1H); HRMS: calcd for C22H24N2O2S+H+, 381.16312; found (ESI-FTMS, [M+H]1+), 381.163. HPLC Method 1: room temperature, 7.258 min, 99.49%, HPLC Method 2: room temperature, 7.817 min, 99.52%.
Example 3C 1-(2-ethylphenyl)-4-(2-naphthylsulfonyl)piperazineStep 3A: Sulfonylation of 1-(2-ethylphenyl)piperazine (293 mg, 1.54 mmol) with naphthalene-2-sulfonyl chloride (350 mg, 1.54 mmol) was carried out according to a similar procedure described for example 3A using anhydrous dichloromethane (5 mL) as solvent and diisopropylethylamine (0.670 mL, 3.85 mmol) as base. 1-(2-ethylphenyl)-4-(2-naphthylsulfonyl)piperazine was obtained in 99% yield (579 mg) as white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 1.02 (t, J=7.45 Hz, 3H) 2.46 (d, J=7.33 Hz, 2H) 2.89 (t, J=4.67 Hz, 4H) 3.12 (s, 4H) 6.90-7.20 (m, 4H) 7.61-7.80 (m, 2H) 7.82 (d, J=8.59 Hz, 1H) 8.12 (d, J=7.83 Hz, 1H) 8.17-8.31 (m, 2H) 8.50 (d, J=1.77 Hz, 1H); HRMS: calcd for C22H24N2O2S+H+, 381.16312; found (ESI-FTMS, [M+H]1+), 381.1631. HPLC Method 1: room temperature, 7.204 min, 99.62%, HPLC Method 2: room temperature, 7.759 min, 99.62%.
Example 3D 1-[4-fluoro-2-(methylsulfonyl)phenyl]-4-(2-naphthylsulfonyl)piperazineStep 3A: Sulfonylation of 1-(4-fluoro-2-(methylsulfonyl)phenyl)piperazine (316.6 mg, 1.23 mmol) with naphthalene-2-sulfonyl chloride (278 mg, 1.54 mmol) was carried out according to a similar procedure described for example 3A using anhydrous dichloromethane (5 mL) as solvent and diisopropylethylamine (0.256 mL, 1.47 mmol) as base. 1-[4-fluoro-2-(methylsulfonyl)phenyl]-4-(2-naphthylsulfonyl)piperazine was obtained in 61.8% yield (340 mg) as white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 3.05 (s, 4H) 3.14 (s, 4H) 3.33 (s, 3H) 7.51-7.67 (m, 2H) 7.67-7.88 (m, 4H) 8.12 (d, J=8.08 Hz, 1H) 8.17-8.31 (m, 2H) 8.51 (d, J=1.52 Hz, 1H). HRMS: calcd for C21H21FN2O4S2+H+, 449.09995; found (ESI-FTMS, [M+H]1+), 449.1003. HPLC Method 1: room temperature, 5.864 min, 97.14%, HPLC Method 2: room temperature, 6.426 min, 97.56%.
Example 3E 1-(2-naphthylsulfonyl)-4-[2-(trifluoromethyl)phenyl]piperazinePreparation of 1-(2-naphthylsulfonyl)-4-[2-(trifluoromethyl)phenyl]piperazine was carried out according to a similar procedure described for example 3A. Yield 85%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.84-3.09 (m, J=9.60 Hz, 4H) 3.12-3.46 (m, 4H) 7.15-7.30 (m, 1H) 7.35 (d, J=8.08 Hz, 1H) 7.44-7.58 (m, 1H) 7.58 (d, J=7.83 Hz, 1H) 7.62-7.74 (m, 2H) 7.79 (d, J=10.36 Hz, 1H) 7.96 (d, J=7.83 Hz, 1H) 7.99-8.17 (m, 2H) 8.38 (s, 1H). HRMS: calcd for C21H19F3N2O2S+H+, 421.11921; found (ESI-FTMS, [M+H]1+), 421.1192; HPLC Method 1, room temperature, 6.78 min, 99.04%; HPLC Method 2, room temperature, 7.43 min, 99.17%.
Example 3F 1-(2-bromophenyl)-4-(2-naphthylsulfonyl)piperazinePreparation of 1-(2-bromophenyl)-4-(2-naphthylsulfonyl)piperazine was carried out according to a similar procedure described for example 3A. Yield 85%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.95-3.19 (m, 4H) 3.19-3.44 (m, 4H) 6.83-6.99 (m, 1H) 6.98-7.12 (m, 1H) 7.19-7.35 (m, 1H) 7.51 (d, J=9.60 Hz, 1H) 7.58-7.74 (m, 2H) 7.80 (d, J=10.61 Hz, 1H) 7.95 (d, J=8.08 Hz, 1H) 8.02 (d, J=8.59 Hz, 2H) 8.38 (s, 1H). HRMS: calcd for C20H19BrN2O2S+H+, 431.04233; found (ESI-FTMS, [M+H]1+), 431.0424. HPLC Method 1, room temperature, 6.85 min, 100%; HPLC Method 2, room temperature, 7.49 min, 99.60%.
Example 4 1-(3-chloropyridin-2-yl)-4-[(3,4-dichlorophenyl)sulfonyl]-trans-2,5-dimethylpiperazineStep 4A: To a stirred solution of 3,4-dichlorobenzene-1-sulfonyl chloride (840 mg, 3.42 mmol) and 2,5-dimethylpiperazine (1.171 g, 10.26 mmol) in anhydrous dichloromethane (5 mL) was added diisopropylethylamine (1.2 mL, 6.84 mmol). The mixture was stirred overnight at room temperature. Reaction was complete as determined by TLC. The reaction mixture was diluted with dichloromethane, washed with water and dried over MgSO4. After solvent evaporation crude product was treated with ethyl acetate/hexanes. Solid impurity was filtered of and the filtrate was concentrated to afford 1-(3,4-dichlorophenylsulfonyl)-2,5-dimethylpiperazine in quantitative yield. It was carried to the next step without further purification.
Step 4B: 1-(3,4-dichlorophenylsulfonyl)-2,5-dimethylpiperazine (1.04 g, 3.22 mmol), 2,3-dichloropyridine (476.5 mg. 3.22 mmol), diisopropylethylamine (1.4 mL, 8.05 mmol) and DMF (1.2 mL) were charged to a microwave vial and the mixture was irradiated at 200° C. for 1 hour. Reaction was complete as determined by TLC. The reaction mixture was diluted with ethyl acetate and washed with water. After solvent evaporation crude product was purified with flash column chromatography to yield 1-(3-chloropyridin-2-yl)-4-[(3,4-dichlorophenyl)sulfonyl]-2,5-dimethylpiperazine in 2% yield (27.1 mg) as yellow solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.08 (d, J=6.57 Hz, 3H) 1.12 (d, J=6.57 Hz, 3H) 3.26 (d, J=13.39 Hz, 1H) 3.44-3.52 (m, 1H) 3.54-3.66 (m, 2H) 4.14-4.37 (m, 2H) 6.84 (dd, J=7.58, 4.80 Hz, 1H) 7.50-7.70 (m, 3H) 7.93 (d, J=2.02 Hz, 1H) 8.15 (dd, J=4.80, 1.77 Hz, 1H). HRMS: calcd for C17H18Cl3N3O2S+H+, 434.02580; found (ESI-FTMS, [M+H]1+), 434.028. HPLC Method 1: room temperature, 7.140 min, 99.62%, HPLC Method 2: room temperature, 7.684 min, 99.56%.
Example 5 Benzyl (3S,5S)-4-[(4-tert-butylphenyl)sulfonyl]-3,5-dimethylpiperazine-1-carboxylateStep 5A: (S)-tert-butyl 1-oxopropan-2-ylcarbamate (Boc-L-Alaninal) (3.0 g, 17.32 mmol) and (R)-1-aminopropan-2-ol (1.95 g, 25.98 mmol) in anhydrous methanol (120 mL) was hydrogenated at 1 atmosphere overnight using palladium, 10% wt. on activated carbon (900 mg) as catalyst. Reaction was complete as determined by TLC using CAN spray to visualize. The reaction mixture was then filtered through a celite bed. After solvent evaporation crude product was diluted with ethyl acetate, washed with saturated NAHCO3 (aq.) and dried over MgSO4. Solvent evaporation afforded tert-butyl (S)-1-[(R)-2-hydroxypropylamino]propan-2-ylcarbamate] in 98.5% yield (3.95 g). It was carried to the next step without further purification.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.14 (d, J=6.57 Hz, 3H) 1.15 (d, J=6.32 Hz, 3H) 1.45 (s, 9H) 2.39 (dd, J=12.13, 9.35 Hz, 1H) 2.53-2.78 (m, 3H) 3.14 (s, 1H) 3.70-3.81 (m, 2H) 4.52 (s, 1H)
Step 5B: To a stirred solution of tert-butyl (S)-1-[(R)-2-hydroxypropylamino]propan-2-ylcarbamate (3.0 g, 12.93 mmol) and diisopropylethylamine (3.38 mL, 19.4 mmol) in anhydrous dichloromethane (100 mL) at 0° C. was added benzyl chloroformate (2.65 g, 15.5 mmol). After stirring at 0° C. for 1 hour, the cooling bath was removed and the reaction mixture was allowed to stir at room temperature for an additional 45 minutes. Reaction was complete as determined by TLC. The reaction mixture was added with 1N HCl and extracted with dichloromethane. Organic layer was washed with water then brine and it was dried over MgSO4. Solvent evaporation afforded benzyl {(2S)-2-[(tert-butoxycarbonyl)amino]propyl}[(2R)-2-hydroxypropyl]carbamate in 84.5% yield (3.95 g) as colorless gummy oil.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.90-1.04 (m, 6H) 1.35 (s, 9H) 1.99 (s, 1H) 3.10-3.22 (m, 2H) 3.28 (d, J=5.56 Hz, 1H) 3.80 (d, J=5.56 Hz, 2H) 4.69 (dd, J=17.18, 4.80 Hz, 1H) 5.00-5.10 (m, 2H) 6.59-6.71 (m, 1H) 7.29-7.42 (m, 5H). HRMS: calcd for C19H30N2O5+H+, 367.22275; found (ESI-FTMS, [M+H]1+), 367.2235.
Step 5C: To a stirred solution of benzyl {(2S)-2-[(tert-butoxycarbonyl)amino]propyl}[(2R)-2-hydroxypropyl]carbamate (1.95 g, 5.32 mmol) and diisopropylethylamine (1.85 mL, 10.64 mmol) in anhydrous dichloromethane (110 mL) was added dimethylaminopyridine (135 mg) and methane sulfonyl chloride (0.535 mL, 6.92 mmol). The mixture was stirred at room temperature for 1 hour. Reaction was complete as determined by TLC. The reaction mixture was concentrated and purified using flash column chromatography. (1R)-2-([(benzyloxy)carbonyl]{(2S)-2-[(tert-butoxycarbonyl)amino]propyl}amino)-1-methylethyl methanesulfonate was obtained in 97.0% yield (2.29 g) as light yellow oil.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.91-1.02 (m, 3H) 1.21-1.32 (m, 3H) 1.35 (s, 9H) 3.05 (d, 3H) 3.22 (d, J=8.59 Hz, 2H) 3.34-3.54 (m, 2H) 3.66-3.88 (m, 1H) 4.76-4.94 (m, 1H) 4.98-5.16 (m, 2H) 6.60-6.76 (m, 1H) 7.23-7.44 (m, 5H).
Step 5D: To a stirred solution of (1R)-2-([(benzyloxy)carbonyl]{(2S)-2-[(tert-butoxycarbonyl)amino]propyl}amino)-1-methylethyl methanesulfonate (2.29 g, 5.15 mmol) in anhydrous dichloromethane (38 mL) was added TFA (38 mL) dropwise at 0° C. The reaction mixture was stirred at room temperature for 1 hour. Reaction was complete as determined by TLC. Most of TFA was azeotropped with dichloroethane. The residue was then diluted with dichloromethane and washed with 2N Na2CO3 (aq.), organic layer was dried over MgSO4. Solvent evaporation afforded (R)-1-(((S)-2-aminopropyl)(benzyloxycarbonyl)amino)propan-2-yl methanesulfonate in quantitative yield (1.8 g) as oil. It was carried to the next step immediately.
Step 5E: (R)-1-(((S)-2-aminopropyl)(benzyloxycarbonyl)amino)propan-2-yl methanesulfonate (1.8 g, 5.15 mmol) dissolved in anhydrous MeOH (120 mL) was heated up to 60° C. for 4 hours. Reaction was complete as determined by TLC. After overnight stirring at room temperature solvent was evaporated to afford (3R,5R)-benzyl 3,5-dimethylpiperazine-1-carboxylate [L31285-103-1] in quantitative yield (1.28 g) as gummy off white solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.31-1.44 (m, 6H) 3.38-3.64 (m, 4H) 3.73-3.96 (m, 2H) 7.29-7.43 (m, 5H) 8.96 (s, 1H).
Step 5F: To a stirred solution of (3R,5R)-benzyl 3,5-dimethylpiperazine-1-carboxylate (500 mg, 2.02 mmol) in anhydrous dichloromethane (8 mL) was added diisopropylethylamine (1.4 mL, (8.08 mmol) followed by 4-tert-butylbenzene-1-sulfonyl chloride (940 mg, 4.04 mmol). The reaction mixture was stirred for 68 hours. Reaction was complete as determined by TLC. After solvent evaporation the crude product was purified by flash column chromatography to afford benzyl (3S,5S)-4-[(4-tert-butylphenyl)sulfonyl]-3,5-dimethylpiperazine-1-carboxylate in 42% yield (377 mg) as light yellow oil.
1H NMR (400 MHz, DMSO-D6) δ ppm 1.12 (d, J=6.57 Hz, 6H) 1.30 (s, 9H) 3.25 (s, 1H) 3.35 (s, 1H) 3.45-3.59 (m, 2H) 4.00 (s, 2H) 5.00-5.15 (m, 2H) 7.21-7.42 (m, 5H) 7.59 (d, J=8.84 Hz, 2H) 7.75 (d, J=8.59 Hz, 2H). HRMS: calcd for C24H32N2O4S+H+, 445.21555; found (ESI-FTMS, [M+H]1+), 445.2169. HPLC Method 1: room temperature, 6.990 min, 98.43%, HPLC Method 2: room temperature, 7.534 min, 99.66%.
Example 6 (2S,6S)-1-[(4-tert-butylphenyl)sulfonyl]-4-(3-chloropyridin-2-yl)-2,6-dimethylpiperazineStep 6A: A solution of benzyl (3S,5S)-4-[(4-tert-butylphenyl)sulfonyl]-3,5-dimethylpiperazine-1-carboxylate (340 mg, 0.77 mmol) in anhydrous MeOH was hydrogenated at 1 atmosphere for 2 days using palladium, 10% wt. on activated carbon (144 mg) as catalyst. Reaction was complete as determined by TLC. The reaction mixture was then filtered through a celite bed. After solvent evaporation crude product was purified via flash column chromatography to afford (2S,6S)-1-[(4-tert-butylphenyl)sulfonyl]-2,6-dimethylpiperazine in 53.9% yield (128 mg) as pale yellow oil.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.23 (s, 3H) 1.24 (s, 3H) 1.33 (s, 9H) 2.63-2.67 (m, 1H) 2.68 (d, J=6.32 Hz, 1H) 2.94 (d, J=3.28 Hz, 1H) 2.97 (d, J=3.54 Hz, 1H) 3.92-4.00 (m, 2H) 7.47 (d, J=8.84 Hz, 2H) 7.75 (d, J=8.84 Hz, 2H). HRMS: calcd for C16H26N2O2S+H+, 311.17877; found (ESI-FTMS, [M+H]1+), 311.179. HPLC Method 1: room temperature, 5.557 min, 99.41%, HPLC Method 2: room temperature, 4.760 min, 100.0%.
Step 6B: To a solution of (2S,6S)-1-[(4-tert-butylphenyl)sulfonyl]-2,6-dimethylpiperazine (120 mg, 0.39 mmol) and 2,3-Dichloropyridine (115 mg, 0.78 mmol) in anhydrous 1,4-Dioxane (0.2 mL) was added diisopropylethylamine (0.201 mL, 1.16 mmol). The mixture was subject to microwave irradiation at 200° C. for 1 hour. Reaction was half complete as determined by TLC. The reaction mixture was diluted with ethyl acetate and washed with saturated NH4Cl (aq.), 10% HCl (aq.), water and brine. Organic layer was dried over MgSO4. Solvent evaporation followed by flash column chromatography afforded (2S,6S)-1-[(4-tert-butylphenyl)sulfonyl]-4-(3-chloropyridin-2-yl)-2,6-dimethylpiperazine in 27.7% yield (45 mg) as off white solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.33 (s, 9H) 1.36 (s, 3H) 1.38 (s, 3H) 3.22 (d, J=6.32 Hz, 1H) 3.25 (d, J=6.32 Hz, 1H) 3.41 (d, J=3.03 Hz, 1H) 3.44 (d, J=3.28 Hz, 1H) 4.19-4.29 (m, 2H) 6.86 (dd, J=7.71, 4.67 Hz, 1H) 7.47 (d, J=8.84 Hz, 2H) 7.59 (dd, J=7.83, 1.52 Hz, 1H) 7.78 (d, J=8.84 Hz, 2H) 8.07-8.22 (m, 1H). HRMS: calcd for C21H28ClN3O2S+H+, 422.16635; found (ESI-FTMS, [M+H]1+), 422.1665. HPLC Method 1: room temperature, 7.378 min, 96.04%, HPLC Method 2: room temperature, 7.756 min, 95.34%.
Example 7Step 7A: tert-butyl 4-[(methylsulfonyl)oxy]piperidine-1-carboxylate. The mesylate was prepared from tert-butyl-4-hydroxy-1-piperidinecarboxylate using the procedure from WO 0053362 Cheng S., et al. To a 0° C. solution of tert-butyl-4-hydroxy-1-piperidinecarboxylate (9.80 g, 49 mmol), Et3N (9.92 g, 13.7 mL, 98 mmol), and CH2Cl2 (90 mL) was added MsCl (6.17 g, 4.20 mL, 53 mmol). After 15 min, the ice bath was removed and the mixture was stirred overnight at room temperature, poured into 1M HCl (90 mL) and extracted with CH2Cl2 (2×60 mL). The organic phase was washed with H2O and brine, dried (MgSO4), and concentrated to afford the mesylate (12.9 g), an off-white solid, in 95% yield.
1H NMR (400 MHz, CDCl3) δ 1.71-1.91 (m, 2H), 1.90-2.15 (m, 2H), 3.04 (s, 3H), 3.18-3.50 (m, 2H), 3.49-3.96 (m, 2H), 4.68-5.04 (m, 1H).
Step 7B: tert-butyl 4-[(3,4-dichlorophenyl)thio]piperidine-1-carboxylate. A suspension of the mesylate from Step 2 (3.8 g, 7.1 mmol), 3,4-dichlorothiophenol (2.9 g, 2.1 m-L), and K2CO3 (3.0 g, 11.4 mmol) in CH3CN (30 mL) was heated in a 90° C. bath for 16 h. The resulting mixture was diluted with H2O (100 mL) and EtOAc (100 mL). The aqueous phase was extracted with EtOAc (50 mL). The combined organic phases were washed with H2O and brine, dried (MgSO4) and concentrated to afford a yellow oil which was purified by SiO2 chromatography (elution with 5 to 10% EtOAc-hex) to afford the thioether (3.97 g), a pale yellow oil, in 80% yield.
1H NMR (400 MHz, CDCl3) δ 1.35-1.59 (m, 11H), 1.92 (d, J=13.1 Hz, 2H), 2.93 (t, J=11.7 Hz, 2H), 3.13-3.32 (m, 1H), 3.96 (s, 2H), 7.23 (d, J=8.3 Hz, 1H), 7.37 (d, J=8.3 Hz, 1 H), 7.49 (s, 1H).
Step 7C: tert-butyl 4-[(3,4-dichlorophenyl)sulfonyl]piperidine-1-carboxylate. To a 0° C. solution to the thioether from Step 2 (2.65 g, 7.3 mmol) in CH2Cl2 (150 mL) was added MCPBA (77%, 3.60 g, 16 mmol). After 2 h, sat. NaHCO3 solution (150 mL) was added and the resulting suspension was stirred at room temperature for 15 min. The organic phase was separated and washed with 1N NaOH (50 mL), H2O (50 mL), and brine (50 mL), dried (MgSO4), and concentrated partially. The crude product was adhered to SiO2 and purified by SiO2 chromatography (elution with 20 to 30% EtOAc-hex) to afford the sulfone (2.79 g), a white solid, in 97% yield.
1H NMR (400 MHz, CDCl3) δ 1.44 (s, 9H), 1.54-1.71 (m, 2H), 1.98 (d, J=11.9 Hz, 2H), 2.67 (br s, 2H), 2.95-3.13 (m, 1H), 4.26 (br s, 2H), 7.67-7.70 (m, 2H), 7.96 (d, J=1.3 Hz, 1H).
Step 7D: 4-[(3,4-dichlorophenyl)sulfonyl]piperidine. A mixture of the sulfone from Step 7C (3.09 g, 7.8 mmol), MeOH (21 mL), and 5N HCl (4.5 mL) was heated to reflux for 1.5 h. The mixture was cooled to room temperature and sat. Na2CO3 solution (80 mL) was added. The mixture was extracted with CH2Cl2 (2×100 mL). The organic phase was washed with H2O and brine, dried (MgSO4) and concentrated to afford the amine (1.82 g), a white foam, in 79% yield.
1H NMR (400 MHz, CDCl3) δ 1.39-1.70 (m, 3H), 2.00 (d, J=12.4 Hz, 2H), 2.57 (t, J=12.4 Hz, 2H), 3.04 (t, J=12.3 Hz, 1H), 3.20 (d, J=12.6 Hz, 2H), 7.68 (q, J=8.3 Hz, 2H), 7.96 (s, 1H).
Step 7E: 2-{4-[(3,4-dichlorophenyl)sulfonyl]piperidin-1-yl}-3-(trifluoromethyl)pyridine. A mixture of the amine from Step 7D (200 mg, 0.68 mmol), 2-chloro-3-(trifluoromethyl)pyridine (200 mg, 1.36 mmol), DIEA (0.36 mL, 2.04 mmol), and 1,4-dioxane (0.10 m-L) was heated in the Emrys Creator microwave to 200° C. for 1 h. The mixture was diluted with sat. NH4Cl (20 mL) and EtOAc (50 mL). The organic phase was washed with 10% HCl (25 mL), H2O (3×25 mL), and brine (25 mL), dried (MgSO4), and concentrated. The resulting yellow oil was purified by SiO2 chromatography (elution with 10 to 30% EtOAc-hexanes), and lyophilized to afford the title compound (0.19 g), a white solid, 64%.
1H NMR (400 MHz, CDCl3) δ 1.80-2.01 (m, 2H), 2.02-2.16 (m, 2H), 2.75-2.95 (m, 2H), 3.02-3.24 (m, 1H), 3.69 (dd, J=10.5, 2.7 Hz, 2H), 6.91-7.13 (m, 1H), 7.69 (d, J=8.3 Hz, 1H), 7.74 (dd, J=8.3, 2.2 Hz, 1H), 7.87 (dd, J=7.8, 1.5 Hz, 1H), 8.00 (d, J=2.0 Hz, 1H), 8.42 (dd, J=4.8, 1.3 Hz, 1H). HRMS: calcd for C17H15Cl2F3N2O2S+H+, 439.02561; found (ESI-FTMS, [M+H]1+), 439.0261; HPLC Method 1: room temperature, 6.56 min, 97.0%. HPLC Method 2: room temperature, 7.24 min, 96.9%.
Example 7B 3-chloro-2-{4-[(3,4-dichlorophenyl)sulfonyl]piperidin-1-yl}pyridineStep 7E: Using the procedure from Example 7A, Step 7E, 4-[(3,4-dichlorophenyl)sulfonyl]piperidine (200 mg, 0.68 mmol) was reacted with 2,3-dichloropyridine (201 mg, 1.36 mmol) to afford the title compound (90 mg), a white solid, in 33% yield.
1H NMR (400 MHz, CDCl3) δ 1.83-2.02 (m, 2H), 2.04-2.21 (m, 2H), 2.70-2.89 (m, 2H), 3.02-3.28 (m, 1H), 3.81-4.05 (m, 2H), 6.86 (dd, J=7.8, 4.8 Hz, 1H), 7.59 (dd, J=7.7, 1.6 Hz, 1H), 7.68 (d, J=8.3 Hz, 1H), 7.74 (dd, J=8.4, 2.1 Hz, 1H), 8.00 (d, J=2.0 Hz, 1H), 8.16 (dd, J=4.8, 1.8 Hz, 1H). HRMS: calcd for C16H15Cl3N2O2S+H+, 404.99925; found (ESI-FTMS, [M+H]1+), 405.0012; HPLC Method 1: room temperature, 6.44 min, 97.4%. HPLC Method 2: room temperature, 7.24 min, 97.9%.
Example 7C 2-{4-[(3,4-dichlorophenyl)sulfonyl]piperidin-1-yl}-5-(trifluoromethyl)pyridineStep 7E: Using the procedure from Example 7A, Step 7E, 4-[(3,4-dichlorophenyl)sulfonyl]piperidine (200 mg, 0.68 mmol) was reacted with 2-chloro-5-(trifluoromethyl)pyridine (172 mg, 0.96 mmol) to afford the title compound (110 mg), a white solid, in 37% yield.
1H NMR (400 MHz, CDCl3) δ 1.66-1.88 (m, 2H), 2.10 (d, J=12.4 Hz, 2H), 2.89 (t, J=12.8 Hz, 2H), 3.07-3.35 (m, 1H), 4.57 (d, J=13.4 Hz, 2H), 6.65 (d, J=8.8 Hz, 1H), 7.57-7.82 (m, 3H), 7.97 (s, 1H), 8.38 (s, 1H). HRMS: calcd for C17H15Cl2F3N2O2S+H+, 439.02561; found (ESI-FTMS, [M+H]1+), 439.0273. HPLC Method 1: room temperature, 6.70 min, 98.8%. HPLC Method 2: room temperature, 7.32 min, 99.8%.
Example 7D 2-{4-[(3,4-dichlorophenyl)sulfonyl]piperidin-1-yl}-3-nitropyridineStep 7E: Using the procedure from Example 7A, Step 7E, 4-[(3,4-dichlorophenyl)sulfonyl]piperidine (150 mg, 0.51 mmol) was reacted with 2-chloro-3-nitropyridine (97 mg, 0.61 mmol) to afford the title compound (212 mg), a yellow solid, in 74% yield.
1H NMR (400 MHz, CDCl3) δ 1.80-1.95 (m, 2H), 2.03-2.13 (m, 2H), 2.95-3.08 (m, 2H), 3.12-3.26 (m, 1H), 3.90-4.01 (m, 2H), 6.81 (dd, J=8.1, 4.5 Hz, 1H), 7.68 (d, J=8.3 Hz, 1H), 7.72 (dd, J=8.4, 1.9 Hz, 1H), 7.98 (d, J=2.0 Hz, 1H), 8.15 (dd, J=8.0, 1.6 Hz, 1H), 8.34 (dd, J=4.5, 1.8 Hz, 1H). HRMS: calcd for C16H15Cl2N3O4S+H+, 416.02331; found (ESI-FTMS, [M+H]1+), 416.0227.
Example 7E 1-{4-[(3,4-dichlorophenyl)sulfonyl]piperidin-1-yl}isoquinolineStep 7E: Using the procedure from Example 7A, Step 7E, 4-[(3,4-dichlorophenyl)sulfonyl]piperidine (Example 1, Step 4, 150 mg, 0.51 mmol) was reacted with 1-chloroisoquinoline (100 mg, 0.61 mmol) to afford the title compound (215 mg), a white solid, in 51% yield.
1H NMR (400 MHz, CDCl3) δ 1.97-2.29 (m, 4H), 2.80-3.05 (m, 2H), 3.08-3.28 (m, 1H), 3.93 (d, J=13.1 Hz, 2H), 7.19-7.36 (m, 2H), 7.53 (t, J=7.7 Hz, 1H), 7.63 (t, J=7.6 Hz, 1H), 7.70 (d, J=8.3 Hz, 1H), 7.77 (t, J=8.1 Hz, 2H), 7.95-8.07 (m, 2H), 8.12 (d, J=5.6 Hz, 1H). HRMS: calcd for C20H18Cl2N2O2S+H+, 421.05388; found (ESI-FTMS, [M+H]1+), 421.0558. HPLC Method 1: room temperature, 4.83 min, 98.8%. HPLC Method 2: room temperature, 6.63 min, 99.8%.
Example 7F 2-{4-[(3,4-dichlorophenyl)sulfonyl]piperidin-1-yl}nicotinonitrileStep 7E: Using the procedure from Example 7A, Step 7E, 4-[(3,4-dichlorophenyl)sulfonyl]piperidine (150 mg, 0.51 mmol) was reacted with 2-chloro-3-cyanopyridine (85 mg, 0.61 mmol) to afford the title compound (202 mg), a white solid, in 77% yield.
1H NMR (400 MHz, CDCl3) δ 1.78-1.96 (m, 2H), 2.11 (d, J=11.9 Hz, 2H), 2.99 (t, J=12.6 Hz, 2H), 3.10-3.27 (m, 1H), 4.50 (d, J=13.6 Hz, 2H), 6.80 (dd, J=7.6, 4.8 Hz, 1H), 7.61-7.75 (m, 2H), 7.78 (d, J=7.6 Hz, 1H), 7.99 (s, 1H), 8.34 (d, J=4.8 Hz, 1H). HRMS: calcd for C17H15Cl2N3O2S+H+, 396.03348; found (ESI-FTMS, [M+H]1+), 396.0337. HPLC Method 1: room temperature, 6.01 min, 99.1%. HPLC Method 2: room temperature, 6.74 min, 99.4%.
Example 7G 3,5-dichloro-4-{4-[(3,4-dichlorophenyl)sulfonyl]piperidin-1-yl}pyridineStep 7E: Using the procedure from Example 7A, Step 7E, 4-[(3,4-dichlorophenyl)sulfonyl]piperidine (150 mg, 0.51 mmol) was reacted with 3,4,5-trichloropyridine (224 mg, 1.22 mmol) to afford the title compound (66 mg), a white solid, in 55% yield.
1H NMR (400 MHz, CDCl3) δ 1.85-2.12 (m, 4H), 2.98-3.17 (m, 1H), 3.19-3.33 (m, 2H), 3.35-3.53 (m, 2H), 7.69 d, J=8.3 Hz, 1H), 7.74 (dd, J=8.3, 2.0 Hz, 1H), 8.00 (d, J=2.0 Hz, 1H), 8.35 (s, 2H). HRMS: calcd for C16H14Cl4N2O2S+H+, 438.96028; found (ESI-FTMS, [M+H]1+), 438.9612.
Example 7H 2-{4-[(3,4-dichlorophenyl)sulfonyl]piperidin-1-yl}quinolineStep 7E: Using the procedure from Example 7A, Step 7E, 4-[(3,4-dichlorophenyl)sulfonyl]piperidine (150 mg, 0.51 mmol) was reacted with 2-chloroquinoline (328 mg, 2.0 mmol) to afford the title compound (39 mg), a white solid, in 18% yield.
1H NMR (400 MHz, CDCl3) δ 1.65-1.92 (m, 2H), 1.95-2.32 (m, 2H), 2.80-3.01 (m, 2H), 2.99-3.35 (m, 1H), 4.63-4.77 (m, 2H), 6.96 (d, J=9.1 Hz, 1H), 7.19-7.28 (m, 1H), 7.50-7.58 (m, 1H), 7.60 (dd, J=8.0, 1.4 Hz, 1H), 7.63-7.74 (m, 3H), 7.90 (d, J=8.8 Hz, 1H), 7.98 (d, J=2.0 Hz, 1H). HRMS: calcd for C20H18Cl2N2O2S+H+, 421.05388; found (ESI-FTMS, [M+H]1+), 421.0543. HPLC Method 1: room temperature, 4.52 min, 99.1%. HPLC Method 2: room temperature, 5.38 min, 99.4%.
Example 7I 2-[4-(2-naphthylsulfonyl)piperidin-1-yl]-3-(trifluoromethyl)pyridineStep 7E: The corresponding naphthyl amine from Step 7D (175 mg, 0.63 mmol) was reacted with 2-chloro-3-(trifluoromethyl)pyridine (231 mg, 1.3 mmol) as in Example 7A, Step 7E to afford the title compound (196 mg), a white powder, in 73% yield.
1H NMR (400 MHz, CDCl3) δ 1.87-2.19 (m, 4H), 2.87 (t, J=12.3 Hz, 2H), 3.16 (t, J=11.9 Hz, 1H), 3.68 (d, J=12.4 Hz, 2H), 6.92-7.07 (m, 1H), 7.57-7.74 (m, 2H), 7.87 (dd, J=16.3, 8.2 Hz, 2H), 7.96 (d, J=7.8 Hz, 1H), 8.03 (d, J=8.6 Hz, 2H), 8.40 (d, J=4.5 Hz, 1H), 8.50 (s, 1H). HRMS: calcd for C21H19F3N2O2S+H+, 421.11921; found (ESI-FTMS, [M+H]1+), 421.1208. HPLC Method 1: room temperature, 6.37 min, 98.4%. HPLC Method 2: room temperature, 7.07 min, 98.7%.
Example 7J 3-chloro-2-[4-(2-naphthylsulfonyl)piperidin-1-yl]pyridineStep 7E: Using the procedure from Example 7A, Step 7E, 4-(2-naphthylsulfonyl)piperidine (Example 1I, Step 3, 175 mg, 0.63 mmol) was reacted with 2,3-dichloropyridine (188 mg, 1.3 mmol) to afford the title compound (119 mg), a white solid, in 48% yield.
1H NMR (400 MHz, CDCl3) δ 1.86-2.08 (m, 2H), 2.07-2.17 (m, 2H), 2.67-2.93 (m, 2H), 2.98-3.30 (m, 1H), 3.94 (dd, J=10.9, 2.3 Hz, 2H), 6.83 (dd, J=7.6, 4.8 Hz, 1H), 7.56 (dd, J=7.8, 1.8 Hz, 1H), 7.60-7.74 (m, 2H), 7.89 (dd, J=8.6, 1.8 Hz, 1H), 7.96 (d, J=8.3 Hz, 1H), 8.00-8.09 (m, 2H), 8.14 (dd, J=4.7, 1.6 Hz, 1H), 8.50 (d, J=1.8 Hz, 1H). HRMS: calcd for C20H19ClN2O2S+H+, 387.09285; found (ESI-FTMS, [M+H]1+), 387.0942. HPLC Method 1: room temperature, 6.25 min, 100%. HPLC Method 2: room temperature, 7.01 min, 100%.
Example 7K 2-[4-(2-naphthylsulfonyl)piperidin-1-yl]-5-(trifluoromethyl)pyridineStep 7E: Using the procedure from Example 7A, Step 7E, 4-(2-naphthylsulfonyl)piperidine (130 mg, 0.51 mmol) was reacted with 2-chloro-5-(trifluoromethyl)pyridine (181 mg, 1.0 mmol) to afford the title compound (180 mg), a white solid, in 84% yield.
1H NMR (400 MHz, CDCl3) δ 1.70-1.88 (m, 2H), 2.02-2.37 (m, 2H), 2.80-2.98 (m, 2H), 3.15-3.40 (m, 1H), 4.54 (d, J=13.6 Hz, 2H), 6.62 (d, J=8.8 Hz, 1H), 7.53-7.77 (m, 3H), 7.85 (dd, J=8.6, 1.8 Hz, 1H), 7.95 (d, J=8.1 Hz, 1H), 7.98-8.08 (m, 2H), 8.29-8.39 (m, 1H), 8.46 (s, 1H). HRMS: calcd for C21H19F3N2O2S+H+, 421.11921; found (ESI-FTMS, [M+H]1+), 421.1207. HPLC Method 1: room temperature, 6.49 min, 99.6%. HPLC Method 2: room temperature, 7.11 min, 99.6%.
Example 7L 3,5-dichloro-4-[4-(2-naphthylsulfonyl)piperidin-1-yl]pyridineStep 7L: Using the procedure from Example 7A, Step 7E, 4-(2-naphthylsulfonyl)piperidine (130 mg, 0.51 mmol) was reacted with 3,4,5-trichloropyridine (182 mg, 1.0 mmol) to afford the title compound (26 mg), a white solid, in 12% yield.
1H NMR (400 MHz, CDCl3) δ 1.91-2.18 (m, 4H), 3.09-3.32 (m, 3H), 3.42 (d, J=12.9 Hz, 2H), 7.59-7.76 (m, 2H), 7.89 (dd, J=8.6, 1.8 Hz, 1H), 7.97 (d, J=8.1 Hz, 1H), 7.99-8.10 (m, 2H), 8.32 (s, 2H), 8.50 (s, 1H). HRMS: calcd for C20H18Cl2N2O2S+H+, 421.05388; found (ESI-FTMS, [M+H]1+), 421.0544. HPLC Method 1: room temperature, 6.43 min, 99.6%. HPLC Method 2: room temperature, 7.21 min, 100%.
Example 7M 2-[4-(2-naphthylsulfonyl)piperidin-1-yl]-3-nitropyridineStep 7E: Using the procedure from Example 7A, Step 7E, 4-(2-naphthylsulfonyl)piperidine (130 mg, 0.51 mmol) was reacted with 2-chloro-3-nitropyridine (158 mg, 1.0 mmol) to afford the title compound (148 mg), a yellow solid, in 73% yield.
1H NMR (400 MHz, CDCl3) δ 1.80-1.99 (m, 2H), 2.11 (dd, J=12.5, 2.1 Hz, 2H), 2.86-3.12 (m, 2H), 3.16-3.34 (m, 1H), 3.94 (d, J=13.4 Hz, 2H), 6.77 (dd, J=8.1, 4.5 Hz, 1H), 7.59-7.77 (m, 1H), 7.86 (dd, J=8.6, 1.8 Hz, 1H), 7.95 (d, J=8.1 Hz, 1H), 7.98-8.08 (m, 2H), 8.12 (dd, J=8.1, 1.8 Hz, 1H), 8.31 (dd, J=4.5, 1.8 Hz, 1H), 8.47 (s, 1H). HRMS: calcd for C20H19N3O4S+H+, 398.11690; found (ESI-FTMS, [M+H]1+), 398.1162. HPLC Method 1: room temperature, 5.94 min, 99.1%. HPLC Method 2: room temperature, 6.64 min, 99.4%.
Example 7N 2-[4-(2-naphthylsulfonyl)piperidin-1-yl]-5-nitropyridineStep 7E: Using the procedure from Example 7A, Step 7E, 4-(2-naphthylsulfonyl)piperidine (Example 1I, Step 3, 130 mg, 0.51 mmol) was reacted with 2-chloro-5-nitropyridine (158 mg, 1.0 mmol) to afford the title compound (63 mg), a yellow solid, in 31% yield.
1H NMR (400 MHz, CDCl3) δ 1.71-1.93 (m, 2H), 2.18 (d, J=10.1 Hz, 2H), 2.88-3.10 (m, 2H), 3.16-3.42 (m, 1H), 4.65 (d, J=13.9 Hz, 2H), 6.56 (d, J=9.3 Hz, 1H), 7.62-7.79 (m, 2H), 7.85 (dd, J=8.6, 1.8 Hz, 1H), 7.96 (d, J=7.8 Hz, 1H), 7.99-8.09 (m, 2H), 8.19 (dd, J=9.6, 2.8 Hz, 1H), 8.46 (d, J=1.8 Hz, 1H), 8.99 (d, J=2.3 Hz, 1H). HRMS: calcd for C20H19N3O4S+H+, 398.11690; found (ESI-FTMS, [M+H]1+), 398.1161. HPLC Method 1: room temperature, 5.94 min, 97.6%. HPLC Method 2: room temperature, 6.63 min, 98.1%.
Example 7O 1-[4-(2-naphthylsulfonyl)piperidin-1-yl]isoquinolineStep 7E: Using the procedure from Example 7A, Step 7E, 4-(2-naphthylsulfonyl)piperidine (130 mg, 0.51 mmol) was reacted with 1-chloroisoquinoline (164 mg, 1.0 mmol) to afford the title compound (151 mg), a white solid, in 31% yield.
1H NMR (400 MHz, CDCl3) δ 2.07-2.28 (m, 4H), 2.77-2.98 (m, 2H), 3.15-3.33 (m, 1H), 3.91 (d, J=13.1 Hz, 2H), 7.23-7.31 (m, 1H), 7.46-7.55 (m, 1H), 7.57-7.63 (m, 1H), 7.64-7.77 (m, 3H), 7.93 (dd, J=8.7, 1.9 Hz, 1H), 7.99 (t, J=9.0 Hz, 2H), 8.02-8.09 (m, 2H), 8.10 (d, J=5.8 Hz, 1H), 8.54 (d, J=1.5 Hz, 1H). HRMS: calcd for C24H22N2O2S+H+, 403.14747; found (ESI-FTMS, [M+H]1+), 403.1477. HPLC Method 1: room temperature, 4.80 min, 99.2%. HPLC Method 2: room temperature, 6.61 min, 99.3%.
Example 7P 2-[4-(2-naphthylsulfonyl)piperidin-1-yl]nicotinonitrileStep 7E: Using the procedure from Example 7A, Step 7E, 4-(2-naphthylsulfonyl)piperidine (Example 1I, Step 3, 130 mg, 0.51 mmol) was reacted with 2-chloro-3-cyanopyridine (139 mg, 1.0 mmol) to afford the title compound (151 mg), a white solid, in 78% yield.
1H NMR (400 MHz, CDCl3) δ 1.84-2.04 (m, 2H), 2.15 (dd, J=12.6, 1.8 Hz, 2H), 2.79-3.09 (m, 2H), 3.15-3.37 (m, 1H), 4.31-4.69 (m, 2H), 6.77 (dd, J=7.6, 4.8 Hz, 1H), 7.60-7.81 (m, 3H), 7.87 (dd, J=8.6, 1.8 Hz, 1H), 7.96 (d, J=8.1 Hz, 1H), 7.99-8.10 (m, 2H), 8.32 (dd, J=4.8, 2.0 Hz, 1H), 8.48 (d, J=1.5 Hz, 1H). HRMS: calcd for C21H19N3O2S+H+, 378.12707; found (ESI-FTMS, [M+H]1+), 378.1275. HPLC Method 1: room temperature, 5.77 min, 99.5%. HPLC Method 2: room temperature, 6.46 min, 99.4%.
Example 7Q 4-(2-naphthylsulfonyl)-1-[2-(trifluoromethyl)phenyl]piperidineStep 7E: A 5 mL microwave reaction vial was charged with 4-(2-naphthylsulfonyl)piperidine (82 mg, 0.30 mmol), 2-bromobenzotrifluoride (67 mg, 0.30 mmol), NaOt-Bu (40 mg, 0.42 mmol), Pd2(dba)3 (26 mg, 0.025 mmol), racemic BINAP (31 mg, 0.05 mmol), and dioxane (1.5 mL). The mixture was degassed with N2, capped, and heated in a 90° C. oil bath for 16 h. The mixture was diluted with CH2Cl2 (10 mL) and filtered through a plug of SiO2. The organic phase was concentrated and purified by SiO2 chromatography (15 to 30% EtOAc-hex) to afford the title compound (63 mg), a yellow oil, in 50% yield.
1H NMR (400 MHz, CDCl3) δ 1.94-2.19 (m, 4H), 2.60-2.77 (m, 2H), 2.92-3.31 (m, 3H), 7.09-7.32 (m, 2H), 7.44-7.52 (m, 1H), 7.56-7.77 (m, 3H), 7.89 (dd, J=8.6, 1.8 Hz, 1H), 7.96 (d, J=8.3 Hz, 1H), 7.99-8.11 (m, 2H), 8.50 (d, J=1.5 Hz, 1H). HRMS: calcd for C22H20F3NO2S+H+, 420.12396; found (ESI-FTMS, [M+H]1+), 420.1245. HPLC Method 1: room temperature, 6.82 min, 98.5%. HPLC Method 2: room temperature, 7.36 min, 98.4%.
Example 7R 3-methyl-2-[4-(2-naphthylsulfonyl)piperidin-1-yl]pyridineStep 7E: Using the procedure from Example 7A, 4-(2-naphthylsulfonyl)piperidine (82 mg, 0.30 mmol) was reacted with 2-bromo-6-methylpyridine (51 mg, 0.30 mmol) to afford the title compound (40 mg), a yellow solid, in 54% yield.
1H NMR (400 MHz, CDCl3) δ 1.88-2.06 (m, 2H), 2.13 (dd, J=12.4, 1.5 Hz, 2H), 2.66-2.82 (m, 2H), 3.07-3.33 (m, 1H), 3.53 (dd, J=10.5, 2.1 Hz, 2H), 6.85 (dd, J=7.3, 5.1 Hz, 1H), 7.38 (dd, J=7.3, 1.3 Hz, 1H), 7.61-7.76 (m, 2H), 7.90 (dd, J=8.6, 1.8 Hz, 1H), 7.96 (d, J=8.1 Hz, 1H), 7.99-8.07 (m, 2H), 8.11 (dd, J=5.3, 1.5 Hz, 1H), 8.50 (d, J=1.8 Hz, 1H). HRMS: calcd for C21H22N2O2S+H+, 367.14747; found (ESI-FTMS, [M+H]1+), 367.148; HPLC Method 1: room temperature, 4.60 min, 94.7%. HPLC Method 2: room temperature, 5.65 min, 91.7%.
Example 7S 2-{4-[(3,4-dichlorophenyl)sulfonyl]piperidin-1-yl}-3-methylpyridineStep 7E: Using the procedure from Example 7A, Step 7E, 4-[(3,4-dichlorophenyl)sulfonyl]piperidine (88 mg, 0.30 mmol) was reacted with 2-bromo-6-methylpyridine (62 mg, 0.040 mL, 0.36 mmol) to afford the title compound (37 mg), a pale yellow solid, in 32% yield.
1H NMR (400 MHz, CDCl3) δ 1.84-2.01 (m, 2H), 2.08 (d, J=12.4 Hz, 2H), 2.24 (s, 3H), 2.68-2.85 (m, 2H), 2.96-3.18 (m, 1H), 3.55 (d, J=10.6 Hz, 2H), 6.87 (dd, J=7.3, 5.1 Hz, 1H), 7.41 (dd, J=7.3, 1.3 Hz, 1H), 7.68 (d, J=8.3 Hz, 1H), 7.74 (dd, J=8.3, 2.1 Hz, 1H), 8.01 (d, J=2.0 Hz, 1H), 8.13 (dd, J=5.2, 1.6 Hz, 1H). HRMS: calcd for C17H18Cl2N2O2S+H+, 385.05388; found (ESI-FTMS, [M+H]1+), 385.0545.
Example 7T 2-({-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}sulfonyl)quinolineStep 7E: The corresponding quinoline amine from Step 7D (140 mg, 0.51 mmol) was reacted with 2-chloro-3-(trifluoromethyl)pyridine (182 mg, 1.0 mmol) as in Example 7A, Step 7E to afford the title compound (101 mg), a white powder, in 47% yield.
1H NMR (400 MHz, CDCl3) δ 2.03-2.25 (m, 4H), 2.88-3.01 (m, 2H), 3.70 (d, J=13.1 Hz, 2H), 3.83-4.02 (m, 1H), 7.02 (dd, J=7.8, 4.8 Hz, 1H), 7.66-7.78 (m, 1H), 7.81-7.92 (m, 2H), 7.92-8.03 (m, 1H), 8.17 (d, J=8.6 Hz, 1H), 8.28 (dd, J=8.6, 1.0 Hz, 1H), 8.42 (dd, J=4.8, 1.3 Hz, 1H), 8.45 (d, J=8.6 Hz, 1H). HRMS: calcd for C20H18F3N3O2S+H+, 422.11446; found (ESI-FTMS, [M+H]1+), 422.1148. HPLC Method 1: room temperature, 6.05 min, 91.1%. HPLC Method 2: room temperature, 6.74 min, 90.7%.
Example 7U 2-{[1-(3,5-dichloropyridin-4-yl)piperidin-4-yl]sulfonyl}quinolineStep 7E: Using the procedure from Example 7A, Step 7E, 2-(piperidin-4-ylsulfonyl)quinoline (150 mg, 0.51 mmol) was reacted with 3,4,5-trichloropyridine (182 mg, 1.0 mmol) to afford the title compound (34 mg), an off-white solid, in 16% yield.
1H NMR (400 MHz, CDCl3) δ 2.06-2.24 (m, 4H), 3.25-3.40 (m, 2H), 3.40-3.52 (m, 2H), 3.84-4.01 (m, 1H), 7.69-7.79 (m, 1H), 7.83-7.92 (m, 1H), 7.97 (d, J=8.1 Hz, 1H), 8.18 (d, J=8.6 Hz, 1H), 8.28 (d, J=8.6 Hz, 1H), 8.34 (s, 2H), 8.47 (d, J=7.8 Hz, 1H). HRMS: calcd for C19H17Cl2N3O2S+H+, 422.04913; found (ESI-FTMS, [M+H]1+), 422.0496. HPLC Method 1: room temperature, 6.11 min, 97.5%. HPLC Method 2: room temperature, 6.91 min, 98.7%.
Example 7V 2-[4-(quinolin-2-ylsulfonyl)piperidin-1-yl]nicotinonitrileStep 7E: Using the procedure from Example 7A, Step 7E, 2-(piperidin-4-ylsulfonyl)quinoline (Example 1T, Step 3, 150 mg, 0.51 mmol) was reacted with 2-chloro-3-cyanopyridine (139 mg, 1.0 mmol) to afford the title compound (166 mg), an off-white solid, in 86% yield.
1H NMR (400 MHz, CDCl3) δ 2.06-2.26 (m, 4H), 2.95-3.28 (m, 2H), 3.90-4.11 (m, 1H), 4.41-4.62 (m, 2H), 6.77 (dd, J=7.8, 4.8 Hz, 1H), 7.67-7.82 (m, 2H), 7.83-7.93 (m, 1H), 7.94-8.02 (m, 1H), 8.16 (d, J=8.3 Hz, 1H), 8.27 (dd, J=8.6, 1.0 Hz, 1H), 8.33 (dd, J=4.8, 2.0 Hz, 1H), 8.46 (d, J=7.8 Hz, 1H). HRMS: calcd for C19H17Cl2N3O2S+H+, 422.04913; found (ESI-FTMS, [M+H]1+), 422.0496; HPLC purity H2O/CH3CN 97.5%, H2O/MeOH 98.7%. HRMS: calcd for C20H18N4O2S+H+, 379.12232; found (ESI-FTMS, [M+H]1+), 379.1227. HPLC Method 1: room temperature, 5.38 min, 100%. HPLC Method 2: room temperature, 6.02 min, 100%.
Example 7W 2-[4-(phenylsulfonyl)piperidin-1-yl]-3-(trifluoromethyl)pyridineStep 7E: To a microwave vial were charged 4-(phenylsulfonyl)piperidine (300 mg, 1.33 mmol), 2-chloro-3-(trifluoromethyl)pyridine, (484 mg, 2.66 mmol), diisopropylethylamine (0.695 mL, 3.99 mmol) and 1,4-Dioxane (0.2 mL). The reaction mixture thus prepared was irradiated at 200° C. for 1 hour. The reaction was complete as determined by TLC. The residue was added with saturated NH4Cl (aq.) and extracted with ethylacetate, washed with 10% HCl (aq.), water then brine. Organic layer was dried over MgSO4. Solvent evaporation afforded 2-[4-(phenylsulfonyl)piperidin-1-yl]-3-(trifluoromethyl)pyridine in 55% yield (270 mg) as white solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.93 (dd, J=12.63, 3.79 Hz, 2H) 2.01-2.13 (m, 2H) 2.78-2.94 (m, 2H) 3.08 (s, 1H) 3.68 (dd, J=10.61, 2.27 Hz, 2H) 7.02 (dd, J=7.83, 4.80 Hz, 1H) 7.60 (t, J=7.58 Hz, 2H) 7.65-7.74 (m, 1H) 7.86 (dd, J=7.83, 1.77 Hz, 1H) 7.88-7.97 (m, 2H) 8.41 (dd, J=4.80, 1.77 Hz, 1H). HRMS: calcd for C17H17F3N2O2S+H+, 371.10356; found (ESI-FTMS, [M+H]1+), 371.1048. HPLC Method 1: room temperature, 5.733 min, 99.40%, HPLC Method 2: room temperature, 6.463 min, 99.24%.
Example 7X 2-{4-[(2-chlorophenyl)sulfonyl]piperidin-1-yl}-3-(trifluoromethyl)pyridineThe title compound was prepared according to a similar procedure described for Example 7A. Yield 74%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.90-2.00 (m, 2H), 2.01-2.14 (m, 2H), 2.86-2.99 (m, 2H), 3.64-3.76 (m, 3H), 7.00-7.06 (m, 1H), 7.46-7.52 (m, 1H), 7.56-7.62 (m, 2H), 7.87 (dd, J=7.7, 1.9 Hz, 1H), 8.10-8.17 (m, 1H), 8.43 (dd, J=4.8, 2.0 Hz, 1H). HRMS: calcd for C17H16ClF3N2O2S+H+, 405.06458; found (ESI-FTMS, [M+H]1+), 405.0661.
Example 7Y 3-chloro-2-{4-[(2-chlorophenyl)sulfonyl]piperidin-1-yl}pyridineUsing the procedure from Example 7A, 4-[(2-chlorophenyl)sulfonyl]piperidine (150 mg, 0.58 mmol) was reacted with 2,3-dichloropyridine (173 mg, 1.16 mmol) to afford the title compound (110 mg), a white solid, in 51% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.93-2.02 (m, 2H), 2.03-2.16 (m, 2H), 2.78-2.88 (m, 2H), 3.66-3.77 (m, 1H), 3.91-4.01 (m, J=110.5, 2.7 Hz, 2H), 6.85 (dd, J=7.8, 4.8 Hz, 1H), 7.46-7.52 (m, 1H), 7.56-7.61 (m, 3H), 8.11-8.15 (m, 1H), 8.16 (dd, J=4.8, 1.8 Hz, 1H). HRMS: calcd for C16H16Cl2N2O2S+H+, 371.03823; found (ESI-FTMS, [M+H]1+), 371.0384.
Example 7Z 3,5-dichloro-4-{4-[(2-chlorophenyl)sulfonyl]piperidin-1-yl}pyridineUsing the procedure from Example 7A, 4-[(2-chlorophenyl)sulfonyl]piperidine (100 mg, 0.38 mmol) was reacted with 2-chloro-5-(trifluoromethyl)pyridine (142 mg, 0.76 mmol) to afford the title compound (22 mg), a white solid, in 14% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.89-2.00 (m, 2H), 2.03-2.17 (m, 2H), 3.24-3.36 (m, 2H), 3.40-3.49 (m, 2H), 3.65-3.77 (m, 1H), 7.44-7.54 (m, 1H), 7.57-7.63 (m, 2H), 8.06-8.19 (m, 1H), 8.35 (s, 2H). HRMS: calcd for C16H15Cl3N2O2S+H+, 404.99925; found (ESI-FTMS, [M+H]1+), 404.9996.
Example 7AA 2-{4-[(3-chlorophenyl)sulfonyl]piperidin-1-yl}-3-(trifluoromethyl)pyridineThe title compound (161 mg, 69% yield) was prepared according to a similar procedure described for example 7A.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.86-2.01 (m, 2H), 2.01-2.13 (m, 2H), 2.88 (t, J=12.3 Hz, 2H), 3.03-3.14 (m, 1H), 3.69 (d, J=12.1 Hz, 2H), 7.03 (dd, J=7.2, 5.2 Hz, 1H), 7.55 (t, J=7.8 Hz, 1H), 7.66 (d, J=7.6 Hz, 1H), 7.80 (d, J=7.6 Hz, 1H), 7.86 (d, J=7.8 Hz, 1H), 7.91 (s, 1H), 8.42 (d, J=4.3 Hz, 1H). HRMS: calcd for C17H16ClF3N2O2S+H+, 405.06458; found (ESI-FTMS, [M+H]1+), 405.0662.
Example 7AB 2-{4-[(3-chlorophenyl)sulfonyl]piperidin-1-yl}-5-(trifluoromethyl)pyridineStep 7E: Using the procedure from Example 7A, Step 7E, 4-[(3-chlorophenyl)sulfonyl]piperidine (150 mg, 0.58 mmol) was reacted with 2-chloro-5-(trifluoromethyl)pyridine (211 mg, 1.16 mmol), DIEA (0.3 ml, 1.74) and 1,4-dioxane (0.2 ml) to afford the title compound (151 mg), a white solid, in 64% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.66-1.83 (m, 2H), 2.03-2.13 (m, 2H), 2.81-2.95 (m, 2H), 3.11-3.30 (m, 1H), 4.43-4.63 (m, 2H), 6.64 (d, J=9.1 Hz, 1H), 7.54 (t, J=8.0 Hz, 1H), 7.59-7.70 (m, 2H), 7.78 (dd, J=7.8, 2.8 Hz, 1H), 7.88 (s, 1H), 8.38 (s, 1H). HRMS: calcd for C17H16ClF3N2O2S+H+, 405.06458; found (ESI-FTMS, [M+H]1+), 405.0655.
Example 7AC 3-chloro-2-{4-[(3-chlorophenyl)sulfonyl]piperidin-1-yl}pyridineStep 1: Using the procedure from Example 7A, 4-[(3-chlorophenyl)sulfonyl]piperidine (150 mg, 0.58 mmol) was reacted with 2,3-dichloropyridine (173 mg, 1.16 mmol), DIEA (0.3 ml, 1.74) and 1,4-dioxane (0.2 ml) to afford the title compound (74 mg), a beige solid, in 34% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.90-2.01 (m, 2H), 2.05-2.13 (m, J=12.3, 2.1 Hz, 2H), 2.74-2.84 (m, 2H), 3.06-3.17 (m, 1H), 3.92-3.99 (m, 2H), 6.85 (dd, J=7.8, 4.8 Hz, 1H), 7.55 (t, J=8.1 Hz, 1H), 7.58 (dd, J=7.8, 1.8 Hz, 1H), 7.64-7.69 (m, 1H), 7.81 (dd, J=8.1, 1.3 Hz, 1H), 7.91 (s, 1H), 8.15 (dd, J=4.7, 1.6 Hz, 1H). HRMS: calcd for C16H16Cl2N2O2S+H+, 371.03823; found (ESI-FTMS, [M+H]1+), 371.0399.
Example 7AD 3,5-dichloro-4-{4-[(3-chlorophenyl)sulfonyl]piperidin-1-yl}pyridineStep 1: Using the procedure from Example 7A, 4-[(3-chlorophenyl)sulfonyl]piperidine (150 mg, 0.58 mmol) was reacted with 3,4,5-trichloropyridine (216 mg, 1.16 mmol), DIEA (0.3 ml, 1.74) and 1,4-dioxane (0.2 ml) to afford the title compound (35 mg), a white solid, in 15% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.86-2.11 (m, 4H), 3.04-3.16 (m, 1H), 3.27 (t, J=12.3 Hz, 2H), 3.43 (d, J=13.4 Hz, 2H), 7.55 (t, J=7.8 Hz, 1H), 7.67 (d, J=7.8 Hz, 1H), 7.81 (d, J=7.8 Hz, 1H), 7.91 (s, 1H), 8.35 (s, 2H). HRMS: calcd for C16H15Cl3N2O2S+H+, 404.99925; found (ESI-FTMS, [M+H]1+), 405.001.
Example 7AE 2-{4-[(3-chlorophenyl)sulfonyl]piperidin-1-yl}-3-nitropyridineStep 1: Using the procedure from Example 7A, 4-[(3-chlorophenyl)sulfonyl]piperidine (100 mg, 0.38 mmol) was reacted with 2-chloro-3-nitropyridine (122 mg, 0.76 mmol), DIEA (0.2 ml, 1.14) and 1,4-dioxane (0.3 ml) to afford the title compound (118 mg), a yellow solid, in 81% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.79-1.96 (m, 2H), 2.02-2.12 (m, J=12.3, 2.7 Hz, 2H), 2.94-3.05 (m, 2H), 3.12-3.24 (m, 1H), 3.86-3.99 (m, 2H), 6.81 (dd, J=8.1, 4.5 Hz, 1H), 7.54 (t, J=7.7 Hz, 1H), 7.63-7.69 (m, 1H), 7.76-7.81 (m, 1H), 7.89 (s, 1H), 8.14 (dd, J=8.1, 1.8 Hz, 1H), 8.33 (dd, J=4.5, 1.8 Hz, 1H). HRMS: calcd for C16H16ClN3O4S+H+, 382.06228; found (ESI-FTMS, [M+H]1+), 382.0624.
Example 7AF 2-{4-[(3-chlorophenyl)sulfonyl]piperidin-1-yl}-5-nitropyridineStep 1: Using the procedure from Example 7A, 4-[(3-chlorophenyl)sulfonyl]piperidine (100 mg, 0.38 mmol) was reacted with 2-chloro-5-nitropyridine (122 mg, 0.76 mmol), DIEA (0.2 ml, 1.14) and 1,4-dioxane (0.3 ml) to afford the title compound (40 mg), a yellow solid, in 28% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.64-1.89 (m, 2H), 2.13 (dd, J=14.3, 1.9 Hz, 2H), 2.91-3.04 (m, 2H), 3.16-3.33 (m, 1H), 4.67 (d, J=13.6 Hz, 2H), 6.59 (d, J=11.0 Hz, 1H), 7.55 (t, J=8.0 Hz, 1H), 7.61-7.72 (m, 1H), 7.74-7.81 (m, 1H), 7.88 (s, 1H), 8.22 (dd, J=9.5, 2.9 Hz, 1H), 9.02 (d, J=2.3 Hz, 1H). HRMS: calcd for C16H16ClN3O4S+H+, 382.06228; found (ESI-FTMS, [M+H]1+), 382.0622.
Example 7AG 1-{4-[(3-chlorophenyl)sulfonyl]piperidin-1-yl}isoquinolineStep 1: Using the procedure from Example 7A, 4-[(3-chlorophenyl)sulfonyl]piperidine (100 mg, 0.38 mmol) was reacted with 1-chloroisoquinoline (131 mg, 0.76 mmol), DIEA (0.2 ml, 1.14) and 1,4-dioxane (0.3 ml) to afford the title compound (4 mg), a beige solid, in 3% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.05-2.25 (broad, m, 4H), 2.87-2.99 (m, 2H), 3.07-3.25 (m, 1H), 3.84-3.98 (m, J=12.6 Hz, 2H), 7.24-7.33 (m, 2H), 7.48-7.70 (m, 3H), 7.76 (d, J=8.3 Hz, 1H), 7.85 (d, J=7.8 Hz, 1H), 7.95 (s, 1H), 8.01 (d, J=8.6 Hz, 1H), 8.12 (d, J=5.6 Hz, 1H). HRMS: calcd for C20H19ClN2O2S+H+, 387.09285; found (ESI-FTMS, [M+H]1+), 387.0933.
Example 7AH 2-{4-[(3-chlorophenyl)sulfonyl]piperidin-1-yl}nicotinonitrileStep 1: Using the procedure from Example 7A, 4-[(3-chlorophenyl)sulfonyl]piperidine (100 mg, 0.38 mmol) was reacted with 2-chloro-3-cyanopyridine (108 mg, 0.76 mmol), DIEA (0.2 ml, 1.14) and 1,4-dioxane (0.3 ml) to afford the title compound (91 mg), a yellow solid, in 62% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.84-1.96 (m, 2H), 2.06-2.14 (m, 2H), 2.93-3.04 (m, 2H), 3.11-3.23 (m, 1H), 4.45-4.54 (m, 2H), 6.80 (dd, J=7.6, 4.8 Hz, 1H), 7.55 (t, J=8.0 Hz, 1H), 7.59-7.67 (m, 1H), 7.72-7.83 (m, 2H), 7.89 (s, 1H), 8.34 (dd, J=4.8, 2.0 Hz, 1H). HRMS: calcd for C17H16ClN3O2S+H+, 362.07245; found (ESI-FTMS, [M+H]1+), 362.0737.
Example 7AI 2-{4-[(3-chlorophenyl)sulfonyl]piperidin-1-yl}-3-fluoropyridineStep 1: Using the procedure from Example 7A, 4-[(3-chlorophenyl)sulfonyl]piperidine (100 mg, 0.38 mmol) was reacted with 2-chloro-3-fluoropyridine (100 mg, 0.76 mmol), DIEA (0.2 ml, 1.14) and 1,4-dioxane (0.3 ml) to afford the title compound (9 mg), a yellow solid, in 7% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.80-1.94 (m, 2H), 2.02-2.14 (m, 2H), 2.78-2.88 (m, 2H), 3.09-3.22 (m, 1H), 4.08-4.25 (m, 2H), 6.74-6.81 (m, 1H), 7.17-7.26 (m, 1H), 7.54 (t, J=8.1 Hz, 1H), 7.61-7.70 (m, 1H), 7.75-7.84 (m, 1H), 7.90 (s, 1H), 7.94-8.04 (m, 1H). HRMS: calcd for C16H16ClFN2O2S+H+, 355.06778; found (ESI-FTMS, [M+H]1+), 355.0693.
Example 7AJ 2-{4-[(4-chlorophenyl)sulfonyl]piperidin-1-yl }-3-(trifluoromethylpyridineStep 7E: The title compound (109 mg, 71% yield), a white solid, was prepared according to a similar procedure described for Example 7A.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.85-1.98 (m, 2H), 1.99-2.13 (m, 2H), 2.87 (t, J=12.3 Hz, 2H), 2.95-3.15 (m, 1H), 3.67 (d, J=12.6 Hz, 2H), 6.95-7.09 (broad, m, 1H), 7.57 (d, J=8.3 Hz, 2H), 7.85 (d, J=5.1 Hz, 3H), 8.41 (broad, s, 1H). HRMS: calcd for C17H16ClF3N2O2S+H+, 405.06458; found (ESI-FTMS, [M+H]1+), 405.0649.
Example 7AK 2-{4-[(4-chlorophenyl)sulfonyl]piperidin-1-yl}-5-(trifluoromethyl)pyridineStep 1: Using the procedure from Example 7A, 4-[(4-chlorophenyl)sulfonyl]piperidine (100 mg, 0.38 mmol) was reacted with 2-chloro-5-(trifluoromethyl)pyridine (138 mg, 0.76 mmol), DIEA (0.27 ml, 1.52 mmol) and 1,4-dioxane (0.3 ml) at 190° C. to afford the title compound (112 mg), a white solid, in 73% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.65-1.84 (m, 2H), 2.09 (d, J=13.4 Hz, 2H), 2.88 (t, J=12.9 Hz, 2H), 3.11-3.25 (m, 1H), 4.55 (d, J=14.9 Hz, 2H), 6.63 (d, J=8.3 Hz, 1H), 7.57 (d, J=6.8 Hz, 2H), 7.62 (d, J=8.8 Hz, 1H), 7.82 (d, J=8.8 Hz, 2H), 8.37 (s, 1H). HRMS: calcd for C17H16ClF3N2O2S+H+, 405.06458; found (ESI-FTMS, [M+H]1+), 405.0663.
Example 7AL 3-chloro-2-{4-[(4-chlorophenyl)sulfonyl]piperidin-1-yl}pyridineStep 7E: Using the procedure from Example 7A, 4-[(4-chlorophenyl)sulfonyl]piperidine (100 mg, 0.38 mmol) was reacted with 2,3-dichloropyridine (114 mg, 0.76 mmol), DIEA (0.27 ml, 1.52) and 1,4-dioxane (0.3 ml) at 190° C. to afford the title compound (56 mg), a white solid, in 40% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.79-1.97 (m, 2H), 2.02-2.22 (m, 2H), 2.77 (t, J=12.6 Hz, 2H), 2.97-3.19 (m, 1H), 3.94 (d, J=11.6 Hz, 2H), 6.71-6.95 (m, 1H), 7.58 (d, J=7.6 Hz, 3H), 7.85 (d, J=8.3 Hz, 2H), 8.15 (s, 1H). HRMS: calcd for C16H16Cl2N2O2S+H+, 371.03823; found (ESI-FTMS, [M+H]1+), 371.0385.
Example 7AM 3,5-dichloro-4-{4-[(4-chlorophenyl)sulfonyl]piperidin-1-yl}pyridineStep 1: Using the procedure from Example 7A, 4-[(4-chlorophenyl)sulfonyl]piperidine (100 mg, 0.38 mmol) was reacted with 3,4,5-trichloropyridine (141 mg, 0.76 mmol), DIEA (0.27 ml, 1.52) and 1,4-dioxane (0.3 ml) at 190° C. to afford the title compound (51 mg), a white solid, in 33% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.86-2.00 (m, 2H), 2.01-2.13 (m, 2H), 2.97-3.13 (m, 1H), 3.25 (t, J=12.3 Hz, 2H), 3.42 (d, J=12.4 Hz, 2H), 7.58 (d, 2H), 7.76-7.91 (m, 2H), 8.34 (s, 2H). HRMS: calcd for C16H15Cl3N2O2S+H+, 404.99925; found (ESI-FTMS, [M+H]1+), 405.0012.
Example 7AN 1-{4-[(4-chlorophenyl)sulfonyl]piperidin-1-yl}isoquinolineStep 1: Using the procedure from Example 7A, 4-[(4-chlorophenyl)sulfonyl]piperidine (100 mg, 0.38 mmol) was reacted with 1-chloroisoquinoline (131 mg, 0.76 mmol), DIEA (0.27 ml, 1.52) and 1,4-dioxane (0.3 ml) at 190° C. to afford the title compound (15 mg), an off-white solid, in 10% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.00-2.19 (m, 4H), 2.81-2.99 (m, 2H), 3.05-3.28 (m, 1H), 3.92 (d, J=13.1 Hz, 2H), 7.27 (d, J=6.1 Hz, 1H), 7.43-7.54 (m, 1H), 7.56-7.64 (m, 3H), 7.75 (d, J=8.1 Hz, 1H), 7.81-7.94 (m, 2H), 8.00 (d, J=9.1 Hz, 1H), 8.12 (d, J=5.8 Hz, 1H). HRMS: calcd for C20H19ClN2O2S+H+, 387.09285; found (ESI-FTMS, [M+H]1+), 387.0935.
Example 7AO 2-{4-[(4-chlorophenyl)sulfonyl]piperidin-1-yl}quinolineStep 1: Using the procedure from Example 1A, 4-[(4-chlorophenyl)sulfonyl]piperidine (100 mg, 0.38 mmol) was reacted with 2-chloroquinoline (124 mg, 0.76 mmol), DIEA (0.27 ml, 1.52) and 1,4-dioxane (0.3 ml) at 190° C. to afford the title compound (11 mg), a white solid, in 8% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.69-1.85 (m, 2H), 2.13 (d, J=13.1 Hz, 2H), 2.91 (t, J=13.3 Hz, 2H), 3.08-3.27 (m, 1H), 4.71 (d, J=13.9 Hz, 2H), 6.96 (d, J=7.8 Hz, 1H), 7.20-7.30 (m, 1H), 7.46-7.62 (m, 4H), 7.68 (d, J=8.6 Hz, 1H), 7.83 (d, J=8.3 Hz, 2H), 7.89 (d, J=9.3 Hz, 1H). HRMS: calcd for C20H19ClN2O2S+H+, 387.09285; found (ESI-FTMS, [M+H]1+), 387.0947.
Example 7AP 2-{4-[(4-chlorophenyl)sulfonyl]piperidin-1-yl}-3-fluoropyridineStep 1: Using the procedure from Example 7A, 4-[(4-chlorophenyl)sulfonyl]piperidine (100 mg, 0.38 mmol) was reacted with 2-chloro-3-fluoropyridine (78 μl, 0.76 mmol), DIEA (0.27 ml, 1.52) and 1,4-dioxane (0.3 ml) at 190° C. to afford the title compound (18 mg), a white solid, in 13% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.75-1.92 (m, 2H), 2.01-2.13 (m, 2H), 2.67-2.88 (m, 2H), 3.04-3.18 (m, 1H), 4.14-4.23 (m, 2H), 6.71-6.81 (m, 1H), 7.17-7.26 (m, 1H), 7.51-7.61 (m, 2H), 7.79-7.87 (m, 2H), 7.93-8.02 (m, 1H). HRMS: calcd for C16H16ClFN2O2S+H+, 355.06778; found (ESI-FTMS, [M+H]1+), 355.0691.
Example 7AQ 2-{4-[(4-chlorophenyl)sulfonyl]piperidin-1-yl}-4-(trifluoromethyl)pyridineStep 1: Using the procedure from Example 1A, 4-[(4-chlorophenyl)sulfonyl]piperidine (100 mg, 0.38 mmol) was reacted with 2-chloro-4-(trifluoromethyl)pyridine (99 μl, 0.76 mmol), DIEA (0.27 ml, 1.52) and 1,4-dioxane (0.3 ml) at 190° C. to afford the title compound (49 mg), an off-white solid, in 32% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.66-1.82 (m, 2H), 2.10 (dd, J=13.9, 3.3 Hz, 2H), 2.75-2.93 (m, 2H), 3.08-3.24 (m, 1H), 4.50 (d, J=13.6 Hz, 2H), 6.73-6.83 (m, 2H), 7.50-7.62 (m, 2H), 7.76-7.87 (m, 2H), 8.28 (d, J=5.1 Hz, 1H). HRMS: calcd for C17H16ClF3N2O2S+H+, 405.06458; found (ESI-FTMS, [M+H]1+), 405.0665.
Example 7AR 2-{4-[(4-tert-butylphenyl)sulfonyl]piperidin-1-yl}-3-(trifluoromethyl)pyridineThe title compound (75 mg, 49% yield), a white solid, was obtained according to a similar procedure described for Example 7A.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.37 (s, 9H), 1.85-2.01 (m, 2H), 2.01-2.17 (m, 2H), 2.69-2.89 (m, 2H), 2.94-3.16 (m, 1H), 3.69 (d, J=13.1 Hz, 2H), 7.01 (dd, J=7.8, 4.8 Hz, 1H), 7.48-7.65 (m, 2H), 7.75-7.94 (m, 3H), 8.41 (d, J=4.8 Hz, 1H). HRMS: calcd for C21H25F3N2O2S+H+, 427.16616; found (ESI-FTMS, [M+H]1+), 427.1666.
Example 7AS 2-{4-[(4-tert-butylphenyl)sulfonyl]piperidin-1-yl}-5-(trifluoromethyl)pyridineThe title compound (119 mg), an off-white solid, was obtained in 77% yield according to a similar procedure described for example 7A.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.36 (s, 9H), 1.67-1.81 (m, 2H), 2.05-2.17 (m, 2H), 2.83-2.93 (m, 2H), 3.11-3.24 (m, 1H), 4.54 (d, J=13.6 Hz, 2H), 6.63 (d, J=9.1 Hz, 1H), 7.54-7.59 (m, 2H), 7.60-7.66 (m, 1H), 7.71-7.85 (m, 2H), 8.36 (s, 1H). HRMS: calcd for C21H25F3N2O2S+H+, 427.16616; found (ESI-FTMS, [M+H]1+), 427.1675.
Example 7AT 2-{4-[(4-tert-butylphenyl)sulfonyl]piperidin-1-yl}-3-chloropyridineStep 1: Using the procedure from Example 7A, 4-[(4-tert-butylphenyl)sulfonyl]piperidine (100 mg, 0.36 mmol) was reacted with 2,3-dichloropyridine (108 mg, 0.72 mmol), DIEA (0.25 ml, 1.44) and 1,4-dioxane (0.3 ml) at 185° C. to afford the title compound (40 mg), a white solid, in 28% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.37 (s, 9H), 1.88-2.02 (m, 2H), 2.10 (dd, J=12.1, 2.0 Hz, 2H), 2.68-2.85 (m, 2H), 3.00-3.20 (m, 1H), 3.94 (d, J=13.1 Hz, 2H), 6.84 (dd, J=7.8, 4.8 Hz, 1H), 7.49-7.63 (m, 3H), 7.83 (d, J=8.6 Hz, 2H), 8.15 (dd, J=4.8, 1.5 Hz, 1H). HRMS: calcd for C20H25ClN2O2S+H+, 393.13980; found (ESI-FTMS, [M+H]1+), 393.141.
Example 7AU 4-{4-[(4-tert-butylphenyl)sulfonyl]piperidin-1-yl}-3,5-dichloropyridineStep 1: Using the procedure from Example 7A, 4-[(4-tert-butylphenyl)sulfonyl]piperidine (100 mg, 0.36 mmol) was reacted with 3,4,5-trichloropyridine (134 mg, 0.72 mmol), DIEA (0.25 ml, 1.44) and 1,4-dioxane (0.3 ml) at 185° C. to afford the title compound (16 mg), a white solid, in 10% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.37 (s, 9H), 1.90-2.03 (m, 2H), 2.03-2.11 (m, 2H), 3.02-3.12 (m, 1H), 3.18-3.31 (m, 2H), 3.37-3.48 (m, 2H), 7.60 (d, J=8.8 Hz, 2H), 7.83 (d, J=8.6 Hz, 2H), 8.33 (s, 2H). HRMS: calcd for C20H24Cl2N2O2S+H+, 427.10083; found (ESI-FTMS, [M+H]1+), 427.1028.
Example 7AV 1-{4-[(4-tert-butylphenyl)sulfonyl]piperidin-1-yl}isoquinolineStep 1: Using the procedure from Example 7A, 4-[(4-tert-butylphenyl)sulfonyl]piperidine (150 mg, 0.53 mmol) was reacted with 1-chloroisoquinoline (183 mg, 1.06 mmol), DIEA (0.37 ml, 2.12) and 1,4-dioxane (0.2 ml) at 185° C. to afford the title compound (40 mg), a white solid, in 18% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.38 (s, 9H), 2.08-2.21 (m, 4H), 2.84-2.97 (m, 2H), 3.04-3.21 (m, 1H), 3.92 (d, J=12.9 Hz, 2H), 7.23-7.28 (m, 1H), 7.48-7.54 (m, 1H), 7.58-7.66 (m, 3H), 7.75 (d, J=8.1 Hz, 1H), 7.87 (d, J=8.3 Hz, 2H), 8.01 (d, J=8.3 Hz, 1H), 8.11 (d, J=−5.8 Hz, 1H). HRMS: calcd for C24H29N2O2S+H+, 409.19442; found (ESI-FTMS, [M+H]1+), 409.1959.
Example 7AX 2-{4-[(4-tert-butylphenyl)sulfonyl]piperidin-1-yl}quinolineStep 1: Using the procedure from Example 7A, 4-[(4-tert-butylphenyl)sulfonyl]piperidine (150 mg, 0.53 mmol) was reacted with 2-chloroquinoline (175 mg, 1.06 mmol), DIEA (0.37 ml, 2.12) and 1,4-dioxane (0.2 ml) at 185° C. to afford the title compound (39 mg), a white solid, in 18% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.35 (s, 9H), 1.70-1.86 (m, 2H), 2.15 (d, J=12.9 Hz, 2H), 2.83-2.96 (m, 2H), 3.13-3.23 (m, 1H), 4.69 (d, J=13.6 Hz, 2H), 6.95 (d, J=9.1 Hz, 1H), 7.20-7.28 (m, 1H), 7.50-7.61 (m, 4H), 7.67 (d, J=8.3 Hz, 1H), 7.80 (d, J=8.3 Hz, 2H), 7.88 (d, J=9.3 Hz, 1H). HRMS: calcd for C24H28N2O2S+H+, 409.19442; found (ESI-FTMS, [M+H]1+), 409.1952.
Example 7AY 2-{4-[(4-tert-butylphenyl)sulfonyl]piperidin-1-yl}-3-fluoropyridineStep 1: Using the procedure from Example 7A, 4-[(4-tert-butylphenyl)sulfonyl]piperidine (100 mg, 0.36 mmol) was reacted with 2-chloro-3-fluoropyridine (74 μl, 0.72 mmol), DIEA (0.25 ml, 1.44) and 1,4-dioxane (0.3 ml) at 185° C. to afford the title compound (13 mg), a white solid, in 10% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.36 (s, 9H), 1.79-1.92 (m, 2H), 2.10 (d, J=12.9 Hz, 2H), 2.78-2.87 (m, 2H), 3.05-3.17 (m, 1H), 4.18 (d, J=13.1 Hz, 2H), 6.72-6.78 (m, 1H), 7.17-7.25 (m, 1H), 7.58 (d, J=8.6 Hz, 2H), 7.81 (d, J=8.3 Hz, 2H), 7.95-7.99 (m, 1H). HRMS: calcd for C20H25FN2O2S+H+, 377.16935; found (ESI-FTMS, [M+H]1+), 377.1705.
Example 7AZ 2-{4-[(4-tert-butylphenyl)sulfonyl]piperidin-1-yl}-4-(trifluoromethyl)pyridineStep 1: Using the procedure from Example 7A, 4-[(4-tert-butylphenyl)sulfonyl]piperidine (100 mg, 0.36 mmol) was reacted with 2-chloro-4-(trifluoromethyl)pyridine (94 μl, 0.72 mmol), DIEA (0.25 ml, 1.44) and 1,4-dioxane (0.3 ml) at 185° C. to afford the title compound (60 mg), an off-white solid, in 39% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.36 (s, 9H), 1.68-1.82 (m, 2H), 2.12 (d, J=11.4 Hz, 2H), 2.82-2.92 (m, 2H), 3.11-3.22 (m, 1H), 4.49 (d, J=13.1 Hz, 2H), 6.75-6.79 (m, J=3.5 Hz, 2H), 7.58 (d, J=8.6 Hz, 2H), 7.80 (d, J=8.3 Hz, 2H), 8.27 (d, J=5.6 Hz, 1H). HRMS: calcd for C21H25F3N2O2S+H+, 427.16616; found (ESI-FTMS, [M+H]1+), 427.1681.
Example 7BB 2-{4-[(4-tert-butylphenyl)sulfonyl]piperidin-1-yl}-3-methylpyridineThe title compound (90 mg), a white solid, was obtained in 67% yield according to a similar procedure described for example 7A.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.37 (s, 9H), 1.87-2.02 (m, 2H), 2.05-2.14 (m, 2H), 2.24 (s, 3H), 2.69-2.80 (m, 2H), 3.01-3.12 (m, 1H), 3.53 (dd, J=10.6, 2.0 Hz, 2H), 6.86 (dd, J=7.3, 4.8 Hz, 1H), 7.35-7.42 (m, 1H), 7.59 (d, J=8.8 Hz, 2H), 7.83 (d, J=8.6 Hz, 2H), 8.12 (dd, J=5.2, 1.6 Hz, 1H). HRMS: calcd for C21H28N2O2S+H+, 373.19442; found (ESI-FTMS, [M+H]1+), 373.1941.
Example 7BC 4-[(4-tert-butylphenyl)sulfonyl]-1-(2-methylphenyl)piperidineStep 1: Using the procedure from Example 7A, 4-[(4-tert-butylphenyl)sulfonyl]piperidine (100 mg, 0.36 mmol) was reacted with 2-bromotoluene (53 μl, 0.43 mmol) to afford the title compound (59 mg), a yellow solid, in 44% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.37 (s, 9H), 1.90-2.01 (m, 2H), 2.04-2.12 (m, 2H), 2.26 (s, 3H), 2.53-2.66 (m, 2H), 2.94-3.08 (m, 1H), 3.22 (d, J=1.9 Hz, 2H), 6.90-7.02 (m, 2H), 7.10-7.18 (m, 2H), 7.59 (d, J=8.6 Hz, 2H), 7.83 (d, J=8.8 Hz, 2H). HRMS: calcd for C22H29NO2S+H+, 372.19917; found (ESI-FTMS, [M+H]1+), 372.1988.
Example 7BD 4-[(4-tert-butylphenyl)sulfonyl]-1-[2-(trifluoromethyl)phenyl]piperidineStep 7E: Using the procedure from Example 7A, 4-[(4-tert-butylphenyl)sulfonyl]piperidine (100 mg, 0.36 mmol) was reacted with 2-bromobenzotrifluoride (59 μl, 0.43 mmol) to afford the title compound (26 mg), a white solid, in 17% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.37 (s, 9H), 1.90-2.02 (m, 2H), 2.02-2.10 (m, 2H), 2.63-2.74 (m, 2H), 2.95-3.05 (m, 1H), 3.17 (d, J=11.6 Hz, 2H), 7.22 (t, J=7.7 Hz, 1H), 7.24-7.29 (m, 1H), 7.49 (t, J=7.1 Hz, 1H), 7.56-7.63 (m, 3H), 7.83 (d, J=8.8 Hz, 2H). HRMS: calcd for C22H26F3NO2S+H+, 426.17091; found (ESI-FTMS, [M+H]1+), 426.1706.
Example 8 4-(3-chloropyridin-2-yl)-1-[(3,4-dichlorophenyl)sulfonyl]-cis-2,6-dimethylpiperazineStep 8A: 2,6-dimethylpiperazine (291 mg, 2.55 mmol) and 2,3-dichloropyridine (377.4 mg, 2.55 mmol) were charged to a microwave vial, dissolved in DMF (0.25 mL) and added with diisopropylethylamine (1.1 mL, 6.38 mmol). The reaction mixture was irradiated at 165° C. for 30 minutes. The reaction was complete as determined by TLC. After solvent removal the crud product was purified via flush column chromatography to afford 1-(3-chloropyridin-2-yl)-3,5-dimethylpiperazine in 64.4% yield (370 mg).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.18 (d, J=6.32 Hz, 6H) 2.40-2.63 (m, 2H) 3.02-3.24 (m, 2H) 3.66-3.82 (m, 2H) 6.83 (dd, J=7.58, 4.80 Hz, 1H) 7.58 (dd, J=7.71, 1.64 Hz, 1H) 8.18 (dd, J=4.80, 1.77 Hz, 1H).
Step 8B: 1-(3-chloropyridin-2-yl)-3,5-dimethylpiperazine (370 mg, 1.644 mmol) was dissolved in anhydrous dichloromethane (6 mL) added with 3,4-dichlorobenzene sulfonyl chloride (509 mg, 1.97 mmol) and diisopropylethylamine (0.72 mL, 4.11 mmol). The reaction mixture thus prepared was stirred overnight at room temperature. The reaction was complete as determined by TLC. It was purified via flush column chromatography to afford 4-(3-chloropyridin-2-yl)-1-[(3,4-dichlorophenyl)sulfonyl]-2,6-dimethylpiperazin in 13% yield (110 mg) as a sticky solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.60 (d, J=6.82 Hz, 6H) 2.69 (dd, J=12.38, 4.29 Hz, 2H) 3.56 (d, J=12.38 Hz, 2H) 4.01-4.36 (m, 2H) 6.90 (dd, J=7.83, 4.80 Hz, 1H) 7.56 (d, J=8.34 Hz, 1H) 7.61 (d, J=6.06 Hz, 1H) 7.66 (d, J=8.34 Hz, 1H) 7.94 (s, 1H) 8.15 (d, J=6.57 Hz, 1H). HRMS: calcd for C17H18Cl3N3O2S+H+, 434.02580; found (ESI-FTMS, [M+H]1+), 434.0272.
Example 9Step 9A: A mixture of tert-butyl piperazine-1-carboxylate 1.04 g, (5.6 mmol), 2-bromo-5-fluoro benzotrifluoride (1.21 g, 5.0 mmol), tris(dibenzylidineacetone)dipalladium (0) (45.8 mg, 0.05 mmol), rac-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (93.4 mg, 0.15 mmol) and sodium tert-butoxide (600 mg, 6.25 mmol) were charged to a microwave vial. Toluene (10.0 mL) was introduced under nitrogen atmosphere and the reaction mixture was irradiated at 110° C. for 30 minutes. Reaction was complete as determined by TLC. The reaction was repeated four times. Reaction mixtures were combined, diluted with ethylacetate, washed with water, saturated brine then dried over MgSO4 and concentrated. The crude product was purified via flash column chromatography to yield tert-butyl-4-(4-fluoro-2-(trifluoromethyl)phenyl)piperazine-1-carboxylate in quantitative yield (6.8 g) as yellow oil.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.49 (s, 9H) 2.82 (t, J=4.80 Hz, 4H) 3.55 (s, 4H) 7.15-7.26 (m, 1H) 7.27-7.39 (m, 2H). HPLC Method 1: room temperature, 7.000 min, 96.34%. HPLC Method 2: room temperature, 7.609 min, 97.90%.
Step 9B: To a stirred solution of tert-butyl-4-(4-fluoro-2-(trifluoromethyl)phenyl)piperazine-1-carboxylate (6.8 g, 19.5 mmol) in anhydrous dichloromethane (90 mL) was added TFA (45 mL) dropwise at 0° C. The reaction mixture was stirred at 0° C. for 15 minutes then the cooling bath was removed and it was allowed to stir at room temperature for 2 hours. Reaction was complete as determined by TLC. Most of TFA was azeotropped with dichloroethane. The residue was then diluted with dichloromethane and washed with saturated Na2CO3 (aq.). Organic layer was dried over MgSO4. Solvent evaporation afforded 1-(4-fluoro-2-trifluoromethyl)phenyl)piperazine in 79.9% yield (3.86 g) as light brown oil. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.78-2.90 (m, 4H) 2.96-3.04 (m, 4H) 7.18-7.25 (m, 1H) 7.29-7.42 (m, 2H).
Step 9C: To a stirred solution of 1-(4-fluoro-2-(trifluoromethyl)phenyl)piperazine (386 mg, 1.555 mmol) and 3,4-dichlorobenzene-1-sulfonyl chloride (381.8 mg, 1.555 mmol) in anhydrous dichloromethane (3 mL) was added diisopropylethylamine (1.35 mL, 7.775 mmol). The mixture was stirred at room temperature for 30 minutes. Reaction was complete as determined by TLC. The reaction mixture was diluted with dichloromethane, washed with saturated Na2CO3 (aq.), water then brine. Organic layer was dried over MgSO4. The reaction mixture was purified via flash column chromatography to yield 1-[(3,4-dichlorophenyl)sulfonyl]-4-[4-fluoro-2-trifluoromethyl)phenyl]piperazine in 75.7% yield (538 mg) as white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 2.93 (t, J=4.67 Hz, 4H) 3.08 (s, 4H) 7.47-7.61 (m, 2H) 7.68-7.82 (m, 2H) 7.94-8.04 (m, 2H). HRMS: calcd for C17H14Cl2F4N2O2S+H+, 457.01619; found (ESI-FTMS, [M+H]1+), 457.0168. HPLC Method 1: room temperature, 7.212 min, 99.42%. HPLC Method 2: room temperature, 7.768 min, 99.76%.
Example 9B 1-[(2-chlorophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]piperazineStep 9C: Sulfonylation of 1-(4-fluoro-2-(trifluoromethyl)phenyl)piperazine (386 mg, 1.55 mmol) with 2-chlorobenzene-1-sulfonyl chloride (382.2 mg, 1.555 mmol) was carried out according to a similar to the representative sulfonation procedure described in Example 1 using anhydrous dichloromethane (3 mL) as solvent and diisopropylethylamine (1.35 mL, 7.775 mmol) as base. 1-[(2-chlorophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]piperazine was obtained in 73.3% yield (481.8 mg) as white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 2.90 (t, J=4.67 Hz, 4H) 3.27 (s, 4H) 7.50-7.57 (m, 2H) 7.57-7.65 (m, 1H) 7.66-7.79 (m, 3H) 8.01 (dd, J=7.83, 1.52 Hz, 1H). HRMS: calcd for C17H15ClF4N2O2S+H+, 423.05516; found (ESI-FTMS, [M+H]1+), 423.0558. HPLC Method 1: room temperature, 6.787 min, 98.54%. HPLC Method 2: room temperature, 7.371 min, 99.64%.
Example 9C 1-[(4-chlorophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]piperazineStep 9C: Sulfonylation of 1-(4-fluoro-2-(trifluoromethyl)phenyl)piperazine (386 mg, 1.55 mmol) with 4-chlorobenzene-1-sulfonyl chloride (328.2 mg, 1.555 mmol) was carried out according to the representative sulfonation procedure described in Example 1 using anhydrous dichloromethane (3 mL) as solvent and diisopropylethylamine (1.35 mL, 7.775 mmol) as base. 1-[(4-chlorophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]piperazine was obtained in 69.2% yield (455 mg) as white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 2.93 (t, J=4.29 Hz, 4H) 3.02 (s, 4H) 7.48-7.60 (m, 2H) 7.73 (dd, J=8.72, 5.18 Hz, 1H) 7.75-7.85 (m, 4H). HRMS: calcd for C17H15ClF4N2O2S+H+, 423.05516; found (ESI-FTMS, [M+H]1+), 423.0557. HPLC Method 1: room temperature, 6.908 min, 95.67%. HPLC Method 2: room temperature, 7.474 min, 99.78%.
Example 9D 1-[(5-chloro-2-naphthyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]piperazineStep 1C: Sulfonylation of 1-(4-fluoro-2-(trifluoromethyl)phenyl)piperazine (193 mg, 3.888 mmol) with 5-chloronaphthalene-2-sulfonyl chloride (202.1 mg, 0.777 mmol) was carried out according to the representative sulfonation procedure described in Example 1 using anhydrous dichloromethane (3 mL) as solvent and diisopropylethylamine (0.7 mL, 3.887 mmol) as base. 1-[(5-chloro-2-naphthyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]piperazine was obtained in 69% yield (256 mg) as white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 2.94 (t, J=4.55 Hz, 4H) 3.09 (s, 4H) 7.41-7.59 (m, 2H) 7.64-7.79 (m, 2H) 7.97 (dd, J=6.95, 5.94 Hz, 2H) 8.29 (d, J=8.34 Hz, 1H) 8.45 (d, J=8.84 Hz, 1H) 8.61 (d, J=1.77 Hz, 1H). HRMS: calcd for C21H17ClF4N2O2S+H+, 473.07081; found (ESI-FTMS, [M+H]1+), 473.0715. HPLC Method 1: room temperature, 7.443 min, 99.05%. HPLC Method 2: room temperature, 7.909 min, 99.73%.
Example 9E 1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-4-[5-fluoro-2-(trifluoromethyl)phenyl]piperazine1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-4-[5-fluoro-2-(trifluoromethyl)phenyl]piperazine was prepared in a similar fashion as described in step 9C for example 9A.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.71 (s, 3H) 2.96-3.08 (m, 4H) 3.38 (d, 4H) 6.95 (dd, J=16.17, 2.27 Hz, 1H) 7.02 (dd, J=9.73, 2.40 Hz, 1H) 7.49 (dd, J=8.59, 2.02 Hz, 1H) 7.61 (dd, J=8.84, 6.06 Hz, 1H) 7.79 (d, J=8.59 Hz, 1H) 7.84 (d, J=2.02 Hz, 1H). HRMS: calcd for C20H17ClF4N2O2S2+H+, 493.04288; found (ESI-FTMS, [M+H]1+), 493.0433.
Example 9F 1-[4-fluoro-2-(trifluoromethyl)phenyl]-4-(2-naphthylsulfonyl)piperazine1-[4-fluoro-2-(trifluoromethyl)phenyl]-4-(2-naphthylsulfonyl)piperazine was prepared in a similar fashion as described in step 9C for example 9A. Yield 25%.
1H NMR (400 MHz, DMSO-D6) δ ppm 2.93 (t, J=4.67 Hz, 4H) 3.07 (s, 4H) 7.46-7.59 (m, 2H) 7.66-7.84 (m, 4H) 8.12 (d, J=8.08 Hz, 1H) 8.23 (t, J=9.22 Hz, 2H) 8.49 (s, 1H). HRMS: calcd for C21H18F4N2O2S+H+, 439.10979; found (ESI-FTMS, [M+H]1+), 439.1092; HPLC Method 1, room temperature, 6.97 min, 92.19%; HPLC method 2, room temperature, 7.54 min, 96.62%.
Example 10Step 10A. A solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (3.7 g, 23 mmol) and triphenyl phosphine (12.23 g, 46 mmol) in 50 ml THF was mixed in an ice-H2O bath. A solution of diethyl azodicarboxylate (8.37 g, 46 mmol) in 50 ml THF was added drop-wise, followed by 2,6-dichlorophenol (3.87 g, 23 mmol). The mixture was warmed up to room temperature and stirred for 22 hr. Solvent was removed under vacuum and crude product was purified with column chromatography. tert-Butyl 4-(2,6-dichlorophenoxy)piperidine-1-carboxylate was obtained in 75% yield.
Step 10B. tert-Butyl 4-(2,6-dichlorophenoxy)piperidine-1-carboxylate (5.54 g) was mixed with 50 ml of mixture of TFA and CH2Cl2 (1:1). The mixture was stirred at room temperature for 4 hours. The solvents were removed under vacuum residue was Freeze-dried using CH3CN/water system. The desired 4-(2,6-dichlorophenoxy)piperidine was obtained as TFA salt (white solid) in 100% yield.
Step 10C: piperazine or piperidine (0.5 mmol) was mixed with 2 ml of CH2Cl2 and diisopropylethyl amine (1 mmol), aryl sulfonyl chloride (0.5 mmol) was added in one portion. The reaction mixture was stirred at room temperature, and progress of the reaction was monitored by TLC. When the reaction was completed, the reaction mixture was loaded onto silica gel column the product was isolated and purified by column chromatography. The following compounds were prepared using this general procedure.
Example 10A N-(4-{[4-(2,6-dichlorophenoxy)piperidin-1-yl]sulfonyl}phenyl)acetamideThe desired product was obtained in 34% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.85-2.15 (m, 4H) 2.18-2.29 (m, 3H) 2.91-3.08 (m, 2H) 3.33-3.51 (m, 2H) 4.21-4.40 (m, 1H) 6.96 (t, 1H) 7.27 (d, 2H) 7.42 (s, 1H) 7.64-7.78 (m, 4H). HRMS: calcd for C19H20Cl2N2O4S+H+, 443.05936; found (ESI-FTMS, [M+H]1+), 443.0592.
Example 10B 4-(2,6-dichlorophenoxy)-1-[(3,4-dimethoxyphenyl)sulfonyl]piperidineThe desired product was obtained in 42% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.88-2.22 (m, 4H) 2.91-3.08 (m, 2H) 3.28-3.55 (m, 2H) 3.94 (d, J=7.58 Hz, 6H) 4.26-4.45 (m, 1H) 6.93-7.02 (m, 2H) 7.21-7.31 (m, 3H) 7.40 (dd, J=8.34, 2.02 Hz, 1H). HRMS: calcd for C19H21Cl2NO5S+H+, 446.05902; found (ESI-FTMS, [M+H]1+), 446.0585.
Example 10C 4-(2,6-dichlorophenoxy)-1-[(3,4-dichlorophenyl)sulfonyl]piperidineThe desired product was obtained in 48% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.89-2.23 (m, 4H) 2.98-3.18 (m, 2H) 3.34-3.50 (m, 2H) 4.29-4.46 (m, 1H) 6.97 (t, 1H) 7.24-7.27 (m, 2H) 7.59-7.64 (m, 2H) 7.88 (d, J=1.77 Hz, 1H). HRMS: calcd for C17H15Cl4NO3S+H+, 453.95995; found (ESI-FTMS, [M+H]1+), 453.959.
Example 10D 4-(2,6-dichlorophenoxy)-1-[(2,4-difluorophenyl)sulfonyl]piperidineThe desired product was obtained in 36% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.83-2.18 (m, 4H) 3.18-3.40 (m, 2H) 3.55-3.72 (m, 2H) 4.32-4.50 (m, 1H) 6.89-7.12 (m, 3H) 7.27 (d, J=3.28 Hz, 2H) 7.46-7.59 (m, 1H). HRMS: calcd for C17H15Cl2F2NO3S+H+, 422.01905; found (ESI-FTMS, [M+H]1+), 422.0187.
Example 10E 1-[(3,4-dichlorobenzyl)sulfonyl]-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 58% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.82-2.10 (m, 4H) 3.11-3.32 (m, 2H) 3.37-3.66 (m, 2H) 4.34-4.52 (m, 1H) 6.99 (t, 1H) 7.25-7.27 (m, 1H) 7.27-7.30 (m, 2H) 7.47 (d, J=8.34 Hz, 1H) 7.53 (d, J=2.02 Hz, 1H). HRMS: calcd for C18H17Cl4NO3S+H+, 467.97560; found (ESI-FTMS, [M+H]1+), 467.9742.
Example 10F 4-(2,6-dichlorophenoxy)-1-(2-naphthylsulfonyl)piperidineThe desired product was obtained in 36% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.89-2.29 (m, 4H) 2.97-3.18 (m, 2H) 3.43-3.63 (m, 2H) 4.21-4.37 (m, 1H) 6.93 (t, 1H) 7.24 (t, 2H) 7.56-7.72 (m, 2H) 7.78 (dd, J=8.59, 1.77 Hz, 1H) 7.93 (d, J=7.58 Hz, 1H) 7.99 (d, J=8.84 Hz, 2H) 8.36 (d, J=1.26 Hz, 1H). HRMS: calcd for C21H19Cl2NO3S+H+, 436.05354; found (ESI-FTMS, [M+H]1+), 436.0529.
Example 10G 1-(1-benzothien-2-ylsulfonyl)-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 56% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.94-2.21 (m, 4H) 3.01-3.26 (m, 2H) 3.49-3.70 (m, 2H) 4.27-4.43 (m, 1H) 6.95 (t, 1H) 7.26 (s, 2H) 7.43-7.55 (m, 2H) 7.82 (s, 1H) 7.89 (t, 2H). HRMS: calcd for C19H17Cl2NO3S2+H+, 442.00996; found (ESI-FTMS, [M+H]1+), 442.0091.
Example 10H 1-(1-benzothien-3-ylsulfonyl)-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 49% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.87-2.14 (m, 4H) 2.96-3.27 (m, 2H) 3.50-3.69 (m, 2H) 4.18-4.40 (m, 1H) 6.94 (t, 1H) 7.23 (d, J=8.08 Hz, 2H) 7.37-7.55 (m, 2H) 7.90 (dd, 1H) 8.19 (s, 1H) 8.28 (dd, J=6.95, 1.14 Hz, 1H). HRMS: calcd for C19H17Cl2NO3S2+H+, 442.00996; found (ESI-FTMS, [M+H]1+), 442.0093.
Example 10I 1-[(2-chlorophenyl)sulfonyl]-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 64% yield as colorless semi-solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.91-2.13 (m, 4H) 3.19-3.35 (m, 2H) 3.64-3.78 (m, 2H) 4.33-4.51 (m, 1H) 6.98 (t, 1H) 7.27 (d, 2H) 7.37-7.44 (m, 1H) 7.45-7.59 (m, 2H) 8.08 (dd, J=7.83, 1.77 Hz, 1H). HRMS: calcd for C17H16Cl3NO3S+H+, 419.99892; found (ESI-FTMS, [M+H]1+), 419.9985.
Example 10J 1-[(2-bromophenyl)sulfonyl]-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 80% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.90-2.16 (m, 4H) 3.24-3.35 (m, 2H) 3.67-3.81 (m, 2H) 4.30-4.49 (m, 1H) 6.98 (t, 1H) 7.29 (d, J=8.08 Hz, 2H) 7.36-7.50 (m, 2H) 7.76 (dd, J=7.96, 1.39 Hz, 1H) 8.12 (dd, J=7.71, 1.89 Hz, 1H); HRMS: calcd for C17H16BrCl2NO3S+H+, 463.94840; found (ESI-FTMS, [M+H]1+), 463.9478.
Example 10K 1-[(2-chlorophenyl)sulfonyl]-4-(2,6-dichlorophenoxy piperidine1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.90-2.18 (m, 4H) 3.24-3.35 (m, 2H) 3.66-3.77 (m, 2H) 4.34-4.51 (m, 1H) 6.98 (t, 1H) 7.28 (s, 1H) 7.29-7.31 (m, 1H) 7.40 (t, 1H) 7.45-7.58 (m, 2H) 8.08 (dd, J=7.83, 1.26 Hz, 1H). HRMS: calcd for C17H16Cl3NO3S+H+, 419.99892; found (ESI-FTMS, [M+H]1+), 419.9985.
Example 10L 2-{[4-(2,6-dichlorophenoxy)piperidin-1-yl]sulfonyl}benzonitrileThe desired product was obtained in 70% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.89-2.15 (m, 4H) 3.23-3.41 (m, 2H) 3.56-3.70 (m, 2H) 4.35-4.45 (m, 1H) 6.97 (t, 1H) 7.29 (s, 1H) 7.68-7.80 (m, 2H) 7.90 (dd, J=7.33, 1.77 Hz, 1H) 8.08 (dd, J=7.58, 1.26 Hz, 1H); HRMS: calcd for C18H16Cl2N2O3S+H+, 411.03314; found (ESI-FTMS, [M+H]1+), 411.0323.
Example 10M 4-(2,6-dichlorophenoxy)-1-[(2-nitrophenyl)sulfonyl]piperidineThe desired product was obtained in 82% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.92-2.19 (m, 4H) 3.20-3.45 (m, 2H) 3.62-3.78 (m, 2H) 4.31-4.51 (m, 1H) 6.99 (t, 1H) 7.29 (d, J=8.08 Hz, 2H) 7.61-7.65 (m, 1H) 7.68-7.75 (m, 2H) 8.00-8.05 (m, 1H); HRMS: calcd for C17H16Cl2N2O5S+H+, 431.02297; found (ESI-FTMS, [M+H]1+), 431.0216.
Example 10N 4-(2,6-dichlorophenoxy)-1-[(4-phenoxyphenyl)sulfonyl]piperidineThe desired product was obtained in 50% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.92-2.21 (m, 4H) 2.90-3.10 (m, 2H) 3.32-3.52 (m, 2H) 4.27-4.45 (m, 1H) 6.97 (t, 1H) 7.03-7.12 (m, 4H) 7.23 (t, 1H) 7.26 (s, 1H) 7.28 (s, 1H) 7.36-7.45 (m, 2H) 7.71-7.76 (m, 2H). HRMS: calcd for C23H21Cl2NO4S+H+, 478.06411; found (ESI-FTMS, [M+H]1+), 478.063.
Example 10O 4-(2,6-dichlorophenoxy)-1-{[2-(trifluoromethyl)phenyl]sulfonyl}piperidineThe desired product was obtained in 72% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.91-2.13 (m, 4H) 3.19-3.37 (m, 2H) 3.59-3.73 (m, 2H) 4.35-4.49 (m, 1H) 6.98 (t, 1H) 7.29 (d, J=8.08 Hz, 2H) 7.68-7.77 (m, 2H) 7.89-7.93 (m, 1H) 8.13-8.18 (m, 1H). HRMS: calcd for C18H16Cl2F3NO3S+H+, 454.02528; found (ESI-FTMS, [M+H]1+), 454.0244.
Example 10P 1-[(4-chlorophenyl)sulfonyl]-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 74% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.88-2.16 (m, 4H) 2.97-3.13 (m, 2H) 3.31-3.51 (m, 2H) 4.26-4.41 (m, 1H) 6.97 (t, 1H) 7.26 (d, 2H) 7.48-7.56 (m, 2H) 7.70-7.76 (m, 2H). HRMS: calcd for C17H16Cl3NO3S+H+, 419.99892; found (ESI-FTMS, [M+H]1+), 419.9982.
Example 10Q 4-(2,6-dichlorophenoxy)-1-(2-thienylsulfonyl)piperidineThe desired product was obtained in 74% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.92-2.21 (m, 4H) 3.03-3.15 (m, 2H) 3.38-3.55 (m, 2H) 4.31-4.48 (m, 1H) 6.97 (t, 1H) 7.15 (t, J=5.05, 3.79 Hz, 1H) 7.26 (s, 1H) 7.28 (s, 1H) 7.56 (dd, J=3.66, 1.39 Hz, 1H) 7.62 (dd, J=4.93, 1.39 Hz, 1H). HRMS: calcd for C15H15Cl2NO3S2+H+, 391.99431; found (ESI-FTMS, [M+H]1+), 391.9934.
Example 10R 1-(biphenyl-3-ylsulfonyl)-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 87% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.93-2.17 (m, 4H) 2.95-3.10 (m, 2H) 3.42-3.55 (m, 2H) 4.23-4.43 (m, 1H) 6.94 (t, 1H) 7.26 (d, J=2.53 Hz, 2H) 7.37-7.45 (m, 1H) 7.45-7.52 (m, 2H) 7.57-7.66 (m, 3H) 7.73-7.79 (m, 1H) 7.79-7.85 (m, 1H) 7.99 (t, J=1.77 Hz, 1H). HRMS: calcd for C23H21Cl2NO3S+H+, 462.06919; found (ESI-FTMS, [M+H]1+), 462.0675.
Example 10S 1-[(4′-bromobiphenyl-4-yl)sulfonyl]-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 90% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.87-2.19 (m, 4H) 3.00-3.16 (m, 2H) 3.38-3.52 (m, 2H) 4.28-4.43 (m, 1H) 6.95 (t, J=8.08 Hz, 1H) 7.25 (d, J=7.83 Hz, 2H) 7.47 (d, J=8.34 Hz, 2H) 7.61 (d, J=8.34 Hz, 2H) 7.70 (d, J=8.34 Hz, 2H) 7.85 (d, J=8.34 Hz, 2H).
Example 10T 1-(dibenzo[b,d]furan-2-ylsulfonyl)-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 95% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.93-2.18 (m, 4H) 2.93-3.14 (m, 2H) 3.40-3.59 (m, 2H) 4.21-4.37 (m, 1H) 6.93 (t, 1H) 7.22 (d, J=7.83 Hz, 2H) 7.42 (t, 1H) 7.55 (t, 1H) 7.63 (d, 1H) 7.70 (d, J=9.35 Hz, 1H) 7.90 (dd, J=8.59, 2.02 Hz, 1H) 8.01 (d, J=7.83 Hz, 1H) 8.42 (d, J=1.26 Hz, 1H). HRMS: calcd for C23H19Cl2NO4S+H+, 476.04846; found (ESI-FTMS, [M+H]1+), 476.0474.
Example 10U 1-(dibenzo[b,d]thien-2-ylsulfonyl)-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 97% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.93-2.20 (m, 4H) 2.97-3.13 (m, 2H) 3.47-3.61 (m, 2H) 4.22-4.34 (m, 1H) 6.92 (t, 1H) 7.22 (d, J=8.08 Hz, 2H) 7.51-7.58 (m, 2H) 7.83 (dd, J=8.34, 1.77 Hz, 1H) 7.86-7.94 (m, 1H) 8.00 (d, J=8.59 Hz, 1H) 8.21-8.28 (m, 1H) 8.56 (d, J=1.77 Hz, 1H). HRMS: calcd for C23H19Cl2NO3S2+H+, 492.02561; found (ESI-FTMS, [M+H]1+), 492.0271.
Example 10V 1-(dibenzo[b,d]thien-3-ylsulfonyl)-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 93% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.92-2.16 (m, 4H) 3.00-3.14 (m, 2H) 3.45-3.61 (m, 2H) 4.21-4.36 (m, 1H) 6.93 (t, 1H) 7.23 (d, J=8.08 Hz, 2H) 7.48-7.60 (m, 2H) 7.85 (dd, J=8.34, 1.77 Hz, 1H) 7.91 (dd, J=6.57, 1.26 Hz, 1H) 8.20-8.26 (m, 1H) 8.27-8.34 (m, 2H). HRMS: calcd for C23H19Cl2NO3S2+H+, 492.02561; found (ESI-FTMS, [M+H]1+), 492.0247.
Example 10W 4-(2,6-dichlorophenoxy)-1-[(4′-fluorobiphenyl-4-yl)sulfonyl]piperidineThe desired product was obtained in 93% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.89-2.17 (m, 4H) 2.98-3.13 (m, 2H) 3.36-3.55 (m, 2H) 4.28-4.40 (m, 1H) 6.95 (t, 1H) 7.17 (t, 2H) 7.26 (d, 2H) 7.54-7.62 (m, 2H) 7.70 (d, 2H) 7.84 (d, 2H). HRMS: calcd for C23H20Cl2FNO3S+H+, 480.05977; found (ESI-FTMS, [M+H]1+), 480.06.
Example 10X 1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 97% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.95-2.18 (m, 4H) 2.65-2.74 (m, 3H) 3.17-3.31 (m, 2H) 3.55-3.77 (m, 2H) 4.29-4.45 (m, 1H) 6.96 (t, 1H) 7.27 (d, 2H) 7.46 (dd, J=8.59, 2.02 Hz, 1H) 7.76 (d, J=8.59 Hz, 1H) 7.81 (d, J=2.02 Hz, 1H). HRMS: calcd for C20H18Cl3NO3S2+H+, 489.98664; found (ESI-FTMS, [M+H]1+), 489.9852.
Example 11Step 11A: To a stirred solution of p-toluenesulfonyl chloride (39.28 mmol) in dichloromethane (160 mL) was added 4-hydroxypiperidine (40.07 mmol) dropwise, followed by 13.7 ml i-Pr2NEt. The mixture was stirred at room temperature for 3 h. Solvent was removed under vacuum and crude product was purified with flash column chromatography to yield 4-hydroxypiperidin sulfonamide (I).
Step 11B: A solution of aryl alcohol (1.17 mmol) and triphenyl phosphine (0.349 g, 1.33 mmol) in 2 ml THF was mixed in an ice-H2O bath. A solution of diethyl azodicarboxylate (0.232 g, 1.33 mmol) in 2 ml THF was added drop-wise, followed by 4-hydroxypiperidin sulfonamide (I) (0.78 mmol). The mixture was warmed up to room temperature and stirred for 22 hr. Solvent was removed under vacuum and crude product was purified with column chromatography. The following compounds were prepared using this procedure.
Example 11A 4-(2,4-dichlorophenoxy)-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in 33% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.87-2.05 (m, 4H) 2.44 (s, 3H) 2.95-3.11 (m, 2H) 3.20-3.35 (m, 2H) 4.34-4.52 (m, 1H) 6.80 (d, J=8.84 Hz, 1H) 7.12 (dd, J=8.84, 2.53 Hz, 2H) 7.22-7.38 (m, 3H) 7.65 (d, J=8.08 Hz, 2H).
Example 11B 1-[(4-methylphenyl)sulfonyl]-4-phenoxypiperidineThe desired product was obtained in 80% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.83-2.17 (m, 4H) 2.45 (s, 3H) 2.98-3.28 (m, 4H) 4.23-4.45 (m, 1H) 6.80 (d, J=7.58 Hz, 2H) 6.93 (t, J=7.45 Hz, 3H) 7.24 (t, 3H) 7.34 (d, J=8.08 Hz, 2H) 7.66 (d, J=8.34 Hz, 2H).
Example 11C 4-(2-chlorophenoxy)-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in 72% yield as white solid. 1H NMR (400 MHz, Acetone) δ ppm 1.82-1.97 (m, 2H) 1.96-2.05 (m, J=10.11 Hz, 2H) 2.47 (s, 3H) 3.06-3.24 (m, 4H) 4.55-4.75 (m, J=3.28 Hz, 1H) 6.89-6.99 (m, 1H) 7.16 (dd, 1H) 7.25 (t, 1H) 7.35 (dd, 1H) 7.48 (d, J=8.59 Hz, 2H) 7.70 (d, 2H).
Example 11D 4-(2-methoxyphenoxy)-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in 25% yield as oil-like liquid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.85-2.08 (m, 4H) 2.44 (s, 3H) 2.97-3.16 (m, 2H) 3.18-3.35 (m, 2H) 3.70 (s, 3H) 4.17-4.38 (m, 1H) 6.80-6.89 (m, 3H) 6.90-7.00 (m, 1H) 7.33 (d, J=8.08 Hz, 2H) 7.67 (d, J=8.08 Hz, 2H).
Example 11D 3-({1-[(4-methylphenyl)sulfonyl]piperidin-4-yl}oxy)pyridineThe desired product was obtained in 44% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.84-1.99 (m, 2H) 1.98-2.11 (m, 2H) 2.46 (s, 3H) 3.16 (t, J=5.56 Hz, 4H) 4.26-4.53 (m, 1H) 7.07-7.15 (m, 1H) 7.14-7.22 (m, 1H) 7.35 (d, J=8.08 Hz, 2H) 7.67 (d, J=8.34 Hz, 2H) 8.20 (d, J=3.03 Hz, 2H).
Example 11E 4-(2-fluorophenoxy)-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in 40% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.82-2.11 (m, 4H) 2.39-2.52 (m, 3H) 2.95-3.29 (m, 4H) 4.24-4.44 (m, 1H) 6.85-6.97 (m, 2H) 6.96-7.11 (m, 2H) 7.34 (d, J=8.34 Hz, 2H) 7.66 (d, J=8.34 Hz, 2H).
Example 11F 4-(biphenyl-4-yloxy)-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in 30% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.84-2.12 (m, 4H) 2.41-2.53 (m, 3H) 3.03-3.25 (m, 4H) 4.36-4.49 (m, 1H) 6.87 (dd, 2H) 7.30 (t, 1H) 7.35 (d, J=7.83 Hz, 2H) 7.37-7.43 (m, 2H) 7.44-7.54 (m, 4H) 7.67 (d, 2H).
Example 11G 4-(4-methoxyphenoxy)-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in 30% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.82-2.08 (m, 4H) 2.37-2.52 (m, 3H) 3.02-3.27 (m, 4H) 3.71-3.80 (m, 3H) 4.16-4.27 (m, 1H) 6.69-6.81 (m, 4H) 7.34 (d, J=8.08 Hz, 2H) 7.66 (d, J=8.08 Hz, 2H).
Example 11H 1-[(4-methylphenyl)sulfonyl]-4-[2-(trifluoromethyl)phenoxy]piperidineThe desired product was obtained in 44% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.90-2.11 (m, 4H) 2.45 (s, 3H) 2.80-2.99 (m, 2H) 3.28-3.49 (m, 2H) 4.54-4.72 (m, 1H) 6.89 (d, 1H) 6.96 (t, 1H) 7.33 (d, 2H) 7.42 (t, 1H) 7.51 (t, 1H) 7.64 (d, 2H).
Example 11I 4-(2,6-dichlorophenoxy)-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in 40% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.87-2.19 (m, 4H) 2.44 (s, 3H) 2.88-3.05 (m, 2H) 3.29-3.54 (m, 2H) 4.17-4.43 (m, 1H) 6.96 (t, 1H) 7.26 (d, 2H) 7.33 (d, J=8.08 Hz, 2H) 7.67 (d, 2H), HRMS: calcd for C18H19Cl2NO3S+H+, 400.05354; found (ESI-FTMS, [M+H]1+), 400.0534.
Example 11J 4-(2-methylphenoxy)-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in 35% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.88-2.07 (m, 7H) 2.45 (s, 3H) 2.98-3.11 (m, 2H) 3.12-3.25 (m, 2H) 4.35-4.47 (m, 1H) 6.72 (d, 1H) 6.84 (t, 1H) 7.03-7.15 (m, 2H) 7.34 (d, 2H) 7.66 (d, 2H)
Example 11K 2-({1-[(4-methylphenyl)sulfonyl]piperidin-4-yl}oxy)benzonitrileThe desired product was obtained in 27% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.93-2.16 (m, 4H) 2.44 (s, 3H) 3.04-3.20 (m, 2H) 3.25-3.41 (m, 2H) 4.47-4.62 (m, 1H) 6.90 (d, J=8.34 Hz, 1H) 6.99 (t, 3H) 7.34 (d, J=7.83 Hz, 2H) 7.43-7.56 (m, 2H) 7.66 (d, J=8.34 Hz, 2H).
Example 11L 1-[(4-methylphenyl)sulfonyl]-4-(2-nitrophenoxy)piperidineThe desired product was obtained in 43% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.90-2.10 (m, 4H) 2.46 (s, 3H) 2.88-3.07 (m, 2H) 3.26-3.50 (m, 2H) 4.57-4.74 (m, 1H) 7.01 (t, 3H) 7.35 (d, 2H) 7.47 (t, 1H) 7.64 (d, 2H) 7.76 (dd, 1H).
Example 11M 4-[(2-methoxybenzyl)oxy]-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in 65% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.72-1.86 (m, 2H) 1.86-1.97 (m, 2H) 2.43 (s, 3H) 2.88-3.01 (m, 2H) 3.14-3.28 (m, 2H) 3.45-3.52 (m, 1H) 3.76 (s, 3H) 4.48 (s, 2H) 6.83 (d, J=8.34 Hz, 1H) 6.89 (t, 1H) 7.15-7.35 (m, 4H) 7.64 (d, J=8.34 Hz, 2H).
Example 11N 4-(2-bromophenoxy)-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in % yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.92-2.05 (m, 4H) 2.45 (s, 3H) 2.95-3.10 (m, 2H) 3.25-3.41 (m, 2H) 4.44-4.62 (m, J=3.79, 3.79 Hz, 1H) 6.82 (q, 2H) 7.19 (t, 1H) 7.35 (d, 2H) 7.45 (dd, 1H) 7.66 (d, 2H), HRMS: calcd for C18H20BrNO3S+H+, 410.04200; found (ESI-FTMS, [M+H]1+), 410.0411.
Example 11O 4-(2,6-dimethylphenoxy)-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in 41% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.79-2.04 (m, 4H) 2.16-2.23 (m, 6H) 2.43 (s, 3H) 2.53-2.68 (m, 2H) 3.54-3.67 (m, J=1.87 Hz, 2H) 3.69-3.87 (m, 1H) 6.82-6.93 (m, 1H) 6.97 (dd, 2H) 7.32 (d, 2H) 7.65 (d, 2H), HRMS: calcd for C20H25NO3S+H+, 360.16279; found (ESI-FTMS, [M+H]1+), 360.1617.
Example 11P 4-(2-ethylphenoxy)-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in 14% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.94 (t, J=7.58 Hz, 3H) 1.85-2.10 (m, 4H) 2.36 (q, J=7.58 Hz, 2H) 2.44 (s, 3H) 2.89-3.06 (m, 2H) 3.18-3.41 (m, 2H) 4.37-4.58 (m, 1H) 6.73 (dd, 1H) 6.85 (t, 1H) 7.03-7.15 (m, 2H) 7.33 (d, J=7.83 Hz, 2H) 7.66 (d, 2H), HRMS: calcd for C20H25NO3S+H+, 360.16279; found (ESI-FTMS, [M+H]1+), 360.1617.
Example 11Q 1-[(4-methylphenyl)sulfonyl]-4-(2-propylphenoxy)piperidineThe desired product was obtained in 19% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.73 (t, J=7.33 Hz, 3H) 1.26-1.45 (m, 2H) 1.81-2.06 (m, 4H) 2.19-2.36 (m, 2H) 2.44 (s, 3H) 2.81-3.04 (m, 2H) 3.23-3.40 (m, 2H) 4.47 (t, J=4.04 Hz, 1H) 6.70 (d, 1H) 6.83 (t, 1H) 7.01-7.15 (m, 2H) 7.34 (d, 2H) 7.64 (d, 2H); HRMS: calcd for C21H27NO3S+H+, 374.17844; found (ESI-FTMS, [M+H]1+), 374.1785.
Example 11R 4-(2-isopropylphenoxy)-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in 36% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.00 (d, J=7.07 Hz, 6H) 1.91-2.07 (m, 4H) 2.44 (s, 3H) 2.85-3.10 (m, 3H) 3.14-3.38 (m, 2H) 4.30-4.56 (m, 1H) 6.72 (d, J=7.83 Hz, 1H) 6.89 (t, 1H) 7.08 (t, 1H) 7.15 (dd, J=7.45, 1.64 Hz, 1H) 7.33 (d, J=8.08 Hz, 2H) 7.65 (d, 2H); HRMS: calcd for C21H27NO3S+H+, 374.17844; found (ESI-FTMS, [M+H]1+), 374.1789.
Example 11S 4-(2-chloro-6-methylphenoxy)-1-[(4-methylphenyl)sulfonyl]piperidineThe desired product was obtained in 35% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δδ ppm 1.89-2.10 (m, 4H) 2.21 (s, 3H) 2.43 (s, 3H) 2.67-2.81 (m, 2H) 3.45-3.66 (m, 2H) 3.99-4.22 (m, 1H) 6.91 (t, J=7.71 Hz, 1H) 7.04 (d, J=7.58 Hz, 1H) 7.16 (dd, J=7.71, 1.39 Hz, 1H) 7.33 (d, J=7.83 Hz, 2H) 7.66 (d, J=8.34 Hz, 2H); HRMS: calcd for C19H22ClNO3S+H+, 380.10817; found (ESI-FTMS, [M+H]1+), 380.1085.
Example 11T 2-chloro-3-({1-[(4-methylphenyl)sulfonyl]piperidin-4-yl}oxy)pyridineThe desired product was obtained in 30% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.96-2.02 (m, 4H) 2.45 (s, 3H) 2.93-3.07 (m, 2H) 3.29-3.40 (m, 2H) 4.48-4.58 (m, 1H) 7.16 (d, J=3.03 Hz, 2H) 7.35 (d, J=8.08 Hz, 2H) 7.66 (d, 2H) 7.99 (t, J=3.16 Hz, 1H); HRMS: calcd for C17H19ClN2O3S+H+, 367.08777; found (ESI-FTMS, [M+H]1+), 367.0884.
Example 11U 4-(2-bromophenoxy)-1-[(3,4-dimethoxyphenyl)sulfonyl]piperidineThe desired product was obtained in 49% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.88-2.06 (m, 4H) 2.94-3.15 (m, 2H) 3.26-3.43 (m, 2H) 3.95 (d, J=8.59 Hz, 6H) 4.48-4.62 (m, J=3.54, 3.54 Hz, 1H) 6.79-6.89 (m, 4H) 6.97 (d, J=8.34 Hz, 1H) 7.18-7.25 (m, 2H) 7.40 (dd, J=8.46, 2.15 Hz, 1H) 7.47 (dd, J=7.96, 1.64 Hz, 1H). HRMS: calcd for C19H22BrNO5S+H+, 456.04748; found (ESI-FTMS, [M+H]1+), 456.0472.
Example 12Step 12A. To a solution of N-(tert-butoxycarbonyl)-4-piperidone (8.01 g, 39.4 mmol), 2-chloroaniline (5.74 g, 44.1 mmol) and acetic acid (2.80 g, 46.6 mmol) in 200 ml ethylene chloride ethane was added sodium triacetoxyborohydride (8.37 g, 78.8 mmol). The mixture was stirred at room temp for 2.5 days. Added 2N NaOH solution to adjust pH to 10. The organic phase was separated and washed with water, then dried over Na2SO4. Solvent was removed under vacuum and crude product was purified with flash column chromatography to yield tert-butyl-4-(2-chlorophenylamino)piperidine-1-carboxylate in 8.2% yield (1.6 g) as white solid.
Step 12B. tert-butyl-4-(2-chlorophenylamino)piperidine-1-carboxylate (1.54 g, 4.95 mmol) in 20 ml DME was mixed with 20 ml TFA at room temp for 3 hr. Solvent was removed under vacuum to give the desired product (2.2 g).
Step 12C: The product obtained step 12B can then be coupled to the appropriate sulfonyl chloride (e.g., ArSO2Cl) as described elsewhere herein.
Example 12A 1-(1-benzothien-2-ylsulfonyl)-N-(2-chlorophenyl)piperidin-4-amineThe desired product was obtained in 99% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.59-1.75 (m, 2H) 2.09-2.24 (m, 2H) 2.72-2.85 (m, 2H) 3.23-3.45 (m, 1H) 3.75-3.88 (m, 2H) 4.12-4.22 (m, J=7.33, 4.55 Hz, 1H) 6.49-6.68 (m, 2H) 7.07 (t, 1H) 7.26 (t, 1H) 7.44-7.58 (m, 2H) 7.81-7.85 (m, 1H) 7.90 (t, 2H). HRMS: calcd for C19H19ClN2O2S2+H+, 407.06492; found (ESI-FTMS, [M+H]1+), 407.0645.
Example 12B N-(2-chlorophenyl)-1-(dibenzo[b,d]furan-3-ylsulfonyl)piperidin-4-amineThe desired product was obtained in 90% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.61-1.71 (m, 2H) 2.07-2.20 (m, 2H) 2.56-2.72 (m, 2H) 3.22-3.33 (m, 1H) 3.73-3.86 (m, 2H) 4.08-4.19 (m, J=7.07, 7.07, 7.07 Hz, 1H) 6.52 (d, 1H) 6.61 (t, 1H) 7.05 (t, 1H) 7.21 (dd, 1H) 7.45 (t, 1H) 7.59 (t, 1H) 7.67 (d, 1H) 7.79 (dd, 1H) 8.11 (d, 1H). HRMS: calcd for C23H21ClN2O3S+H+, 441.10342; found (ESI-FTMS, [M+H]1+), 441.1031.
Example 12C N-(2-chlorophenyl)-1-[(2-chlorophenyl)sulfonyl]piperidin-4-amineThe desired product was obtained in 63% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.51-1.68 (m, 2H) 2.04-2.21 (m, 2H) 2.95-3.09 (m, 2H) 3.35-3.52 (m, 1H) 3.70-3.92 (m, 2H) 4.10-4.26 (m, J=7.58 Hz, 1H) 6.63 (t, 3H) 7.10 (t, 1H) 7.23-7.26 (m, 1H) 7.36-7.44 (m, 1H) 7.47-7.57 (m, 2H) 8.08 (dd, J=7.71, 1.39 Hz, 1H). HRMS: calcd for C17H18Cl2N2O2S+H+, 385.05388; found (ESI-FTMS, [M+H]1+), 385.0536.
Example 12D N-(2-chlorophenyl)-1-[(3-chlorophenyl)sulfonyl]piperidin-4-amineThe desired product was obtained in 63% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.57-1.71 (m, 2H) 2.09-2.20 (m, 2H) 2.63 (t, 2H) 3.26-3.40 (m, J=3.79 Hz, 1H) 3.63-3.79 (m, 2H) 4.10-4.20 (m, J=8.08 Hz, 1H) 6.53-6.68 (m, 2H) 7.08 (t, 1H) 7.24 (dd, 1H) 7.51 (t, 1H) 7.57-7.64 (m, 1H) 7.64-7.70 (m, 1H) 7.75-7.81 (m, 1H). HRMS: calcd for C17H18Cl2N2O2S+H+, 385.05388; found (ESI-FTMS, [M+H]1+), 385.0537.
Example 12E N-(2-chlorophenyl)-1-[(4-phenoxyphenyl)sulfonyl]piperidin-4-amineThe desired product was obtained in 64% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.57-1.71 (m, 2H) 2.13 (dd, J=13.01, 3.66 Hz, 2H) 2.55-2.72 (m, 2H) 3.23-3.39 (m, J=8.08 Hz, 1H) 3.60-3.71 (m, 2H) 4.10-4.18 (m, J=7.83 Hz, 1H) 6.54-6.72 (m, 2H) 7.03-7.13 (m, 5H) 7.21-7.26 (m, 2H) 7.39-7.46 (m, 2H) 7.70-7.76 (m, 2H). HRMS: calcd for C23H23ClN2O3S+H+, 443.11907; found (ESI-FTMS, [M+H]1+), 443.1198.
Example 12F 1-(biphenyl-4-ylsulfonyl)-N-(2-chlorophenyl)piperidin-4-amineThe desired product was obtained in 60% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.57-1.73 (m, 2H) 2.08-2.22 (m, 2H) 2.58-2.72 (m, 2H) 3.26-3.43 (m, 1H) 3.68-3.81 (m, 2H) 4.07-4.20 (m, J=7.83 Hz, 1H) 6.53-6.65 (m, 2H) 7.06 (t, 1H) 7.23 (dd, 1H) 7.40-7.47 (m, 1H) 7.47-7.55 (m, 2H) 7.60-7.66 (m, 2H) 7.73-7.79 (m, 2H) 7.82-7.87 (m, 2H). HRMS: calcd for C23H23ClN2O2S+H+, 427.12415; found (ESI-FTMS, [M+H]1+), 427.1247.
Example 13The desired product was obtained in 90% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.07-3.31 (m, 4H) 3.51-3.72 (m, 4H) 6.74-6.84 (m, 1H) 7.22 (t, 1H) 7.58-7.67 (m, 2H) 7.87 (d, J=1.52 Hz, 1H) 7.98 (d, 1H).
Example 13B 2-{4-[(3,4-dichlorophenyl)sulfonyl]piperazin-1-yl}nicotinonitrileThe desired product was obtained in 70% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.09-3.31 (m, 4H) 3.63-3.88 (m, 4H) 6.84 (dd, J=7.58, 4.80 Hz, 1H) 7.55-7.70 (m, 2H) 7.79 (dd, J=7.58, 2.02 Hz, 1H) 7.87 (d, J=1.77 Hz, 1H) 8.35 (dd, J=4.93, 1.90 Hz, 1H).
Example 13C 1-[(3,4-dichlorophenyl)sulfonyl]-4-(3-nitropyridin-2-yl)piperazineThe desired product was obtained in 45% yield as white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.11-3.27 (m, 4H) 3.48-3.66 (m, 4H) 6.85 (dd, J=7.96, 4.67 Hz, 1H) 7.54-7.71 (m, 2H) 7.86 (t, J=2.02 Hz, 1H) 8.15 (dd, J=8.08, 1.77 Hz, 1H) 8.34 (dd, J=4.55, 1.77 Hz, 1H).
Step 13AA: 1′-Benzyl-3-methyl-2′,3′,5′,6′-tetrahydro-1′H-[2,4′]bipyridinyl-4′-ol. Following the procedure of N. I. Carruthers et al. (J. Med. Chem. 2005, 48, 1857-1872), to a −78° C. solution of 2-bromo-3-methylpyridine (10.0 g, 7.1 mL, 57.1 mmol) in THF (150 mL) was added drop wise a solution of n-BuLi (2.5 M in hexanes, 25.1 mL, 62.8 mmol) over 10 min. After 1.5 h a solution of N-benzyl-4-piperidone (10.8 g, 57.1 mmol) in THF (20 mL) was added drop wise over 15 min and the mixture was allowed to slowly warm to room temperature overnight. After 18 h sat. NH4Cl solution (40 mL) was added and the mixture was concentrated. The resulting residue was diluted with 1N NaHCO3 (100 ml) and extracted with EtOAc. The combined organic phase was washed with brine, dried (MgSO4), and concentrated. Flash chromatography afforded the alcohol (8.1 g), an orange viscous oil, in 50% yield.
Step 13AB: 1′-Benzyl-3-methyl-1′,2′,3′,6′-tetrahydro-[2,4′]bipyridinyl. Thionyl chloride (10 mL) was added slowly drop wise to the alcohol from Step 13AA (6.34 g, 22.45 mmol). After 20 h, the mixture was concentrated, diluted with CH2Cl2 (100 mL) and cooled to 0° C. Sat. NaHCO3 (300 mL) was slowly added to the mixture. The aqueous phase was separated and extracted with CH2Cl2 (2×150 mL). The combined organic extracts were washed with H2O (2×150 mL) and brine (150 mL), dried (MgSO4), and concentrated to afford the olefin (3.54 g), a brown viscous oil, in 60% yield.
1H NMR (400 MHz, MeOD) δ ppm 2.59 (s, 3H), 2.69-2.76 (m, 2H), 3.04 (t, J=5.7 Hz, 2H), 3.44 (q, J=2.8 Hz, 2H), 3.95 (s, 2H), 5.94-5.99 (m, 1H), 7.42 (dd, J=7.7, 4.9 Hz, 1H), 7.49-7.54 (m, 1H), 7.55-7.61 (m, 2H), 7.61-7.66 (m, 2H), 7.88 (d, J=8.6 Hz, 1H), 8.51 (dd, J=4.8, 1.0 Hz, 1H).
Step 13AC: 3-Methyl-1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl. The olefin from Step 13AB (2.97 g, 11.23 mmol) was dissolved in EtOH (100 mL) and transferred to a Parr shaker bottle. 20% Pd(OH)2 (1.48 g) was added, and the mixture was hydrogenated at 60 psi for 20 h. The mixture was filtered and concentrated. The residue was re-dissolved in MeOH (176 ml). 20% Pd(OH)2 (2.0 g) and Acetyl Chloride (1.44 g, 1.3 ml, 18.32 mmol) was added, and the mixture was hydrogenated at 60 psi for 2 d. The mixture was filtered and concentrated and adhered to silica. Purification by flash chromatography (elution with 0 to 20% MeOH—CH2Cl2) to afford the amine (1.51 g), an off-white 76% yield.
1H NMR (400 MHz, MeOD) δ ppm 2.36-2.61 (m, 4H), 2.87 (s, 3H), 3.47-3.58 (m, 3H), 3.77-3.87 (m, 2H), 3.89-4.03 (m, 1H), 8.12 (dd, J=8.1, 5.8 Hz, 1H), 8.69 (d, J=7.1 Hz, 1H), 8.86 (d, J=4.5 Hz, 1H).
Step 13AD: 2-{1-[(2-chlorophenyl)sulfonyl]piperidin-4-yl}-3-methylpyridine. To a solution of the amine from Step 13AC (100 mg, 0.57 mmol) in CH2Cl2 (2.9 mL) was added 2-chlorobenzenesulfonyl chloride (150 mg, 0.097 mL, 0.69 mmol) and sat. NaHCO3 (1.4 mL). The biphasic mixture was stirred at room temperature overnight. The reaction mixture was diluted with CH2Cl2 (3 mL) and poured into a Phase Separator cartridge. The organic phase was concentrated and purified by flash chromatography (elution with 0-30% EtOAc-hex). Lyophilization then afforded the title compound (26 mg), a white solid, in 13% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.79 (d, J=14.1 Hz, 2H), 1.97-2.11 (m, 2H), 2.31 (s, 3H), 2.87-2.96 (m, 3H), 3.99 (dd, J=12.1 Hz, 2H), 7.03 (dd, J=7.6, 4.8 Hz, 1H), 7.36-7.42 (m, 2H), 7.46-7.56 (m, 2H), 8.10 (dd, J=8.0, 1.6 Hz, 1H), 8.39 (d, J=4.8 Hz, 1H). HRMS: calcd for C17H19ClN2O2S+H+, 351.09285; found (ESI-FTMS, [M+H]1+), 351.0934.
Example 13A-2 2-{1-[(4-chlorophenyl)sulfonyl]piperidin-4-yl}-3-methylpyridineUsing the procedure from Example 13A-1, the title compound was prepared and isolated as a white solid in 33% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.80 (d, J=14.4 Hz, 2H), 2.03-2.16 (m, 2H), 2.26 (s, 3H), 2.38-2.49 (m, 2H), 2.73-2.81 (m, 1H), 3.93 (d, J=11.4 Hz, 2H), 7.03 (dd, J=7.6, 4.8 Hz, 1H), 7.39 (d, J=6.6 Hz, 1H), 7.53 (d, J=8.6 Hz, 2H), 7.75 (d, J=8.8 Hz, 2H), 8.38 (d, J=4.8 Hz, 1H). HRMS: calcd for C17H19ClN2O2S+H+, 351.09285; found (ESI-FTMS, [M+H]1+), 351.0935.
Example 13A-3 2-{1-[(2,6-dichlorophenyl)sulfonyl]piperidin-4-yl}-3-methylpyridineUsing the procedure from Example 13A-1, the title compound was isolated as a white solid (82 mg) in 31% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.81 (d, J=14.7 Hz, 2H), 1.94-2.11 (m, 2H), 2.32 (s, 3H), 2.90-2.99 (m, 1H), 2.99-3.09 (m, 2H), 4.07 (d, J=12.4 Hz, 2H), 7.03 (dd, J=7.6, 4.8 Hz, 1H), 7.29-7.35 (m, 1H), 7.41 (d, J=7.6 Hz, 1H), 7.44-7.50 (m, 2H), 8.38 (d, J=6.3 Hz, 1H). HRMS: calcd for C17H18Cl2N2O2S+H+, 385.05388; found (ESI-FTMS, [M+H]1+), 385.0543.
Example 13A-4 2-{1-[(3,4-dichlorophenyl)sulfonyl]piperidin-4-yl}-3-methylpyridineUsing the procedure from Example 13A-1, the title compound (35 mg) was isolated as a white solid in 13% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.76-1.86 (m, J=16.2, 1.3 Hz, 2H), 2.04-2.18 (m, 2H), 2.27 (s, 3H), 2.43-2.55 (m, 2H), 2.74-2.84 (m, 1H), 3.94 (d, J=11.4 Hz, 2H), 7.03 (dd, J=7.7, 4.7 Hz, 1H), 7.39 (d, J=7.6 Hz, 1H), 7.64 (d, J=1.3 Hz, 2H), 7.90 (s, 1H), 8.39 (d, J=6.3 Hz, 1H). HRMS: calcd for C17H18Cl2N2O2S+H+, 385.05388; found (ESI-FTMS, [M+H]1+), 385.0545.
Example 13A-5 2-{1-[(4-tert-butylphenyl)sulfonyl]piperidin-4-yl}-3-methylpyridineUsing the procedure from Example 13A-1, the title compound (105 mg) was isolated as a white solid in 41% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.37 (s, 9H), 1.79 (d, J=14.9 Hz, 2H), 2.02-2.17 (m, 2H), 2.26 (s, 3H), 2.40-2.51 (m, 2H), 2.71-2.84 (m, 1H), 3.95 (d, J=11.4 Hz, 2H), 7.02 (dd, J=7.6, 4.8 Hz, 1H), 7.38 (d, J=8.6 Hz, 1H), 7.55 (d, J=8.8 Hz, 2H), 7.73 (d, J=8.8 Hz, 2H), 8.38 (d, J=6.3 Hz, 1H). HRMS: calcd for C21H28N2O2S+H+, 373.19442; found (ESI-FTMS, [M+H]1+), 373.1946.
Example 13A-6 2-{1-[(4-bromophenyl)sulfonyl]piperidin-4-yl}-3-methylpyridineUsing the procedure from Example 13A-1, the title compound (51 mg) was isolated as a white solid in 27% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.80 (d, J=13.4 Hz, 2H), 2.04-2.16 (m, 2H), 2.26 (s, 3H), 2.39-2.48 (m, 2H), 2.70-2.83 (m, 1H), 3.93 (d, J=11.6 Hz, 2H), 7.03 (dd, J=7.6, 4.8 Hz, 1H), 7.39 (d, J=7.6 Hz, 1H), 7.64-7.73 (m, 4H), 8.39 (d, J=6.1 Hz, 1H). HRMS: calcd for C17H19BrN2O2S+H+, 395.04233; found (ESI-FTMS, [M+H]1+), 395.0432.
Example 13A-7 3-methyl-2-[1-(2-naphthylsulfonyl)piperidin-4-yl]pyridineUsing the procedure from Example 13A-1, the title compound (92 mg) was isolated as a white solid in 36% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.79 (d, J=15.9 Hz, 2H), 2.05-2.18 (m, 2H), 2.21 (s, 3H), 2.42-2.51 (m, 2H), 2.68-2.77 (m, 1H), 4.02 (d, J=11.4 Hz, 2H), 7.01 (dd, J=7.6, 4.8 Hz, 1H), 7.36 (d, J=7.6 Hz, 1H), 7.60-7.71 (m, 2H), 7.82 (dd, J=8.6, 1.8 Hz, 1H), 7.95 (d, J=8.1 Hz, 1H), 8.00 (d, J=8.1 Hz, 2H), 8.35-8.40 (m, 2H). HRMS: calcd for C21H22N2O2S+H+, 367.14747; found (ESI-FTMS, [M+H]1+), 367.1479.
Step 13BA: 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1 carboxylic acid tert-butyl ester. The vinyl triflate was prepared from tert-butyl-4-oxopiperidine-1-carboxylate using the procedure from WO 2004/036649. To a −78° C. solution of diisopropylamine (6.0 mL, 42.1 mmol) in THF (59 mL) was added drop wise a solution of n-BuLi (2.5 M in hexanes, 16.8 mL, 42.1 mmol) over 15 min. After 2 h a solution of the piperidone (7.13 g, 35.1 mmol) in THF (59 mL) was added drop wise over 30 min. After 40 min at −78° C. a solution of N-phenyltrifluoromethanesulfonimide (15.2 g, 42.1 mmol) in THF (59 ml) was added over 25 min. After 2.5 hr at −78° C. the mixture was allowed to slowly warm to room temperature. After 16 h the mixture was diluted with a 1:1 solution of THF and H2O (140 ml). The aqueous phase was extracted with EtOAc. The combined organic phase was washed with brine, dried (MgSO4), and concentrated to give 29.6 g of a brown solid. The crude product was adhered to silica and eluted with 15% EtOAc/Hex to give 18.3 g of a yellow oil. Purification by flash chromatography (elution with 0 to 15% EtOAc-Hex) afforded 13.26 g of a yellow viscous oil, a mixture of the vinyl triflate and phenyl amine. The oil was dissolved in EtOAc washed with 5% Citric acid, 1N NaOH and brine dried (MgSO4), and concentrated to afford the vinyl triflate (6.06 g), a yellow oil, in 52% yield. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.48 (s, 9H), 2.40-2.52 (m, J=2.9, 1.4 Hz, 2H), 3.63 (t, J=5.6 Hz, 2H), 4.05 (d, J=2.8 Hz, 2H), 5.77 (s, 1H).
Step 13BB: 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester. A mixture of the vinyl triflate from Step 13BA (3.0 g, 9.05 mmol), bis(pinacolato)diboron (2.53 g, 9.96 mmol), Dichloro[1-1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (0.020 g, 0.27 mmol), bis(diphenylphosphino)ferrocene (0.15 g, 0.27 mmol) and potassium acetate (2.66 g, 27.15 mmol) in 1,4-dioxane (53 ml) was degassed with N2 and heated to 80° C. After 17 h, the mixture was cooled to room temperature, filtered through celite eluting with EtOAc. The filtrate was concentrated, adhered to silica and chromatographed (elution with 5 to 20% EtOAc-Hex) to afford the boronate (1.91 g), a white solid, in 68% yield. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.26 (s, 12H), 1.46 (s, 9H), 2.22 (s, 2H), 3.44 (t, J=5.3 Hz, 2H), 3.95 (d, J=2.3 Hz, 2H), 6.46 (s, 1H).
Step 13BC: 3-Trifluoromethyl-3′,6′-dihydro-2′H-[2,4′]bipyridinyl-1′-carboxylic acid tert-butyl ester. A mixture of the boronate from Step 13BB (1.49 g, 4.82 mmol), Dichloro[1-1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (703 mg, 0.96 mmol), 2-Bromo-3-(trifluoromethyl)pyridine (1.33 g, 5.78 mmol) and sodium carbonate (2.04 g, 19.28 mmol) in a 7:3:2 solution of dimethoxyethane/H2O/EtOH (30 ml) was degassed with N2 and heated at 80° C. After 20 h the mixture was cooled to room temperature and diluted with equal portions of EtOAc and H2O, the aqueous phase was then extracted with EtOAc. The combined organic phase was washed with brine, dried (MgSO4) and concentrated. Purification by flash chromatography (elution with 0 to 30% EtOAc-Hex) afforded the desired product (1.24 g), an orange oil, in 78% yield. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.50 (s, 9H), 2.51 (s, 2H), 3.67 (s, 2H), 4.07 (s, 2H), 5.76 (s, 1H), 7.34 (dd, J=8.1, 4.8 Hz, 1H), 7.99 (d, J=8.1 Hz, 1H), 8.75 (d, J=4.8 Hz, 1H).
Step 13BD: 3-Trifluoromethyl-3′,4′,5′,6′-tetrahydro-2′H-[2,4′]bipyridinyl-1′-carboxylic acid tert-butyl ester. The olefin from Step 13BC (1.23 g, 3.75 mmol) was dissolved in EtOH (100 mL) and transferred to a Parr shaker bottle. 10% Pd/C (1.0 g) was added, and the mixture was hydrogenated at 60 psi for 16 h. The mixture was filtered, fresh Pd/C (3.0 g) was added, and the mixture was hydrogenated at 60 psi for 2 d. The mixture was filtered and concentrated to afford the piperidine (1.22 g), brown viscous oil, in 98% yield. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.48 (s, 9H), 1.71 (d, J=12.9 Hz, 2H), 1.86-2.08 (m, 2H), 2.83 (broad, s, 2H), 3.05-3.24 (m, 1H), 4.25 (broad, s, 2H), 7.24 (dd, J=8.1, 4.8 Hz, 1H), 7.91 (d, J=8.1 Hz, 1H), 8.73 (d, J=4.3 Hz, 1H).
Step 13BE: 3-Trifluoromethyl-1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl. A mixture of the piperidine from Step 13BD (1.22 g, 3.69 mmol), MeOH (15 mL), and 6N HCl (2.2 mL) was heated to reflux for 3 h. The mixture was cooled to room temperature and diluted with sat. Na2CO3 solution (30 mL). The mixture was extracted with CH2Cl2 (2×50 mL). The organic phase was washed with H2O and brine, dried (MgSO4) and concentrated to afford the amine (608 mg), an off-white solid, 72% yield. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.75 (d, J=13.4 Hz, 2H), 1.90-2.05 (m, 2H), 2.38 (s, 1H), 2.75-2.85 (m, 2H), 3.19 (t, J=12.1 Hz, 1H), 3.22-3.29 (m, 2H), 7.23 (dd, J=7.8, 4.8 Hz, 1H), 7.90 (d, J=6.8 Hz, 1H), 8.74 (d, J=3.8 Hz, 1H).
Step 13BF: 2-{1-[(2-chlorophenyl)sulfonyl]piperidin-4-yl}-3-(trifluoromethyl)pyridine. To a solution of the amine from Step 13BE (100 mg, 0.43 mmol) in CH2Cl2 (2.9 mL) was added 2-chlorobenzenesulfonyl chloride (113 mg, 73 μl, 0.52 mmol) and sat. NaHCO3 (1.4 mL). The biphasic mixture was stirred at room temperature overnight. The reaction mixture was diluted with CH2Cl2 (3 mL) and poured into a Phase Separator cartridge. The organic phase was concentrated and purified by flash chromatography (elution with 0-20% EtOAc-hex). Lyophilization then afforded the title compound (121 mg), a white solid, in 70% yield. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.79 (d, J=13.6 Hz, 2H), 2.09-2.23 (m, 2H), 2.82-2.92 (m, 2H), 3.08 (t, J=1.9 Hz, 1H), 4.02 (d, J=12.4 Hz, 2H), 7.21-7.27 (m, 1H), 7.37-7.44 (m, 1H), 7.46-7.52 (m, 1H), 7.53-7.59 (m, 1H), 7.89 (dd, J=8.0, 1.6 Hz, 1H), 8.09 (d, J=6.3 Hz, 1H), 8.73 (d, J=3.5 Hz, 1H). HRMS: calcd for C17H16ClF3N2O2S+H+, 405.06458; found (ESI-FTMS, [M+H]1+), 405.0652.
Example 13B-2 2-{1-[(4-chlorophenyl)sulfonyl]piperidin-4-yl}-3-(trifluoromethyl)pyridineUsing the procedure from Example 13B-1, the title compound (168 mg) was prepared and isolated as a white solid in 97% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.80 (d, J=12.6 Hz, 2H), 2.13-2.27 (m, 2H), 2.34-2.45 (m, 2H), 2.94 (t, J=11.4 Hz, 1H), 3.95 (d, J=11.6 Hz, 2H), 7.21-7.28 (m, 1H), 7.54 (d, J=8.3 Hz, 2H), 7.74 (d, J=8.6 Hz, 2H), 7.89 (d, J=7.8 Hz, 1H), 8.73 (d, J=4.8 Hz, 1H). HRMS: calcd for C17H16ClF3N2O2S+H+, 405.06458; found (ESI-FTMS, [M+H]1+), 405.065.
Example 13B-3 2-{1-[(3,4-dichlorophenyl)sulfonyl]piperidin-4-yl}-3-(trifluoromethyl)pyridineUsing the procedure from Example 13B-1, the title compound (178 mg) was prepared and isolated as a white solid in 94% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.82 (d, J=14.1 Hz, 2H), 2.13-2.28 (m, 2H), 2.39-2.50 (m, 2H), 2.89-3.02 (m, 1H), 3.96 (d, J=11.6 Hz, 2H), 7.22-7.29 (m, 1H), 7.59-7.68 (m, 2H), 7.86-7.93 (m, 2H), 8.73 (d, J=4.8 Hz, 1H). HRMS: calcd for C17H15Cl2F3N2O2S+H+, 439.02561; found (ESI-FTMS, [M+H]1+), 439.0256.
Example 13B-4 2-{1-[(4-tert-butylphenyl)sulfonyl]piperidin-4-yl}-3-(trifluoromethyl)pyridineUsing the procedure from Example 13AA, the title compound (172 mg) was prepared and isolated as a white solid in 94% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.38 (s, 9H), 1.79 (d, J=12.9 Hz, 2H), 2.13-2.30 (m, 2H), 2.35-2.45 (m, 2H), 2.94 (t, J=11.6 Hz, 1H), 3.96 (d, J=9.6 Hz, 2H), 7.24 (dd, J=8.1, 4.8 Hz, 1H), 7.56 (d, J=8.6 Hz, 2H), 7.67-7.76 (m, 2H), 7.88 (d, J=8.1 Hz, 1H), 8.73 (d, J=3.5 Hz, 1H). HRMS: calcd for C21H25F3N2O2S+H+, 427.16616; found (ESI-FTMS, [M+H]1+), 427.1662.
Example 13B-5 2-[1-(2-naphthylsulfonyl)piperidin-4-yl]-3-(trifluoromethyl)pyridineUsing the procedure from Example 13AA, the title compound (168 mg) was isolated as a white solid in 93% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.79 (d, J=13.1 Hz, 2H), 2.16-2.29 (m, 2H), 2.38-2.48 (m, 2H), 2.89 (t, J=11.2 Hz, 1H), 4.04 (d, J=11.4 Hz, 2H), 7.23 (dd, J=8.0, 4.7 Hz, 1H), 7.59-7.70 (m, 2H), 7.80 (dd, J=8.6, 1.8 Hz, 1H), 7.86 (d, J=8.1 Hz, 1H), 7.95 (d, J=7.8 Hz, 1H), 7.98-8.04 (m, 2H), 8.38 (s, 1H), 8.72 (d, J=4.8 Hz, 1H). HRMS: calcd for C21H19F3N2O2S+H+, 421.11921; found (ESI-FTMS, [M+H]1+), 421.1189.
Example 13B-6 2-{1-[(2,6-dichlorophenyl)sulfonyl]piperidin-4-yl}-3-(trifluoromethyl)pyridineUsing the procedure from Example 13AA, the title compound (126 mg) was isolated as a white solid in 67% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.81 (d, J=13.1 Hz, 2H), 2.08-2.22 (m, 2H), 2.92-3.05 (m, 2H), 3.13 (t, J=11.9 Hz, 1H), 4.11 (d, J=12.4 Hz, 2H), 7.20-7.28 (m, 1H), 7.29-7.36 (m, 1H), 7.44-7.52 (m, 2H), 7.90 (d, J=7.8 Hz, 1H), 8.72 (d, J=4.5 Hz, 1H). HRMS: calcd for C17H15Cl2F3N2O2S+H+, 439.02561; found (ESI-FTMS, [M+H]1+), 439.0255.
Example 14Step 14A: 1-Benzyl-4-[2-(trifluoromethyl)phenyl]piperidin-4-ol. Following the procedure of N. I. Carruthers et al. (J. Med. Chem. 2005, 48, 1857-1872), to a −78° C. solution of 2-bromobenzotrifluoride (12.9 g, 7.8 mL, 57 mmol) in THF (225 mL) was added dropwise a solution of n-BuLi (2.5 M in hexanes, 26 mL, 65 mmol) over 10 min. After 1 h, the reaction mixture was stirred at 0° C. for 10 min, recooled to −78° C., and a solution of N-benzyl-4-piperidone (10.7 g, 57 mmol) in THF (40 mL) was added dropwise via addition funnel over 10 min. After 2 h at −78° C., sat. NH4Cl solution (200 mL) was added and the mixture was warmed to room temperature. The aqueous phase was extracted with EtOAc (2×200 mL). The organic phase was washed with H2O (200 mL) and brine (150 mL), dried (MgSO4), and concentrated. Flash chromatography afforded the alcohol (2.7 g), a yellow oil, slightly contaminated with piperidone starting material, in ˜15% yield.
Step 14B: 1-Benzyl-4-[2-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine. Thionyl chloride (10 mL) was added slowly dropwise to the alcohol from Step 14A (4.9 g, 14.6 mmol). After 2 h, the mixture was concentrated, diluted with CH2Cl2 (50 mL), and added slowly to a stirred solution of sat. NaHCO3 (200 mL). The aqueous phase was separated and extracted with CH2Cl2 (2×150 mL). The combined organic extracts were washed with H2O (2×150 mL) and brine (150 mL), dried (MgSO4), and concentrated. Flash chromatography (elution with 10-30% EtOAc-hexanes) afforded the olefin (2.75 g), a yellow oil, in 59% yield. 1H NMR (400 MHz, CDCl3) δ 2.38 (dd, J=4.5, 2.8 Hz, 2H), 2.70 (t, J=5.7 Hz, 2H), 3.14 (q, J=2.9 Hz, 2H), 3.66 (s, 2H), 5.57 (s, 1H), 7.22-7.30 (m, 2H), 7.31-7.42 (m, 5H), 7.47 (t, J=7.6 Hz, 1H), 7.63 (d, J=7.1 Hz, 1H).
Step 14C: Following the procedure of N. I. Carruthers et al. (J. Med. Chem. 2005, 48, 1857-1872), the olefin from Step 14B (2.99 g, 9.4 mmol) was dissolved in EtOH (50 mL) and transferred to a Parr shaker bottle. 10% Pd/C (wet Degussa, 3.0 g) was added, and the mixture was hydrogenated at 50 psi for 16 h. The mixture was filtered, fresh Pd/C (3.0 g) was added, and the mixture was hydrogenated at 50 psi for 2 d. The mixture was filtered and concentrated to afford a beige solid that was purified by flash chromatography (elution with 10% MeOH—CH2Cl2 to 0.1% Et3N-10% MeOH—CH2Cl2) to afford the amine (1.24 g), a yellow oil, contaminated with Et3N, in ˜57% yield. 1H NMR (400 MHz, CDCl3) δ 1.62-1.87 (m, 4H), 2.70-2.84 (m, 2H), 2.97-3.10 (m, 1H), 3.19 (d, J=11.6 Hz, 2H), 7.18-7.35 (m, 1H), 7.44-7.56 (m, 2H), 7.61 (d, J=7.8 Hz, 1H).
Step 14D: To a solution of the amine from Step 14C (150 mg, 0.65 mmol) in CH2Cl2 (4 mL) was added 3-chlorobenzenesulfonyl chloride (165 mg, 0.11 mL, 0.78 mmol) and saturated NaHCO3 (2 mL). The biphasic mixture was stirred for 6 h. The reaction mixture was diluted with CH2Cl2 (3 mL) and poured into a Phase Separator cartridge. The organic phase was concentrated and purified by flash chromatography (elution with 2-10% EtOAc-hex). Lyophilization then afforded the title compound (176 mg), a white solid, in 67% yield.
1H NMR (400 MHz, CDCl3) δ 1.80-2.01 (m, 4H), 2.26-2.49 (m, 2H), 2.69-2.94 (m, 1H), 3.98 (d, J=11.9 Hz, 2H), 7.31 (t, J=7.7 Hz, 1H), 7.41 (d, J=7.8 Hz, 1H), 7.48-7.58 (m, 2H), 7.58-7.65 (m, 2H), 7.66-7.72 (m, 1H), 7.79 (t, J=1.9 Hz, 1H). HRMS: calcd for C18H17ClF3NO2S+H+, 404.06934; found (ESI-FTMS, [M+H]1+), 404.0692. HPLC Method 1: room temperature, 6.99 min, 99.2%. HPLC Method 2: room temperature, 7.54 min, 97.7%.
Example 14B 1-[(4-chlorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperidineUsing the procedure from Example 14A, Step 14D, 1-benzyl-4-[2-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine (Example 14A, Step 14C, 150 mg, 0.65 mmol) was reacted with 4-chlorobenzenesulfonyl chloride (165 mg, 0.78 mmol) to afford the title compound (219 mg), a white solid, in 84% yield.
1H NMR (400 MHz, CDCl3) δ 1.74-1.98 (m, 4H), 2.26-2.43 (m, 2H), 2.68-2.95 (m, 1H), 3.96 (d, J=11.9 Hz, 2H), 7.31 (t, J=7.6 Hz, 1H), 7.41 (d, J=7.8 Hz, 1H), 7.48-7.57 (m, 3H), 7.61 (d, J=7.8 Hz, 1H), 7.74 (d, J=8.8 Hz, 2H). HRMS: calcd for C18H17ClF3NO2S+H+, 404.06934; found (ESI-FTMS, [M+H]1+), 404.0696. HPLC Method 1: room temperature, 6.99 min, 99.6%. HPLC Method 2: room temperature, 7.53 min, 99.4%.
Example 14C 1-[(3,4-dichlorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperidineUsing the procedure from Example 14A, 1-benzyl-4-[2-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine (Example 14A, Step 14C, 150 mg, 0.65 mmol) was reacted with 3,4-dichlorobenzenesulfonyl chloride (191 mg, 0.12 mL, 0.78 mmol) to afford the title compound (211 mg), a white solid, in 74% yield.
1H NMR (400 MHz, CDCl3) δ 1.77-1.96 (m, 4H), 2.29-2.58 (m, 2H), 2.72-3.00 (m, 1H), 3.97 (d, J=12.1 Hz, 2H), 7.32 (t, J=7.7 Hz, 1H), 7.41 (d, J=7.8 Hz, 1H), 7.54 (t, J=7.5 Hz, 1H), 7.58-7.69 (m, 3H), 7.88 (d, J=1.8 Hz, 1H). HRMS: calcd for C18H16Cl2F3NO2S+H+, 438.03036; found (ESI-FTMS, [M+H]1+), 438.0303. HPLC Method 1: room temperature, 7.31 min, 99.3%. HPLC Method 2: room temperature, 7.84 min, 99.4%.
Example 14D 1-[(4-tert-butylphenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperidineUsing the procedure from Example 14A, Step 14D, 1-benzyl-4-[2-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine (Example 14A, Step 14C, 150 mg, 0.65 mmol) was reacted with 4-tert-butylbenzenesulfonyl chloride (182 mg, 0.78 mmol) to afford the title compound (135 mg), a white solid, in 49% yield.
1H NMR (400 MHz, CDCl3) δ 1.71-1.97 (m, 4H), 2.24-2.53 (m, 2H), 2.69-2.99 (m, 1H), 3.97 (d, J=11.9 Hz, 2H), 7.30 (t, J=7.7 Hz, 1H), 7.40 (d, J=7.8 Hz, 1H), 7.48-7.63 (m, 4H), 7.72 (d, J=8.6 Hz, 2H). HRMS: calcd for C22H26F3NO2S+H+, 426.17091; found (ESI-FTMS, [M+H]1+), 426.1714. HPLC Method 1: room temperature, 7.52 min, 99.5%. HPLC Method 2: room temperature, 7.85 min, 99.3%.
Example 14E 1-(2-naphthylsulfonyl)-4-[2-(trifluoromethyl)phenyl]piperidineUsing the procedure from Example 14A, the title compound (235 mg) was isolated as a white solid, in 86% yield.
1H NMR (400 MHz, CDCl3) δ 1.68-2.09 (m, 4H), 2.26-2.62 (m, 2H), 2.52-3.04 (m, 1H), 4.05 (d, J=11.6 Hz, 2H), 7.29 (t, J=7.6 Hz, 1H), 7.40 (d, J=7.8 Hz, 1H), 7.51 (t, J=7.6 Hz, 1H), 7.58 (d, J=8.1 Hz, 1H), 7.61-7.74 (m, 2H), 7.80 (dd, J=8.6, 1.8 Hz, 1H), 7.96 (d, J=8.1 Hz, 1H), 7.98-8.12 (m, 2H), 8.37 (d, J=1.5 Hz, 1H). HRMS: calcd for C22H20F3NO2S+H+, 420.12396; found (ESI-FTMS, [M+H]1+), 420.1244. HPLC Method 1: room temperature, 7.12 min, 99.4%. HPLC Method 2: room temperature, 7.66 min, 99.3%.
Example 14F 1-[(2,6-dichlorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperidineUsing the procedure from Example 14A, the title compound (236 mg) was isolated as a white solid, in 83% yield.
1H NMR (400 MHz, CDCl3) δ 1.79-1.96 (m, 4H), 2.86-3.01 (m, 2H), 3.02-3.13 (m, 1H), 4.12 (d, J=12.9 Hz, 2H), 7.28-7.38 (m, 2H), 7.42 (d, J=7.8 Hz, 1H), 7.46-7.57 (m, 3H), 7.62 (d, J=8.1 Hz, 1H). HRMS: calcd for C18H16Cl2F3NO2S+H+, 438.03036; found (ESI-FTMS, [M+H]1+), 438.0307. HPLC Method 1: room temperature, 7.03 min, 99.2%. HPLC Method 2: room temperature, 7.53 min, 99.1%.
Example 14G 1-[(4-bromophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperidineUsing the procedure from Example 14A, the title compound (209 mg) was isolated as a white solid, in 72% yield.
1H NMR (400 MHz, CDCl3) δ 1.78-1.97 (m, 4H), 2.28-2.41 (m, 2H), 2.75-2.92 (m, 1H), 3.96 (d, J=12.1 Hz, 2H), 7.31 (t, J=7.7 Hz, 1H), 7.41 (d, J=7.8 Hz, 1H), 7.53 (t, J=7.7 Hz, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.66 (d, J=8.7 Hz, 2H), 7.72 (d, J=8.7 Hz, 2H). HRMS: calcd for C18H17BrF3NO2S+H+, 448.01882; found (ESI-FTMS, [M+H]1+), 448.0192. HPLC Method 1: room temperature, 7.06 min, 99.7%. HPLC Method 2: room temperature, 7.58 min, 99.4%.
Example 14H 1-[(2-fluorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperidineUsing the procedure from Example 14A, the title compound (25 mg) was isolated as a white solid, in 15% yield.
1H NMR (400 MHz, CDCl3) δ 1.80-1.96 (m, 4H), 2.54-2.71 (m, 2H), 2.87-3.03 (m, 1H), 4.04 (d, J=12.1 Hz, 2H), 7.18-7.37 (m, 3H), 7.42 (d, J=8.1 Hz, 1H), 7.53 (t, J=7.7 Hz, 1H), 7.57-7.66 (m, 2H), 7.82-7.96 (m, 1H). HRMS: calcd for C18H17F4NO2S+H+, 388.09889; found (ESI-FTMS, [M+H]1+), 388.0991. HPLC Method 1: room temperature, 6.64 min, 98.1%. HPLC Method 2: room temperature, 7.22 min, 97.0%.
Example 14I 1-[(3-fluorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperidineUsing the procedure from Example 14A, the title compound (93 mg) was isolated as a white solid, in 55% yield.
1H NMR (400 MHz, CDCl3) δ 1.73-2.02 (m, 4H), 2.28-2.55 (m, 2H), 2.75-3.07 (m, 1H), 3.98 (d, J=111.9 Hz, 2H), 7.28-7.39 (m, 2H), 7.41 (d, J=8.1 Hz, 1H), 7.46-7.65 (m, 5H). HRMS: calcd for C18H17F4NO2S+H+, 388.09889; found (ESI-FTMS, [M+H]1+), 388.0991. HPLC Method 1: room temperature, 6.71 min, 98.7%. HPLC Method 2: room temperature, 7.32 min, 100%.
Example 14J 4-[2-(trifluoromethyl)phenyl]-1-{[2-(trifluoromethyl)phenyl]sulfonyl}piperidineUsing the procedure from Example 14A, the title compound (110 mg) was isolated as a white solid, in 57% yield.
1H NMR (400 MHz, CDCl3) δ 1.75-2.00 (m, 4H), 2.60-2.90 (m, 2H), 2.94-3.14 (m, 1H), 4.00 (d, J=12.9 Hz, 2H), 7.31 (t, J=7.7 Hz, 1H), 7.43 (d, J=7.8 Hz, 1H), 7.53 (t, J=7.5 Hz, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.66-7.81 (m, 2H), 7.86-8.00 (m, 1H), 8.07-8.24 (m, 1H). HRMS: calcd for C19H17F6NO2S+H+, 438.09569; found (ESI-FTMS, [M+H]1+), 438.0958. HPLC Method 1: room temperature, 6.89 min, 99.1%. HPLC Method 2: room temperature, 7.37 min, 100%.
Example 14K 4-[2-(trifluoromethyl)phenyl]-1-{[3-(trifluoromethyl)phenyl]sulfonyl}piperidineUsing the procedure from Example 14A, the title compound (92 mg) was isolated as a white solid, in 48% yield.
1H NMR (400 MHz, CDCl3) δ 1.78-2.13 (m, 4H), 2.26-2.50 (m, 2H), 2.78-3.11 (m, 1H), 4.01 (d, J=12.1 Hz, 2H), 7.32 (t, J=7.7 Hz, 1H), 7.41 (d, J=8.1 Hz, 1H), 7.54 (t, J=7.6 Hz, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.74 (t, J=7.8 Hz, 1H), 7.91 (d, J=7.8 Hz, 1H), 7.99 (d, J=7.8 Hz, 1H), 8.06 (s, 1H). HRMS: calcd for C19H17F6NO2S+H+, 438.09569; found (ESI-FTMS, [M+H]1+), 438.0959. HPLC Method 1: room temperature, 6.98 min, 98.4%. HPLC Method 2: room temperature, 7.52 min, 98.9%.
Example 14L 4-[2-(trifluoromethyl)phenyl]-1-{[4-(trifluoromethyl)phenyl]sulfonyl}piperidineUsing the procedure from Example 14A, the title compound (90 mg) was isolated as a white solid, in 47% yield.
1H NMR (400 MHz, CDCl3) δ 1.74-2.00 (m, 4H), 2.21-2.53 (m, 2H), 2.67-3.27 (m, 1H), 4.00 (d, J=11.4 Hz, 2H), 7.32 (t, J=7.7 Hz, 1H), 7.40 (d, J=7.6 Hz, 1H), 7.53 (t, J=7.6 Hz, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.85 (d, J=8.3 Hz, 2H), 7.93 (d, J=8.3 Hz, 2H). HRMS: calcd for C19H17F6NO2S+H+, 438.09569; found (ESI-FTMS, [M+H]1+), 438.0959. HPLC Method 1: room temperature, 7.03 min, 99.3%. HPLC Method 2: room temperature, 7.53 min, 99.0%.
Example 14M 1-[(4-methoxyphenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperidineUsing the procedure from Example 14A, the title compound (117 mg) was isolated as a white solid, in 67% yield.
1H NMR (400 MHz, CDCl3) δ 1.66-2.04 (m, 4H), 2.19-2.46 (m, 2H), 2.51-3.09 (m, 1H), 3.90 (s, 3H), 3.94 (d, J=11.4 Hz, 2H), 7.03 (d, J=8.8 Hz, 2H), 7.30 (t, J=7.7 Hz, 1H), 7.42 (d, J=8.1 Hz, 1H), 7.53 (t, J=7.6 Hz, 1H), 7.60 (d, J=7.6 Hz, 1H), 7.73 (d, J=9.1 Hz, 2H). HRMS: calcd for C19H20F3NO3S+H+, 400.11887; found (ESI-FTMS, [M+H]1+), 400.1192. HPLC Method 1: room temperature, 6.63 min, 99.0%. HPLC Method 2: room temperature, 7.27 min, 98.5%.
Example 14N 1-{[4-(trifluoromethoxy)phenyl]sulfonyl}-4-[2-(trifluoromethyl)phenyl]piperidineUsing the procedure from Example 14A, the title compound (126 mg) was isolated as a white solid, in 64% yield.
1H NMR (400 MHz, CDCl3) δ 1.72-2.02 (m, 4H), 2.26-2.55 (m, 2H), 2.75-3.01 (m, 1H), 3.98 (t, J=11.9 Hz, 2H), 7.31 (t, J=7.6 Hz, 1H), 7.40 (appar d, J=8.1 Hz, 3H), 7.53 (t, J=7.7 Hz, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.85 (d, J=8.8 Hz, 2H). HRMS: calcd for C19H17F6NO3S+H+, 454.09061; found (ESI-FTMS, [M+H]1+), 454.0909. HPLC Method 1: room temperature, 7.09 min, 89.7%. HPLC Method 2: room temperature, 7.57 min, 89.9%.
Example 14O 1-[(4-bromo-3-fluorophenyl)sulfonyl]-4-[2-(trifluoromethyl)phenyl]piperidineUsing the procedure from Example 14A, the title compound (115 mg) was isolated as a white solid, in 57% yield.
1H NMR (400 MHz, CDCl3) δ 1.70-2.06 (m, 4H), 2.28-2.51 (m, 2H), 2.74-3.07 (m, 1H), 3.96 (d, J=11.1 Hz, 2H), 7.32 (t, J=7.6 Hz, 1H), 7.41 (d, J=7.6 Hz, 1H), 7.46 (dd, J=8.3, 1.3 Hz, 1H), 7.50-7.57 (m, 2H), 7.61 (d, J=7.8 Hz, 1H), 7.78 (dd, J=8.3, 6.6 Hz, 1H). HRMS: calcd for C18H16BrF4NO2S+H+, 466.00940; found (ESI-FTMS, [M+H]1+), 466.0097. HPLC Method 1: room temperature, 7.11 min, 98.7%. HPLC Method 2: room temperature, 7.68 min, 98.2%.
Example 15Step 15A: To a stirred solution of piperazine-2-one (353.3 mg, 3.5 mmol) and naphthalene-2-sulfonyl chloride (800 mg, 3.5 mmol) in anhydrous dichloromethane (15 mL) was added diisopropylethylamine (1.54 mL, 8.8 mmol). The mixture was stirred for 30 min. Reaction was complete as determined by TLC. The reaction mixture was filtered, washed with hexane to give a first batch. The mother liquor was washed with saturated ammonium chloride, then washed with saturated brine, separated, dried over sodium sulphate. Then hexane was added, lots of precipitate formed. The was filtered, washed with hexane to give a second batch. The two batches were combined to yield 4-(naphthalene-2-sulfonyl)-piperazin-2-one in 92.5% yield (947 mg) as an off-white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.35-3.40 (m, 2H) 3.42-3.48 (m, 2H) 3.79 (s, 2H) 6.11 (s, 1H) 7.63-7.73 (m, 2H) 7.77 (dd, J=8.72, 1.89 Hz, 1H) 7.94 (d, J=7.83 Hz, 1H) 7.98-8.05 (m, 2H) 8.38 (s, 1H).
Step 15B: An oven-dried microwave vial was charged with of 4-(naphthalene-2-sulfonyl)-piperazin-2-one (100 mg, 0.34 mmol), 2-bromo-3-trifluoromethylpyridine (115.3 mg, 0.51 mmol), powdered anhydrous potassium carbonate (94 mg, 0.68 mmol), and CuI (6.5 mg, 0.034 mmol). The vial was purged and back-filled with N2. Anhydrous 1,4-dioxane (1.2 mL) was added, followed by 3.7 μL (0.034 mmol) of N,N′-dimethyl-1,2-ethylenediamine. The blue suspension was heated in a 110° C. oil bath for 48 hr. After cooling to room temperature, the brown suspension was diluted with H2O and EtOAc. The layers were separated, and the aqueous layer was washed with EtOAc (2×). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by prep HPLC to provide 4.8 mg (3.2%) of 4-(Naphthalene-2-sulfonyl)-1-(3-trifluoromethyl-pyridin-2-yl)-piperazin-2-one as a light yellow solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.38-3.46 (m, 1H) 3.57-3.66 (m, 1H) 3.68-3.79 (m, 1H) 3.82-3.91 (m, 1H) 3.98-4.09 (m, 2H) 7.46 (dd, J=7.83, 4.80 Hz, 1H) 7.64-7.74 (m, 2H) 7.81 (dd, J=8.59, 1.77 Hz, 1H) 7.94-8.09 (m, 4H) 8.42 (d, J=1.77 Hz, 1H) 8.71 (dd, J=5.05, 1.77 Hz, 1H). HRMS: calcd for C20H16F3N3O3S+H+, 436.09372; found (ESI-FTMS, [M+H]1+), 436.0936.
Example 15B 4-(3,4-dichloro-benzenesulfonyl)-1-(3-trifluoromethyl-pyridin-2-yl)-piperazin-2-oneStep 15A: Sulfonylation of piperazine-2-one (326.2 mg, 3.3 mmol) with 3,4-dichlorobenzene-sulfonyl chloride (800 mg, 3.3 mmol) was carried out according to a similar procedure described for example 15A using anhydrous dichloromethane (8 mL) as solvent and diisopropylethylamine (1.42 mL, 8.2 mmol) as base. 4-(3,4-dichloro-benzenesulfonyl)-piperazin-2-one was obtained in 90.3% yield (912 mg) as white solid. 1H NMR (400 MHz, DMSO-D6) δ ppm 3.17-3.24 (m, 2H) 3.25-3.30 (m, 2H) 3.59 (s, 2H) 7.79 (dd, J=8.46, 2.15 Hz, 1H) 7.94 (d, J=8.34 Hz, 1H) 8.06 (d, J=2.02 Hz, 1H) 8.08 (s, 1H).
Step 15B: Amidation of 4-(3,4-dichloro-benzenesulfonyl)-piperazin-2-one (150 mg, 0.49 mmol) with 2-bromo-3-trifluoromethylpyridine (164.5 mg, 0.73 mmol) was carried out according to a similar procedure described for example 15A using powdered anhydrous potassium carbonate (134.1 mg, 0.97 mmol) as base, CuI (9.2 mg, 0.049 mmol) as catalyst, N,N′-dimethyl-1,2-ethylenediamine (5.2 μL, 0.049 mmol) as ligand, and anhydrous 1,4-dioxane (1.8 mL) as solvent. 4-(3,4-dichloro-benzenesulfonyl)-1-(3-trifluoromethyl-pyridin-2-yl)-piperazin-2-one was obtained in 10% yield (21 mg) as an off-white solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.38-3.47 (m, 1H) 3.57-3.65 (m, 1H) 3.68-3.76 (m, 1H) 3.82-3.89 (m, 1H) 3.98-4.08 (m, 2H) 7.46-7.53 (m, 1H) 7.64-7.72 (m, 2H) 7.93 (d, J=1.77 Hz, 1H) 8.09 (dd, J=7.96, 1.39 Hz, 1H) 8.75 (dd, J=4.80, 1.26 Hz, 1H); HRMS: calcd for C16H12Cl2F3N3O3S+H+, 454.00013; found (ESI-FTMS, [M+H]1+), 454; HPLC Method 1: room temperature, 5.484 min, 100%, HPLC Method 2: room temperature, 6.418 min, 97.52%.
Example 16 Example 16A 1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-olStep 16A: A mixture of (R)-2-methyl-piperazine (300 mg, 2.99 mmol), 2-bromo benzotrifluoride (612 mg, 2.72 mmol), tris(dibenzylidineacetone)dipalladium (0) (24.72 mg, 0.027 mmol), rac-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (51.06 mg, 0.082 mmol) and sodium tert-butoxide (326.77 mg, 3.4 mmol) were charged to a microwave vial. Toluene (3.0 mL) was introduced under nitrogen atmosphere and the reaction mixture was irradiated at 110° C. for 30 minutes. Reaction was complete as determined by TLC. The reaction was repeated at (R)-2-methyl-piperazine (1.0 g, 9.98 mmol). Reaction mixtures were combined, diluted with dichloromethane, washed with water, saturated brine then dried over Na2SO4 and concentrated. The crude product was purified via flash column chromatography to yield (R)-3-methyl-1-(2-trifluoromethyl-phenyl)-piperazine as yellow oil (1.23 g, 39.6% yield). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.07 (d, J=6.32 Hz, 3H) 2.41-2.51 (m, 1H) 2.74-2.84 (m, 1H) 2.90-2.98 (m, 2H) 3.00-3.13 (m, 3H) 7.18-7.25 (m, 1H) 7.35 (d, J=8.08 Hz, 1H) 7.47-7.55 (m, 1H) 7.62 (d, J=7.83 Hz, 1H).
Step 16B: To a stirred solution of (R)-3-methyl-1-(2-trifluoromethyl-phenyl)-piperazine (500 mg, 2.05 mmol) and 4-acetylbenzenesulfonyl chloride (448.23 mg, 2.05 mmol) in anhydrous dichloromethane (6 mL) was added diisopropylethylamine (0.71 mL, 4.1 mmol). The mixture was stirred at room temperature for over night. Reaction was complete as determined by TLC. The reaction mixture was purified via flash column chromatography to yield (R)-1-{4-[2-methyl-4-(2-trifluoromethyl-phenyl)-piperazine-1-sulfonyl]-phenyl}-ethanone in 74.0% yield (646.7 mg) as a light yellow solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.20 (d, J=6.57 Hz, 3H) 2.67 (s, 3H) 2.75-2.83 (m, 2H) 2.98 (d, J=10.11 Hz, 1H) 3.06 (d, J=10.11 Hz, 1H) 3.33-3.43 (m, 1H) 3.76 (d, J=10.61 Hz, 1H) 4.26 (d, J=6.82 Hz, 1H) 7.23-7.30 (m, 2H) 7.52 (t, J=7.71 Hz, 1H) 7.62 (d, J=8.08 Hz, 1H) 7.89-7.99 (m, 2H) 8.07-8.14 (m, 2H).
Step 16C: To a 50 mL flask containing (R)-1-{4-[2-methyl-4-(2-trifluoromethyl-phenyl)-piperazine-1-sulfonyl]-phenyl}-ethanone (200 mg, 0.47 mmol) and 2.34 mL of 0.5 M TMS-CF3 was added 0.47 mL of 1.0 M tetrabutylammonium fluoride in THF at 0° C. After stirring for 4 h, the solution was diluted with saturated NaHCO3, extracted (2×CH2Cl2), washed with brine and dried over Na2SO4, and concentrated under reduced pressure. Purification by flash column chromatography to yield 1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-ol in 31.8% yield (74.1 mg) as a colorless oil.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.19-1.29 (m, 3H) 1.84 (s, 3H) 2.56 (s, 1H) 2.72-2.82 (m, 2H) 2.92-2.98 (m, 1H) 3.03 (dd, J=11.12, 3.54 Hz, 1H) 3.32-3.45 (m, 1H) 3.74 (d, J=13.14 Hz, 1H) 4.26 (dd, J=6.44, 3.41 Hz, 1H) 7.21-7.30 (m, 2H) 7.48-7.55 (m, 1H) 7.59-7.65 (m, 1H) 7.77 (d, J=8.34 Hz, 2H) 7.85-7.92 (m, 2H). HPLC Method 1: room temperature, 6.486 min, 99.56%, HPLC Method 2: room temperature, 7.222 min, 98.64%.
Example 16B (2R)-1-[(2-chlorophenyl)sulfonyl]-2-methyl-4-[2-(trifluoromethyl)phenyl]piperazineThe title compound was prepared according to a similar procedure for Example 16A, step 16B. Yield 86%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.35 (d, J=6.82 Hz, 3H) 2.75-2.84 (m, 2H) 2.96 (dd, J=11.24, 2.91 Hz, 1H) 3.12 (dd, J=11.12, 3.54 Hz, 1H) 3.53-3.63 (m, 1H) 3.73 (d, J=13.14 Hz, 1H) 4.11-4.20 (m, 1H) 7.22-7.28 (m, 1H) 7.32 (d, J=7.83 Hz, 1H) 7.38-7.43 (m, 1H) 7.47-7.57 (m, 3H) 7.64 (dd, J=7.83, 1.26 Hz, 1H) 8.15 (dd, J=7.96, 1.64 Hz, 1H). HPLC Method 1: room temperature, 6.950 min, 99.45%, HPLC Method 2: room temperature, 7.436 min, 99.80%.
Example 16C (2R)-1-[(3,4-dichlorophenyl)sulfonyl]-2-methyl-4-[2-(trifluoromethyl)phenyl]piperazineThe title compound was prepared according to a similar procedure for Example 16A, step 16B. Yield 92.3%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.20-1.29 (m, 3H) 2.74-2.86 (m, 2H) 2.93-3.12 (m, 2H) 3.32-3.43 (m, 1H) 3.71 (d, J=12.63 Hz, 1H) 4.18-4.27 (m, 1H) 7.23-7.32 (m, 3H) 7.53 (t, J=7.83 Hz, 1H) 7.59-7.70 (m, 3H) 7.94 (d, J=2.02 Hz, 1H). HPLC Method 1: room temperature, 7.363 min, 96.36%, HPLC Method 2: room temperature, 7.845 min, 96.64%.
Example 16D (2R)-1-[(4-chlorophenyl)sulfonyl]-2-methyl-4-[2-(trifluoromethyl)phenyl]piperazineThe title compound was prepared according to a similar procedure for Example 16A, step 16B. Yield 90.5%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.21 (d, J=6.57 Hz, 3H) 2.74-2.83 (m, 2H) 2.97 (d, J=10.86 Hz, 1H) 3.06 (dd, J=11.12, 3.54 Hz, 1H) 3.31-3.41 (m, 1H) 3.71 (d, J=12.63 Hz, 1H) 4.17-4.27 (m, 1H) 7.22-7.31 (m, 2H) 7.46-7.56 (m, 3H) 7.63 (d, J=7.83 Hz, 1H) 7.75-7.83 (m, 2H). HPLC Method 1: room temperature, 7.044 min, 97.87%, HPLC Method 2: room temperature, 7.541 min, 98.11%.
Example 16E (2R)-1-[(5-chloro-2-thienyl)sulfonyl]-2-methyl-4-[2-(trifluoromethyl)phenyl]piperazineThe title compound was prepared according to a similar procedure for Example 16A, step 16B. Yield 70.7%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.30 (d, J=6.82 Hz, 3H) 2.76-2.87 (m, 2H) 2.96-3.03 (m, 1H) 3.09 (dd, J=11.12, 3.54 Hz, 1H) 3.35-3.48 (m, 1H) 3.70 (d, J=12.63 Hz, 1H) 4.24 (d, J=6.82 Hz, 1H) 6.95 (d, J=4.04 Hz, 1H) 7.24-7.34 (m, 2H) 7.38 (d, J=4.04 Hz, 1H) 7.54 (t, J=7.71 Hz, 1H) 7.61-7.68 (m, 1H). HPLC Method 1: room temperature, 7.162 min, 99.59%, HPLC Method 2: room temperature, 7.621 min, 99.80%.
Example 16F (2R)-1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-2-methyl-4-[2-(trifluoromethyl)phenyl]piperazineThe title compound was prepared according to a similar procedure for Example 16A, step 16B. Yield 86.1%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.33 (d, J=6.82 Hz, 3H) 2.69 (s, 3H) 2.78-2.89 (m, 2H) 2.94-3.04 (m, 1H) 3.12 (d, J=10.86 Hz, 1H) 3.45-3.57 (m, 1H) 3.82 (d, J=12.88 Hz, 1H) 4.31 (d, J=6.82 Hz, 1H) 7.22-7.31 (m, 2H) 7.46 (dd, J=8.59, 2.02 Hz, 1H) 7.49-7.54 (m, 1H) 7.62-7.66 (m, 1H) 7.77 (d, J=8.59 Hz, 1H) 7.80 (d, J=2.02 Hz, 1H). HPLC Method 1: room temperature, 7.710 min, 99.78%, HPLC Method 2: room temperature, 8.038 min, 99.77%.
Example 16G (2R)-1-[(5-chloro-2-naphthyl)sulfonyl]-2-methyl-4-[2-(trifluoromethyl)phenyl]piperazineThe title compound was prepared according to a similar procedure for Example 16A, step 16B. Yield 88.8%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.22 (d, J=6.82 Hz, 3H) 2.76-2.84 (m, 2H) 2.98 (d, J=12.63 Hz, 1H) 3.05-3.11 (m, 1H) 3.38-3.47 (m, 1H) 3.78-3.84 (m, 1H) 4.30 (s, 1H) 7.21-7.30 (m, 2H) 7.47-7.57 (m, 2H) 7.62 (dd, J=7.83, 1.26 Hz, 1H) 7.74 (dd, J=7.58, 1.01 Hz, 1H) 7.88-7.96 (m, 2H) 8.41-8.46 (m, 2H). HPLC Method 1: room temperature, 7.566 min, 99.33%, HPLC Method 2: room temperature, 7.951 min, 99.11%.
Example 17Step 17A: tert-Butyl {1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}carbamate. A mixture of 4-(tertbutoxycarbonylamino)piperidine (1.0 g, 5.0 mmol), 2-chloro-4-trifluoromethylpiperidine (3.6 g, 20.0 mmol), DIEA (6.0 mL, 30.0 mmol), and dioxane (2.0 mL) was heated in a microwave reactor at 150° C. for 2 h. the mixture was cooled, diluted with CH2Cl2 (50 mL), and poured in 1N HCl (100 mL). The aqueous phase was extracted with CH2Cl2 (2×100 mL). The combined organic extracts were washed with H2O and brine, dried (MgSO4), and concentrated. Purification by SiO2 chromatography afforded the tert-butyl carbamate (1.39 g), a pale yellow oil, in 80% yield.
1H NMR (400 MHz, CDCl3) δ 1.46 (s, 9H), 1.48-1.68 (m, 2H), 2.04 (d, J=12.4 Hz, 2H), 2.80-3.10 (m, 2H), 3.54 (d, J=13.1 Hz, 2H), 3.65 (br s, 1H), 4.52 (br s, 1H), 6.98 (dd, J=7.7, 4.7 Hz, 1H), 7.85 (dd, J=7.7, 1.9 Hz, 1H), 8.42 (dd, J=4.8, 2.0 Hz, 1H).
Step 17B: 1-[3-(Trifluoromethyl)pyridin-2-yl]piperidin-4-amine. A solution of TFA (10 mL) and CH2Cl2 (10 mL) was added to a flask containing the tert-butyl carbamate from Step 17A (1.39 g, 4.0 mmol). After 1 h, the mixture was concentrated, diluted with CH2Cl2 (100 mL), washed with 1N NaOH (100 mL), H2O (100 mL) and brine (100 mL), dried (MgSO4), and concentrated to afford the amine (0.57 g, 57%), a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 1.38-1.70 (m, 2H), 1.75-2.08 (m, 2H), 2.44 (br s, 2H), 2.71-3.21 (m, 3H), 3.59 (d, J=13.4 Hz, 2H), 6.76-7.13 (m, 1H), 7.85 (dd, J=7.7, 1.9 Hz, 1H), 8.41 (dd, J=4.8, 1.3 Hz, 1H).
Step 17C: 1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-amine (100 mg, 0.42 mmol) was reacted with 2-chlorobenzenesulfonyl chloride (106 mg, 0.50 mmol) to afford the title compound (73 mg), a white solid, in 41% yield.
1H NMR (400 MHz, CDCl3) δ 1.46-1.72 (m, 2H), 1.76-1.93 (m, 2H), 2.70-3.07 (m, 2H), 3.27-3.39 (m, 1H), 3.40-3.61 (m, 2H), 5.04 (d, J=7.6 Hz, 1H), 6.99 (dd, J=7.5, 4.4 Hz, 1H), 7.37-7.49 (m, 1H), 7.49-7.64 (m, 2H), 7.84 (dd, J=7.7, 1.9 Hz, 1H), 8.14 (dd, J=7.6, 1.3 Hz, 1H), 8.40 (dd, J=4.8, 1.5 Hz, 1H). HRMS: calcd for C17H17ClF3N3O2S+H+, 420.07548; found (ESI-FTMS, [M+H]1+), 420.0756. HPLC Method 1: room temperature, 6.69 min, 97.0%. HPLC Method 2: room temperature, 6.18 min, 97.0%.
Example 17B 3-chloro-N-{1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}benzenesulfonamideStep 17C: Using the procedure from Example 17A, Step 17C, 1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-amine (100 mg, 0.42 mmol) was reacted with 3-chlorobenzenesulfonyl chloride (106 mg, 0.50 mmol) to afford the title compound (71 mg), a white solid, in 40% yield.
1H NMR (400 MHz, CDCl3) δ 1.51-1.70 (m, 2H), 1.79-1.97 (m, 2H), 2.81-2.99 (m, 2H), 3.21-3.56 (m, 3H), 4.64 (d, J=7.8 Hz, 1H), 7.00 (dd, J=8.2, 5.2 Hz, 1H), 7.48 (t, J=8.1 Hz, 1H), 7.54-7.62 (m, 1H), 7.73-7.82 (m, 1H), 7.85 (dd, J=8.0, 1.6 Hz, 1H), 7.91 (t, J=1.8 Hz, 1H), 8.41 (dd, J=4.8, 1.3 Hz, 1H). HRMS: calcd for C17H17ClF3N3O2S+H+, 420.07548; found (ESI-FTMS, [M+H]1+), 420.0759. HPLC Method 1: room temperature, 6.18 min, 95.9%. HPLC Method 2: room temperature, 6.94 min, 96.2%.
Example 17C 4-chloro-N-{1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}benzenesulfonamideUsing the procedure from Example 17A, the title compound (142 mg) was isolated as a white solid, in 81% yield.
1H NMR (400 MHz, CDCl3) δ 1.51-1.70 (m, 2H), 1.75-1.95 (m, 2H), 2.86-3.02 (m, 2H), 3.28-3.41 (m, 1H), 3.41-3.57 (m, 2H), 4.61 (d, J=7.8 Hz, 1H), 6.86-7.07 (m, 1H), 7.50 (d, J=8.8 Hz, 1H), 7.67 (d, J=8.8 Hz, 2H), 7.78 (d, J=8.8 Hz, 1H), 7.81-7.93 (m, 2H), 8.41 (dd, J=4.7, 1.4 Hz, 1H). HRMS: calcd for C17H17ClF3N3O2S+H+, 420.07548; found (ESI-FTMS, [M+H]1+), 420.0761. HPLC Method 1: room temperature, 6.26 min, 98.5%. HPLC Method 2: room temperature, 6.95 min, 98.5%.
Example 17D 4-bromo-N-{1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}benzenesulfonamideStep 17C: Using the procedure from Example 17A, the title compound (47 mg) was isolated as a white solid, in 24% yield.
1H NMR (400 MHz, CDCl3) δ 1.45-1.73 (m, 2H), 1.77-1.96 (m, 2H), 2.64-3.09 (m, 2H), 3.21-3.73 (m, 3H), 4.57 (d, J=7.8 Hz, 1H), 7.00 (dd, J=6.8, 4.8 Hz, 1H), 7.67 (d, J=8.8 Hz, 2H), 7.78 (d, J=8.8 Hz, 2H), 7.85 (dd, J=8.0, 1.9 Hz, 1H), 8.41 (dd, J=4.8, 1.3 Hz, 1H). HRMS: calcd for C17H17BrF3N3O2S+H+, 464.02497; found (ESI-FTMS, [M+H]1+), 464.0258. HPLC Method 1: room temperature, 6.26 min, 95.4%. HPLC Method 2: room temperature, 7.02 min, 95.1%.
Example 17E 3-fluoro-N-{1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}benzenesulfonamideStep 17C: Using the procedure from Example 17A, the title compound (73 mg) was isolated as a white solid, in 43% yield.
1H NMR (400 MHz, CDCl3) δ 1.48-1.71 (m, 2H), 1.82-1.99 (m, 2H), 2.69-3.09 (m, 2H), 3.20-3.59 (m, 3H), 4.63 (d, J=7.8 Hz, 1H), 7.00 (dd, J=7.8, 4.8 Hz, 1H), 7.27-7.39 (m, 1H), 7.42-7.59 (m, 1H), 7.57-7.67 (m, 1H), 7.67-7.79 (m, 1H), 7.85 (dd, J=7.8, 1.8 Hz, 1H), 8.41 (dd, J=4.8, 1.3 Hz, 1H). HRMS: calcd for C17H17F4N3O2S+H+, 404.10503; found (ESI-FTMS, [M+H]1+), 404.1056. HPLC Method 1: room temperature, 5.90 min, 97.8%. HPLC Method 2: room temperature, 6.67 min, 97.7%.
Example 17F 4-bromo-3-fluoro-N-{1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}benzenesulfonamideStep 17C: Using the procedure from Example 17A, the title compound (137 mg) was isolated as a white solid, in 68% yield.
1H NMR (400 MHz, CDCl3) δ 1.49-1.70 (m, 2H), 1.90 (dd, J=12.5, 3.9 Hz, 2H), 2.82-3.05 (m, 2H), 3.18-3.56 (m, 3H), 4.57 (d, J=8.1 Hz, 1H), 7.01 (dd, J=7.3, 5.1 Hz, 1H), 7.58 (dd, J=8.3, 1.5 Hz, 1H), 7.66 (dd, J=7.8, 2.0 Hz, 1H), 7.74 (dd, J=8.3, 6.6 Hz, 1H), 7.85 (dd, J=7.8, 1.8 Hz, 1H), 8.41 (dd, J=4.7, 1.4 Hz, 1H). HRMS: calcd for C17H16BrF4N3O2S+H+, 482.01555; found (ESI-FTMS, [M+H]1+), 482.0164. HPLC Method 1: room temperature, 6.35 min, 98.0%. HPLC Method 2: room temperature, 7.14 min, 97.6%.
Example 17G 3,4-dichloro-N-{1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}benzenesulfonamideStep 17C: Using the procedure from Example 17A, the title compound (95 mg) was isolated as a white solid, in 50% yield.
1H NMR (400 MHz, CDCl3) δ 1.50-1.70 (m, 2H), 1.82-1.99 (m, 2H), 2.82-3.10 (m, 2H), 3.19-3.57 (m, 3H), 4.65 (d, J=7.8 Hz, 1H), 7.01 (dd, J=7.1, 4.8 Hz, 1H), 7.61 (d, J=8.3 Hz, 1H), 7.73 (dd, J=8.3, 2.0 Hz, 1H), 7.85 (dd, J=7.8, 1.8 Hz, 1H), 8.00 (d, J=2.3 Hz, 1H), 8.41 (dd, J=4.8, 1.8 Hz, 1H). HRMS: calcd for C17H16Cl2F3N3O2S+H+, 454.03651; found (ESI-FTMS, [M+H]1+), 454.0372. HPLC Method 1: room temperature, 6.55 min, 96.6%. HPLC Method 2: room temperature, 7.32 min, 96.8%.
Example 17H N-{1-[3-(trifluoromethylpyridin-2-yl]piperidin-4-yl}naphthalene-2-sulfonamideStep 17C: Using the procedure from Example 17A, the title compound (114 mg) was isolated as a white solid, in 62% yield.
1H NMR (400 MHz, CDCl3) δ 1.59 (dd, 3H), 1.79-1.96 (m, 2H), 2.76-2.99 (m, 2H), 3.26-3.62 (m, 3H), 4.58 (d, J=8.1 Hz, 1H), 6.98 (dd, J=8.1, 5.1 Hz, 1H), 7.59-7.71 (m, 2H), 7.82 (dd, J=7.8, 2.0 Hz, 1H), 7.87 (dd, J=8.7, 1.9 Hz, 1H), 7.90-7.96 (m, 1H), 7.99 (d, J=8.8 Hz, 2H), 8.38 (dd, J=4.8, 1.8 Hz, 1H), 8.49 (d, J=1.3 Hz, 1H). HRMS: calcd for C21H20F3N3O2S+H+, 436.13011; found (ESI-FTMS, [M+H]1+), 436.1303. HPLC Method 1: room temperature, 6.30 min, 95.0%. HPLC Method 2: room temperature, 7.04 min, 95.5%.
Example 17I 4-tert-butyl-N-{1-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}benzenesulfonamideStep 17C: Using the procedure from Example 17A, the title compound (107 mg) was isolated as a white solid, in 58% yield.
1H NMR (400 MHz, CDCl3) δ 1.35 (s, 9H), 1.55-1.67 (m, 2H), 1.89 (dd, J=12.5, 4.2 Hz, 2H), 2.82-2.97 (m, 2H), 3.26-3.41 (m, 1H), 3.41-3.57 (m, 2H), 4.41 (d, J=7.6 Hz, 1H), 6.91-7.03 (m, 1H), 7.52 (d, J=8.8 Hz, 2H), 7.73-7.90 (m, 3H), 8.40 (dd, J=4.8, 1.3 Hz, 1H). HRMS: calcd for C21H26F3N3O2S+H+, 442.17706; found (ESI-FTMS, [M+H]1+), 442.1773. HPLC Method 1: room temperature, 6.74 min, 88.8%. HPLC Method 2: room temperature, 7.34 min, 92.4%.
Example 18The piperazine or piperidine derivative (1.0 mmol) was mixed with 5 ml of CH2Cl2 and diisopropylethyl amine (2.4 mmol), aryl or alkyl acid chloride (1.2 mmol) or alkyl or aryl chloroformate (1.2 mmol) was added in one portion. The reaction mixture was stirred at room temperature and monitored by TLC (2-24 hrs). When the reaction was completed, the reaction mixture was loaded onto a silica gel column to remove high polar impurities. The product was isolated and purified by column chromatography. The following compounds were prepared using this general procedure.
Example 18A 1-(1-adamantylcarbonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 90% yield as a oil. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.59-1.88 (m, 6H) 2.01-2.13 (m, 9H) 3.24-3.32 (m, 4H) 3.78-3.93 (m, 4H) 7.02-7.11 (m, 1H) 7.92 (dd, J=7.71, 1.89 Hz, 1H) 8.46 (dd, J=4.93, 1.89 Hz, 1H). HRMS: calcd for C21H26F3N3O+H+, 394.21007; found (ESI-FTMS, [M+H]1+), 394.2097.
Example 18B 1-(cyclohexylcarbonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 75% yield as a colorless oil. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.19-1.40 (m, 3H) 1.48-1.65 (m, J=11.87, 2.78 Hz, 2H) 1.64-1.94 (m, 5H) 2.46-2.57 (m, 1H) 3.19-3.37 (m, 4H) 3.60-3.83 (m, 4H) 7.02-7.12 (m, J=7.83, 4.80 Hz, 1H) 7.92 (dd, J=7.71, 1.89 Hz, 1H) 8.47 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C17H22F3N3O+H+, 342.17877; found (ESI-FTMS, [M+H]1+), 342.1784.
Example 18C 1-[(4-chlorophenyl)acetyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineThe desired product was obtained in 68% yield as a colorless oil. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.11-3.18 (m, 2H) 3.19-3.27 (m, 2H) 3.55-3.65 (m, 2H) 3.73 (s, 2H) 3.76-3.82 (m, 2H) 7.00-7.09 (m, J=7.83, 4.80 Hz, 1H) 7.17-7.23 (m, 2H) 7.28-7.33 (m, 2H) 7.85-7.93 (m, J=7.58, 1.77 Hz, 1H) 8.44 (dd, J=4.93, 1.39 Hz, 1H). HRMS: calcd for C18H17ClF3N3O+H+, 384.10850; found (ESI-FTMS, [M+H]1+), 384.108.
Example 18D Adamantan-1-yl-[4-(2,6-dichloro-phenoxy)-piperidin-1-yl]-methanoneThe desired product was obtained in 85% yield as a colorless oil. mp 191-199, 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.68-1.82 (m, 9H) 1.83-1.98 (m, 6H) 1.97-2.13 (m, 4H) 3.29-3.49 (m, 2H) 4.09-4.28 (m, 2H) 4.43-4.54 (m, 1H) 6.99 (t, 1H) 7.29-7.31 (m, 1H) 7.31-7.33 (m, 1H).
Example 18E 1-[(4-chlorophenyl)acetyl]-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 70% yield as a oil. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.68-1.83 (m, 2H) 1.86-2.00 (m, 2H) 3.22-3.39 (m, 1H) 3.42-3.56 (m, 1H) 3.73 (s, 2H) 3.77-3.91 (m, 1H) 4.01-4.14 (m, 1H) 4.36-4.49 (m, 1H) 6.98 (t, 1H) 7.18-7.23 (m, 2H) 7.27-7.34 (m, 4H). HRMS: calcd for C19H18Cl3NO2+H+, 398.04759; found (ESI-FTMS, [M+H]1+), 398.0492.
Example 18F 1-(cyclohexylcarbonyl)-4-(2,6-dichlorophenoxy)piperidineThe desired product was obtained in 85% yield as a colorless oil. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.16-1.40 (m, 3H) 1.42-1.64 (m, 2H) 1.62-1.87 (m, 5H) 1.87-2.09 (m, J=14.15, 14.15 Hz, 4H) 2.43-2.58 (m, 1H) 3.25-3.41 (m, 2H) 3.79-3.98 (m, J=13.39 Hz, 1H) 4.06-4.21 (m, 1H) 4.40-4.55 (m, 1H) 6.99 (t, 1H) 7.29-7.31 (m, 1H) 7.30-7.33 (m, 1H). HRMS: calcd for C18H23Cl2NO2+H+, 356.11786; found (ESI-FTMS, [M+H]1+), 356.1197.
Example 18G tert-butyl 4-[(3,4-dichlorophenyl)sulfonyl]piperazine-1-carboxylateThe desired product was obtained in 80% yield as a white solid. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.33-1.52 (m, 9H) 2.91-3.09 (m, 4H) 3.45-3.64 (m, 4H) 7.57 (dd, 1H) 7.63 (d, 1H) 7.84 (d, J=2.02 Hz, 1H).
Example 19Step 19A: To a stirred solution of 3-isopropyl-1-methylcyclopentanecarboxylic acid (89 mg, 0.52 mmol) and 1-(3-(trifluoromethyl)pyridin-2-yl)piperazine (242 mg, 1.04 mmol) in N,N-dimethylformamide (1 mL) was added benzotriazole-1yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (700 mg, 1.56 mmol). The reaction was heated in a microwave at 150° C. for 5 minutes. The reaction mixture was purified with HPLC to yield 1-[(3-isopropyl-1-methylcyclopentyl)carbonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine in 42% yield (83.3 mg) as off-white solid.
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.90 (t, J=6.57 Hz, 6H) 1.12-1.45 (m, 5H) 1.47-1.69 (m, 3H) 1.76-1.90 (m, 2H) 2.20-2.43 (m, 1H) 3.12-3.35 (m, 4H) 3.59-3.87 (m, 4H) 7.06 (dd, J=7.83, 4.80 Hz, 1H) 7.90 (dd, J=7.83, 1.77 Hz, 1H) 8.46 (dd, J=4.67, 1.39 Hz, 1H). HRMS: calcd for C20H28F3N3O+H+, 384.22572; found (ESI-FTMS, [M+H]1+), 384.2253. HPLC Method 1: room temperature, 7.177 min, 97.88%. HPLC Method 2: room temperature, 7.801 min, 99.06%.
Example 19B 1-[(2,2-dichloro-1-methylcyclopropyl)carbonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineStep 19A: Coupling of 1-(3-(trifluoromethyl)pyridin-2-yl)piperazine (271 mg, 1.17 mmol) with 2,2-dichloro-1-methylcyclopropanecarboxylic acid (100 mg, 0.59 mmol) was carried out according to a similar procedure described for example 19A using N,N-dimethylformamide (1 mL) as solvent and benzotriazole-1yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (700 mg, 1.56 mmol) as coupling agent. 1-[(2,2-dichloro-1-methylcyclopropyl)carbonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine was obtained in 56% yield (127 mg) as colorless oil.
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.42 (d, J=7.58 Hz, 1H) 1.57 (s, 3H) 2.11 (d, J=7.58 Hz, 1H) 3.13-3.34 (m, 2H) 3.35-3.47 (m, 2H) 3.63-3.81 (m, 3H) 3.81-4.20 (m, 1H) 6.94-7.21 (m, 1H) 7.93 (dd, J=7.83, 1.77 Hz, 1H) 8.48 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C15H16Cl2F3N3O+H+, 382.06953; found (ESI-FTMS, [M+H]1+), 382.069. HPLC Method 1: room temperature, 6.036 min, 100.00%. HPLC Method 2: room temperature, 7.073 min, 99.71%.
Example 19C 1-(cyclohexylacetyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineStep 19A: Coupling of 1-(3-(trifluoromethyl)pyridin-2-yl)piperazine (271 mg, 1.17 mmol) with 2-cyclohexylacetic acid (100 mg, 0.70 mmol) was carried out according to a similar procedure described for example 19A using N,N-dimethylformamide (1 mL) as solvent and benzotriazole-1yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (700 mg, 1.56 mmol) as coupling agent. 1-(cyclohexylacetyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine was obtained in 56% yield (140 mg) as colorless oil.
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.90-1.37 (m, 5H) 1.59-1.89 (m, 6H) 2.27 (d, J=6.82 Hz, 2H) 3.15-3.36 (m, 4H) 3.56-3.71 (m, 2H) 3.70-3.86 (m, 2H) 7.07 (dd, J=7.33, 5.05 Hz, 1H) 7.90 (dd, J=7.71, 1.89 Hz, 1H) 8.46 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C18H24F3N3O+H+, 356.19442; found (ESI-FTMS, [M+H]1+), 356.1942. HPLC Method 1: room temperature, 6.253 min, 98.75%. HPLC Method 2: room temperature, 7.279 min, 97.47%.
Example 19D 1-(cyclopentylacetyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineStep 19A: Coupling of 1-(3-(trifluoromethyl)pyridin-2-yl)piperazine (271 mg, 1.17 mmol) with 2-cyclopentylacetic acid (100 mg, 0.78 mmol) was carried out according to a similar procedure described for example 19A using N,N-dimethylformamide (1 mL) as solvent and benzotriazole-1yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (700 mg, 1.56 mmol) as coupling agent. 1-(cyclopentylacetyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine was obtained in 43% yield (114 mg) as colorless oil.
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.03-1.36 (m, 2H) 1.41-1.79 (m, 4H) 1.72-1.97 (m, 2H) 2.10-2.32 (m, 1H) 2.42 (d, J=7.33 Hz, 2H) 3.06-3.37 (m, 4H) 3.48-3.77 (m, 2H) 3.71-4.06 (m, 2H) 7.07 (dd, J=7.33, 4.80 Hz, 1H) 7.91 (dd, J=7.83, 1.77 Hz, 1H) 8.46 (dd, J=4.67, 1.39 Hz, 1H). HRMS: calcd for C17H22F3N3O+H+, 342.17877; found (ESI-FTMS, [M+H]1+), 342.1784. HPLC Method 1: room temperature, 6.082 min, 100.00%. HPLC Method 2: room temperature, 7.121 min, 99.55%.
Example 19E 1-[(2,2,3,3-tetramethylcyclopropyl)carbonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineStep 19A: Coupling of 1-(3-(trifluoromethyl)pyridin-2-yl)piperazine (271 mg, 1.17 mmol) with 2,2,3,3-tetramethylcyclopropanecarboxylic acid (100 mg, 0.70 mmol) was carried out according to a similar procedure described for example 1A using N,N-dimethylformamide (1 mL) as solvent and benzotriazole-1yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (700 mg, 1.56 mmol) as coupling agent. 1-[(2,2,3,3-tetramethylcyclopropyl)carbonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine was obtained in 67% yield (166 mg) as colorless oil.
HRMS: calcd for C18H24F3N3O+H+, 356.19442; found (ESI-FTMS, [M+H]1+), 356.1942. HPLC Method 1: room temperature, 6.399 min, 99.04%. HPLC Method 2: room temperature, 7.328 min, 98.59%.
Example 19F 1-[(4-methylcyclohexyl)acetyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineStep 19A: Coupling of 1-(3-(trifluoromethyl)pyridin-2-yl)piperazine (271 mg, 1.17 mmol) with 2-(4-methylcyclohexyl)acetic acid (100 mg, 0.64 mmol) was carried out according to a similar procedure described for example 19A using N,N-dimethylformamide (1 mL) as solvent and benzotriazole-1yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (700 mg, 1.56 mmol) as coupling agent. 1-[(4-methylcyclohexyl)acetyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine was obtained in 43% yield (102 mg) as colorless oil.
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.08 (s, 1H) 1.19 (d, J=2.27 Hz, 12H) 2.79-3.52 (m, 4H) 3.50-3.99 (m, 4H) 7.06 (dd, J=7.45, 5.18 Hz, 1H) 7.90 (dd, J=7.83, 1.77 Hz, 1H) 8.46 (dd, J=4.80, 1.52 Hz, 1H). HRMS: calcd for C19H26F3N3O+H+, 370.21007; found (ESI-FTMS, [M+H]1+), 370.2097. HPLC Method 1: room temperature, 6.761 min, 100.00%. HPLC Method 2: room temperature, 7.578 min, 100.00%.
Example 19G 1-(bicyclo[2.2.1]hept-2-ylacetyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineStep 19A: Coupling of 1-(3-(trifluoromethyl)pyridin-2-yl)piperazine (271 mg, 1.17 mmol) with 2-(bicyclo[2.2.1]heptan-2-yl)acetic acid (100 mg, 0.65 mmol) was carried out according to a similar procedure described for example 19A using N,N-dimethylformamide (1 mL) as solvent and benzotriazole-1yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (700 mg, 1.56 mmol) as coupling agent. 1-(bicyclo[2.2.1]hept-2-ylacetyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine was obtained in 82% yield (195 mg) as colorless oil.
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.56-0.83 (m, 1H) 0.98-1.67 (m, 6H) 1.75-1.98 (m, 1H) 2.07-2.61 (m, 5H) 3.10-3.38 (m, 4H) 3.56-3.69 (m, 2H) 3.70-3.84 (m, 2H) 7.06 (dd, J=7.83, 4.80 Hz, 1H) 7.90 (dd, J=7.71, 1.89 Hz, 1H) 8.46 (dd, J=4.80, 1.52 Hz, 1H). HRMS: calcd for C19H24F3N3O+H+, 368.19442; found (ESI-FTMS, [M+H]1+), 368.1941. HPLC Method 1: room temperature, 6.489 min, 99.72%. HPLC Method 2: room temperature, 7.421 min, 99.63%.
Example 19H 1-[(3-methylcyclohexyl)carbonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineStep 19A: Coupling of 1-(3-(trifluoromethyl)pyridin-2-yl)piperazine (271 mg, 1.17 mmol) with 3-methylcyclohexanecarboxylic acid (100 mg, 0.70 mmol) was carried out according to a similar procedure described for example 19A using N,N-dimethylformamide (1 mL) as solvent and benzotriazole-1yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (700 mg, 1.56 mmol) as coupling agent. 1-[(3-methylcyclohexyl)carbonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine was obtained in 45% yield (112 mg) as colorless oil.
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.87-1.06 (m, 3H) 1.12-1.92 (m, 7H) 1.93-2.13 (m, 1H) 2.46-2.64 (m, 1H) 2.70-2.90 (m, 1H) 3.10-3.39 (m, 4H) 3.55-3.84 (m, 4H) 7.06 (dd, J=7.07, 4.80 Hz, 1H) 7.90 (dd, J=7.83, 1.77 Hz, 1H) 8.46 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C18H24F3N3O+H+, 356.19442; found (ESI-FTMS, [M+H]1+), 356.1942. HPLC Method 1: room temperature, 6.420 min, 98.80%. HPLC Method 2: room temperature, 7.354 min, 98.10%.
Example 19I 1-[(2-methylcyclohexyl)carbonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazineStep 19A: Coupling of 1-(3-(trifluoromethyl)pyridin-2-yl)piperazine (271 mg, 1.17 mmol) with 2-methylcyclohexanecarboxylic acid (100 mg, 0.70 mmol) was carried out according to a similar procedure described for example 19A using N,N-dimethylformamide (1 mL) as solvent and benzotriazole-1yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (700 mg, 1.56 mmol) as coupling agent. 1-[(2-methylcyclohexyl)carbonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine was obtained in 45% yield (112 mg) as colorless oil.
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.95 (d, J=7.07 Hz, 3H) 1.13-2.17 (m, 9H) 2.65-2.83 (m, 1H) 3.06-3.41 (m, 4H) 3.51-3.74 (m, 3H) 3.80-3.98 (m, 1H) 7.06 (dd, J=7.83, 4.80 Hz, 1H) 7.90 (dd, J=7.58, 1.77 Hz, 1H) 8.46 (dd, J=4.80, 1.26 Hz, 1H). HRMS: calcd for C18H24F3N3O+H+, 356.19442; found (ESI-FTMS, [M+H]1+), 356.1942. HPLC Method 1: room temperature, 6.388 min, 99.03%. HPLC Method 2: room temperature, 7.333 min, 99.27%.
Example 20Step 20A: 2,6-dichlorobromobenzene (2.26 g, 10 mmole), N-Boc-piperazine (2.05 g, 11 mmole), Pd2(dba)3 (92 mg, 1 mol %), BINAP (187 mg, 3 mol %), and sodium tert-butoxide (1.15 g, 12 mmole) were charged in a microwave vessel. The vessel was capped, purged with nitrogen, and 20 mL toluene added. The reaction mixture was heated to 110° C. for 30 minutes in the microwave and then the mixture was filtered through celite, rinsing with EtOAc. The filtrate was evaporated and then filtered through a pad of silica gel, eluting with dichloromethane. Evaporation gave crude 4-(2,6-Dichloro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester as an orange oil that was taken on to the next step without further purification.
Step 20B: 4-(2,6-Dichloro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (crude material from Step 20A) was dissolved in 50 mL dichloromethane and TFA (25 mL) was added and the mixture stirred at room temperature for 1 hour. The solvent was evaporated, then co-evaporated 3 times with dichloromethane. Obtain 1-(2,6-Dichloro-phenyl)-piperazine, trifluoroacetic acid salt, as a yellow crystalline solid. ESI-MS: m/e=231 [M+H]+.
Step 20C: 1-(2,6-Dichloro-phenyl)-piperazine, trifluoroacetic acid salt (207 mg, 0.6 mmole) and DIPEA (0.32 mL, 1.8 mmole) were dissolved in 2.5 mL dichloromethane and 2-chlorophenylsulfonyl chloride (152 mg, 0.72 mmole) was added and stirred at room temperature for 1 hour. The reaction mixture was partitioned between water and dichloromethane and the organic layer dried over Na2SO4 and evaporated. The crude product was purified by flash chromatography using a gradient of 2% EtOAc/Hex to 10% EtOAc/Hex. Obtain the title compound in 37% yield as a white crystalline solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.23-3.29 (m, 4H) 3.41-3.48 (m, 4H) 7.00 (t, J=8.08 Hz, 1H) 7.23-7.28 (m, 1H) 7.38-7.45 (m, 2H) 7.48-7.59 (m, 2H) 8.09 (dd, J=7.96, 1.64 Hz, 1H). HRMS: calcd for C16H15Cl3N2O2S+H+, 404.99925; found (ESI-FTMS, [M+H]1+), 404.9992. HPLC Method 1: room temperature, 7.013 min, 98.61%, HPLC Method 2: room temperature, 7.531 min, 98.77%.
Example 20B 1-[(4-chlorophenyl)sulfonyl]-4-(2,6-dichlorophenyl)piperazineThe title compound was obtained in 42% yield as a white crystalline solid according to a similar procedure described for example 20A.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.15-3.21 (m, 4H) 3.28-3.33 (m, 4H) 6.97-7.03 (m, 1H) 7.23-7.28 (m, 4H) 7.53-7.57 (m, 1H) 7.72-7.77 (m, 1H). HRMS: calcd for C16H15Cl3N2O2S+H+, 404.99925; found (ESI-FTMS, [M+H]1+), 404.9991. HPLC Method 1: room temperature, 7.104 min, 100.00%, HPLC Method 2: room temperature, 7.624 min, 100.00%.
Example 20C 1-(2,6-dichlorophenyl)-4-[(3,4-dichlorophenyl)sulfonyl]piperazineThe title compound was obtained in 40% yield as a white crystalline solid according to a similar procedure described for example 20A.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.17-3.22 (m, 4H) 3.28-3.33 (m, 4H) 7.01 (t, J=7.96 Hz, 1H) 7.22-7.28 (m, 2H) 7.60-7.67 (m, 2H) 7.89 (d, J=1.77 Hz, 1H). HRMS: calcd for C16H14Cl4N2O2S+H+, 438.96028; found (ESI-FTMS, [M+H]1+), 438.96. HPLC Method 1: room temperature, 7.440 min, 100.00%, HPLC Method 2: room temperature, 7.935 min, 100.00%.
Example 21Step 21A: 3-fluoro-2-trifluoromethylbromobenzene (2.43 g, 10 mmole), N-Boc-piperazine (2.05 g, 11 mmole), Pd2(dba)3 (92 mg, 1 mol %), BINAP (187 mg, 3 mol %), and sodium tert-butoxide (1.15 g, 12 mmole) were charged in a microwave vessel. The vessel was capped, purged with nitrogen, and 20 mL toluene added. The reaction mixture was heated to 110° C. for 30 minutes in the microwave and then the mixture was filtered through celite, rinsing with EtOAc. The filtrate was evaporated and then filtered through a pad of silica gel, eluting with dichloromethane. Evaporation gave crude 4-(3-fluoro-2-trifluoromethyl)-piperazine-1-carboxylic acid tert-butyl ester as a red oil that was taken on to the next step without further purification. ESI-MS: m/e=293 [M-tBu]+.
Step 21B: 4-(3-fluoro-2-trifluoromethyl)-piperazine-1-carboxylic acid tert-butyl ester (crude material from Step 21A) was dissolved in 50 mL dichloromethane and TFA (25 mL) was added and the mixture stirred at room temperature for 1 hour. The solvent was evaporated, then co-evaporated 3 times with dichloromethane. Obtain 1-(3-Fluoro-2-trifluoromethyl-phenyl)-piperazine, trifluoroacetic acid salt, as a low-melting red solid. ESI-MS: m/e=249 [M+H]+.
Step 21C: 1-(3-Fluoro-2-trifluoromethyl-phenyl)-piperazine, trifluoroacetic acid salt (217 mg, 0.6 mmole) and DIPEA (0.32 mL, 1.8 mmole) were dissolved in 2.5 mL dichloromethane and 2-chlorophenylsulfonyl chloride (152 mg, 0.72 mmole) was added and stirred at room temperature overnight. The reaction mixture was partitioned between water and dichloromethane and the organic layer dried over Na2SO4 and evaporated. The crude product was purified by flash chromatography using a gradient of 5% EtOAc/Hex to 25% EtOAc/Hex. The title compound was obtained in 54% yield as a white solid.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.01 (t, J=4.80 Hz, 4H) 3.46 (br.s, 4H) 6.90-7.03 (m, 2H) 7.25-7.27 (m, 1H) 7.40-7.59 (m, 3H) 8.07 (dd, J=7.83, 1.77 Hz, 1H). HRMS: calcd for C17H15ClF4N2O2S+H+, 423.05516; found (ESI-FTMS, [M+H]1+), 423.0555. HPLC Method 1: room temperature, 6.625 min, 100.00%, HPLC Method 2: room temperature, 7.202 min, 100.00%.
Example 21B 1-[(4-chlorophenyl)sulfonyl]-4-[3-fluoro-2-(trifluoromethyl)phenyl]piperazineThe title compound was obtained in 56% yield as a white solid according to a similar procedure described for example 21A.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.04 (t, J=4.42 Hz, 4H) 3.17 (br.s, 4H) 6.90-7.04 (m, 2H) 7.41-7.50 (m, 1H) 7.52-7.59 (m, 2H) 7.69-7.76 (m, 2H). HRMS: calcd for C17H15ClF4N2O2S+H+, 423.05516; found (ESI-FTMS, [M+H]1+), 423.0555. HPLC Method 1: room temperature, 6.786 min, 86.35%, HPLC Method 2: room temperature, 7.317 min, 82.80%.
Example 21C 1-[(3,4-dichlorophenyl)sulfonyl]-4-[3-fluoro-2-(trifluoromethyl)phenyl]piperazineThe title compound was obtained in 52% yield as a white solid according to a similar procedure described for example 21A.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.05 (t, J=4.55 Hz, 4H) 3.20 br. (s, 4H) 6.92-7.03 (m, 1H) 7.25-7.27 (m, 1H) 7.42-7.50 (m, 1H) 7.58-7.63 (m, 1H) 7.64-7.68 (m, 1H) 7.88 (d, J=2.02 Hz, 1H). HRMS: calcd for C17H14Cl2F4N2O2S+H+, 457.01619; found (ESI-FTMS, [M+H]1+), 457.0166. HPLC Method 1: room temperature, 7.105 min, 100.00%, HPLC Method 2: room temperature, 7.635 min, 99.39%.
Example 21D 1-[(4-tert-butylphenyl)sulfonyl]-4-[3-fluoro-2-(trifluoromethyl)phenyl]piperazineThe title compound was obtained in 30% yield as a white solid according to a similar procedure described for example 21A.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.38 (s, 9H) 3.03 (t, J=4.55 Hz, 4H) 3.20 (br.s, 4H) 6.93 (dd, J=10.86, 8.34 Hz, 1H) 6.98-7.03 (m, 1H) 7.41-7.49 (m, 1H) 7.55-7.60 (m, 2H) 7.68-7.73 (m, 2H). HRMS: calcd for C21H24F4N2O2S+H+, 445.15674; found (ESI-FTMS, [M+H]1+), 445.1571. HPLC Method 1: room temperature, 7.28 min, 99.04%, HPLC Method 2: room temperature, 7.66 min, 99.34%.
Example 21E 1-[3-fluoro-2-(trifluoromethyl)phenyl]-4-(2-naphthylsulfonyl)piperazineThe title compound was obtained in 62% yield as a white solid according to a similar procedure described for example 21A.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.04 (t, J=4.42 Hz, 4H) 3.23 (br.s, 4H) 6.88-6.96 (m, 1H) 7.00 (d, J=8.34 Hz, 1H) 7.39-7.49 (m, 1H) 7.60-7.73 (m, 2H) 7.75-7.81 (m, 1H) 7.92-8.06 (m, 3H) 8.37 (s, 1H). HRMS: calcd for C21H18F4N2O2S+H+, 439.10979; found (ESI-FTMS, [M+H]1+), 439.11. HPLC Method 1: room temperature, 6.896 min, 97.58%, HPLC Method 2: room temperature, 7.44 min, 96.54%.
Example 22Step 22A: 4-Oxo-piperidine-1-carboxylic acid tert-butyl ester (2.99 g, 15 mmole), morpholine (1.4 mL, 15.8 mmole), acetic acid (1.0 mL, 18 mmole) were dissolved in 30 mL dichloroethane and sodium triacetoxyborohydride (6.36 g, 30 mmole) was added and the reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with dichloromethane and then washed with 2N NaOH, water, and dried (MgSO4). Filtration and evaporation gave 3.84 g (95%) 4-morpholin-4-yl-piperidine-1-carboxylic acid tert-butyl ester as a colorless oil that solidified on standing.
Step 22B: 4-morpholin-4-yl-piperidine-1-carboxylic acid tert-butyl ester (3.85 g, 14.2) was dissolved in 25 mL dichloromethane and 20 mL trifluoroacetic acid was added and stirred at room temperature for 90 minutes. The reaction mixture was then evaporated then co-evaporated twice with dichloromethane. The semisolid residue was triturated with 75 mL ether, stirred at room temperature 1 hour, then filtered to give 5.03 g of 4-piperidin-4-yl-morpholine, bis-trifluoroacetic acid salt (89%) as a white solid.
Step 22C: 4-piperidin-4-yl-morpholine, bis-trifluoroacetic acid salt (299 mg, 0.75 mmole) and DIPEA (0.54 mL, 3 mmole) were dissolved in 2 mL dichloromethane and 2-chlorophenylsulfonyl chloride (189 mg, 0.9 mmole) was added and the reaction mixture stirred at room temperature overnight. The reaction was diluted with dichloromethane, washed with water and dried over Na2SO4. The organic layer was evaporated then dissolved in 5 mL EtOAc then 2-3 mL 1M HCl/EtOAc was added and stirred at room temperature. The resulting solid was filtered to give 225 mg (75%) of 4-{1-[(2-chlorophenyl)sulfonyl]piperidin-4-yl}morpholine, hydrochloric acid salt as a white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 1.61-1.75 (m, 2H) 2.19 (d, J=11.87 Hz, 2H) 2.69-2.82 (m, 2H) 2.97-3.10 (m, 2H) 3.26-3.43 (m, 3H) 3.77-3.89 (m, 4H) 3.92-3.99 (m, 2H) 7.55-7.61 (m, 1H) 7.67-7.75 (m, 2H) 7.99 (dd, J=7.96, 1.39 Hz, 1H). HPLC Method 1: room temperature, 3.297 min, 100.00%, HPLC Method 2: room temperature, 2.869 min, 100.00%.
Example 22A 4-{1-[(3,4-dichlorophenyl)sulfonyl]piperidin-4-yl}morpholineThe title compound was obtained in 53% yield as a white solid according to a similar procedure described for example 22A.
1H NMR (400 MHz, DMSO-D6) δ ppm 1.66-1.80 (m, 2H) 2.16 (d, J=12.63 Hz, 2H) 2.29-2.39 (m, 2H) 2.96-3.08 (m, 2H) 3.15-3.24 (m, 1H) 3.29-3.39 (m, 2H) 3.73-3.85 (m, 4H) 3.96 (d, J=13.89 Hz, 2H) 7.74 (dd, J=8.34, 2.02 Hz, 1H) 7.95 (d, J=8.34 Hz, 1H) 8.00 (d, J=2.02 Hz, 1H). HPLC Method 1: room temperature, 4.046 min, 100.00%, HPLC Method 2: room temperature, 3.978 min, 100.00%.
Example 23The following compounds can be prepared according to the following scheme.
ESI-MS, [M+H]1+: 389.02.
Example 23B 1-bicyclo[2.2.1]hept-2-yl-4-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]piperazineESI-MS, [M+H]1+: 425.02.
Example 23C 1-(3,4-dichlorophenylsulfonyl)-4-(tetrahydro-2H-pyran-4-yl)piperazineESI-MS, [M+H]1+: 378.97.
Example 24The following compounds can be prepared according to the following scheme.
Yield 41.5%. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.94-3.02 (m, 4H) 3.07-3.23 (m, 4H) 3.67-3.74 (m, 4H) 3.80-3.89 (m, 4H) 6.66 (d, J=9.09 Hz, 1H) 7.18-7.43 (m, 3H) 7.77 (dd, J=9.09, 2.53 Hz, 1H) 8.54 (d, J=2.53 Hz, 1H). HPLC Method 1: room temperature, 6.215 min, 99.73%, HPLC Method 2: room temperature, 7.042 min, 100%.
Example 24B N-[4-({4-[4-fluoro-2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]pyrrolidine-1-carboxamideYield 81.02%. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.93-2.12 (m, 4H) 2.95 (t, J=4.67 Hz, 4H) 3.14 (s, 4H) 3.51 (t, J=6.69 Hz, 4H) 6.44 (s, 1H) 7.17-7.42 (m, 3H) 7.60-7.75 (m, 4H). HPLC Method 1: room temperature, 6.059 min, 100%, HPLC Method 2: room temperature, 6.941 min, 100%.
Example 24C N-[3-chloro-4-({4-[4-fluoro-2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]azepane-1-carboxamideYield 90.72%. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.61-1.67 (m, 4H) 1.81 (s, 4H) 2.91 (t, J=4.67 Hz, 4H) 3.39 (s, 4H) 3.48-3.57 (m, 4H) 6.55 (s, 1H) 7.19-7.40 (m, 4H) 7.80 (d, J=2.27 Hz, 1H) 7.94 (d, J=8.84 Hz, 1H). HPLC Method 1: room temperature, 6.963 min, 99.43%, HPLC Method 2: room temperature, 7.575 min, 99.58%.
Example 24D 4-(5-{[4-(4-fluorophenyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)morpholineYield 39.3%. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.17 (s, 8H) 3.63-3.74 (m, 4H) 3.75-3.90 (m, 4H) 6.63 (d, J=9.09 Hz, 1H) 6.78-6.90 (m, 2H) 6.88-7.03 (m, 2H) 7.78 (dd, J=9.09, 2.53 Hz, 1H) 8.54 (d, J=1.77 Hz, 1H). HPLC Method 1: room temperature, 5.506 min, 100%, HPLC Method 2: room temperature, 6.343 min, 100%.
Example 24E N-(4-{[4-(4-fluorophenyl)piperazin-1-yl]sulfonyl}phenyl)pyrrolidine-1-carboxamideYield 73.1%. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.97-2.06 (m, 4H) 3.15 (s, 8H) 3.49 (t, J=6.57 Hz, 4H) 6.41 (s, 1H) 6.79-6.87 (m, 2H) 6.95 (dd, J=9.09, 8.08 Hz, 2H) 7.59-7.65 (m, 2H) 7.66-7.73 (m, 2H). HPLC Method 1: room temperature, 5.469 min, 100%, HPLC Method 2: room temperature, 6.325 min, 100%.
Example 24F N-(3-chloro-4-{[4-(4-fluorophenyl)piperazin-1-yl]sulfonyl}phenyl)azepane-1-carboxamideYield 60.8%. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.59-1.67 (m, 4H) 1.74-1.84 (m, 4H) 3.07-3.16 (m, 4H) 3.37-3.45 (m, 4H) 3.47-3.56 (m, 4H) 6.56 (s, 1H) 6.81-6.89 (m, 2H) 6.91-7.02 (m, 2H) 7.38 (dd, J=8.72, 2.15 Hz, 1H) 7.76 (d, J=2.27 Hz, 1H) 7.94 (d, J=8.59 Hz, 1H). HPLC Method 1: room temperature, 6.382 min, 98.96%, HPLC Method 2: room temperature, 7.144 min, 99.00%.
Example 25The following compounds can be prepared according to the following scheme.
1H NMR (400 MHz, DMSO-D6) δ ppm 1.50-1.69 (m, 6H) 2.91 (d, J=4.29 Hz, 4H) 2.99 (s, 4H) 3.20-3.29 (m, 4H) 7.07 (d, J=8.08 Hz, 1H) 7.14 (s, 1H) 7.29 (d, J=8.34 Hz, 1H) 7.40-7.61 (m, 3H) 7.65-7.77 (m, 1H). HRMS: calcd for C22H25F4N3O2S+H+, 472.16763; found (ESI-FTMS, [M+H]1+), 472.1681. HPLC Method 1: room temperature, 7.301 min, 98.52%. HPLC Method 2: room temperature, 7.746 min, 98.54%.
Example 25B 4-[3-({4-[4-fluoro-2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]morpholine1H NMR (400 MHz, DMSO-D6) δ ppm 2.91 (t, J=4.29 Hz, 4H) 3.00 (s, 4H) 3.16-3.26 (m, 4H) 3.70-3.81 (m, 4H) 7.10-7.21 (m, 2H) 7.26-7.36 (m, 1H) 7.44-7.61 (m, 3H) 7.73 (d, J=5.05 Hz, 1H). HRMS: calcd for C21H23F4N3O3S+H+, 474.14690; found (ESI-FTMS, [M+H]1+), 474.1464. HPLC Method 1: room temperature, 7.157 min, 98.07%. HPLC Method 2: room temperature, 6.452 min, 97.21%.
Example 25C 1-[4-fluoro-2-(trifluoromethyl)phenyl]-4-[(3-pyrrolidin-1 ylphenyl)sulfonyl]piperazine1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.03-2.09 (m, 4H) 2.95 (t, J=4.80 Hz, 4H) 3.19 (s, 4H) 3.29-3.39 (m, 4H) 6.75 (dd, J=8.08, 2.27 Hz, 1H) 6.84-6.90 (m, 1H) 7.00 (d, J=8.59 Hz, 1H) 7.19-7.26 (m, 1H) 7.27-7.39 (m, 3H). HRMS: calcd for C21H23F4N3O2S+H+, 458.15198; found (ESI-FTMS, [M+H]1+), 458.1525. HPLC Method 1: room temperature, 7.221 min, 97.78%. HPLC Method 2: room temperature, 7.718 min, 97.61%.
Example 26The following compounds can be prepared according to the following scheme.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.71 (s, 3H) 3.24-3.31 (m, 4H) 3.37 (d, J=4.29 Hz, 4H) 6.48-6.67 (m, 3H) 7.12-7.23 (m, 1H) 7.47 (dd, J=8.59, 2.02 Hz, 1H) 7.76 (dd, J=8.59, 0.51 Hz, 1H) 7.82 (dd, J=2.02, 0.51 Hz, 1H). HRMS: calcd for C19H18ClFN2O2S2+H+, 425.05550; found (ESI-FTMS, [M+H]1+), 425.0557. HPLC Method 1: room temperature, 7.123 min, 99.58%. HPLC Method 2: room temperature, 7.698 min, 99.75%.
Example 26B 1-[(5-chloro-2-naphthyl)sulfonyl]-4-(3-fluorophenyl)piperazine1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.25 (d, J=3.54 Hz, 8H) 6.45-6.66 (m, 3H) 7.07-7.22 (m, 1H) 7.49-7.60 (m, 1H) 7.76 (dd, J=7.45, 1.14 Hz, 1H) 7.82-7.98 (m, 2H) 8.38 (d, J=2.02 Hz, 1H) 8.44 (d, J=8.84 Hz, 1H). HRMS: calcd for C20H18ClFN2O2S+H+, 405.08343; found (ESI-FTMS, [M+H]1+), 405.0838. HPLC Method 1: room temperature, 7.571 min, 99.44%. HPLC Method 2: room temperature, 6.963 min, 99.64%.
Example 27The following compounds can be prepared according to the following scheme.
Step 27A): To a solution of piperazin-2-one (1.0 g, 10.0 mmol) in DMF (1.0 mL) was added 2-chloro-3-trifluoromethylpyridine (2.0 g, 11.0 mmol) and DIPEA (2.0 mL, 12.0 mmol). The reaction mixture was heated to 150° C. under microwave conditions for one hour, after which maximum attainable conversion to desired product was judged complete by LCMS. The crude reaction mixture was quenched with H2O (5 mL), resulting in precipitation of the desired product, in >75% purity. The crude solid was then dissolved in ethyl acetate (25 mL) and washed with brine (2×10 mL). The organic layer was dried over Na2SO4, decanted, and concentrated in vacuo, and the resultant crude oil was purified via normal phase SiO2 column chromatography using a 50%-100% ethyl acetate/hexanes solvent gradient. The desired product was isolated in >99% purity, 30% yield (720 mg).
1H NMR (400 MHz, DMSO-D6) δ ppm 3.21-3.28 (m, 2H) 3.39-3.46 (m, 2H) 3.76 (s, 2H) 7.23 (dd, J=7.58, 5.05 Hz, 1H) 7.96 (s, 1H) 8.11 (dd, J=7.83, 1.77 Hz, 1H) 8.54 (dd, J=4.80, 1.52 Hz, 1H); LCMS: calcd for C10H10F3N3O+H+, 246.08; found ([M+H]1+), 246.19; HPLC Method 1: room temperature, 4.16 min, 89.3%. HPLC Method 2: room temperature, 4.1214 min, 95.92%.
Step 27B: A solution of 4-(3-(trifluoromethyl)pyridin-2-yl)piperazin-2-one (150 mg, 0.61 mmol) in anhydrous THF (2.0 mL) was cooled to −78° C., followed by drop-wise addition of LHMDS (0.92 mL, 0.92 mmol (1.0 M in THF)). The reaction was allowed to stir five minutes after which a solution of 5-chloro-3-methyl-2-benzothiophene sulfonyl chloride in anhydrous THF (221 mg, 0.79 mmol in 1 mL) was added drop-wise. The reaction mixture was allowed to stir at −78° C. for approximately two hours, after which it was judged complete by TLC. The reaction was quenched with excess H2O (10 mL), extracted into ethyl acetate (3×10 mL), and finally washed with aqueous NaHCO3 (2×10 mL). The organic layers were combined and dried over Na2SO4, decanted, and concentrated in vacuo. The resultant crude oil was purified via normal phase SiO2 column chromatography using a 5%-20% EA/Hex solvent gradient. The desired product, was isolated in >95% purity, 3.5% yield (10 mg).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.77 (s, 3H) 3.62-3.68 (m, 2H) 3.99 (s, 2H) 4.02-4.08 (m, 2H) 7.12 (dd, J=7.96, 4.93 Hz, 1H) 7.49 (d, J=8.72, 1.89 Hz, 1H) 7.85 (d, J=1.77 Hz, 1H) 7.94 (dd, J=7.96, 1.64 Hz, 1H) 8.33 (dd, J=4.80, 1.26 Hz, 1H); LCMS: calcd for C198H15ClF3N3O3S2+H+, 490.02; found ([M+H]1+), 490.05; HPLC Method 1: room temperature, 6.771 min, 97.56%. HPLC Method 2: room temperature, 3.375 min, 97.92%.
Example 27B 3-(2-(naphthalen-2-yl)ethylsulfonyl)-1-(3-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-oneStep 27A: Prepared according to the procedure for example 27A, affording 50 mg of the desired sulfonamide in >95% purity (21% yield).
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.49-3.54 (m, 2H) 3.57-3.64 (m, 2H) 3.73-3.78 (m, 2H) 3.99 (s, 2H) 4.04-4.09 (m, 2H) 7.10 (dd, J=7.83, 4.80 Hz, 1H) 7.39-7.44 (m, 2H) 7.49-7.55 (m, 1H) 7.55-7.62 (m, 1H) 7.79 (dd, J=6.82, 2.78 Hz, 1H) 7.88 (dd, J=8.08, 0.76 Hz, 1H) 7.94 (dd, J=7.71, 1.89 Hz, 1H) 8.04 (d, J=8.59 Hz, 1H) 8.37 (dd, J=4.80, 1.77 Hz, 1H); LCMS: calcd for C21H18F3N32O3S+H+, 450.10; found ([M+H]1+), 450.23; HPLC Method 1: room temperature, 6.448 min, 98.49%. HPLC Method 2: room temperature, 7.151 min, 99.25%.
Example 28The following compounds can be prepared according to the following scheme.
Step 28A: 1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-4-(3-trifluoromethyl-pyridin-2-yl)-piperazine (142.5 mg, 0.3 mmol), Pd2(dba)3 (13.7 mg, 0.015 mmol), t-BuONa (82.7 mg, 0.84 mmol) and the ligand (9 mg, 0.03 mmol) were mixed in a sealed tube which was flushed with N2. To this was added toluene (2 mL) and then morpholine (21 μL, 0.24 mmol). The resultant mixture was heated at 80° C. for 4 hours. The solvent was removed under vacuum and the crude product was purified with flash column chromatography to yield 4-{3-Methyl-2-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonyl]-benzo[b]thiophen-5-yl}-morpholine in 52% yield (82 mg) as white solid. HRMS: calcd for C23H25F3N4O3S2+H+, 527.13929; found (ESI-FTMS, [M+H]1+), 527.1392.
Example 28B 1-(3-Methyl-5-piperazin-1-yl-benzo[b]thiophene-2-sulfonyl)-4-(3-trifluoromethyl-pyridin-2-yl)-piperazineStep 28A: 1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-4-(3-trifluoromethyl-pyridin-2-yl)-piperazine (142.5 mg, 0.3 mmol), Pd2(dba)3 (13.7 mg, 0.015 mmol), t-BuONa (82.7 mg, 0.84 mmol) and the ligand (9 mg, 0.03 mmol) were mixed in a sealed tube which was flushed with N2. To this was added toluene (2 mL) and then 1-BOC-piperazine (67.1 mg, 0.36 mmol). The resultant mixture was heated at 80° C. for 3 hours. The solvent was removed under vacuum and the crude product was purified with flash column chromatography to yield 4-{3-methyl-2-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonyl]-benzo[b]thiophen-5-yl}-piperazine-1-carboxylic acid tert-butyl ester 68% yield (128 mg) as white solid.
Step 28B: To a solution of 4-{3-methyl-2-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonyl]-benzo[b]thiophen-5-yl}-piperazine-1-carboxylic acid tert-butyl ester (95 mg, 0.18 mmol) in DCM (4 mL) was added TFA (1 mL). The resultant mixture was stirred at ambient temperature for 3 hours. The solvent was removed under vacuum. The crude product was triturated with ether then water to give 1-(3-Methyl-5-piperazin-1-yl-benzo[b]thiophene-2-sulfonyl)-4-(3-trifluoromethyl-pyridin-2-yl)-piperazine as a light yellow solid (51 mg, 66%).
Example 28C 1-(4-Piperidin-1-yl-benzenesulfonyl)-4-(3-trifluoromethyl-pyridin-2-yl)-piperazineStep 28A: 4-bromobenzenesulfonyl)-4-(3-trifluoromethyl-pyridin-2-yl)-piperazine (135.5 mg, 0.3 mmol), Pd2(dba)3 (13.7 mg, 0.015 mmol), t-BuONa (82.7 mg, 0.84 mmol) and the ligand (9 mg, 0.03 mmol) were mixed in a sealed tube which was flushed with N2. To this was added toluene (2 mL) and then piperidine (35 μL, 0.36 mmol). The resultant mixture was heated at 80° C. for 2 hours. The solvent was removed under vacuum and the crude product was purified with flash column chromatography to yield 1-(4-Piperidin-1-yl-benzenesulfonyl)-4-(3-trifluoromethyl-pyridin-2-yl)-piperazine in 85% yield (116 mg) as white solid.
Example 28D 4-{4-[4-(3-Trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonyl]-phenyl}-morpholineStep 28A: 4-bromobenzenesulfonyl)-4-(3-trifluoromethyl-pyridin-2-yl)-piperazine (135.5 mg, 0.3 mmol), Pd2(dba)3 (13.7 mg, 0.015 mmol), t-BuONa (82.7 mg, 0.84 mmol) and the ligand (9 mg, 0.03 mmol) were mixed in a sealed tube which was flushed with N2. To this was added toluene (2 mL) and then morpholine (31.5 μL, 0.36 mmol). The resultant mixture was heated at 80° C. for 2 hours. The solvent was removed under vacuum and the crude product was purified with flash column chromatography to yield 4-{4-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonyl]-phenyl}-morpholine in 78% yield (106 mg) as a white solid.
Example 28E 1-Methyl-{4-{4-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonyl]-phenyl}}-piperazineStep 28A: 4-bromobenzenesulfonyl)-4-(3-trifluoromethyl-pyridin-2-yl)-piperazine (135.5 mg, 0.3 mmol), Pd2(dba)3 (13.7 mg, 0.015 mmol), t-BuONa (82.7 mg, 0.84 mmol) and the ligand (9 mg, 0.03 mmol) were mixed in a sealed tube which was flushed with N2. To this was added toluene (2 mL) and then morpholine (31.5 μL, 0.36 mmol). The resultant mixture was heated at 80° C. for 2 hours. The solvent was removed under vacuum and the crude product was purified with flash column chromatography to yield 1-Methyl-{4-{4-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonyl]-phenyl}}-piperazine in 67% yield (93 mg) as a yellow solid.
Example 29 Example 29AStep 1: (R)-2-methyl-piperazine (3.5 g, 34.9 mmol), 2-bromo-5-fluoro benzotrifluoride (7.74 g, 31.7 mmol), BINAP (0.59 g, 0.95 mmol), tBuONa (4.58 g, 47.65 mmol) and Pd2(dba)3 (0.29 g, 0.32 mmol) were mixed in the flask and purged with N2. Anhydrous toluene (50 mL) was added and purged with N2 again. The resulting mixture was heated in an oil bath at 100° C. under N2 for 3 hours. The mixture was cooled to room temperature, diluted with dichloromethane (150 mL), washed with H2O (30 mL) first, then washed with saturated brine (30 mL). The combined organic layer was dried over Na2SO4, concentrated down under reduced pressure to give a brown color liquid as crude. The crude product was purified on silica gel column eluted with 5-10% MeOH in DCM to give (3R)-1-[4-fluoro-2-(trifluoromethyl)phenyl]-3-methylpiperazine as a light yellow oil (6.85 g, 82%).
Step 2: To a solution of (3R)-1-[4-fluoro-2-(trifluoromethyl)phenyl]-3-methylpiperazine (2.5 g, 9.53 mmol) in DCM (50 mL) at 0° C. was added 3-acetyl benzenesulfonyl chloride (2.08 g, 9.53 mmol) and DIPEA (3.32 mL, 19.06 mmol). The resultant mixture was stirred at room temperature overnight, then washed with H2O first, the aqueous layer was extracted with DCM (2×50 mL). The combined organic layer was dried over Na2SO4. The crude product was purified on SiO2 gel column eluted with 30-40% EtOAc in hexanes to give 1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]ethanone as an off white solid (3.7 g, 90%). Step 3: To 1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]ethanone (3.7 g, 8.33 mmol) was added TMS-CF3 (50 mL, 25 mmol, 0.5 M in THF) at room temperature. This was cooled down to 0° C. in an ice bath, then TBAF (8.33 mL, 8.33 mmol, 1.0 M in THF) was added slowly. The resultant mixture was stirred at 0° C. for 30 min, then stirred at room temperature for 5 hours. The resultant mixture was diluted with saturated NaHCO3 (40 mL), washed with DCM (100 mL). This was separated, the organic layer was washed with saturated brine, dried over Na2SO4. The crude product was purified on SiO2 gel column eluted with 30-50% EtOAc in Hexanes first, then purified again on SiO2 gel column eluted with 2.5% MeOH in DCM to give 1,1,1-trifluoro-2-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propan-2-ol as a white solid (2.76 g, 64%).
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.15-1.23 (m, 3H) 1.85 (s, 3H) 2.55 (s, 1H) 2.66-2.76 (m, 2H) 2.87 (d, J=9.85 Hz, 1H) 2.92-3.00 (m, 1H) 3.32-3.41 (m, 1H) 3.75 (d, J=13.14 Hz, 1H) 4.22-4.24 (m, 1H) 7.18-7.23 (m, 2H) 7.32 (dd, J=8.59, 2.02 Hz, 1H) 7.58 (t, J=7.83 Hz, 1H) 7.79-7.89 (m, 2H) 8.10 (d, J=5.56 Hz, 1H). HRMS: calcd for C21H21F7N2O3S+H+, 515.12339; found (ESI-FTMS, [M+H]1+), 515.123. HPLC Method 1: room temperature, 6.882 min, 99.13%, HPLC Method 2: room temperature, 7.550 min, 100%.
Step 4: The product of step 3 (2.97 g 5.78 mmol) was separated by chiral column. The diastereomers were separated using prep SFC (15% IPA/85% CO2, chiralpak AS-H) to provide:
(2R)-1,1,1-trifluoro-2-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propan-2-ol as a white solid (1.32 g). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.21 (dd, J=6.44, 5.18 Hz, 3H) 1.84 (s, 3H) 2.63 (s, 1H) 2.67-2.75 (m, 2H) 2.84-2.90 (m, 1H) 2.95 (dd, J=10.99, 3.41 Hz, 1H) 3.31-3.41 (m, 1H) 3.75 (d, J=12.88 Hz, 1H) 4.18-4.27 (m, 1H) 7.19-7.23 (m, 2H) 7.32 (dd, J=8.59, 2.02 Hz, 1H) 7.58 (t, J=7.83 Hz, 1H) 7.81 (d, J=7.83 Hz, 1H) 7.85-7.88 (m, 1H) 8.11 (s, 1H); HRMS: calcd for C21H21F7N2O3S+H+, 515.12339; found (ESI-FTMS, [M+H]1+), 515.12488; and
(2S)-1,1,1-trifluoro-2-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propan-2-ol as a white solid (1.26 g). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.17-1.23 (m, 3H) 1.85 (d, J=1.01 Hz, 3H) 2.54 (s, 1H) 2.66-2.73 (m, 2H) 2.87 (d, J=8.34 Hz, 1H) 2.97 (dd, J=11.24, 3.41 Hz, 1H) 3.32-3.41 (m, 1H) 3.75 (d, J=12.88 Hz, 1H) 4.24 (s, 1H) 7.18-7.24 (m, 2H) 7.29-7.35 (m, 1H) 7.58 (t, J=8.08 Hz, 1H) 7.80-7.88 (m, 2H) 8.10 (s, 1H); HRMS: calcd for C21H21F7N2O3S+H+, 515.12339; found (ESI-FTMS, [M+H]1+), 515.12492.
Example 29B1-(3-bromo-benzenesulfonyl)-4-(4-fluoro-2-trifluoromethyl-phenyl)-2-methyl-piperazine was prepared from the corresponding sulfonyl chloride and piperazine according to the sulfonation methods described above (diisopropylethylamine/CH2Cl2). A dry sample 1-(3-bromo-benzenesulfonyl)-4-(4-fluoro-2-trifluoromethyl-phenyl)-2-methyl-piperazine (Compound B, 3.43 g, 7.14 mmol) was dissolved in 50 mL dry THF at 25° C. under nitrogen. The solution was cooled to −78° C. n-BuLi (2.59 M in hexane, 2.89 mL, 7.49 mmol) was added in 20 seconds. The resulting yellow solution was stirred at −78° C. for 30 seconds, and 1,1,1-trifluoro-propan-2-one (0.70 mL, 7.49 mmol) was added in less than 5 seconds. After the reaction mixture was stirred at −78° C. for 30 min, water (0.5 mL) was added. The cooling bath was removed. The reaction mixture was warmed to 25° C. and concentrated to yield a yellow oily residue, which was dissolved in 10 mL toluene. Combiflash of the toluene solution (40 g silica gel column, ethyl acetate:hexane=5:95 to 30:70 in 50 min) afforded 1,1,1-trifluoro-2-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propan-2-ol (3.05 g, 82%) as a white solid.
The following compounds were prepared using a procedures similar to those described in Example 29A.
Example 29C 1,1,1-trifluoro-2-[4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propan-2-olThe title compound was obtained in 51.4% yield (166.6 mg) as a light yellow solid. HRMS: calcd for C21H21F7N2O3S+H+, 515.12339; found (ESI-FTMS, [M+H]1+), 515.1227. HPLC Method 1: room temperature, 6.580 min, 99.41%, HPLC Method 2: room temperature, 7.307 min, 98.12%.
Example 29D 1,1,1-trifluoro-2-[4-({(2R)-4-[3-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propan-2-olYield 85.1%. HRMS: calcd for C21H21F7N2O3S+H+, 515.12339; found (ESI-FTMS, [M+H]1+), 515.1247. HPLC Method 1: room temperature, 6.679 min, 99.48%, HPLC Method 2: room temperature, 7.333 min, 99.0%.
Example 29E 3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)benzoic acidYield 12.1%. HRMS: calcd for C19H18F4N2O4S+H+, 447.09962; found (ESI-FTMS, [M+H]1+), 447.1008. HPLC Method 1: room temperature, 6.210 min, 90.00%, HPLC Method 2: room temperature, 7.226 min, 95.84%.
Example 29F (2R)-1-[(5-bromo-2-methoxyphenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineYield 72.9%. HRMS: calcd for C19H19BrF4N2O3S+H+, 511.03086; found (ESI-FTMS, [M+H]1+), 511.0293.
Example 29G 1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[3-(trifluoromethyl)pyridin-4-yl]piperazin-1-yl}sulfonyl)phenyl]propan-2-olYield 87.5%. HRMS: calcd for C20H21F6N3O3S+H+, 498.12806; found (ESI-FTMS, [M+H]1+), 498.1289.
Example 29H 1,1,1-trifluoro-2-(4-{[(2R)-4-(4-fluoro-2-methylphenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)propan-2-olYield 42.9%. HRMS: calcd for C21H24F4N2O3S+H+, 461.15165; found (ESI-FTMS, [M+H]1+), 461.1519.
Example 29I 2-(4-{[(2R)-4-(2-chloro-4-fluorophenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)-1,1,1-trifluoropropan-2-olYield 63.6%. HRMS: calcd for C20H21ClF4N2O3S+H+, 481.09703; found (ESI-FTMS, [M+H]1+), 481.0975.
Example 29J 5-fluoro-2-((3R)-3-methyl-4-{[4-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)phenyl]sulfonyl}piperazin-1-yl)benzonitrileYield 83.8%. HRMS: calcd for C21H21F4N3O3S+H+, 472.13125; found (ESI-FTMS, [M+H]1+), 472.1316.
Example 29K 2-(3-{[(2R)-4-(2-chloro-4-fluorophenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)-1,1,1-trifluoropropan-2-olYield 63.6%. HRMS: calcd for C20H21ClF4N2O3S+H+, 481.09703; found (ESI-FTMS, [M+H]1+), 481.09623.
Example 29L 1,1,1-trifluoro-2-(4-{[(2R)-4-(4-fluoro-2-methoxyphenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)propan-2-olYield 76.6%. HRMS: calcd for C21H24F4N2O4S+H+, 477.14657; found (ESI-FTMS, [M+H]1+), 477.14454.
Example 29M 1,1,1-trifluoro-2-(3-{[(2R)-4-(4-fluoro-2-methylphenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)propan-2-olYield 82.2%. HRMS: calcd for C21H24F4N2O3S+H+, 461.15165; found (ESI-FTMS, [M+H]1+), 461.15059.
Example 29N 2-(3-{[(2R)-4-(2-chloro-4-fluorophenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)propan-2-olYield 88%. HRMS: calcd for C21H21ClF6N2O3S+H+, 531.09383; found (ESI-FTMS, [M+H]1+), 531.09359.
Example 29O 1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[2-(trifluoromethoxy)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-olYield 88%. HRMS: calcd for C21H22F6N2O4S+H+, 513.12772; found (ESI-FTMS, [M+H]1+), 513.12786.
Example 29P 4-((3R)-3-methyl-4-{[4-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)phenyl]sulfonyl}piperazin-1-yl)-3-(trifluoromethyl)benzonitrileYield 46.7%. HRMS: calcd for C22H21F6N3O3S+H+, 522.12806; found (ESI-FTMS, [M+H]1+), 522.12846.
Example 29Q 2-(4-{[(2R)-4-(2,4-dichlorophenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)-1,1,1-trifluoropropan-2-olYield 82.6%. HRMS: calcd for C20H2)Cl2F3N2O3S+H+, 497.06748; found (ESI-FTMS, [M+H]1+), 497.06732.
Example 29R 2-(4-{[(2R)-4-(2-chloro-4-methylphenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)-1,1,1-trifluoropropan-2-olYield 86.9%. HRMS: calcd for C21H24ClF3N2O3S+H+, 477.12210; found (ESI-FTMS, [M+H]1+), 477.12206.
Example 29S 2-[3-({(2R)-4-[4-chloro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-1,1,1-trifluoropropan-2-olYield 86.2%. HRMS: calcd for C21H21ClF6N2O3S+H+, 531.09383; found (ESI-FTMS, [M+H]1+), 531.09365.
Example 29T 1,1,1-trifluoro-2-[3-({(2R)-2-methyl-4-[2-(trifluoromethoxy)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-olYield 89.9%. HRMS: calcd for C21H22F6N2O4S+H+, 513.12772; found (ESI-FTMS, [M+H]1+), 513.12744.
Example 29U 4-((3R)-3-methyl-4-{[3-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)phenyl]sulfonyl}piperazin-1-yl)-3-(trifluoromethyl)benzonitrileYield 43.9%. HRMS: calcd for C22H21F6N3O3S+H+, 522.12806; found (ESI-FTMS, [M+H]1+), 522.12844.
Example 29T′ 2-(3-{[(2R)-4-(2,4-dichlorophenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)-1,1,1-trifluoropropan-2-olYield 84.5%. HRMS: calcd for C20H21Cl2F3N2O3S+H+, 497.06748; found (ESI-FTMS, [M+H]1+), 497.0673.
Example 29U′ 2-(3-{[(2R)-4-(2-chloro-4-methylphenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)-1,1,1-trifluoropropan-2-olYield 86.9%. HRMS: calcd for C21H24ClF3N2O3S+H+, 477.12210; found (ESI-FTMS, [M+H]1+), 477.12238.
Example 29V 2-(3-{[(2R)-4-{6-[1-amino-2,2,2-trifluoro-1-(trifluoromethyl)ethyl]pyridin-3-yl}-2-methylpiperazin-1-yl]sulfonyl}phenyl)-1,1,1-trifluoropropan-2-olStep A: A mixture of (R)-2-methyl-piperazine (1.0 g, 9.98 mmol), 5-bromo 2-cyanopyridine (1.66 g, 9.08 mmol), tris(dibenzylidineacetone)dipalladium (0) (83.15 mg, 0.0908 mmol), rac-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (169.37 mg, 0.272 mmol) and sodium tert-butoxide (1.09 g, 11.35 mmol) were charged to a microwave vial. Toluene (10.0 mL) was introduced under nitrogen atmosphere and the reaction mixture was irradiated at 110° C. for 35 minutes. Reaction was complete as determined by TLC. Reaction mixtures was diluted with dichloromethane, washed with water, saturated brine then dried over Na2SO4 and concentrated. The crude product was purified via flash column chromatography to yield 5-[(3R)-3-methylpiperazin-1-yl]pyridine-2-carbonitrile as brown color oil (1.15 g, 39.1% yield).
Step B: To a stirred solution of 5-[(3R)-3-methylpiperazin-1-yl]pyridine-2-carbonitrile (250 mg, 1.24 mmol) and 3-acetylbenzenesulfonyl chloride (270.3 mg, 1.24 mmol) in anhydrous dichloromethane (4 mL) was added diisopropylethylamine (0.43 mL, 2.48 mmol). The mixture was stirred at room temperature for over night. Reaction was complete as determined by TLC. The reaction mixture was purified via flash column chromatography to yield 5-{(3R)-4-[(3-acetylphenyl)sulfonyl]-3-methylpiperazin-1-yl}pyridine-2-carbonitrile in 80.3% yield (383 mg) as a light yellow solid.
Step C: To a 50 mL flask containing 5-{(3R)-4-[(3-acetylphenyl)sulfonyl]-3-methylpiperazin-1-yl}pyridine-2-carbonitrile (383 mg, 0.996 mmol) and 6.0 mL of 0.5 M TMS-CF3, was added 0.996 mL of 1.0 M tetrabutylammonium fluoride in THF at 0° C. After stirring for 2 h, the solution was diluted with saturated NaHCO3, extracted (2×CH2Cl2), washed with brine and dried over Na2SO4, and concentrated under reduced pressure. Purification by flash column chromatography to yield 2-(3-{[(2R)-4-{6-[1-amino-2,2,2-trifluoro-1-(trifluoromethyl)ethyl]pyridin-3-yl}-2-methylpiperazin-1-yl]sulfonyl}phenyl)-1,1,1-trifluoropropan-2-ol as a light yellow solid. HRMS: calcd for C22H23F9N4O3S+H+, 595.14199; found (ESI-FTMS, [M+H]1+), 595.14231.
Example 29W 2-(3-{[(2R)-4-(2,4-difluorophenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)-1,1,1-trifluoropropan-2-olYield 67.8%. HRMS: calcd for C20H21F5N2O3S+H+, 465.12658; found (ESI-FTMS, [M+H]1+), 465.12772.
Example 29X 1,1,1-trifluoro-2-[3-({(2R)-2-methyl-4-[4-(1H-tetrazol-5-yl)-2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-olThe compound of Example 29U, 4-((3R)-3-methyl-4-{[3-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)phenyl]sulfonyl}piperazin-1-yl)-3-(trifluoromethyl)benzonitrile, was used as starting material to make the title compound. A mixture of 4-((3R)-3-methyl-4-{[3-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)phenyl]sulfonyl}piperazin-1-yl)-3-(trifluoromethyl)benzonitrile (300 mg, 0.58 mmol), NaN3 (112.5 mg, 1.73 mmol), Et3NHCl (238.1 mg, 1.73 mmol) were charged to a microwave vial. Toluene (3 mL) was introduced under nitrogen atmosphere and the reaction mixture was heated at 100° C. over night in an oil bath. Reaction was complete as determined by TLC. Reaction mixtures was diluted with EtoAc, washed with 10% HCl until pH=6-7. The organic layer was dried over Na2SO4 and concentrated. The crude product was purified via prep HPLC under acidic condition to yield 1,1,1-trifluoro-2-[3-({(2R)-2-methyl-4-[4-(1H-tetrazol-5-yl)-2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-ol as a white solid (111.2 mg, 34.3 yield %). HRMS: calcd for C22H22F6N6O3S+H+, 565.14510; found (ESI-FTMS, [M+H]1+), 565.14524.
Example 29Y 1,1,1,3,3,3-hexafluoro-2-[4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propan-2-amineThe title compound was prepared in a manner similar to that described in Example 29V. In step B, 4-cyanobenzenesulfonyl chloride was used as starting material to make intermediate. Yield 5.3%. HRMS: calcd for C21H19F10N3O2S+H+, 568.11110; found (ESI-FTMS, [M+H]1+), 568.11129.
Example 29Z 4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)benzamideYield 31.9%. HRMS: calcd for C19H19F4N3O3S+H+, 446.11560; found (ESI-FTMS, [M+H]1+), 446.11559.
Example 29AA 1,1,1,3,3,3-hexafluoro-2-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propan-2-amineThe title compound was prepared in a manner similar to that described in Example 29V. In step B, 3-cyanobenzenesulfonyl chloride was used as starting material to make intermediate. Yield 24.1%. HRMS: calcd for C21H19F10N3O2S+H+, 568.11110; found (ESI-FTMS, [M+H]1+), 568.11142.
Example 29AB 3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)benzamideYield 18.8%. HRMS: calcd for C19H19F4N3O3S+H+, 446.11560; found (ESI-FTMS, [M+H]1+), 446.11556.
Example 29AC 5-[(3R)-3-methyl-4-{[3-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)phenyl]sulfonyl}piperazin-1-yl]pyridine-2-carbonitrileYield 82.2%. HRMS: calcd for C20H21F3N4O3S+H+, 455.13592; found (ESI-FTMS, [M+H]1+), 455.13594.
Example 29AD 2-[4-({(2R)-4-[4-[1-amino-2,2,2-trifluoro-1-(trifluoromethyl)ethyl]-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-1,1,1-trifluoropropan-2-olThe title compound was prepared in a manner similar to that described in Example 29V. HRMS: calcd for C24H23F12N3O3S+H+, 662.13412; found (ESI-FTMS, [M+H]1+), 662.13495.
Example 29AD′ 2-(3-{[(2R)-4-{4-[1-amino-2,2,2-trifluoro-1-(trifluoromethyl)ethyl]-2-(trifluoromethyl)phenyl}-2-methylpiperazin-1-yl]sulfonyl}phenyl)-1,1,1-trifluoropropan-2-olThe title compound was prepared in a manner similar to that described in Example 29V. HRMS: calcd for C24H23F12N3O3S+H+, 662.13412; found (ESI-FTMS, [M+H]1+), 662.13513.
Example 29AE (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-({5-[5-(trifluoromethyl)isoxazol-3-yl]-2-thienyl}sulfonyl)piperazineYield 70-80%. HRMS: calcd for C20H16F7N3O3S2+H+, 544.05940; found (ESI-FTMS, [M+H]1+), 544.05847.
Example 29AF 4-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)pyridin-2-yl]morpholineYield 54.8%. HRMS: calcd for C21H24F4N4O3S+H+, 489.15780; found (ESI-FTMS, [M+H]1+), 489.15913.
Example 29AG N-[3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]morpholine-4-carboxamideYield 85.0%. HRMS: calcd for C23H25ClF4N4O4S+H+, 565.12939; found (ESI-FTMS, [M+H]1+), 565.1304.
Example 29AH 4-[(3R)-4-{[3-(1-hydroxy-1-methylethyl)phenyl]sulfonyl}-3-methylpiperazin-1-yl]-3-(trifluoromethyl)benzonitrileYield 65%. HRMS: calcd for C22H24F3N3O3S+H+, 468.15632; found (ESI-FTMS, [M+H]1+), 468.15712.
Example 29AI 1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-olHRMS: calcd for C21H22F6N2O3S+H+, 497.13281; found (ESI-FTMS, [M+H]1+), 497.1322;
Example 29AJ (S)-1,1,1-trifluoro-2-(4-((R)-2-methyl-4-(2-(trifluoromethyl)phenyl)piperazin 1-ylsulfonyl)phenyl)propan-2-olThe title compound was prepared by resolving the enantiomeric mixture of Example 29AI, (1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-ol), using preparative SPC. Solvent evaporation afforded (S)-1,1,1-trifluoro-2-(4-((R)-2-methyl-4-(2-(trifluoromethyl)phenyl)piperazin-1-ylsulfonyl)phenyl)propan-2-ol as a white solid (80.4 mg).
Example 29AK (R)-1,1,1-trifluoro-2-(4-((R)-2-methyl-4-(2-(trifluoromethyl)phenyl)piperazin-1-ylsulfonyl)phenyl)propan-2-olThe title compound was prepared by resolving the enantiomeric mixture of Example 29AI, (1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-ol), using preparative SPC. Solvent evaporation afforded (R)-1,1,1-trifluoro-2-(4-((R)-2-methyl-4-(2-(trifluoromethyl)phenyl)piperazin-1-ylsulfonyl)phenyl)propan-2-ol as a white solid (70.2 mg).
Example 29AL (2R)-1-[(3-bromophenyl)sulfonyl]-4-(2-chloro-4-fluorophenyl)-2-methylpiperazineHRMS: calcd for C17H17BrClFN2O2S+H+, 446.99394; found (ESI-FTMS, [M+H]1+), 446.99325;
Example 29AM (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(4-piperazin-1-yl-1-naphthyl)sulfonyl]piperazineStep 2A and 2B: The intermediate (2R)-1-[(4-bromo-1-naphthyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine was prepared according to a similar procedure for Example II-1A, step 1A and step 1B.
Step 2C: A mixture of (2R)-1-[(4-bromo-1-naphthyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine (250 mg, 0.47 mmol), 4-methyl-piperazine-1-carboxylic acid tert-butyl ester (175.1 mg, 0.94 mmol), tris(dibenzylidineacetone)dipalladium (0) (4.3 mg, 0.0047 mmol), rac-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (8.78 mg, 0.014 mmol) and sodium tert-butoxide (56.5 mg, 0.59 mmol) were charged to a microwave vial. Toluene (3.0 mL) was introduced under nitrogen atmosphere and the reaction mixture was irradiated at 110° C. for 35 minutes. Reaction was complete as determined by TLC. Reaction mixtures was diluted with dichloromethane, washed with water, saturated brine then dried over Na2SO4 and concentrated. The crude product was purified via flash column chromatography to yield tert-butyl 4-[4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-1-naphthyl]piperazine-1-carboxylate as yellow gum (200.1 mg, 66.9% yield).
Step 2D: To a 50 mL flask containing tert-butyl 4-[4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-1-naphthyl]piperazine-1-carboxylate (185.2 mg) and 5 mL of CH2Cl2 was added 3 mL of TFA. This was stirred at room temperature for 4.5 hr. Reaction was complete as determined by TLC. Solvent and TFA was removed under vacuum. The resulting residue was dissolved in CH2Cl2, washed with sat. K2CO3 until pH=8, then washed with saturated brine, dried over Na2SO4 and concentrated down to yield (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(4-piperazin-1-yl-1-naphthyl)sulfonyl]piperazine as a yellow solid (136.3 mg, 87.3% yield). HRMS: calcd for C26H28F4N4O2S+H+, 537.19418; found (ESI-FTMS, [M+H]1+), 537.1968. HPLC Method 1: room temperature, 5.003 min, 94.44%, HPLC Method 2: room temperature, 6.254 min, 93.74%.
Example 29AN (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[4-(4-methylpiperazin-1-yl)-1-naphthyl]sulfonyl}piperazineThe title compound was prepared according to a similar procedure for Example II-4A Yield 71.3%. HRMS: calcd for C27H30F4N4O2S+H+, 551.20983; found (ESI-FTMS, [M+H]+), 551.2119. HPLC Method 1: room temperature, 5.058 min, 92.54%, HPLC Method 2: room temperature, 6.187 min, 92.23%.
Example 29AO 2-[4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propan-2-ol41.5% yield. HRMS: calcd for C21H24F4N2O3S+H+, 461.15165; found (ESI-FTMS, [M+H]1+), 461.1517.
Example 29AP 2-(4-{[(2R)-4-(2-chloro-4-fluorophenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)propan-2-olYield 72.5%. HRMS: calcd for C20H24ClFN2O3S+H+, 427.12529; found (ESI-FTMS, [M+H]1+), 427.12476.
Example 29AQ 2-(3-{[(2R)-4-(2-chloro-4-fluorophenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)propan-2-olYield 81.5%. HRMS: calcd for C20H24ClFN2O3S+H+, 427.12529; found (ESI-FTMS, [M+H]1+), 427.12517.
Example 29AR 4-((3R)-3-methyl-4-{[3-(4-methylpiperazin-1-yl)phenyl]sulfonyl}piperazin-1-yl)-3-(trifluoromethyl)benzonitrileYield 59.8%. HRMS: calcd for C24H28F3N5O2S+H+, 508.19885; found (ESI-FTMS, [M+H]1+), 508.20129.
Example 29AS 4-{(3R)-4-[(3-bromophenyl)sulfonyl]-3-methylpiperazin-1-yl}-3-(trifluoromethyl)benzonitrileYield 85.2%. HRMS: calcd for C19H17BrF3N3O2S+H+, 488.02497; found (ESI-FTMS, [M+H]1+), 488.02487.
Example 29AT (2R)-1-[(3-bromophenyl)sulfonyl]-4-(2,4-dichlorophenyl)-2-methylpiperazineYield 98.6%. HRMS: calcd for C17H17BrCl2N2O2S+H+, 462.96439; found (ESI-FTMS, [M+H]1+), 462.9633.
Example 29AU (2R)-4-(2,4-dichlorophenyl)-2-methyl-1-{[3-(4-methylpiperazin-1-yl)phenyl]sulfonyl}piperazineYield 78%. HRMS: calcd for C22H28Cl2N4O2S+H+, 483.13828; found (ESI-FTMS, [M+H]1+), 483.13912.
Example 29AV (2R)-1-[(3-bromophenyl)sulfonyl]-2-methyl-4-(2,4,5-trifluorophenyl)piperazineYield 95.6%. HRMS: calcd for C17H16BrF3N2O2S+H+, 449.01407; found (ESI-FTMS, [M+H]1+), 449.0139.
Example 29AW (2R)-2-methyl-1-{[3-(4-methylpiperazin-1-yl)phenyl]sulfonyl}-4-(2,4,5-trifluorophenyl)piperazineYield 80%. HRMS: calcd for C22H27F3N4O2S+H+, 469.18796; found (ESI-FTMS, [M+H]1+), 469.1891.
Example 29AX 3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenolStep A: (R)-2-methyl-piperazine (3.88 g, 38.70 mmol), 2-bromo, 5-fluoro benzotrifluoride (8.55 g, 35.18 mmol), tris(dibenzylidineacetone)dipalladium (0) (32.0 mg g, 0.35 mmol), rac-2,2′-bis(diphenylphosphino)-1,1-binaphthyl (657.0 mg, 1.06 mmol) and sodium tert-butoxide (5.07 g, 52.77 mmol) were charged to a reaction flask. Toluene (40 mL) was introduced under nitrogen atmosphere and the reaction mixture was heated up at 110° C. for 5.0 hours. Reaction was complete as determined by TLC. The reaction mixture was diluted with dichloromethane, washed with water, saturated brine then dried over MgSO4 and concentrated. The crude product was purified via flash column chromatography to yield (R)-1-(4-fluoro-2-(trifluoromethyl)phenyl)-3-methylpiperazine as a light brown oil (3.1 g, 33.6% yield).
Step B: To a stirred solution of (R)-1-(4-fluoro-2-(trifluoromethyl)phenyl)-3-methylpiperazine (5.34 g, 21.86 mmol) in anhydrous dichloromethane (20 mL) was added diisopropylethylamine (10.3 mL, 59.1 mmol) at 0° C. The reaction mixture was stirred at room temperature for 15 minutes then 3-Methoxy benzene sulfonyl chloride (2.44 g, 11.82 mmol) dissolved in dichloromethane (10 mL) was introduced dropwise. The cooling bath was removed and the mixture was stirred at room temperature for 0.5 hour. Reaction was complete as determined by TLC. The reaction mixture was diluted with dichloromethane washed with saturated NaHCO3 (aqueous), dried over MgSO4 and concentrated. The crude product was purified via flash column chromatography to yield (R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-1-(3-methoxyphenylsulfonyl)-2-methylpiperazine in quantitative yield (5.10 g) as a white solid.
Step C: A stirred solution of (R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-1-(3-methoxyphenylsulfonyl)-2-methylpiperazine (2.22 g, 5.13 mmol) in anhydrous dichloromethane (60 mL) was cooled down to −50° C. (acetone+dry ice bath). BBr3 (1M in CH2Cl2) was added dropwise via addition funnel while keeping the temperature between −50° C. and −55° C. Then the reaction mixture was stirred at −50° C. to −20° C. for 3 hours. Reaction was complete as determined by TLC. The reaction mixture was quenched with water and diluted with dichloromethane. pH was adjusted to 7 using saturated NaHCO3 (aqueous) and it was allowed to stir for 20 minutes. The layers were separated; the organic layer was dried over MgSO4 and concentrated. The reaction was repeated in 2.85 g scale. The combined crud products were purified via flash column chromatography to yield 3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenol in 96% yield (4.07 g) as a white solid. HRMS: calcd for C18H18F4N2O3S+H+, 419.10470; found (ESI-FTMS, [M+H]1+), 419.104; HPLC Method 1: room temperature, 6.318 min, 100%, HPLC Method 2: room temperature, 7.220 min, 99.48%.
Example 29AY 2-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenoxy]-N,N-dimethylethanamineYield 98.75%. HRMS: calcd for C22H27F4N3O3S+H+, 490.17820; found (ESI-FTMS, [M+H]1+), 490.17796; HPLC Method 1: room temperature, 5.899 min, 98.23%, HPLC Method 2: room temperature, 4.828 min, 98.75%.
Example 29AZ 3-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenoxy]-N,N-dimethylpropan-1-amineYield 57.2%. HRMS: calcd for C23H29F4N3O3S+H+, 504.19385; found (ESI-FTMS, [M+H]1+), 504.19386; HPLC Method 1: room temperature, 5.970 min, 97.87%, HPLC Method 2: room temperature, 4.881 min, 98.31%.
Example 29BA 4-{(3R)-4-[(3-hydroxyphenyl)sulfonyl]-3-methylpiperazin-1-yl}-3-(trifluoromethyl)benzonitrileA light yellow solid (615 mg, 96.4 yield %). HRMS: calcd for C19H18F3N3O3S+H+, 426.10937; found (ESI-FTMS, [M+H]1+), 426.10931.
Example 29BB 4-{(3R)-4-[(3-methoxyphenyl)sulfonyl]-3-methylpiperazin-1-yl}-3-(trifluoromethyl)benzonitrileYield 92.7%. HRMS: calcd for C20H20F3N3O3S+H+, 440.12502; found (ESI-FTMS, [M+H]1+), 440.12536.
Example 29BC 4-((3R)-3-methyl-4-{[3-(1H-1,2,4-triazol-1-yl)phenyl]sulfonyl}piperazin-1-yl)-3-(trifluoromethyl)benzonitrileStep 8A: 4-[(3R)-3-methylpiperazin-1-yl]-3-(trifluoromethyl)benzonitrile was prepared according to procedures similar to those described above.
Step 8B: 4-{(3R)-4-[(3-fluorophenyl)sulfonyl]-3-methylpiperazin-1-yl}-3-(trifluoromethyl)benzonitrile was prepared according to procedures similar to those described above.
Step 8C: A mixture of 4-{(3R)-4-[(3-fluorophenyl)sulfonyl]-3-methylpiperazin-1-yl}-3-(trifluoromethyl)benzonitrile (349 mg, 0.82 mmol), 1,2,4-triazole (112.6 mg, 1.64 mmol), K2CO3 (226.7 mg, 1.64 mmol), and CuI (15.6 mg, 0.082 mmol) were charged to a microwave vial. NMP (3 mL) was introduced under nitrogen atmosphere and the reaction mixture was heated at 166° C. for 3 hr in an oil bath. Reaction was complete as determined by TLC. Reaction mixtures was diluted with dichloromethane, washed with water, saturated brine then dried over Na2SO4 and concentrated. The crude product was purified via prep HPLC under neutral condition to yield 4-((3R)-3-methyl-4-{[3-(1H-1,2,4-triazol-1-yl)phenyl]sulfonyl}piperazin-1-yl)-3-(trifluoromethyl)benzonitrile as a light tan color solid (176.8 mg, 45.3% yield). HRMS: calcd for C21H19F3N6O2S+H+, 477.13150; found (ESI-FTMS, [M+H]1+), 477.13303.
Example 29BD 4-{(3R)-4-[(3-fluorophenyl)sulfonyl]-3-methylpiperazin-1-yl}-3-(trifluoromethyl)benzonitrileYield 92.1%. HRMS: calcd for C19H17F4N3O2S+H+, 428.10503; found (ESI-FTMS, [M+H]1+), 428.1049.
Example 29BE 4-((3R)-3-methyl-4-{[3-(4H-1,2,4-triazol-4-yl)phenyl]sulfonyl}piperazin-1-yl)-3-(trifluoromethyl)benzonitrileHRMS: calcd for C21H19F3N6O2S+H+, 477.13150; found (ESI-FTMS, [M+H]1+), 477.13273.
Example 29BF (2R)-4-(2,4-dichlorophenyl)-2-methyl-1-{[3-(1H-1,2,4-triazol-1-yl)phenyl]sulfonyl}piperazineYield 48.5%. HRMS: calcd for C19H19Cl2N5O2S+H+, 452.07092; found (ESI-FTMS, [M+H]1+), 452.07066.
Example 29BG (2R)-2-methyl-1-{[3-(1H-1,2,4-triazol-1-yl)phenyl]sulfonyl}-4-(2,4,5-trifluorophenyl)piperazineYield 11.3%. HRMS: calcd for C19H18F3N5O2S+H+, 438.12060; found (ESI-FTMS, [M+H]1+), 438.12062.
Example 29BH (2R)-1-[(3-bromophenyl)sulfonyl]-4-[2,5-difluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-methylpiperazineHRMS: calcd for Cl9H18BrF2N5O2S+H+, 498.04054; found (ESI-FTMS, [M+H]1+), 498.04153.
Example 29BI 4-[(3R)-3-methyl-4-{[3-(1H-1,2,4-triazol-1-yl)phenyl]sulfonyl}piperazin-1-yl]benzonitrileYield 40.7%. HRMS: calcd for C20H20N6O2S+H+, 409.14412; found (ESI-FTMS, [M+H]1+), 409.14386.
Example 29BJ 5-[(3R)-3-methyl-4-{[3-(1H-1,2,4-triazol-1-yl)phenyl]sulfonyl}piperazin-1-yl]pyridine-2-carbonitrileYield 59.0%. HRMS: calcd for C19H19N7O2S+H+, 410.13937; found (ESI-FTMS, [M+H]1+), 410.13914.
Example 29BK 2-[3-({(2R)-4-[4-(aminomethyl)-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-1,1,1-trifluoropropan-2-olStep 9A: To a flask containing 4-((3R)-3-methyl-4-{[3-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)phenyl]sulfonyl}piperazin-1-yl)-3-(trifluoromethyl)benzonitrile (50 mg, 0.10 mmol) and 2 mL of THF was added CoCl2 (32.5 mg, 0.25 mmol) at 0° C., then NaBH4 (28.4 mg, 0.75 mmol) was added, followed by adding 1 mL of MeOH. The reaction mixture was stirred at 0° C. for 0.5 hr. Reaction was complete as determined by TLC. The reaction mixture was filtered, washed with EtoAc. The filtrate was washed with H2O, then washed with sat. brine and dried over Na2SO4, and concentrated under reduced pressure. Purification by flash column chromatography to yield 2-[3-({(2R)-4-[4-(aminomethyl)-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-1,1,1-trifluoropropan-2-ol as a white solid. Yield 29%. HRMS: calcd for C22H25F6N3O3S+H+, 526.15936; found (ESI-FTMS, [M+H]1+), 526.15985.
Example 29BL 2-[3-({(2R)-4-[4-(aminomethyl)-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propan-2-olThe title compound was prepared according to a similar procedure for Example II-9A. Yield 41.0% HRMS: calcd for C22H28F3N3O3S+H+, 472.18762; found (ESI-FTMS, [M+H]1+), 472.18899.
Example 29BM 4-chloro-2-fluoro-5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)benzamideStep A: The intermediate (3R)-1-[4-fluoro-2-(trifluoromethyl)phenyl]-3-methylpiperazine was prepared according to procedures similar to those described herein.
Step B: To a stirred solution of 4-chloro-5-chlorosulfonyl-2-fluoro-benzoic acid (306.4 mg, 1.20 mmol) in anhydrous dichloromethane (5 mL) was added TMSCl (0.43 mL, 3.42 mmol). This was stirred at room temperature for 30 min. Then added a solution of (3R)-1-[4-fluoro-2-(trifluoromethyl)phenyl]-3-methylpiperazine (300 mg, 1.14 mmol) in anhydrous dichloromethane (3 mL), followed by adding diisopropylethylamine (1.19 mL, 6.84 mmol) slowly. The mixture was stirred at room temperature for 3 hr. Reaction was complete as determined by TLC. The reaction mixture was diluted with H2O, extracted (2×CH2Cl2), washed with brine and dried over Na2SO4, and concentrated under reduced pressure. Purification by flash column chromatography to yield 4-chloro-2-fluoro-5-[4-(4-fluoro-2-trifluoromethyl-phenyl)-2-methyl-piperazine-1-sulfonyl]-benzoic acid as a dark yellow solid.
Step C: To a flask containing 4-chloro-2-fluoro-5-[4-(4-fluoro-2-trifluoromethyl-phenyl)-2-methyl-piperazine-1-sulfonyl]-benzoic acid (645 mg, 1.29 mmol) and 10 mL of anhydrous THF was added CDI (628.97 mg, 3.88 mmol). The reaction mixture was refluxed under N2 for 2.5 hr. The reaction mixture was cooled down to room temperature, then 15 mL of NH3H2O was added, this was stirred at room temperature for 2 hr. Acidified the reaction mixture with 6N HCl until pH=4-5, extracted (2×EtoAc), washed with brine and dried over Na2SO4, and concentrated under reduced pressure. Purification by prep HPLC under neutral condition to yield 4-chloro-2-fluoro-5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)benzamide as an off-white solid (6.0 mg, 0.9% yield). HRMS: calcd for C19H17ClF5N3O3S+H+, 498.06720; found (ESI-FTMS, [M+H]1+), 498.06793.
Example 29BN 2-chloro-4-fluoro-5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)benzoic acidYield 19.3%. HRMS: calcd for C19H16ClF5N2O4S+H+, 499.05122; found (ESI-FTMS, [M+H]1+), 499.05277.
Example 29BO 3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-4-methoxybenzamideYield 75.6%. HRMS: calcd for C20H21F4N3O4S+H+, 476.12617; found (ESI-FTMS, [M+H]1+), 476.12811.
Example 29BP 4-chloro-3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)benzamideYield 32.5%. HRMS: calcd for C19H18ClF4N3O3S+H+, 480.07663; found (ESI-FTMS, [M+H]1+), 480.07798.
Example 29BQ 1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[1-oxido-3-(trifluoromethyl)pyridin-4-yl]piperazin-1-yl}sulfonyl)phenyl]propan-2-olTo a flask containing 1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[3-(trifluoromethyl)pyridin-4-yl]piperazin-1-yl}sulfonyl)phenyl]propan-2-ol (60 mg, 0.12 mmol) and 1.5 mL of DCM/MeOH (9/1, v/v) was added MMPP (74.6 mg, 0.15 mmol). The resulting slurry was stirred at room temperature over night. Reaction was complete as determined by TLC. This was filtered, washed with DCM. The filtrate was concentrated under reduced pressure. Purification by flash column chromatography to yield 1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[1-oxido-3-(trifluoromethyl)pyridin-4-yl]piperazin-1-yl}sulfonyl)phenyl]propan-2-ol as a white solid (13.5 mg, 21.9 yield). HRMS: calcd for C20H21F6N3O4S+H+, 514.12297; found (ESI-FTMS, [M+H]1+), 514.12174.
Example 29BR 1,1,1-trifluoro-2-[3-({4-[4-fluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl}sulfonyl)phenyl]propan-2-olPrepared according to scheme II-12. HRMS: calcd for C21H20F7NO3S+H+, 500.11249; found (ESI-FTMS, [M+H]1+), 500.11256.
Example 29BR N-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-N,1-dimethylpyrrolidin-3-amineStep A: (R)-1-(4-fluoro-2-(trifluoromethyl)phenyl)-3-methylpiperazine was prepared according to procedures similar to those described above using 2-bromo, 5-fluorobenzotrifluoride was used as starting material. Yield 57.4%.
Step B: (R)-1-(3-bromophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine was prepared according to procedures similar to those described above using 2-Bromobenzene sulfonyl chloride as starting material. Yield 93.6%.
Step 5C: N-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-N,1-dimethylpyrrolidin-3-amine was prepared according to procedures similar to those described above except instead of conventional heating, microwave irradiation was used at 110° C., for 30 minutes and N,N′-dimethyl-3-aminopyrrolidine was used as starting material. Yield 36.8%. HRMS: calcd for C24H30F4N4O2S+H+, 515.20983; found (ESI-FTMS, [M+H]1+), 515.2104; HPLC Method 1: room temperature, 4.854 min, 99.40%, HPLC Method 2: room temperature, 5.969 min, 99.20%.
Example 29BS (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[3-(4-methylpiperazin-1-yl)phenyl]sulfonyl}piperazineYield 27.9%. HRMS: calcd for C23H27F4N3O2S+H+, 486.18328; found (ESI-FTMS, [M+H]1+), 486.18327;
Example 29BT N-{1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidin-3-yl}-N-methylacetamideYield 25.3%. HRMS: calcd for C25H30F4N4O3S+H+, 543.20475; found (ESI-FTMS, [M+H]1+), 543.20336; HPLC Method 1: room temperature, 6.629 min, 96.40%, HPLC Method 2: room temperature, 7.462 min, 96.06%.
Example 29BU {(2S)-1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidin-2-yl}methanolYield 54.4%. HRMS: calcd for C23H27F4N3O3S+H+, 502.17820; found (ESI-FTMS, [M+H]1+), 502.17748;
Example 29BV (3R)-1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidin-3-olYield 76.6%. HRMS: calcd for C22H25F4N3O3S+H+, 488.16255; found (ESI-FTMS, [M+H]1+), 488.16359;
Example 29BW {(2R)-1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidin-2-yl}methyl acetateYield 54.0%. HRMS: calcd for C25H29F4N3O4S+H+, 544.18877; found (ESI-FTMS, [M+H]1+), 544.18921.
Example 29BX (methyl 1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidine-3-carboxylateHRMS: calcd for C24H27F4N3O4S+H+, 530.17312; found (ESI-FTMS, [M+H]1+), 530.17135
Example 29BY 1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidine-3-carboxylic acidThe title compound was obtained by hydrolyzing (1-(3-((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)pyrrolidin-2-yl)methyl acetate using 1N NaOH. Yield 90%. HRMS: calcd for C23H25F4N3O4S+H+, 516.15747; found (ESI-FTMS, [M+H]1+), 516.15646.
Example 29BZ {(2R)-1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidin-2-yl}methanolYield 29.0%. HRMS: calcd for C23H27F4N3O3S+H+, 502.17820; found (ESI-FTMS, [M+H]1+), 502.17972.
Example 29CA 1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidin-3-olHRMS: calcd for C22H25F4N3O3S+H+, 488.16255; found (ESI-FTMS, [M+H]1+), 488.1636.
Example 29CB 1-(3-{[(2R)-4-(2-chloro-4-fluorophenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)pyrrolidin-3-olHRMS: calcd for C21H25ClFN3O3S+H+, 454.13619; found (ESI-FTMS, [M+H]1+), 454.13559.
Example 29CC (2R)-4-(2-chloro-4-fluorophenyl)-2-methyl-1-({3-[4-(2-oxo-2-pyrrolidin-1 ylethyl)piperazin-1-yl]phenyl}sulfonyl)piperazineHRMS: calcd for C27H35ClFN5O3S+H+, 564.22059; found (ESI-FTMS, [M+H]1+), 564.22189.
Example 29CD (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-1-({3-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]phenyl}sulfonyl)-2-methylpiperazineHRMS: calcd for C24H29F4N3O3S+H+, 516.19385; found (ESI-FTMS, [M+H]1+), 516.19562.
Example 29CE (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[3-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]sulfonyl}piperazineHRMS: calcd for C27H34F4N4O2S+H+, 555.24113; found (ESI-FTMS, [M+H]1+), 555.24346.
Example 29CF (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-({3-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]phenyl}sulfonyl)piperazineHRMS: calcd for C28H35F4N5O3S+H+, 598.24695; found (ESI-FTMS, [M+H]1+), 598.2501.
Example 29CG (3S)-1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidin-3-olHRMS: calcd for C22H25F4N3O3S+H+, 488.16255; found (ESI-FTMS, [M+H]1+), 488.16074.
Example 29CH (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(3-pyrrolidin-1-ylphenyl)sulfonyl]piperazineHRMS: calcd for C22H25F4N3O2S+H+, 472.16763; found (ESI-FTMS, [M+H]1+), 472.16822.
Example 29CI 1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidin-3-amineHRMS: calcd for C22H26F4N4O2S+H+, 487.17853; found (ESI-FTMS, [M+H]1+), 487.18047.
Example 29CJ 4-({1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidin-3-yl}carbonyl)morpholineYield 31.6%. HRMS: calcd for C27H32F4N4O4S+H+, 585.21531; found (ESI-FTMS, [M+H]1+), 585.21414; HPLC Method 1: room temperature, 6.641 min, 97.09%, HPLC Method 2: room temperature, 7.428 min, 95.08%.
Example 29CK N-cyclohexyl-1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidine-3-carboxamideYield 16.8%. HRMS: calcd for C29H36F4N4O3S+H+, 597.25170; found (ESI-FTMS, [M+H]1+), 597.25049; HPLC Method 1: room temperature, 7.319 min, 96.16%, HPLC Method 2: room temperature, 7.893 min, 98.77%.
Example 29CL N,N-diethyl-1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidine-3-carboxamideYield 39.4%. HRMS: calcd for C27H34F4N4O3S+H+, 571.23605; found (ESI-FTMS, [M+H]1+), 571.23575; HPLC Method 1: room temperature, 7.171 min, 100%, HPLC Method 2: room temperature, 7.710 min, 100%.
Example 29CM 1-(5-((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)thiophen-2-yl)pyrrolidine-2-carboxamideStep 15C: tert-butyl 1-(5-((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)thiophen-2-yl)pyrrolidine-2-carboxylate was prepared according to for a procedure similar to the Buchwald couplings described herein. Yield 19%
Step 15D: tert-butyl 1-(5-((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)thiophen-2-yl)pyrrolidine-2-carboxylate (316.0 mg, 0.547 mmol), CeCl3.7H2O (815.0 mg, 2.19 mmol) and KI (363.0 mg, 2.19 mmol) charged to a microwave vial were added with CH3CN (12 mL) and water (0.2 mL). The reaction mixture was subjected to microwave irradiation at 110° C. for 1 hour. This reaction was repeated twice. Both reaction mixtures were then combined and the supernatant clear solution was transferred into a flask, added with CH2Cl2 and stirred at room temperature. Solid was filtered off, filtrate concentrated, dried under high vacuum to yield crude 1-(5-((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)thiophen-2-yl)pyrrolidine-2-carboxylic acid which will be used as it is for the next step.
Step 15E: Crude 1-(5-((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)thiophen-2-yl)pyrrolidine-2-carboxylic acid (570 mg, 1.094 mmol) charged to a reaction flask was dissolved in THF (23 mL). To it was added CDI (649 mg, 4.38 mmol) and the reaction mixture was heated to reflux for 1 hour. After cooling down to room temperature excess NH4OH (28% NH3) (23 ml) was added dropwise via addition funnel. The reaction mixture was left to stir at room temperature for 10 minutes, then it was diluted with ethyl acetate, acidified (pH acidic) using 10% HCl (aqueous) and stirred for 5 minutes. The layers were separated, and the organic layer was washed with saturated brine, dried over MgSO4, concentrated. Crude product containing a significant amount of starting acid by TLC was subjected to the same reaction and work up conditions. After reaction completion crude was purified via flash column chromatography to yield 1-(5-((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)thiophen-2-yl)pyrrolidine-2-carboxamide as white solid (180 mg, 31% yield). HRMS: calcd for C21H24F4N4O3S2+H+, 521.12987; found (ESI-FTMS, [M+H]1+), 521.13026.
Example 29CN (R)-2-chloro-3-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)benzamideThe title compound was prepared in a manner similar to that described in Example 29CM. Yield 24.8%. HRMS: calcd for C23H25ClF4N4O3S+H+, 549.13448; found (ESI-FTMS, [M+H]1+), 549.13507.
Example 29CO 1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]pyrrolidine-3-carboxamideHRMS: calcd for C23H26F4N4O3S+H+, 515.17345; found (ESI-FTMS, [M+H]1+), 515.17243;
Example 29CP 1-[2-chloro-3-({(2R)-4-[4-cyano-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]prolinamideYield 52.0%. HRMS: calcd for C24H25ClF3N5O3S+H+, 556.13915; found (ESI-FTMS, [M+H]1+), 556.13923.
Example 29CQ 1-[3-({(2R)-4-[4-cyano-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]prolinamideHRMS: calcd for C24H26F3N5O3S+H+, 522.17812; found (ESI-FTMS, [M+H]1+), 522.17711.
Example 29CR 1-(3-((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)pyrrolidine-2-carboxamideHRMS: calcd for C23H26F4N4O3S+H+, 515.17345; found (ESI-FTMS, [M+H]1+), 515.17506.
Example 29CS 1-(3-((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)pyrrolidine-2-carboxylic acidHRMS: calcd for C23H25F4N3O4S+H+, 516.15747; found (ESI-FTMS, [M+H]1+), 516.15865.
Example 29CT 2-fluoro-5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)benzamideStep 16A and 16B: The intermediate 2-fluoro-5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)benzonitrile was prepared according to procedures similar to those described in Example 29A.
Step 16C: To a flask containing 2-fluoro-5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)benzonitrile (399 mg, 0.90 mmol) was added a mixture of TFA/H2SO4 (4 mL, 2/2 v/v). The reaction mixture was stirred at room temperature for 5 days. Reaction was complete as determined by TLC. Slowly poured the reaction mixture to the ice, then neutralized the reaction mixture with 3N NaOH until pH=7-8, extracted with EtOAc (2×150 mL). The combined organic layer was washed with sat. brine and dried over Na2SO4, and concentrated under reduced pressure. Purification by prep HPLC under neutral condition to yield 2-fluoro-5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)benzamide as a white solid (243.7 mg, 58.4%). HRMS: calcd for C19H18F5N3O3S+H+, 464.10618; found (ESI-FTMS, [M+H]1+), 464.10639.
Example 29CU 1,1,1-trifluoro-2-(3-((2R,6S)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2,6-dimethylpiperazin-1-ylsulfonyl)phenyl)propan-2-olA white solid (2.76 g, 66%). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.49 (d, 6H) 1.78-1.89 (m, 3H) 2.43-2.78 (m, 5H) 4.08-4.26 (m, 2H) 7.07-7.15 (m, 1H) 7.16-7.22 (m, 1H) 7.29-7.37 (m, 1H) 7.51-7.63 (m, 1H) 7.77-7.84 (m, 1H) 7.88-7.95 (m, 1H) 8.08-8.15 (m, 1H). HPLC Method 1: room temperature, 6.955 min, 99.23%, HPLC Method 2: room temperature, 7.574 min, 97.80%.
Example 29CV 4-{(3R)-3-methyl-4-[(5-piperazin-1-yl-2-thienyl)sulfonyl]piperazin-1-yl}benzonitrileYield 59.9%. HRMS: calcd for C20H25N5O2S2+H+, 432.15224; found (ESI-FTMS, [M+H]1+), 432.15278.
Example 29CW (2R)-1-[(3-bromophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineStep 1A: A mixture of 1 (7.92 g, 79.07 mmol), 2 (18.3 g, 75.3 mmol), BINAP (2.81 g, 4.52 mmol), tBuONa (10.86 g, 112.95 mmol) and Pd2(dba)3 (2.07 g, 2.259 mmol) was mixed and purged with N2. Anhydrous toluene (200 mL) was added and purged with N2 again. The resultant mixture was heated in an oil bath at 100° C. under N2 for 5 hours. After cooling, diluted with EtOAc (200 mL), filtered through a pad of Celite and washed with EtOAc (200 mL). The combined organic layer was washed with aq. NaHCO3. The aqueous layer was back extracted with EtOAc (2×100 mL). The combined organic layer was dried over Na2SO4. The crude product was purified on SiO2 gel column eluted with 0-25% MeOH in EtOAc to give 3 as a light yellow oil (14.5 g, 73%).
Step 1B: To a solution of (R)-1-(4-fluoro-2-(trifluoromethyl)phenyl)-3-methylpiperazine (5 g, 19 mmol) in DCM (50 mL) at 0° C. was added DIPEA (6.62 mL, 38 mmol) 3-bromophenylsulfonyl chloride (3.29 mL, 22.8 mmol). The resultant mixture was stirred at room temperature overnight, then washed with aq. NaHCO3. The aqueous layer was extracted with DCM (2×50 mL). The combined organic layer was dried over Na2SO4. The crude product was purified on SiO2 gel column eluted with 5-15% EtOAc in hexanes to give 4 as a white solid (7.9 g, 86%). HRMS: calcd for C18H17BrF4N2O2S+H+, 481.02030; found (ESI-FTMS, [M+H]1+), 481.0208.
Example 29CX (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[3-(4-methylpiperazin-1-yl)phenyl]sulfonyl}piperazineStep 1C: A mixture of (2R)-1-[(3-bromophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine (8 g, 16.667 mmol), N-Me-piperazine (2.22 mL, 20 mmol), bis-t-Bu-biphenylphosphine (298.2 mg, 1.0 mmol), tBuONa (2.4 g, 25 mmol) and Pd2(dba)3 (305.2 mg, 0.333 mmol) was mixed and purged with N2. Anhydrous toluene (80 mL) was added and purged with N2 again. The resultant mixture was heated in an oil bath at 110° C. under N2 for 5 hours. After cooling, diluted with EtOAc (100 mL), filtered through a pad of Celite and washed with EtOAc (100 mL). The combined organic layer was washed with aq. NaHCO3. The aqueous layer was back extracted with EtOAc (2×50 mL). The combined organic layer was dried over Na2SO4. The crude product was purified on SiO2 gel column eluted with 0-25% MeOH in EtOAc to give the desired product as a light yellow solid (6.5 g, 78%). HRMS: calcd for C23H28F4N4O2S+H+, 501.19418; found (ESI-FTMS, [M+H]1+), 501.1944.
Example 29CY (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(3-piperazin-1-ylphenyl)sulfonyl]piperazineStep 1D: To a solution of (R)-tert-butyl 4-(3-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)piperazine-1-carboxylate (970 mg, 1.655 mmol) in DCM (15 mL) was added TFA (5 mL) at room temperature. The resultant mixture was stirred for 4 h then bascified with 5% aq. NH3. The precipitate was collected and washed with water to give the desired product as a light yellow solid (795 mg, 99%). HRMS: calcd for C22H26F4N4O2S+H+, 487.17853; found (ESI-FTMS, [M+H]1+), 487.17747.
Example 29CZ (2R)-1-{[3-(4-ethylpiperazin-1-yl)phenyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineStep 1E: To a solution of (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(3-piperazin-1-ylphenyl)sulfonyl]piperazine (120 mg, 0.247 mmol) in MeOH (2 mL) was added CH3CHO (12 mg, 0.27 mmol), HOAc (17.7 μL, 0.3 mmol) and NaBH3CN (8 mg, 0.125 mmol) at room temperature. The resultant mixture was stirred till disappearance of starting material as monitored by LCMS. The solvent was removed. The crude product was purified by SiO2 column eluted with DCM/MeOH to give the desired product as a light yellow solid (116 mg, 100%). HRMS: calcd for C24H30F4N4O2S+H+, 515.20983; found (ESI-FTMS, [M+H]1+), 515.20891.
The following examples (Examples 29DA to 29EK) were prepared using procedures similar to those described in Examples 29CW-29CZ.
Example 29DA (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-1-{[3-(4-isopropylpiperazin-1-yl)phenyl]sulfonyl}-2-methylpiperazineYield 100%. HRMS: calcd for C25H32F4N4O2S+H+, 529.22548; found (ESI-FTMS, [M+H]1+), 529.22456.
Example 29DB (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-1-{[3-(4-isobutylpiperazin-1-yl)phenyl]sulfonyl}-2-methylpiperazineYield 65%. HRMS: calcd for C26H34F4N4O2S+H+, 543.24113; found (ESI-FTMS, [M+H]1+), 543.2412.
Example 29DC (2R)-1-{[3-(4-cyclohexylpiperazin-1-yl)phenyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineYield 56%. HRMS: calcd for C29H36F4N4O2S+H+, 569.25678; found (ESI-FTMS, [M+H]1+), 569.25578.
Example 29DD (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-({3-[4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl]phenyl}sulfonyl)piperazineYield 63%. HRMS: calcd for C27H34F4N4O3S+H+, 571.23605; found (ESI-FTMS, [M+H]1+), 571.23507.
Example 29DE (2R)-1-{[3-(4-acetylpiperazin-1-yl)phenyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineYield 58%. HRMS: calcd for C24H28F4N4O3S+H+, 529.18910; found (ESI-FTMS, [M+H]1+), 529.1879.
Example 29DF Methyl 4-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperazine-1-carboxylateYield 97%. HRMS: calcd for C24H28F4N4O4S+H+, 545.18401; found (ESI-FTMS, [M+H]1+), 545.1827.
Example 29DG N-ethyl-4-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperazine-1-carboxamideYield 71%. HRMS: calcd for C24H28F4N4O4S+H+, 545.18401; found (ESI-FTMS, [M+H]1+), 545.1827.
Example 29DH (2R)-1-[(5-bromo-2-thienyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineYield 95%. HRMS: calcd for C16H15BrF4N2O2S2+H+, 486.97672; found (ESI-FTMS, [M+H]1+), 486.9753
Example 29DI (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(5-pyridin-2-yl-2-thienyl)sulfonyl]piperazineYield 77%. HRMS: calcd for C21H19F4N3O2S2+H+, 486.09276; found (ESI-FTMS, [M+H]1+), 486.09151.
Example 29DJ (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[5-(1,3-oxazol-5-yl)-2-thienyl]sulfonyl}piperazineYield 58%. HRMS: calcd for C19H17F4N3O3S2+H+, 476.07202; found (ESI-FTMS, [M+H]1+), 476.07045.
Example 29DK (2R)-1-[(4-bromo-5-chloro-2-thienyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineHRMS: calcd for C16H14BrClF4N2O2S2+H+, 520.93774; found (ESI-FTMS, [M+H]1+), 520.93796;
Example 29DM (2R)-1-[(5-chloro-2-thienyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineHRMS: calcd for C16H15ClF4N2O2S2+H+, 443.02723; found (ESI-FTMS, [M+H]1+), 443.02752.
Example 29DN (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[3-(5-methyl-2-furyl)phenyl]sulfonyl}piperazineHRMS: calcd for C23H22F4N2O3S+H+, 483.13600; found (ESI-FTMS, [M+H]1+), 483.13551.
Example 29DO 4-[(3R)-4-{[3-(2,4-dimethyl-1,3-thiazol-5-yl)phenyl]sulfonyl}-3-methylpiperazin-1-yl]-3-(trifluoromethyl)benzonitrileHRMS: calcd for C24H23F3N4O2S2+H+, 521.12873; found (ESI-FTMS, [M+H]1+), 521.12984.
Example 29DP (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[3-(trifluoromethoxy)phenyl]sulfonyl}piperazineYield 84%. HRMS: calcd for C19H17F7N2O3S+H+, 487.09208; found (ESI-FTMS, [M+H]1+), 487.09309.
Example 29DQ (2R)-1-{[3-(difluoromethoxy)phenyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineYield 84%. HRMS: calcd for C19H18F6N2O3S+H+, 469.10151; found (ESI-FTMS, [M+H]1+), 469.10142.
Example 29DR (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[5-(4-methylpiperazin-1-yl)-2-thienyl]sulfonyl}piperazineYield 54%. MS (LC-ESIMS) m/z 507.2.
Example 29DS 4-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]morpholineYield 59%. MS (LC-ESIMS) m/z 494.0
Example 29DT (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(5-piperidin-1-yl-2-thienyl)sulfonyl]piperazineYield 50%. MS (LC-ESIMS) m/z 492.1.
Example 29DT (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(5-piperidin-1-yl-2-thienyl)sulfonyl]piperazineYield 81%. HRMS: calcd for C20H24F4N4O2S2+H+, 493.13495; found (ESI-FTMS, [M+H]1+), 493.13585.
Example 29DU (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-({5-[(3R)-3-methylpiperazin-1-yl]-2-thienyl}sulfonyl)piperazineYield 82%. HRMS: calcd for C21H26F4N4O2S2+H+, 507.15060; found (ESI-FTMS, [M+H]1+), 507.15115.
Example 29DV (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-({5-[(3S)-3-methylpiperazin-1-yl]-2-thienyl}sulfonyl)piperazineYield 59%. HRMS: calcd for C21H26F4N4O2S2+H+, 507.15060; found (ESI-FTMS, [M+H]1+), 507.1505.
Example 29DW 1-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]-N,N-dimethylpiperidin-4-amineYield 70%. MS (LC-ESIMS) m/z 535.1.
Example 29DX 4-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]-2,6-cis-dimethylmorpholineYield 67%. HRMS: calcd for C22H27F4N3O3S2+H+, 522.15027; found (ESI-FTMS, [M+H]1+), 522.14978.
Example 29DY 4-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]piperazin-2-oneYield 77%. MS (LC-ESI-MS) m/z 507.3.
Example 29DZ 1-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]piperidine-4-carboxamideYield 37%. HRMS: calcd for C22H26F4N4O3S2+H+, 535.14552; found (ESI-FTMS, [M+H]1+), 535.14646.
Example 29EA (2R)-1-({5-[3,5-cis-dimethylpiperazin-1-yl]-2-thienyl}sulfonyl)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineYield 52.2%. HRMS: calcd for C22H28F4N4O2S2+H+, 521.16625; found (ESI-FTMS, [M+H]1+), 521.16822.
Example 29EA 1-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]piperidine-4-carboxylic acidHRMS: calcd for C22H25F4N3O4S2+H+, 536.12954; found (ESI-FTMS, [M+H]1+), 536.13032.
Example 29EB (2R)-1-{[5-(4-acetylpiperazin-1-yl)-2-thienyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineYield 85%. HRMS: calcd for C22H26F4N4O3S2+H+, 535.14552; found (ESI-FTMS, [M+H]1+), 535.14534.
Example 29EC (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-1-{[5-(4-isobutyrylpiperazin-1-yl)-2-thienyl]sulfonyl}-2-methylpiperazineYield 56%. HRMS: calcd for C24H30F4N4O3S2+H+, 563.17682; found (ESI-FTMS, [M+H]1+), 563.17644.
Example 29ED Methyl 4-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]piperazine-1-carboxylateYield 78%. HRMS: calcd for C22H26F4N4O4S2+H+, 551.14043; found (ESI-FTMS, [M+H]1+), 551.14026.
Example 29EE Isopropyl 4-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]piperazine-1-carboxylateYield 84%. HRMS: calcd for C24H30F4N4O4S2+H+, 579.17173; found (ESI-FTMS, [M+H]1+), 579.17159.
Example 29EF 4-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]-N-isopropylpiperazine-1-carboxamideYield 91%. HRMS: calcd for C24H31F4N5O3S2+H+, 578.18772; found (ESI-FTMS, [M+H]1+), 578.18767.
Example 29EG (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-1-{[5-(4-isopropylpiperazin-1-yl)-2-thienyl]sulfonyl}-2-methylpiperazineYield 73%. HRMS: calcd for C23H30F4N4O2S2+H+, 535.18190; found (ESI-FTMS, [M+H]1+), 535.18259.
Example 29EH (2R)-1-{[5-(4-cyclohexylpiperazin-1-yl)-2-thienyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineYield 77%. HRMS: calcd for C26H34F4N4O2S2+H+, 575.21320; found (ESI-FTMS, [M+H]1+), 575.21408.
Example 29EI (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-({5-[4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl]-2-thienyl}sulfonyl)piperazineYield 69%. HRMS: calcd for C25H32F4N4O3S2+H+, 577.19247; found (ESI-FTMS, [M+H]1+), 577.19308.
Example 29EJ 2-{4-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]piperazin-1-yl}ethanolYield 69%. HRMS: calcd for C22H28F4N4O3S2+H+, 537.16117; found (ESI-FTMS, [M+H]1+), 537.16153.
Example 29EK 1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperidin-4-olYield 36%. HRMS: calcd for C23H27F4N3O3S+H+, 502.17820; found (ESI-FTMS, [M+H]1+), 502.17957.
Example 29EL 1,1,1,3,3,3-hexafluoro-2-[4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propan-2-olStep 2A: To a solution of (R)-1-(4-bromophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine (265 mg, 0.55 mmol) in dry THF (2.5 mL) was added tBuLi (0.65 mL, 1.7 M in pentane, 1.1 mmol) at −78° C. The resultant mixture was stirred for 5 min then CF3COCF3 was bubbled into the solution and stirred another 30 min before quenched by addition of aq. NH4Cl. The aq. layer was extracted with DCM and combined organic layer was dried over MgSO4. The crude product was purified on SiO2 gel column eluted with hexanes/EtOAc to give the desired product as a white solid (125 mg, 40%). HRMS: calcd for C21H18F10N2O3S+H+, 569.09512; found (ESI-FTMS, [M+H]1+), 569.0967.
The following examples (29EM to 29EU) were prepared using procedures similar to those in Scheme III-2.
Example 29EM 4-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-1-methylpiperidin-4-olYield 34%. HRMS: calcd for C24H29F4N3O3S+H+, 516.19385; found (ESI-FTMS, [M+H]1+), 516.19400.
Example 29EN 4-[4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-1-methylpiperidin-4-olYield 26%. HRMS: calcd for C24H29F4N3O3S+H+, 516.19385; found (ESI-FTMS, [M+H]1+), 516.1939.
Example 29EO 2,2,2-trifluoro-1-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]ethanone Example 29EP 2-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]propan-2-olYield 70%. HRMS: calcd for C19H22F4N2O3S2+H+, 467.10807; found (ESI-FTMS, [M+H]1+), 467.10824.
Example 29EQ 1,1,1-trifluoro-2-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]propan-2-olYield 86%. HRMS: calcd for C19H19F7N2O3S2+H+, 521.07980; found (ESI-FTMS, [M+H]1+), 521.07991.
Example 29ER 5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)thiophene-2-carboxylic acidYield 86%. HRMS: calcd for C17H16F4N2O4S2+H+, 453.05604; found (ESI-FTMS, [M+H]1+), 453.05652.
Example 29ES 3,3,3-trifluoro-2-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]-2-hydroxypropanoic acidHRMS: calcd for C17H16F4N2O4S2+H+, 453.05604; found (ESI-FTMS, [M+H]1+), 453.05652.
Example 29ET (2S)-1,1,1-trifluoro-2-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]propan-2-olPrepared by chiral HPLC separation of Example 29EQ. MS (LC-ESIMS) m/z 521.1. MS (LC-ESIMS) m/z 519.2.
Example 29EU (2R)-1,1,1-trifluoro-2-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]propan-2-olPrepared by chiral HPLC separation of Example 29EQ. MS (LC-ESIMS) m/z 520.7. MS (LC-ESIMS) m/z 519.0.
Example 29EV 5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-N,N-dimethylthiophene-2-carboxamideStep 3A: To a solution of 5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)thiophene-2-carboxylic acid (260 mg, 0.575 mmol) in DCM (5 mL) was added (COCl)2 (150.5 μL, 1.726 mmol) and DMF (1 small drop). The resultant mixture was stirred for 3 h. The solvent was evaporated and the crude residue was redissolved in dioxane (5 mL). To this was added 2N NH3 in EtOH (2 mL). The reaction mixture was stirred for 6 h then concentrated. The crude product was purified on SiO2 column eluted with hexanes/EtOAc to give the titled compound (less polar fraction, a side product) as a light yellow solid (48 mg, 17%). HRMS: calcd for C19H21F4N3O3S2+H+, 480.10332; found (ESI-FTMS, [M+H]1+), 480.1042.
Example 29EW 5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)thiophene-2-carboxamideMethod 1: Prepared according to Step 3A in Example 29EV as the major product, as a white solid (180 mg, 69%).
Method 2: To a solution of 5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)thiophene-2-carboxylic acid (1.15 g, 2.54 mmol) in THF (10 mL) was added Im2CO (825.1 mg, 5.08 mmol). The resultant mixture was stirred for 4 h. To this was added 2N NH3 in EtOH (6.3 mL). The reaction mixture was stirred overnight then concentrated. The crude product was purified by HPLC to give the titled compound as a white solid (789 mg, 69%). HRMS: calcd for C17H17F4N3O3S2+H+, 452.07202; found (ESI-FTMS, [M+H]1+), 452.07369.
Example 29EX tert-butyl 4-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperidine-1-carboxylateStep 4A: A reaction mixture of (R)-1-(3-bromophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine (1.008 g, 2.1 mmol), boronate ester (620 mg, 2 mmol), PdCl2(dppf) (43.9 mg, 0.06 mmol), dppf (33.3 mg, 0.06 mmol) and KOAc (589 mg, 6 mmol) in dioxane (8 mL) was degassed and sealed. The reaction mixture was heated to 80° C. for 3 h then 100° C. for 2 h. It was diluted with DCM after cooling and washed with brine. The crude product was purified on SiO2 gel column eluted with hexanes/EtOAc to give (R)-tert-butyl 4-(3-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate as a light yellow solid (628 mg, 54%).
Step 4B: To a solution of (R)-tert-butyl 4-(3-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate (620 mg, 1.06 mmol) in MeOH (50 mL) was added Pd/C (˜100 mg). The mixture was purged with nitrogen and then stirred under H2 balloon at room temperature for 2 h. The reaction mixture was filtered through Celite and concentrated. The crude product was purified by SiO2 gel column eluted with hexanes/EtOAc to give the titled compound as a light yellow solid (569 mg, 92%). HRMS: calcd for C28H35F4N3O4S+H+, 586.23572; found (ESI-FTMS, [M+H]1+), 586.23585.
Example 29EY (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(3-piperidin-4-ylphenyl)sulfonyl]piperazineStep 4C: To a solution of tert-butyl 4-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperidine-1-carboxylate (540 mg, 0.923 mmol) in DCM (15 mL) was added TFA (5 mL). The reaction mixture was stirred at room temperature for 2 h and washed with aq. Na2CO3. The organic layer was dried over Na2SO4, concentrated and redissolved in Et2O and acidified with 1N HCl in Et2O to give the titled compound as a white solid (427 mg, 89%). HRMS: calcd for C23H27F4N3O2S+H+, 486.18328; found (ESI-FTMS, [M+H]1+), 486.18382.
Example 29EZ (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[3-(1-methylpiperidin-4-yl)phenyl]sulfonyl}piperazineStep 4D: To a solution of (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(3-piperidin-4-ylphenyl)sulfonyl]piperazine (81 mg, 0.155 mmol) in MeOH (2 mL) was added (CHO)n 27 mg, 0.93 mmol), HOAc (13.7 μL, 0.23 mmol) and NaBH3CN (6 mg, 0.093 mmol). The reaction mixture was stirred at room temperature overnight then 50° C. till disappearance of starting material. The reaction was diluted with DCM and quenched with aq. NaHCO3. The organic layer was separated and dried over Na2SO4 and purified on SiO2 gel column eluted with hexanes/EtOAc to give the desired product as a sticky oil (65 mg, 84%). It was redissolved in Et2O and acidified with 1N HCl in Et2O and triturated with hexanes/Et2O to give the titled compound as a white solid. HRMS: calcd for C24H29F4N3O2S+H+, 500.19893; found (ESI-FTMS, [M+H]1+), 500.19765.
Example 29FA (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-1-{[3-(1-isopropylpiperidin-4-yl)phenyl]sulfonyl}-2-methylpiperazinePrepared according to the synthesis of Example 29EZ in Step 4D from (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(3-piperidin-4-ylphenyl)sulfonyl]piperazine (81 mg, 0.155 mmol) and acetone (23 μL, 0.31 mmol) as a sticky oil (75 mg, 92%). It was redissolved in Et2O and acidified with 1N HCl in Et2O and triturated with hexanes/Et2O to give the titled compound as a white solid. HRMS: calcd for C26H33F4N3O2S+H+, 528.23023; found (ESI-FTMS, [M+H]1+), 528.22834.
Example 29FB (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(5-piperidin-4-yl-2-thienyl)sulfonyl]piperazinePrepared according to the synthesis of Example 29EY in Step 4C from (R)-tert-butyl 4-(5-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)thiophen-2-yl)piperidine-1-carboxylate (150 mg, 0.253 mmol) in DCM (3 mL) and TFA (1 mL), purified by SiO2 column eluted with EtOAc/MeOH to give the titled compound as a white solid (75 mg, 60%). HRMS: calcd for C21H25F4N3O2S2+H+, 492.13970; found (ESI-FTMS, [M+H]1+), 492.14043.
Example 29FC 2-(4-{[(2R)-4-(2,4-difluorophenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)-1,1,1-trifluoropropan-2-olStep 5A: To a solution of (R)-1-(4-(4-(2,4-difluorophenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)ethanone (360 mg, 0.87 mmol, prepared according to procedures similar to those described in Example 29A) was added TMSCF3 (5.2 mL, 0.5 M in THF, 2.6 mmol) and TBAF (0.87 mL, 1 M in THF, 1.0 mmol) at 0° C. The resultant mixture was stirred for 6 h then rt overnight. It was washed with aq. NH4Cl and aq. layer was extracted with DCM. The organic layer was dried over Na2SO4. The crude product was purified on SiO2 column eluted with hexanes/EtOAc to give the desired product as a white solid (329 mg, 81%). HRMS: calcd for C20H21F5N2O3S+H+, 465.12658; found (ESI-FTMS, [M+H]1+), 465.12565.
Example 29FD 2-(4-{[(2R)-4-(2,4-difluorophenyl)-2-methylpiperazin-1-yl]sulfonyl}phenyl)propan-2-olStep 5B: To a solution of (R)-1-(4-(4-(2,4-difluorophenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)ethanone (220 mg, 0.558 mmol, prepared according to procedures similar to those described in Example 29A in THF (3 mL) was added MeLi (0.42 mL, 1.6 M in THF, 0.67 mmol) at −78° C. The resultant mixture was stirred for 6 h then quenched with aq. NH4Cl and aq. layer. It was extracted with DCM. The organic layer was dried over Na2SO4. The crude product was purified on SiO2 column eluted with hexanes/EtOAc to give the desired product as a white solid (167 mg, 73%). HRMS: calcd for C20H24F2N2O3S+H+, 411.15484; found (ESI-FTMS, [M+H]1+), 411.15477.
Example 29FE 1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-olPrepared according to procedures similar those described in Example 29FC from (R)-1-(4-(2-methyl-4-(4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)phenyl)piperazin-1-ylsulfonyl)phenyl)ethanone (180 mg, 0.344 mmol), as a white solid (87.6 mg, 43%). HRMS: calcd for C26H32F6N4O3S+H+, 595.21721; found (ESI-FTMS, [M+H]1+), 595.21453.
Example 29FF (R)-2-(3-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)propan-2-olPrepared according to procedures similar those described in Example 29FD from (R)-1-(3-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)ethanone, as a white solid. HRMS: calcd for C21H24F4N2O3S+H+, 461.15165; found (ESI-FTMS, [M+H]1+), 461.1523.
Example 29FG 1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[3-(1H-1,2,4-triazol-1-yl)-2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-olPrepared according to procedures similar those described in Example 29FC from (R)-1-(4-(4-(3-(1H-1,2,4-triazol-1-yl)-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)ethanone, as a white solid. HRMS: calcd for C23H23F6N5O3S+H+, 564.14985; found (ESI-FTMS, [M+H]1+), 564.14965.
Example 29FH (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[3-(1H-imidazol-1-yl)phenyl]sulfonyl}piperazineStep 6A: A suspension of (R)-1-(3-bromophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine (168 mg, 0.35 mmol), 1,2-trans-diaminomethylcyclohexane (2.9 mg, 0.015 mmol), K3PO4 (8.5 mmg, 0.06 mmol) and Imidazole (41 mg, 0.6 mmol) in dioxane (0.6 mL) was degassed and heated to 120° C. in a sealed tube till disappearance of starting material as monitored by LCMS. The crude reaction mixture was filtered through a pad of Celite and washed with EtOAc. The crude product was purified on SiO2 column eluted with hexanes/EtOAc to give the desired product as a white solid (123 mg, 75%). HRMS: calcd for C21H20F4N4O2S+H+, 469.13158; found (ESI-FTMS, [M+H]1+), 469.13336.
Example 29FI (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[3-(1H-pyrazol-1-yl)phenyl]sulfonyl}piperazinePrepared according to procedures similar to those described in Example 29FH from (R)-1-(3-bromophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine (168 mg, 0.35 mmol), and Imidazole (41 mg, 0.6 mmol) as a white solid (152.3 mg, 93%). HRMS: calcd for C21H20F4N4O2S+H+, 469.13158; found (ESI-FTMS, [M+H]1+), 469.13318.
Example 29FJ (2R)-2-methyl-1-{[3-(1H-1,2,4-triazol-1-yl)phenyl]sulfonyl}-4-[4-(1H-1,2,4-triazol-1-yl)-2-(trifluoromethyl)phenyl]piperazinePrepared according to procedures similar to those described in Example 29FH from (R)-1-(3-bromophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine (96 mg, 0.2 mmol), salicylaldoxime (2.8 mg, 0.02 mmol), K3PO4 (8.5 mmg, 0.06 mmol) and triazole (27.6 mg, 0.4 mmol) in DMF (0.4 mL) as a white solid (major product, 89.4 mg, 86%). HRMS: calcd for C22H21F3N8O2S+H+, 519.15330; found (ESI-FTMS, [M+H]1+), 519.15377.
Example 29FK 1-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]piperazin-2-onePrepared by acid treatment (1N HCl in EtOAc) of tert-butyl 4-(5-((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)thiophen-2-yl)-3-oxopiperidine-1-carboxylate, as a white solid [tert-butyl 4-(5-((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)thiophen-2-yl)-3-oxopiperidine-1-carboxylate was prepared according to procedures similar to those described in Example 29FH from (R)-1-(5-bromothiophen-2-ylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine (292 mg, 0.6 mmol), and tert-butyl 3-oxopiperazine-1-carboxylate (181 mg, 0.9 mmol) as a white solid (major product, 89.4 mg, 86%)]. HRMS: calcd for C20H22F4N4O3S2+H+, 507.11422; found (ESI-FTMS, [M+H]1+), 507.11461.
Example 29FL (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[3-(1H-1,2,4-triazol-1-yl)phenyl]sulfonyl}piperazinePrepared according to procedures similar to those described in Example 29FH from (R)-1-(3-bromophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine, without using ligand, as a white solid. HRMS: calcd for C20H19F4N5O2S+H+, 470.12683; found (ESI-FTMS, [M+H]1+), 470.1276.
Example 29FM (2R)-1-{[2-chloro-4-(1H-1,2,4-triazol-1-yl)phenyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazinePrepared according to procedures similar to those described in Example 29FH from (R)-1-(2-chloro-4-fluorophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine, without using ligand, as a white solid. HRMS: calcd for C20H18ClF4N5O2S+H+, 504.08786; found (ESI-FTMS, [M+H]1+), 504.08778.
Example 29FN (2R)-1-{[3-chloro-4-(1H-1,2,4-triazol-1-yl)phenyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazinePrepared according to procedures similar to those described in Example 29FH from (R)-(3-chloro-4-fluorophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine, without using ligand, as a white solid. HRMS: calcd for C20H18ClF4N5O2S+H+, 504.08786; found (ESI-FTMS, [M+H]1+), 504.08934.
Example 29FO 3-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]-2-methylpropanoic acidStep 7A: To a solution of (R)-1-(5-bromothiophen-2-ylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine (389 mg, 0.8 mmol), Pd2(dba)3 (22 mg, 0.024 mmol), ZnF2 (41.6 mg, 0.4 mmol) and P(tBu3)HBF4 (13.9 mg, 0.048 mmol) in DMF (1 mL) was added ketene acetal (0.256 mL, 1.2 mmol) under nitrogen. The resultant mixture was stirred at 100° C. for 3 h. After cooling, it was diluted with EtOAc and washed with brine. Dried over MgSO4. The crude product was purified on SiO2 gel column eluted with hexanes/EtOAc to give 3-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]-2-methylpropanoic acid methyl ester as a light yellow sticky oil (285 mg, 70%).
Step 7B: To a solution of 3-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]-2-methylpropanoic acid methyl ester (115 mg, 0.2 mmol) in THF (3 mL) was added LiOH (excess) and water (3 mL). The reaction mixture was stirred at rt overnight and acidified with 1N aq. HCl, then extracted with EtOAc. The organic layer was dried over Na2SO4. The crude product was purified on SiO2 column eluted with hexanes/EtOAc to give the titled compounds as a light yellow solid (94 mg, 95%). HRMS: calcd for C20H22F4N2O4S2+H+, 495.10299; found (ESI-FTMS, [M+H]1+), 495.10293.
Example 29FP 2-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-2-methylpropanoic acidPrepared according to procedures similar to those described in Example 29FO. Yield 87%. HRMS: calcd for C22H24F4N2O4S+H+, 489.14657; found (ESI-FTMS, [M+H]1+), 489.14748.
Example 29FQ 2-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-2-methylpropanamidePrepared according to the procedures similar to those described in Example 29FO. Yield 73%. HRMS: calcd for C22H25F4N3O3S+H+, 488.16255; found (ESI-FTMS, [M+H]1+), 488.164.
Example 29FR 3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)benzamideStep 9A: A mixture of (R)-3-chloro-4-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)benzonitrile (290 mg, 0.626 mmol) in H2SO4 (3 mL) and TFA (6 mL) was stirred at rt overnight. To this was added ice-water. The precipitate was collected by filtration and washed with water to give the desired product as a white solid (267.5 mg, 89%). HRMS: calcd for C19H18ClF4N3O3S+H+, 480.07663; found (ESI-FTMS, [M+H]1+), 480.07642.
Example 29FS (2S)-3,3,3-trifluoro-2-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propane-1,2-diolStep A: (2R)-1-[(3-bromophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine (960 mg, 2.0 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (559 mg, 2.2 mmol), PdCl2(dppf)2 (82 mg, 0.1 mmol) and KOAc (588 mg, 6 mmol) in DMSO (5 mL) was degassed and heated in a sealed tube in an oil bath at 60° C. for 12 hours. After cooling, diluted with Et2O and washed with brine and extracted with Et2O. The combined organic layer was dried over Na2SO4. The crude product was purified on SiO2 gel column eluted with hexanes/EtOAc to give the desired product (R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylsulfonyl)piperazine (916 mg, 87%).
Step B: A solution of (R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylsulfonyl)piperazine (106 mg, 0.2 mmol) and Pd(PPh3 (12 mg, 0.01 mmol) in THF (2 mL) was degassed and then added Na2CO3 (0.6 mL, 1.0 M in water, 0.6 mmol) and 2-bromo-3,3,3-trifluoroprop-1-ene (105 mg, 0.6 mmol) under N2. The resultant mixture was heated in a sealed tube in an oil bath at 60° C. overnight. After cooling, diluted with Et2O (10 mL), washed with brine and extracted with Et2O. The combined organic layer was dried over Na2SO4. The crude product was purified on SiO2 gel column eluted with hexanes/EtOAc to give (R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methyl-1-(3-(3,3,3-trifluoroprop-1-en-2-yl)phenylsulfonyl)piperazine as a colorless oil (83 mg, 85%).
Step C: A slurry of (R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methyl-1-(3-(3,3,3-trifluoroprop-1-en-2-yl)phenylsulfonyl)piperazine was dissolved in aqueous tBuOH (1:1 vol) with slight heating via heat gun, under continuous stirring until 75% of the solid was in solution. The solution was allowed to cool slightly, (T=40-50° C. max), and then slowly added to a flask containing 5 mol % (DHQ)Phal ligand, and 1.0 eq. MeSO2NH2 at 0° C. Immediately following, AD mix α (1.5 g/mmol of substrate) was added to the solution, and it was allowed to stir at 0° C., never exceeding 2-3° C. for 48 hours, after which it can be judged complete by TLC (EtOAc/Hexanes 1/5 vol). Workup: Add excess saturated aqueous Na2S2O3 and allow the reaction to stir for 20-30 minutes, warming to room temperature, and extract into DCM. The organic layer was dried over Na2SO4 and washed with brine. The crude product was purified on SiO2 gel column eluted with hexanes/EtOAc to give the desired product as a white solid. HRMS: calcd for C21H21F7N2O4S+H+, 531.11830; found (ESI-FTMS, [M+H]1+), 531.11699.
Example 29FT (2S)-3,3,3-trifluoro-2-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]propane-1,2-diolThe title compound was according to the procedure described in Example 29FS except that AD mix cc was replaced with AD mix P. HRMS: calcd for C21H21F7N2O4S+H+, 531.11830; found (ESI-FTMS, [M+H]1+), 531.11675.
Example 29FU (2S,4S)-1-[(3-bromophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperidineStep 11A: A reaction mixture of 4-fluoro-2-(trifluoromethyl)benzoyl fluoride (1.36 mL, 10 mmol), dimethyl 2-oxopropylphosphonate (1.366 mL, 10 mmol) and K2CO3 (1.65 g, 12 mmol) in MeCN (20 mL) was stirred at room temperature for 26 h. It was then diluted with EtOAc and washed with brine. The organic layer was dried over Na2SO4 and crude product was purified on SiO2 gel column eluted with hexanes/EtOAc to give the desired product (E)-4-(4-fluoro-2-(trifluoromethyl)phenyl)but-3-en-2-one (2.3 g, 99%).
Step B: A solution of (E)-4-(4-fluoro-2-(trifluoromethyl)phenyl)but-3-en-2-one (696 mg, 3.0 mmol), and Jacobsen [(s,s)-(salen)]2Al (69.2 mg, 0.045 mmol) and ethyl cyanoacetate (383.8 mL, 3.6 mmol) in cyclohexane (13 mL) was stirred at room temperature for 24 h. The solvent was removed, and the crude product was purified on SiO2 gel column eluted with hexanes/EtOAc to give the desired product (2R,3R)-ethyl 2-cyano-3-(4-fluoro-2-(trifluoromethyl)phenyl)-5-oxohexanoate (750 mg, 72%).
Step C: A solution of (2R,3R)-ethyl 2-cyano-3-(4-fluoro-2-(trifluoromethyl)phenyl)-5-oxohexanoate (750 mg, 2.17 mmol) in DMSO (20 mL) and water (10 mL) was heated to 130° C. in microwave oven for 1.5 h. It was diluted with water (80 mL) and extracted with Et2O (3×80 mL). The organic layer was dried over MgSO4. The crude product was purified on SiO2 gel column eluted with hexanes/EtOAc to give the desired product (S)-3-(4-fluoro-2-(trifluoromethyl)phenyl)-5-oxohexanenitrile (500 mg, 84%).
Step D: To a solution of (S)-3-(4-fluoro-2-(trifluoromethyl)phenyl)-5-oxohexanenitrile (482 mg, 1.76 mmol) was added NaBH4 in MeOH (10 mL) at 0° C. The reaction was stirred for 20 minutes and quenched with aq. NH4Cl and then extracted with DCM. The organic layer was dried over MgSO4 and the crude product mixture was purified on SiO2 gel column eluted with hexanes/EtOAC to give the desired product (3S)-3-(4-fluoro-2-(trifluoromethyl)phenyl)-5-hydroxyhexanenitrile (390 mg, 81%, 3.5:1 mixture).
Step E: To a solution of (3S)-3-(4-fluoro-2-(trifluoromethyl)phenyl)-5-hydroxyhexanenitrile (340 mg, 1.23 mmol) in DCE (6 mL) was added TEA (516 mL, 3.9 mmol) and then MsCl (124.4 mL, 1.61 mmol) at 0° C. It was stirred at room temperature overnight and washed with brine. The crude reaction product was purified on SiO2 gel column eluted with hexanes/EtOAc to give the desired mesylate (420 mg, 97%).
Step F: To a solution of mesylate, obtained from Step E, in MeOH was added Pd/C (˜60 mg). The reaction mixture was stirred under H2 at 50 psi for 4 days. It was then filtered through a pad of Celite. The resultanted methanol solution was concentrated (˜5 mL). To this was added DIPEA (436 ml-L, 2.5 mmol). The reaction mixture was then heated in microwave oven at 100° C. for 30 minutes. The solvent was removed under vacuum. The crude product was purified on SiO2 column eluted with EtOAc/MeOH to give the desired product (2S,4S)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperidine as single diastereomer (150 mg, 51%).
Step G: Prepared from (2S,4S)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperidine (120 mg, 0.46 mmol) and 3-bromophenylsulfonyl chloride (99.4 mL, 0.69 mmol) according to scheme III-11 in 97% yield. HRMS: calcd for C19H18BrF4NO2S+H+, 480.02505; found (ESI-FTMS, [M+H]1+), 480.02396.
Example 29FV 1-[3-({(2S,4S)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperidin-1-yl}sulfonyl)phenyl]-4-methylpiperazineThe title compound was prepared in a manner similar to that described in Example 29FU. Yield 24%. HRMS: calcd for C24H29F4N3O2S+H+, 500.19893; found (ESI-FTMS, [M+H]1+), 500.19814.
Example 29FW (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-1-[(4-methoxyphenyl)sulfonyl]-2-methylpiperazineStep 1. A 1 L round bottom flask was charged with a stirbar, (R)-2-Methylpiperazine (20.0 g, 200.0 mmol), Sodium tert-butoxide (28.0 g, 300 mmol), BINAP (12.4 g, 20 mmol), and Pd2(dba)3. The flask was sealed and vacuum-purged with N2 three times. Toluene (500.0 mL) was then added under N2, followed by 2-Bromo-5-Fluorobenzotrifluoride (31.4 mL, 220.0 mmol). The reaction mixture was heated to 105° C. under thermal conditions for three hours, upon which the reaction cooled to room temperature, and diluted with diethyl ether (2.0 L) and filtered through celite, to remove inorganics and excess BINAP. The filtrate was collected and the product was extracted into 10% HCl (2×500 mL). The organic layers were then discarded and the aqueous layer was basified to pH 10 using 3MNaOH (˜300 mL). Product was then extracted into ether (3×500 mL). The organic layers were combined and dried over Na2SO4, decanted, and concentrated in vacuo, and the resultant crude oil (>95% purity by 1H-NMR) was taken on to the next step without further purification. 90% yield (51 g).
Step 2: To solution of 1-(4-Fluoro-2-trifluoromethyl-phenyl)-3-methyl-piperazine (200 mg, 0.76 mmol) and DIPEA (0.33 mL, 1.90 mmol) in DCM (8.0 mL) was added 4-Methoxybenzenesulfonyl chloride. The reaction was allowed to stir over a 12-16 hr period, after which it was judged complete by TLC. The reaction mixture was concentrated in-vacuo, and the resultant crude oil was purified via normal phase SiO2 column chromatography using a 2%-10% EtOAc/Hex solvent gradient. The desired product, was isolated in >95% purity. HRMS: calcd for C19H20F4N2O3S+H+, 433.12035; found ([M+H]+), 433.12037.
Example 29FX 4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)benzonitrileStep 2: Prepared according to the procedure for Example 29FW, step 2, with the exception of a slightly more polar solvent system for purification (2%-20% EtOAc/Hex) affording 230 mg of the desired sulfonamide in >95% purity (65% yield). HRMS: calcd for C19H17F4N3O2S+H+, 428.10503; found ([M+H]+), 428.1057; HPLC Method 1: room temperature, 6.822 min, 92.14%. HPLC Method 2: room temperature, 7.395 min, 90.74%.
Example 29FY (2R)-1-[(4-bromo-2-chlorophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineStep 2: Prepared according to the procedure for Example 29FW, step 2, affording 850 mg of the desired sulfonamide in >95% purity (72% yield). HRMS: calcd for C18H16BrClF4N2O2S+H+, 514.98132; found ([M+H]+), 514.98153; HPLC Method 1: room temperature, 7.704 min, 99.20%. HPLC Method 2: room temperature, 8.125 min, 98.12%.
Example 29FZ (2R)-1-[(4,5-dichloro-2-thienyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineStep 2: Prepared according to the procedure for Example 29FW, step 2, affording 900 mg of the desired sulfonamide in >95% purity (83% yield). HRMS: calcd for C16H14Cl2F4N2O2S2+H+, 476.98826; found ([M+H]+), 476.9865; HPLC Method 1: room temperature, 7.771 min, 96.52%. HPLC Method 2: room temperature, 8.194 min, 97.28%.
Example 29GA (2R)-1-[(3-chloro-2-methylphenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineStep 2: Prepared according to the procedure for Example 29FW, step 2, affording 876 mg of the desired sulfonamide in >95% purity (80% yield). HRMS: calcd for C19H19ClF4N2O2S+H+, 451.08646; found ([M+H]+), 451.0849; HPLC Method 1: room temperature, 7.623 min, 96.58%. HPLC Method 2: room temperature, 8.050 min, 96.36%.
Example 29GB (2R)-1-[(2,3-dichlorophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineStep 2: Prepared according to the procedure for Example 29FW, step 2, affording 876 mg of the desired sulfonamide in >95% purity (83% yield). HRMS: calcd for C18H16Cl2F4N2O2S+H+, 471.03184; found ([M+H]+), 471.0303; HPLC Method 1: room temperature, 7.529 min, 100%. HPLC Method 2: room temperature, 7.972 min, 99.21%.
Example 29GC (2R)-1-[(3-fluorophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineStep 2: Prepared according to the procedure for Example 29FW, step 2, affording 1.1 g of the desired sulfonamide in >95% purity (87% yield). HRMS: calcd for C18H17F5N2O2S+H+, 421.10036; found ([M+H]+), 421.0991.
Example 29GD 3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)anilineStep 2: Prepared according to the procedure for Example 29FW, step 2, affording 330 mg of 4-(4-Fluoro-2-trifluoromethyl-phenyl)-2-methyl-1-(3-nitro-benzenesulfonyl)-piperazine in >95% purity (47% yield).
Step 3: A solution of 4-(4-Fluoro-2-trifluoromethyl-phenyl)-2-methyl-1-(3-nitro-benzenesulfonyl)-piperazine (330 mg, 0.8 mmol) and a catalytic amount of 10% Pd/C in EtOAc (25 mL) was stirred under H2 (1 atm) at ambient temperature for two hours, after which the reduction was judged complete by TLC. The H2 removed under vacuum, and the reaction mixture was filtered through celite, and rinsed with EtOAc (3×25 mL), and the filtrate was concentrated in vacuo, affording 180 mg of the desired sulfonamide in >95% purity (62% yield). HRMS: calcd for C18H19F4N3O2S+H+, 418.12068; found ([M+H]+), 418.12119.
Example 29GE (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-(2-thienylsulfonyl)piperazineStep 2: Prepared according to the procedure for Example 29FW, step 2, affording 330 mg of the desired sulfonamide in >95% purity (98% yield). HRMS: calcd for C16H16F4N2O2S2+H+, 409.06621; found ([M+H]+), 409.06656; HPLC Method 1: room temperature, 7.382 min, 88.19%. HPLC Method 2: room temperature, 6.871 min, 78.28%.
Example 29GF 4-{(3R)-4-[(4-bromo-2-chlorophenyl)sulfonyl]-3-methylpiperazin-1-yl}-3-(trifluoromethyl)benzonitrileStep 2: Prepared according to the procedure for Example 29FW, step 2, with the exception of a slightly more polar solvent system for purification (2%-30% EtOAc/Hex) affording 150 mg of the desired sulfonamide in >95% purity (33% yield). HRMS: calcd for C19H16BrClF3N3O2S+H+, 521.98600; found ([M+H]+), 521.98688.
Example 29GG 4-{(3R)-4-[(4-bromo-2-fluorophenyl)sulfonyl]-3-methylpiperazin-1-yl}-3-(trifluoromethyl)benzonitrileStep 2: Prepared according to the procedure for Example 29FW, step 2, with the exception of a slightly more polar solvent system for purification (2%-30% EtOAc/Hex) affording 200 mg of the desired sulfonamide in >95% purity (45% yield). HRMS: calcd for C19H16BrF4N3O2S+H+, 506.01555; found ([M+H]+), 506.01605.
Example 29GH (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazineStep 2: Prepared according to the procedure for Example 29FW, step 2, affording the desired sulfonamide in >95% purity. HRMS: calcd for C19H17F7N2O3S+H+, 487.09208; found ([M+H]+), 487.09215; HPLC Method 1: room temperature, 7.660 min, 92.30%. HPLC Method 2: room temperature, 7.797 min, 83.08%.
Example 29GI 4-[3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]morpholineA 5-mL microwave vial was charged with a stirbar, (2R)-1-[(4-bromo-2-chlorophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine (250 mg, 0.49 mmol), Sodium tert-butoxide (77 mg, 0.74 mmol), BINAP (31 mg, 0.05 mmol), and Pd2(dba)3 (25 mg, 0.03 mmol). The vial was sealed and vacuum-purged with N2 three times. Toluene (2.0 mL) was then added under N2, followed by morpholine (0.05 mL, 0.53 mmol). The reaction mixture was heated to 75° C. under thermal conditions for 30 minutes, upon which the reaction was judged complete by LCMS. The reaction mixture was diluted with EtOAc (100 mL), and filtered through celite to remove inorganics. The filtrate was concentrated in vacuo and the crude product was directly loaded onto a SiO2 column and purified via normal phase chromatography (5%-50% EtOAc/Hexanes gradient), affording the desired compound in >95% purity. HRMS: calcd for C22H24ClF4N3O3S+H+, 522.12358; found ([M+H]+), 522.12358; HPLC Method 1: room temperature, 7.125 min, 100%. HPLC Method 2: room temperature, 7.664 min, 100%.
Example 29GJ (2R)-1-[(2-chloro-4-piperidin-1-ylphenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazinePrepared according to the procedure for Example 29GI, affording the desired compound in >95% purity. HRMS: calcd for C23H26ClF4N3O2S+H+, 520.14431; found ([M+H]+), 520.1445; HPLC Method 1: room temperature, 7.914 min, 79.25%. HPLC Method 2: room temperature, 8.209 min, 78.92%.
Example 29GK (2R)-1-{[2-chloro-4-(4-methylpiperazin-1-yl)phenyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazinePrepared according to the procedure for Example 29GI, with the exception of purification which was done on reversed phase HPLC, under acidic conditions, (10%-90% ACN/H2O gradient), affording the desired compound in >95% purity. HRMS: calcd for C23H27ClF4N4O2S+H+, 535.15521; found ([M+H]+), 535.1576; HPLC Method 1: room temperature, 4.647 min, 89.88%. HPLC Method 2: room temperature, 5.774 min, 93.13%.
Example 29GL (2R)-1-[(4-tert-butoxy-2-chlorophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineBuchwald Reaction Prepared according to the procedure for Example 29GI, without an amine, (excess NaOtBu as nucleophile), affording the desired compound in >95% purity. HPLC Method 1: room temperature, 8.041 min, 97.87%. HPLC Method 2: room temperature, 8.296 min, 98.22%.
Example 29GM (2R)-1-[(4-tert-butoxy-2-fluorophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineBuchwald Reaction Prepared according to the procedure for Example 29GI, affording the desired compound in >95% purity. HRMS: calcd for C23H27F5N4O2S+H+, 493.15788; found ([M+H]+), 493.15802.
Example 29GN 3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-N,N-dimethylanilineBuchwald Amination Prepared according to the procedure for Example 29GI, affording the desired compound in >95% purity. HRMS: calcd for C20H22ClF4N3O2S+H+, 480.11301; found ([M+H]+), 480.1129; HPLC Method 1: room temperature, 7.390 min, 82.15%. HPLC Method 2: room temperature, 7.824 min, 76.87%.
Example 29GO (2R)-1-[(2-chloro-4-pyrrolidin-1-ylphenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineBuchwald Amination Prepared according to the procedure for Example 29GI, affording the desired compound in >95% purity. HRMS: calcd for C22H24ClF4N3O2S+H+, 506.12866; found ([M+H]+), 506.12849; HPLC Method 1: room temperature, 7.786 min, 87.96%. HPLC Method 2: room temperature, 8.019 min, 86.35%.
Example 29GP N-tert-butyl-3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)anilineBuchwald Amination: Prepared according to the procedure for Example 29GI, affording the desired compound in >95% purity. HRMS: calcd for C22H26ClF4N3O2S+H+, 508.14431; found ([M+H]+), 508.14549; HPLC Method 1: room temperature, 7.622 min, 95.55%. HPLC Method 2: room temperature, 7.963 min, 72.56%.
Example 29GQ 3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-N-isobutylanilineBuchwald Amination Prepared according to the procedure for Example 29GI, affording the desired compound in >95% purity. HRMS: calcd for C22H26ClF4N3O2S+H+, 508.14431; found ([M+H]+), 508.1442; HPLC Method 1: room temperature, 7.692 min, 88.44%. HPLC Method 2: room temperature, 8.035 min, 81.22%.
Example 29GR 1-[3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperidin-4-olBuchwald Amination Prepared according to the procedure for Example 29GI, with the exception of the use of a more polar solvent system for purification (20%-100% EtOAc/Hexanes) affording the desired compound in >95% purity. HPLC Method 1: room temperature, 6.637 min, 84.22%. HPLC Method 2: room temperature, 7.517 min, 83.74%.
Example 29GS (2R)-1-({2-chloro-4-[(3S)-3-methylpiperazin-1-yl]phenyl}sulfonyl)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineBuchwald Amination Prepared according to the procedure for Example 29GI, with the exception of purification protocol; product precipitated out of the organic layer as it was being concentrated in vacuo, and upon filtration, it was afforded in >95% purity. HRMS: calcd for C23H27ClF4N4O2S+H+, 535.15521; found ([M+H]+), 535.15532; HPLC Method 1: room temperature, 5.139 min, 92.40%. HPLC Method 2: room temperature, 6.299 min, 100%.
Example 29GT 1-[3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-N,N-dimethylpiperidin-4-amineBuchwald Amination: Prepared according to the procedure for Example 29GI, with the exception of purification using a more polar solvent system (0%-10% MeOH/EtOAc) affording the desired compound in >95% purity. HRMS: calcd for C25H31ClF4N4O2S+H+, 563.18651; found ([M+H]+), 563.18857; HPLC Method 1: room temperature, 5.258 min, 85.99%. HPLC Method 2: room temperature, 6.356 min, 100%.
Example 29GU 4-[3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]thiomorpholine 1,1-dioxidePrepared according to the procedure for Example 29GI, with the exception of purification using a more polar solvent system (5%-40% EtOAc/Hexanes) affording the desired compound in >95% purity. HRMS: calcd for C22H24ClF4N3O4S2+H+, 570.09056; found ([M+H]+), 570.09181; HPLC Method 1: room temperature, 6.908 min, 89.31%. HPLC Method 2: room temperature, 7.186 min, 60.60%.
Example 29GV 4-[3-fluoro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]morpholinePrepared according to the procedure for Example 29GI, affording 100 mg of the desired compound in >95% purity (49% yield). HRMS: calcd for C22H24F5N3O3S+H+, 506.15313; found ([M+H]+), 506.15321.
Example 29GW 4-[3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-2,6-cis-dimethylmorpholinePrepared according to the procedure for Example 29GI, affording the desired compound in >95% purity. HRMS: calcd for C24H28ClF4N3O3S+H+, 550.15488; found ([M+H]+), 550.15497; HPLC Method 1: room temperature, 7.454 min, 98.89%. HPLC Method 2: room temperature, 6.334 min, 87.84%.
Example 29GX 1-[3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperidine-4-carboxylic acidPrepared according to the procedure for Example 29GI, with the ethyl ester of the amine, affording the ethyl ester of the desired compound in >95% purity. Removal of the ester group was achieved under basic conditions (KOH(aq)/THF), yielding the desired acid compound. HRMS: calcd for C24H26ClF4N3O4S+H+, 564.13414; found ([M+H]+), 564.13421; HPLC Method 1: room temperature, 7.942 min, 92.23%. HPLC Method 2: room temperature, 7.591 min, 92.35%.
Example 29GY 4-[3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperazin-2-onePrepared according to the procedure for Example 29GI, with the exception of purification protocol; the crude solid afforded after workup was triturated with EtOAc, yielding the desired compound in >95% purity. HRMS: calcd for C22H23ClF4N4O3S+H+, 535.11883; found ([M+H]+), 535.11947.
Example 29GZ 1-[3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperidine-4-carboxamidePrepared according to the procedure for Example 29GI, affording the desired compound in >95% purity. HRMS: calcd for C24H27ClF4N4O3S+H+, 563.15013; found ([M+H]+), 563.15087. HPLC Method 1: room temperature, 7.358 min, 87.78%. HPLC Method 2: room temperature, 6.165 min, 86.98%.
Example 29HA (2R)-1-({2-chloro-4-[(3R)-3-methylpiperazin-1-yl]phenyl}sulfonyl)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineBuchwald Amination Prepared according to the procedure for Example 29GI, affording the desired compound in >95% purity. HRMS: calcd for C23H27ClF4N4O2S+H+, 535.15521; found ([M+H]+), 535.15631; HPLC Method 1: room temperature, 5.209 min, 85.44%. HPLC Method 2: room temperature, 6.358 min, 84.83%.
Example 29HB 1-[3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperazin-2-oneBuchwald Amination: Prepared according to the procedure for Example 29GI, with the 4-Boc-protected amine, affording the Boc-protected analog of the desired compound in >95% purity. Removal of the Boc group was achieved under acidic conditions (TFA/DCM), yielding the desired free amine. HRMS: calcd for C22H23ClF4N4O3S+H+, 535.11883; found ([M+H]+), 535.11947.
Example 29HC (2R)-1-{[2-chloro-4-(4-fluoropiperidin-1-yl)phenyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazinePrepared according to the procedure for Example 29GI, affording the desired compound in >95% purity. HRMS: calcd for C21H24F5N3O2S2+H+, 510.13028; found ([M+H]+), 510.12968.
Example 29HD (2R)-1-{[3-(4,4-difluoropiperidin-1-yl)phenyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazinePrepared according to the procedure for Example 29GI, affording the desired compound in >95% purity. HRMS: calcd for C21H23F6N3O2S2+H+, 522.16444; found ([M+H]+), 522.16468.
Example 29HE 4-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-4-methoxyphenyl]morpholinePrepared from 1-(5-Bromo-2-methoxy-benzenesulfonyl)-4-(4-fluoro-2-trifluoromethyl-phenyl)-2-methyl-piperazine and morpholine using sodium tert-butoxide, BINAP, Pd2 dba3 and toluene, affording the desired compound in >95% purity. HRMS: calcd for C23H27F4N3O4S+H+, 518.17312; found ([M+H]+), 518.1716.
Example 29HF (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-1-[(2-methoxy-5-piperidin-1-ylphenyl)sulfonyl]-2-methylpiperazinePrepared according to Example 29HE, affording the desired compound in >95% purity. HRMS: calcd for C24H29F4N3O3S+H+, 516.19385; found ([M+H]+), 516.1943; HPLC Method 1: room temperature, 6.597 min, 84.34%. HPLC Method 2: room temperature, 7.739 min, 88.94%.
Example 29HG (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-1-{[2-methoxy-5-(4-methylpiperazin-1-yl)phenyl]sulfonyl}-2-methylpiperazinePrepared according to Example 29HE, with the exception of purification by reversed phase HPLC under acidic conditions (10%-90% ACN/H2O), affording the desired compound in >95% purity. HRMS: calcd for C24H30F4N4O3S+H+, 531.20475; found ([M+H]+), 531.2064; HPLC Method 1: room temperature, 4.514 min, 87.19%. HPLC Method 2: room temperature, 5.435 min, 89.27%.
Example 29HH 4-[2-chloro-3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]morpholineHRMS: calcd for C22H24ClF4N3O3S+H+, 522.12358; found ([M+H]+), 522.1237.
Example 29HI (2R)-1-[(2-chloro-3-piperidin-1-ylphenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineHRMS: calcd for C23H26ClF4N3O2S+H+, 520.14431; found ([M+H]+), 520.14552.
Example 29HJ 4-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-ylphenyl}sulfonyl)-2-methylphenyl]morpholineHRMS: calcd for C23H27F4N3O3S+H+, 502.17820; found ([M+H]+), 502.1787.
Example 29HK 4-[3-chloro-5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-ylphenyl}sulfonyl)-2-thienyl]morpholineHRMS: calcd for C20H22ClF4N3O3S2+H+, 528.08000; found ([M+H]+), 528.0800.
Example 29HL (2R)-1-{[3-(4-fluoropiperidin-1-yl)phenyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineHRMS: calcd for C23H26F5N3O2S+H+, 504.17386; found ([M+H]+), 504.17263.
Example 29HM (2R)-1-{[3-(4,4-difluoropiperidin-1-yl)phenyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineHRMS: calcd for C23H25F6N3O2S+H+, 522.16444; found ([M+H]+), 522.16468.
Example 29HN 4-[4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]morpholineHPLC Method 1: room temperature, 6.8951 min, 75.92%. HPLC Method 2: room temperature, 7.523 min, 78.91%.
Example 29HO ethyl 1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperidine-4-carboxylateHRMS: calcd for C20H19F4N5O2S+H+, 470.12683; found ([M+H]+), 470.12538.
Example 29HP 4-{(3R)-4-[(4-tert-butoxy-2-chlorophenyl)sulfonyl]-3-methylpiperazin-1-yl}-3-(trifluoromethyl)benzonitrileHRMS: calcd for C23H25ClF3N3O3S+H+, 516.13300; found ([M+H]+), 516.13467.
Example 29HQ 4-{(3R)-4-[(4-tert-butoxy-2-fluorophenyl)sulfonyl]-3-methylpiperazin-1-yl}-3-(trifluoromethyl)benzonitrile Example 29HR 1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-N,N-dimethylpiperidine-4-carboxamideStep 1: To a solution of ethyl 1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperidine-4-carboxylate (100 mg, 0.18 mmol) in THF (5.0 mL) was added 2.0M KOH (0.5 mL, 1.0 mmol). The reaction was allowed to stir at ambient temperature over a 16 hour period, after which it was judged complete by LCMS. THF was removed in vacuo, and the remaining aqueous solution was acidified to pH 4 via addition of 10% HCl solution drop-wise. The resultant precipitate was filtered and rinsed with cold H2O (3×25 mL), yielding the desired carboxy acid compound in >95% purity. HRMS: calcd for C24H27F4N3O4S+H+, 530.17312; found ([M+H]+), 530.17463.
Step 2: To a solution of 1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperidine-4-carboxylic acid (200 mg, 0.38 mmol) in DMF (4.0 mL) was added BOP (202 mg, 0.46 mmol), DIPEA (0.33 mL, 1.9 mmol), and finally N′N-dimethylamine (0.6 mL, 1.1 mmol). The reaction was allowed to stir at ambient temperature over a 16 hour period, after which it was judged complete by LCMS. The reaction mixture was diluted with EtOAc (50 mL), and washed with saturated NaHCO3(aq) (3×25 mL). The organic layer was dried over Na2SO4, decanted, and concentrated in vacuo. The resultant crude oil was purified on a normal phase SiO2 column (20%-80% EtOAc/Hexanes) affording the desired amide in >95% purity. HRMS: calcd for C26H32F4N4O3S+H+, 557.22040; found ([M+H]+), 557.22195.
Example 29HS (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-({3-[4-(pyrrolidin-1-ylcarbonyl)piperidin-1-yl]phenyl}sulfonyl)piperazinePrepared according to the procedures of Example 29HR, affording the desired amide in >95% purity. HRMS: calcd for C28H34F4N4O3S+H+, 583.23605; found ([M+H]+), 583.23752.
Example 29HT 4-({1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperidin-4-yl}carbonyl)morpholinePrepared according to the procedures of Example 29HR, affording the desired amide in >95% purity. HRMS: calcd for C28H34F4N4O4S+H+, 599.23096; found ([M+H]+), 599.23172.
Example 29HU N-tert-butyl-1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]piperidine-4-carboxamidePrepared according to the procedure of Example 29HR, affording the desired amide in >95% purity. HRMS: calcd for C28H36F4N4O3S+H+, 585.25170; found ([M+H]+), 585.25309.
Example 29HV 1-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenyl]-N-isobutylpiperidine-4-carboxamidePrepared according to the procedure of Example 29HR, affording the desired amide in >95% purity. HRMS: calcd for C28H36F4N4O3S+H+, 585.25170; found ([M+H]+), 585.25262.
Example 29HW (2R)-1-(biphenyl-3-ylsulfonyl)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineA 5 mL microwave vial was charged with a stir bar, 1-(3-Bromo-benzenesulfonyl)-4-(4-fluoro-2-trifluoromethyl-phenyl)-2-methyl-piperazine (230 mg, 0.48 mmol), phenylboronic acid (65 mg, 0.53 mmol), potassium fluoride (111 mg, 1.92 mmol), and palladium tetrakis (28 mg, 0.024 mmol). The vial was sealed and vacuum-purged with N2, after which aqueous THF (4 mL 3:1 vol) was added. The reaction was heated to 120° C. under microwave conditions for 10 minutes, after which it was judged complete by LCMS. The aqueous layer was removed using a simple pasteur pipet, and the organic phase was diluted with EtOAc (25 mL), and filtered through celite to remove inorganics. The filtrate was concentrated in vacuo and the resultant crude oil was purified using anormal phase SiO2 column chromatography (5%-35% EtOAc/Hexanes), affording the desired biphenyl compound in >95% purity. HRMS: calcd for C24H22F4N2O2S+H+, 479.14109; found ([M+H]+), 479.1394.
Example 29HX (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-[(3-pyridin-4-ylphenyl)sulfonyl]piperazinePrepared according to the procedure for Example 29HW, with the exception of a more polar solvent system during purification (50%-100% EtOAc/Hexanes), affording the desired compound in >95% purity. HRMS: calcd for C23H21F4N3O2S+H+, 480.13633; found ([M+H]+), 480.1355.
Example 29HY 3′-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)biphenyl-4-carboxylic acidSuzuki Coupling: Prepared according to the procedure for Example 29HW, with the exception of a more polar solvent system during purification (50%-100% EtOAc/Hexanes), followed by trituration of the chromatographed material using 100% EtOAc, affording the desired compound in >95% purity. HRMS: calcd for C25H22F4N2O4S+H+, 523.13092; found ([M+H]+), 523.129.
Example 29HZ 3-fluoro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenolStep 1: A solution of (2R)-1-[(4-tert-butoxy-2-fluorophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine (375 mg, 0.76 mmol) in DCM (25 mL) was added TFA (5 mL). The reaction was allowed to stir for 1 hour, after which it was judged complete by LCMS. The reaction was concentrated in vacuo to remove excess TFA, and the crude oil was dissolved in DCM (20 mL) and washed with saturated NaHCO3(aq) (3×25 mL). The organic phase was dried over Na2SO4, and decanted, then concentrated in vacuo affording the desired phenol in >95% purity, which was used in subsequent synthetic steps without purification. HRMS: calcd for C18H17F5N2O3S+H+, 437.09528; found ([M+H]+), 437.09527.
Example 29IA 2-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenolStep 1: Prepared from (2R)-1-[(4-tert-butoxy-2-chlorophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine according to the procedure for example IV-7A, affording the desired phenol in >95% purity. HRMS: calcd for C18H17ClF4N2O3S+H+, 453.06573; found ([M+H]+), 453.06635.
Example 29IB (2R)-1-{[2-chloro-4-(2-methoxyethoxy)phenyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazinePrepared according to Example 29HZ. HRMS: calcd for C21H23ClF4N2O4S+H+, 511.10759; found ([M+H]+), 511.10791.
Example 29IC (2R)-1-[(2-chloro-4-ethoxyphenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazinePrepared according to the procedure in Example 29HZ, affording the desired aryl ether in >95% purity. HRMS: calcd for C20H21ClF4N2O3S+H+, 481.09703; found ([M+H]+), 481.09732.
Example 29ID 2-[3-chloro-4-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)phenoxy]-N,N-dimethylethanaminePrepared according to the procedure in Example 29HZ, affording the desired aryl ether in >95% purity. HRMS: calcd for C22H26ClF4N3O3S+H+, 524.13923; found ([M+H]+), 524.14061.
Example 29IE (2R)-1-{[2-chloro-4-(difluoromethoxy)phenyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazinePurification (5%-50% EtOAc/Hexanes) afforded the desired aryl ether in >95% purity. HRMS: calcd for C19H17ClF6N2O3S+H+, 503.06253; found (ESI-FTMS, [M+H]1+), 503.06351.
Example 29IF (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[3-(4H-1,2,4-triazol-4-yl)phenyl]sulfonyl}piperazineCyclization. A solution of the aniline (400 mg, 0.96 mmol), N′N-dimethyl-formyl-hydrazine (140 mg, 1.15 mmol), and a catalytic amount of pTSA in toluene (20 mL) was heated at reflux (130° C.) under N2 over a 12-16 hour period, after which the reaction was judged complete by LCMS. The reaction was then cooled to ambient temperature and the solvent was concentrated in vacuo, affording a crude oil which was purified by reversed phase HPLC under neutral conditions (30%-90% ACN/H2O), affording the desired 1,3,4-triazole compound in >95% purity. HRMS: calcd for C20H19F4N5O2S+H+, 470.12683; found ([M+H]+), 470.12538.
Example 29IG (2R)-4-(2,4-dichlorophenyl)-2-methyl-1-{[3-(4H-1,2,4-triazol-4-yl)phenyl]sulfonyl}piperazineCyclization: Prepared according to the procedure in Example 29IF, affording the desired 1,3,4-triazole compound in >95% purity. HRMS: calcd for C19H19Cl2N5O2S+H+, 452.07092; found ([M+H]+), 452.07148.
Example 29IH 1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[3-(1H-1,2,4-triazol-1-yl)-2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-olStep 1: A solution of the methyl ketone intermediate (550 mg, 1.25 mmol) and CuI (25 mg, 0.125 mmol) in NMP (10 mL), was heated to 170° C. under thermal conditions over a 12-16 hour period, after which the reaction was judged complete by LCMS. The reaction was then cooled to ambient temperature and clear reaction mixture was directly purified by reversed phase HPLC under neutral conditions (40%-95% ACN/H2O), affording the 1,2,4-triazole methyl ketone intermediate in >95% purity.
Step 2. A solution of the 1,2,4-triazole methyl ketone intermediate (200 mg, 0.4 mmol) in 0.5M TMSCF3 in THF (2.4 mL) under N2 was cooled to 0° C. A solution of 1.0M TBAF/THF (0.4 mL) was then added drop-wise and the reaction was allowed to stir, while warming to room temperature. The reaction was judged complete by LCMS after 1 hour, and was diluted with EtOAc (25 mL), and washed with saturated NaHCO3(aq) and dried over Na2SO4. The crude product was then purified by normal phase SiO2 chromatography (10%-60% EtOAc/Hexanes) affording the desired compound in >95% purity. HRMS: calcd for C23H23F6N5O3S+H+, 564.14985; found ([M+H]+), 564.14965.
Example 29II 1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[4-(1H-1,2,4-triazol-1-yl)-2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-olStep 1: Prepared according to the method described above, affording the 1,2,4-triazole methyl ketone intermediate in >95% purity.
Step 2: Prepared according to the method described above, affording the desired compound in >95% purity. HRMS: calcd for C23H23F6N5O3S+H+, 564.14985; found ([M+H]+), 564.1506.
Example 29IJ 1,1,1-trifluoro-2-[4-({(2R)-2-methyl-4-[5-(1H-1,2,4-triazol-1-yl)-2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]propan-2-olStep 1: Prepared according to the method described above. HRMS: calcd for C23H23F6N5O3S+H+, 564.14985; found ([M+H]+), 564.14905.
Example 29IK 4-[3-chloro-4-({(2R)-2-methyl-4-[4-(1H-1,2,4-triazol-1-yl)-2-(trifluoromethyl)phenyl]piperazin-1-yl}sulfonyl)phenyl]morpholineStep 1. Prepared according to the method described above, affording the 1,2,4-triazole morpholino compound in >95% purity.
Example 29IL (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-{[4-(1H-tetrazol-5-yl)phenyl]sulfonyl}piperazineStep 1: To a solution of the nitrile compound described herein (150 mg, 0.35 mmol) in toluene (3.5 mL) was added Et3N*HCl (139 mg, 1.05 mmol) and NaN3 (66 mg, 1.05 mmol). The reaction was heated to 100° C. under thermal conditions over a 12-16 hour period, after which the reaction was judged complete by LCMS. The reaction was diluted with EtOAc, and washed 3× with 10% HCl. The organic phase was concentrated and the resultant crude solid was triturated with Et2O, affording the desired tetrazole in >95% purity. HRMS: calcd for C19H18F4N6O2S+H+, 471.12208; found ([M+H]+), 471.1225.
Example 29IM 1,1,1-trifluoro-2-[3-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-4-methoxyphenyl]propan-2-olStep i: To a solution of 1-(5-Bromo-2-methoxy-benzenesulfonyl)-4-(4-fluoro-2-trifluoromethyl-phenyl)-2-methyl-piperazine (100 mg, 0.196 mmol) in anhydrous THF (2.0 mL) at −78° C. was added n-BuLi (0.07 mL, 0.205 mmol) drop-wise. The reaction was allowed to stir at −78° C. for several minutes, after which, the CF3-Weinreb-amide reagent (0.024 mL, 0.205 mmol) was added drop-wise. The reaction was stirred and allowed to warm to room temperature over a 4-5 hour period, after which the reaction was judged complete by LCMS. The reaction concentrated in vacuo and the resultant crude oil was purified via normal phase SiO2 chromatography (5%-35% EtOAc/Hexanes), affording the trifluoroacetylated intermediate in >95% purity.
Step ii: A solution of the trifluoroacetylated intermediate in anhydrous THF was cooled to −78° C. Drop-wise, methyl-lithium was added, and the reaction was allowed to stir at −78° C. for 2-3 hours, after which the reaction was judged complete by TLC. The reaction was allowed to warm to ambient temperature, and directly purified by reversed phase HPLC under acidic conditions, affording the desired trifluoropropanol compound in >95% purity. HRMS: calcd for C22H23F7N2O4S+H+, 545.13395; found ([M+H]+), 545.1341.
Example 29IN 1-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]piperidin-4-olHRMS: calcd for C21H25F4N3O3S2+H+, 508.13462; found (ESI-FTMS, [M+H]1+), 508.13469.
Example 29IO (2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-1-{[5-(4-methoxypiperidin-1-yl)-2-thienyl]sulfonyl}-2-methylpiperazineHRMS: calcd for C22H27F4N3O3S2+H+, 522.15027; found ([M+H]+), 522.15046.
Example 29IP (2R)-4-(2,4-dichlorophenyl)-2-methyl-1-[(5-piperazin-1-yl-2-thienyl)sulfonyl]piperazineHRMS: calcd for C19H24Cl2N4O2S2+H+, 475.07905; found ([M+H]+), 475.08118.
Example 29IQ (2R)-1-{[5-(4-fluoropiperidin-1-yl)-2-thienyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineHRMS: calcd for C21H24F5N3O2S2+H+, 510.13028; found (ESI-FTMS, [M+H]1+), 510.12968.
Example 29IR (2R)-1-{[5-(4,4-difluoropiperidin-1-yl)-2-thienyl]sulfonyl}-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazineMS (LC-ESIMS) m/z 527.83.
Example 29IS 4-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]benzoic acidHRMS: calcd for C23H20F4N2O4S2+H+, 529.08734; found ([M+H]+), 529.08803.
Example 29IT 4-[5-({(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}sulfonyl)-2-thienyl]benzamideHRMS: calcd for C23H21F4N3O3S2+H+, 528.10332; found ([M+H]+), 528.10464.
Example 30Compounds described herein can be tested in a cell-based assay using a stable CHO cell line expressing human 11b-HSD1. Cells are plated at 20,000 cells/well in 96 well plates and incubated overnight (12-16 hrs) at 37° C./5% CO2. Cells are treated with different concentration of compound in 90 microliter serum-free media and incubated for 30 minutes at 37° C./5% CO2. 10 ul of 5 micromolar cortisone (final concentration 500 nM) is then added to the cells and the plate is incubated at 37° C./5% CO2 for 120 minutes. 15 microliter of media is withdrawn and amount of cortisol in the media is measured using the DiscoverX HitHunter Cortisol Assay (DiscoverX corp, CA).
All references cited herein, whether in print, electronic, computer readable storage media or other form, are expressly incorporated by reference in their entirety, including but not limited to, abstracts, articles, journals, publications, texts, treatises, internet web sites, databases, patents, and patent publications.
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within claims.
Claims
1-93. (canceled)
94. A method for treating a disease or condition mediated by excess or uncontrolled amounts of cortisol and/or other corticosteroids, the method comprising administering to a subject in need thereof an effective amount of a compound of formula I: wherein:
- R1 is:
- i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
- (ii) C7-C20 aralkyl; heteroaralkyl including 6-20 atoms; arylheterocyclyl including 8-20 atoms; arylcycloalkenyl including 8-20 atoms; or arylheterocycloalkenyl including 8-20 atoms; each of which is optionally substituted with from 1-10 Rb;
- R2 is C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Rc;
- X is S(O)n or S(O)nNR6, wherein n is 1 or 2 and R6 is hydrogen, C1-C12 alkyl, or C3-16 cycloalkyl;
- each of V and Y is, independently, CR7 or N, wherein R7 is hydrogen or C1-C12 alkyl, provided that Y and V cannot both be CR7;
- one, two, three, or four of W1, Z1, W2, and Z2 are each, independently:
- (i) C1-C12 alkyl; or
- (ii) oxo; or
- (iii) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
- (iv) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; and the others are hydrogen;
- Ra at each occurrence is, independently:
- (i) halo; NRdRe; nitro; azido; hydroxy; C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-6 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Ra together form C1-C3 alkylenedioxy;
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- Ra′ at each occurrence is, independently, C1-C12 alkyl, C1-C12 haloalkyl, C2-C12 alkenyl; C1-C12 alkynyl; C3-C16 cycloalkyl; C3-C16 cycloalkenyl, heterocyclyl including 3-16 atoms, heterocycloalkenyl including 3-16 atoms; C7-C20 aralkyl; C6-C16 aryl; heteroaryl including 5-16 atoms; halo; NRdRe; nitro; azido, hydroxy; C1-C12 alkoxy; C1-C12 thioalkoxy; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy; heteroaryloxy including 5-20 atoms; thioaryloxy including 5-20 atoms; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy; C3-C16 cycloalkenyloxy; heterocyclyloxy including 3-16 atoms; heterocycloalkenyloxy including 3-16 atoms; C7-C20 aralkoxy; heteroaralkoxy including 6-20 atoms; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Ra′ together form C1-C3 alkylenedioxy; or 2 Ra′ together form C1-C3 alkylenedioxy;
- Rb at each occurrence is, independently:
- (i) halo; NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra; C2-C12 alkenyloxy; C1-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb′; mercapto; cyano; —C(O)Rg, —C(O)ORg, —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Rb together form C1-C3 alkylenedioxy, or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb′; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- Rb′ at each occurrence is, independently, C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with 1-5 Rj; C2-C12 alkenyl; C2-C12 alkynyl; C3-C16 cycloalkyl; C1-C16 cycloalkenyl, heterocyclyl including 3-16 atoms, heterocycloalkenyl including 3-16 atoms; C7-C20 aralkyl; C6-C16 aryl; heteroaryl including 5-16 atoms; halo; NRdRe; nitro; azido, hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy; C1-C12 thioalkoxy; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy; heteroaryloxy including 5-20 atoms; thioaryloxy including 5-20 atoms; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy; C3-C16 cycloalkenyloxy; heterocyclyloxy including 3-16 atoms; heterocycloalkenyloxy including 3-16 atoms; C7-C20 aralkoxy; heteroaralkoxy including 6-20 atoms; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; or —OC(O)NRdRe; or 2 Rb′ together form C1-C3 alkylenedioxy;
- Rc at each occurrence is, independently:
- (i) halo; nitro; hydroxy; C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; cyano; SO2Rm; or 2 Rc together form C1-C3 alkylenedioxy; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- each of Rd, Re, Rg, Rh, and Rk, at each occurrence is, independently:
- (i) hydrogen; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- Rf is NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; —C(O)Rg, —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe;
- Ri is Rg; ORg; or NRdRe;
- Rj is NRdRe; nitro; azido; hydroxy; oxo; thioxo; ═NRk; C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; C1-C3 alkylenedioxy; —C(O)Rg, —C(O)ORg, —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe;
- Rm is
- (i) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (ii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iii) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra; and
- provided:
- (a) when V and Y are both N, and R2 is substituted pyridyl or pyrimidinyl, then Rc cannot be C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; or SO2Rm; and
- (b) when V and Y are both N, X is SO2, one of Z1 and W2 is CH3, and R2 is phenyl substituted with from 1-5 Rc, then 1 Rc must be halo; C1-C12 haloalkoxy; cyano; or C1-C12 haloalkyl, optionally substituted with from 1-5 Rj; or a pharmaceutically acceptable salt and/or N-oxide thereof.
95-102. (canceled)
103. A method for treating a disease or condition selected from type 2 diabetes, Syndrome X, obesity, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL, atherosclerosis, and a cognitive disorder, the method comprising administering to a subject in need thereof an effective amount of a compound of formula I: wherein:
- R1 is:
- (i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
- (ii) C7-C20 aralkyl; heteroaralkyl including 6-20 atoms; arylheterocyclyl including 8-20 atoms; arylcycloalkenyl including 8-20 atoms; or arylheterocycloalkenyl including 8-20 atoms; each of which is optionally substituted with from 1-10 Rb;
- R2 is C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Rc;
- X is S(O)n or S(O)nNR6, wherein n is 1 or 2, and R6 is hydrogen, C1-C12 alkyl, or C3-C16 cycloalkyl;
- each of V and Y is, independently, CR7 or N, wherein R7 is hydrogen or C1-C12 alkyl, provided that Y and V cannot both be CR7;
- one, two, three, or four of W1, Z1, W2, and Z2 are each, independently:
- (i) C1-C12 alkyl; or
- (ii) oxo; or
- (iii) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
- (iv) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; and the others are hydrogen;
- Ra at each occurrence is, independently:
- (i) halo; NRdRe; nitro; azido; hydroxy; C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf, C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Ra together form C1-C3 alkylenedioxy;
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra′;
- Ra′ at each occurrence is, independently, C1-C12 alkyl, C1-C12 haloalkyl, C2-C12 alkenyl; C2-C12 alkynyl; C3-C16 cycloalkyl; C3-C16 cycloalkenyl, heterocyclyl including 3-16 atoms, heterocycloalkenyl including 3-16 atoms; C7-C20 aralkyl; C6-C16 aryl; heteroaryl including 5-16 atoms; halo; NRdRe; nitro; azido, hydroxy; C1-C12 alkoxy; C1-C12 thioalkoxy; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy; heteroaryloxy including 5-20 atoms; thioaryloxy including 5-20 atoms; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy; C3-C16 cycloalkenyloxy; heterocyclyloxy including 3-16 atoms; heterocycloalkenyloxy including 3-16 atoms; C7-C20 aralkoxy; heteroaralkoxy including 6-20 atoms; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Ra′ together form C1-C3 alkylenedioxy; or 2 Ra′ together form C1-C3 alkylenedioxy;
- Rb at each occurrence is, independently:
- (i) halo; NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb′; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Rb together form C1-C3 alkylenedioxy; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb′; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- Rb′ at each occurrence is, independently, C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with 1-5 Rj; C2-C12 alkenyl; C2-C12 alkynyl; C3-C16 cycloalkyl; C3-C16 cycloalkenyl, heterocyclyl including 3-16 atoms, heterocycloalkenyl including 3-16 atoms; C7-C20 aralkyl; C6-C16 aryl; heteroaryl including 5-16 atoms; halo; NRdRe; nitro; azido, hydroxy; ox, thioxo, ═NRk, C1-C12 alkoxy; C1-C12 thioalkoxy; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy; heteroaryloxy including 5-20 atoms; thioaryloxy including 5-20 atoms; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy; C3-C16 cycloalkenyloxy; heterocyclyloxy including 3-16 atoms; heterocycloalkenyloxy including 3-16 atoms; C7-C20 aralkoxy; heteroaralkoxy including 6-20 atoms; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; or —OC(O)NRdRe; or 2 Rb′ together form C1-C3 alkylenedioxy;
- Rc at each occurrence is, independently:
- (i) halo; nitro; hydroxy; C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; cyano; SO2Rm; or 2 Rc together form C1-C3 alkylenedioxy; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- each of Rd, Re, Rg, Rh, and Rk, at each occurrence is, independently:
- (i) hydrogen; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- Rf is NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; —C(O)Rg, —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe;
- Ri is Rg; ORg; or NRdRe;
- Rj is NRdRe; nitro; azido; hydroxy; oxo; thioxo; ═NRk; C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; C1-C3 alkylenedioxy; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe;
- Rm is
- (i) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (ii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iii) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra; and
- provided:
- (a) when V and Y are both N, and R2 is substituted pyridyl or pyrimidinyl, then Rc cannot be C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; or SO2Rm; and
- (b) when V and Y are both N, X is SO2, one of Z1 and W2 is CH3, and R2 is phenyl substituted with from 1-5 Rc, then 1 Rc must be halo; C1-C12 haloalkoxy; cyano; or C1-C12 haloalkyl, optionally substituted with from 1-5 Rj; or a pharmaceutically acceptable salt and/or N-oxide thereof.
104. The method of claim 103, wherein the disease or condition is type 2 diabetes.
105. The method of claim 103, wherein the disease or condition is Syndrome X.
106. The method of claim 103, wherein the disease or condition is obesity.
107. The method of claim 103, wherein the disease or condition is selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL.
108. The method of claim 103, wherein the disease or condition is atherosclerosis.
109. The method of claim 103, wherein the disease or condition is a cognitive disorder.
110. The method of claim 109, wherein the cognitive disorder is Alzheimer's disease.
111. A method for promoting wound healing, the method comprising administering to a subject in need thereof an effective amount of a compound of formula I: wherein:
- R1 is:
- (i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
- (ii) C7-C20 aralkyl; heteroaralkyl including 6-20 atoms; arylheterocyclyl including 8-20 atoms; arylcycloalkenyl including 8-20 atoms; or arylheterocycloalkenyl including 8-20 atoms; each of which is optionally substituted with from 1-10 Rb;
- R2 is C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Rc;
- X is S(O)n or S(O)nNR6, wherein n is 1 or 2, and R6 is hydrogen, C1-C12 alkyl, or C3-C16 cycloalkyl;
- each of V and Y is, independently, CR7 or N, wherein R7 is hydrogen or C1-C12 alkyl, provided that Y and V cannot both be CR7;
- one, two, three, or four of W1, Z1, W2, and Z2 are each, independently:
- (i) C1-C12 alkyl; or
- (ii) oxo; or
- (iii) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
- (iv) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; and the others are hydrogen;
- Ra at each occurrence is, independently:
- (i) halo; NRdRe; nitro; azido; hydroxy; C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Ra together form C1-C3 alkylenedioxy;
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra′;
- Ra′ at each occurrence is, independently, C1-C12 alkyl, C1-C12 haloalkyl, C2-C12 alkenyl; C2-C12 alkynyl; C3-C16 cycloalkyl; C3-C16 cycloalkenyl, heterocyclyl including 3-16 atoms, heterocycloalkenyl including 3-16 atoms; C7-C20 aralkyl; C6-C16 aryl; heteroaryl including 5-16 atoms; halo; NRdRe; nitro; azido, hydroxy; C1-C12 alkoxy; C1-C12 thioalkoxy; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy; heteroaryloxy including 5-20 atoms; thioaryloxy including 5-20 atoms; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy; C3-C16 cycloalkenyloxy; heterocyclyloxy including 3-16 atoms; heterocycloalkenyloxy including 3-16 atoms; C7-C20 aralkoxy; heteroaralkoxy including 6-20 atoms; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Ra′ together form C1-C3 alkylenedioxy; or 2 Ra′ together form C1-C3 alkylenedioxy;
- Rb at each occurrence is, independently:
- (i) halo; NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb′; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Rb together form C1-C3 alkylenedioxy; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb′; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- Rb′ at each occurrence is, independently, C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with 1-5 Rj; C2-C12 alkenyl; C2-C12 alkynyl; C3-C16 cycloalkyl; C3-C16 cycloalkenyl, heterocyclyl including 3-16 atoms, heterocycloalkenyl including 3-16 atoms; C7-C20 aralkyl; C6-C16 aryl; heteroaryl including 5-16 atoms; halo; NRdRe; nitro; azido, hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy; C1-C12 thioalkoxy; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy; heteroaryloxy including 5-20 atoms; thioaryloxy including 5-20 atoms; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy; C3-C16 cycloalkenyloxy; heterocyclyloxy including 3-16 atoms; heterocycloalkenyloxy including 3-16 atoms; C7-C20 aralkoxy; heteroaralkoxy including 6-20 atoms; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; or —OC(O)NRdRe; or 2 Rb′ together form C1-C3 alkylenedioxy;
- Rc at each occurrence is, independently:
- (i) halo; nitro; hydroxy; C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; cyano; SO2Rm; or 2 Rc together form C1-C3 alkylenedioxy; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- each of Rd, Re, Rg, Rh, and Rk, at each occurrence is, independently:
- (i) hydrogen; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- Rf is NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; —C(O)Rg, —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe;
- Ri is Rg; ORg; or NRdRe;
- Rj is NRdRe; nitro; azido; hydroxy; oxo; thioxo; ═NRk; C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; C1-C3 alkylenedioxy; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe;
- Rm is
- (i) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (ii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iii) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra; and
- provided:
- (a) when V and Y are both N, and R2 is substituted pyridyl or pyrimidinyl, then Rc cannot be C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; or SO2Rm; and
- (b) when V and Y are both N, X is SO2, one of Z1 and W2 is CH3, and R2 is phenyl substituted with from 1-5 Rc, then 1 Rc must be halo; C1-C12 haloalkoxy; cyano; or C1-C12 haloalkyl, optionally substituted with from 1-5 Rj; or a pharmaceutically acceptable salt and/or N-oxide thereof.
112. A method for treating a disease or condition mediated by excess or uncontrolled amounts of cortisol and/or other corticosteroids, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I): wherein:
- R1 is:
- (i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
- (ii) C7-C20 aralkyl or heteroaralkyl including 6-20 atoms; each of which is optionally substituted with from 1-10 Rb;
- R2 is:
- (i) C6-C18 aryl substituted with from 1-10 Rc; or heteroaryl including 5-20 atoms, optionally substituted with from 1-10 Rc; or
- (iii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1;
- X is S(O)n or S(O)nNR6, wherein n is 1 or 2, and R6 is hydrogen, C1-C12 alkyl, or C3-C16 cycloalkyl;
- each of V and Y is, independently, CR7 or N, wherein R7 is hydrogen or C1-C12 alkyl, provided that Y and V cannot both be CR7;
- each of W1, Z1, W2, and Z2 is hydrogen;
- Ra at each occurrence is, independently:
- (i) halo; NRdRe; nitro; azido; hydroxy; C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Ra together form C1-C3 alkylenedioxy;
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra′;
- Ra′ at each occurrence is, independently, C1-C12 alkyl, C1-C12 haloalkyl, C2-C12 alkenyl; C2-C12 alkynyl; C3-C16 cycloalkyl; C3-C16 cycloalkenyl, heterocyclyl including 3-16 atoms, heterocycloalkenyl including 3-16 atoms; C7-C20 aralkyl; C6-C16 aryl; heteroaryl including 5-16 atoms; halo; NRdRe; nitro; azido, hydroxy; C1-C12 alkoxy; C1-C12 thioalkoxy; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy; heteroaryloxy including 5-20 atoms; thioaryloxy including 5-20 atoms; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy; C3-C16 cycloalkenyloxy; heterocyclyloxy including 3-16 atoms; heterocycloalkenyloxy including 3-16 atoms; C7-C20 aralkoxy; heteroaralkoxy including 6-20 atoms; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Ra′ together form C1-C3 alkylenedioxy; or 2 Ra′ together form C1-C3 alkylenedioxy;
- Rb at each occurrence is, independently:
- (i) halo; NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb′; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Rb together form C1-C3 alkylenedioxy; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb′; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- Rb′ at each occurrence is, independently, C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with 1-5 Rj; C2-C12 alkenyl; C2-C12 alkynyl; C3-C16 cycloalkyl; C3-C16 cycloalkenyl, heterocyclyl including 3-16 atoms, heterocycloalkenyl including 3-16 atoms; C7-C20 aralkyl; C6-C16 aryl; heteroaryl including 5-16 atoms; halo; NRdRe; nitro; azido, hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy; C1-C12 thioalkoxy; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy; heteroaryloxy including 5-20 atoms; thioaryloxy including 5-20 atoms; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy; C3-C16 cycloalkenyloxy; heterocyclyloxy including 3-16 atoms; heterocycloalkenyloxy including 3-16 atoms; C7-C20 aralkoxy; heteroaralkoxy including 6-20 atoms; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; or —OC(O)NRdRe; or 2 Rb′ together form C1-C3 alkylenedioxy;
- Rc at each occurrence is, independently:
- (i) halo; nitro; hydroxy; C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; cyano; SO2Rm; or 2 Rc together form C1-C3 alkylenedioxy; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- each of Rd, Re, Rf, Rg, Rh, and Rk, at each occurrence is, independently:
- (i) hydrogen; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- Rf is NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; —C(O)Rg, —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe;
- Ri is Rg; ORg; or NRdRe;
- Rj is NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; C1-C3 alkylenedioxy; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe;
- Rm is
- (i) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (ii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iii) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra; and
- provided:
- (a) when V and Y are both N, and R2 is substituted pyridyl or pyrimidinyl, then Rc cannot be C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; or SO2Rm; and
- (b) when V and Y are both N and X is SO2, then R1 cannot be 4-chlorophenyl; and
- (c) when V and Y are both N and X is SO2, then R1 cannot be 1-chlorophenyl when R2 is: phenyl monosubstituted with hydroxyl, C1-C6 alkoxy, chloro, or nitro; unsubstituted pyridyl; pyridyl monosubstituted with hydroxyl, chloro, or nitro; unsubstituted thiazolyl; thiazolyl monosubstituted with nitro or hydroxymethyl; unsubstituted indolyl; or unsubstituted indazolyl; and
- (d) when V and Y are both N and X is SO2, then R1 cannot be naphthyl when R2 is: unsubstituted pyridyl; unsubstituted pyrimidinyl; phenyl monosubstituted with hydroxyl or C1-C6 alkoxy; unsubstituted thiazolyl; or 5-chloro-2-methylphenyl; and
- (e) when Y is N and V is CH and X is SO2, then R1 cannot be 1-chlorophenyl when R2 is: phenyl monosubstituted with C1-C6 alkoxy or C1-C6 alkyl; or substituted benzo[d]isoxazole; and
- (f) when Y is N and V is CH and X is SO2, then R1 cannot be naphthyl when R2 is phenyl monosubstituted with hydroxymethyl; or a pharmaceutically acceptable salt and/or N-oxide thereof.
113. A method for treating a disease or condition mediated by excess or uncontrolled amounts of cortisol and/or other corticosteroids, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I): wherein:
- R1 is C7-C20 aralkyl, C3-C16 cycloalkyl, or (C1-C12 alkyl)-(C3-C16 cycloalkyl), each of which is optionally substituted with from 1-10 Rb;
- R2 is:
- (i) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Rc; or
- (ii) OR1; SR1; or NR3R4, wherein R3 and R4 are each, independently, hydrogen or R1;
- X is CO;
- each of V and Y is, independently, CR7 or N, wherein R7 is hydrogen or C1-C12 alkyl, provided that Y and V cannot both be CR7;
- each of W1, Z1, W2, and Z2 is, independently:
- (i) hydrogen; or
- (ii) oxo; or
- (iii) C1-C12 alkyl; or
- (iv) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
- (v) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb;
- Ra at each occurrence is, independently:
- (i) halo; NRdRe; nitro; azido; hydroxy; C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Ra together form C1-C3 alkylenedioxy;
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra′;
- Ra′ at each occurrence is, independently, C1-C12 alkyl, C1-C12 haloalkyl, C2-C12 alkenyl; C2-C12 alkynyl; C3-C16 cycloalkyl; C3-C16 cycloalkenyl, heterocyclyl including 3-16 atoms, heterocycloalkenyl including 3-16 atoms; C7-C20 aralkyl; C6-C16 aryl; heteroaryl including 5-16 atoms; halo; NRdRe; nitro; azido, hydroxy; C1-C12 alkoxy; C1-C12 thioalkoxy; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy; heteroaryloxy including 5-20 atoms; thioaryloxy including 5-20 atoms; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy; C3-C16 cycloalkenyloxy; heterocyclyloxy including 3-16 atoms; heterocycloalkenyloxy including 3-16 atoms; C7-C20 aralkoxy; heteroaralkoxy including 6-20 atoms; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Ra′ together form C1-C3 alkylenedioxy; or 2 Ra′ together form C1-C3 alkylenedioxy;
- Rb at each occurrence is, independently:
- (i) halo; NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Rb together form C1-C3 alkylenedioxy; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb′; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- Rb′ at each occurrence is, independently, C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with 1-5 Rj; C2-C12 alkenyl; C2-C12 alkynyl; C3-C16 cycloalkyl; C3-C16 cycloalkenyl, heterocyclyl including 3-16 atoms, heterocycloalkenyl including 3-16 atoms; C7-C20 aralkyl; C6-C16 aryl; heteroaryl including 5-16 atoms; halo; NRdRe; nitro; azido, hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy; C1-C12 thioalkoxy; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy; heteroaryloxy including 5-20 atoms; thioaryloxy including 5-20 atoms; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy; C3-C16 cycloalkenyloxy; heterocyclyloxy including 3-16 atoms; heterocycloalkenyloxy including 3-16 atoms; C7-C20 aralkoxy; heteroaralkoxy including 6-20 atoms; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; or —OC(O)NRdRe; or 2 Rb′ together form C1-C3 alkylenedioxy;
- Rc at each occurrence is, independently:
- (i) halo; nitro; hydroxy; C1-C12 alkoxy optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; cyano; SO2Rm; or 2 Rc together form C1-C3 alkylenedioxy; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- each of Rd, Re, Rg, Rh, and Rk, at each occurrence is, independently:
- (i) hydrogen; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- Rf is NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; —C(O)Rg, —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe;
- Ri is Rg; ORg; or NRdRe;
- Rj is NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; C1-C3 alkylenedioxy; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; and
- Rm is
- (i) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (ii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iii) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra; or a pharmaceutically acceptable salt and/or N-oxide thereof.
114. A method for treating a disease or condition mediated by excess or uncontrolled amounts of cortisol and/or other corticosteroids, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I): wherein:
- R1 is C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra;
- R2 is C6-C16 cycloalkyl; C6-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb;
- X is S(O)n or S(O)nNR6, wherein n is 1 or 2, and R6 is hydrogen, C1-C12 alkyl, or C3-C16 cycloalkyl;
- each of V and Y is, independently, CR7 or N, wherein R7 is hydrogen or C1-C12 alkyl, provided that Y and V cannot both be CR7;
- each of W1, Z1, W2, and Z2 is, independently:
- (i) hydrogen; or
- (ii) oxo; or
- (iii) C1-C12 alkyl; or
- (iv) C6-C18 aryl or heteroaryl including 5-20 atoms, each of which is optionally substituted with from 1-10 Ra; or
- (v) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb;
- Ra at each occurrence is, independently:
- (i) halo; NRdRe; nitro; azido; hydroxy; C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Ra together form C1-C3 alkylenedioxy;
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra′;
- Ra′ at each occurrence is, independently, C1-C12 alkyl, C1-C12 haloalkyl, C2-C12 alkenyl; C2-C12 alkynyl; C3-C16 cycloalkyl; C3-C16 cycloalkenyl, heterocyclyl including 3-16 atoms, heterocycloalkenyl including 3-16 atoms; C7-C20 aralkyl; C6-C16 aryl; heteroaryl including 5-16 atoms; halo; NRdRe; nitro; azido, hydroxy; C1-C12 alkoxy; C1-C12 thioalkoxy; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy; heteroaryloxy including 5-20 atoms; thioaryloxy including 5-20 atoms; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy; C3-C16 cycloalkenyloxy; heterocyclyloxy including 3-16 atoms; heterocycloalkenyloxy including 3-16 atoms; C7-C20 aralkoxy; heteroaralkoxy including 6-20 atoms; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Ra′ together form C1-C3 alkylenedioxy; or 2 Ra′ together form C1-C3 alkylenedioxy;
- Rb at each occurrence is, independently:
- (i) halo; NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb′; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; or 2 Rb together form C1-C3 alkylenedioxy; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb′; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- Rb′ at each occurrence is, independently, C1-C12 alkyl or C1-C12 haloalkyl, each of which is optionally substituted with 1-5 Rj; C2-C12 alkenyl; C2-C12 alkynyl; C3-C16 cycloalkyl; C3-C16 cycloalkenyl, heterocyclyl including 3-16 atoms, heterocycloalkenyl including 3-16 atoms; C7-C20 aralkyl; C6-C16 aryl; heteroaryl including 5-16 atoms; halo; NRdRe; nitro; azido, hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy; C1-C12 thioalkoxy; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy; heteroaryloxy including 5-20 atoms; thioaryloxy including 5-20 atoms; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy; C3-C16 cycloalkenyloxy; heterocyclyloxy including 3-16 atoms; heterocycloalkenyloxy including 3-16 atoms; C7-C20 aralkoxy; heteroaralkoxy including 6-20 atoms; mercapto; cyano; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; or —OC(O)NRdRe; or 2 Rb′ together form C1-C3 alkylenedioxy;
- each of Rd, Re, Rg, Rh, and Rk, at each occurrence is, independently:
- (i) hydrogen; or
- (ii) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (iii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iv) C2-C20 alkenyl or C2-C20 alkynyl; or
- (v) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra;
- Rf is NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra′; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; —C(O)Rg, —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe;
- Ri is Rg; ORg; or NRdRe;
- Rj is NRdRe; nitro; azido; hydroxy; oxo, thioxo, ═NRk, C1-C12 alkoxy or C1-C12 thioalkoxy, each of which is optionally substituted with 1-5 Rf; C1-C12 haloalkoxy; C6-C16 aryloxy, C6-C16 thioaryloxy, heteroaryloxy including 5-20 atoms, or thioaryloxy including 5-20 atoms, each of which is optionally substituted with 1-5 Ra; C2-C12 alkenyloxy; C2-C12 alkynyloxy; C3-C16 cycloalkyloxy, C3-C16 cycloalkenyloxy, heterocyclyloxy including 3-16 atoms, heterocycloalkenyloxy including 3-16 atoms, C7-C20 aralkoxy, or heteroaralkoxy including 6-20 atoms, each of which is optionally substituted with 1-5 Rb; mercapto; cyano; C1-C3 alkylenedioxy; —C(O)Rg, —C(O)ORg; —OC(O)Rg; —C(O)SRg; —SC(O)Rg; —C(S)SRg; —SC(S)Rg; —C(O)NRdRe; —NRhC(O)Ri; —OC(O)NRdRe; and
- Rm is
- (i) C1-C12 alkyl or C1-C12 haloalkyl; each of which is optionally substituted with from 1-5 Rj; or
- (ii) C7-C20 aralkyl; C3-C16 cycloalkyl; heteroaralkyl including 6-20 atoms; C3-C16 cycloalkenyl; heterocyclyl including 3-16 atoms; or heterocycloalkenyl including 3-16 atoms; each of which is optionally substituted with from 1-10 Rb; or
- (iii) C6-C16 aryl or heteroaryl including 5-16 atoms, each of which is optionally substituted with from 1-10 Ra; and
- provided:
- (a) when V and Y are both N and X is SO2, then R1 cannot be 1-chlorophenyl when R2 is unsubstituted adamantyl or substituted or unsubstituted cyclohexyl; and
- (b) when Y is N, V is CH, and X is SO2, then R1 cannot be 1-chlorophenyl when R2 is unsubstituted piperidyl, piperidyl substituted with oxo, unsubstituted morpholinyl, or unsubstituted pyrrolidinyl; or a pharmaceutically acceptable salt thereof.
Type: Application
Filed: Aug 11, 2009
Publication Date: Feb 4, 2010
Inventors: Jason Shaoyun Xiang (Winchester, MA), Eddine Saiah (Brookline, MA), Steve Y. Tam (Wellesley, MA), John C. McKew (Arlington, MA), Lihren Chen (Bedford, MA), Manus Ipek (Watertown, MA), Katherine Lee (West Newton, MA), Huan-Qiu Li (Brighton, MA), Jianchang Li (Carlisle, MA), Wei Li (Acton, MA), Tarek Suhayl Mansour (New City, NY), Vipin Suri (Waltham, MA), Richard Vargas (Lexington, MA), Yuchuan Wu (Acton, MA), Zhao-Kui Wan (Arlington, MA), Jinbo Lee (Andover, MA), Eva Binnun (Boston, MA), Douglas P. Wilson (Ayer, MA)
Application Number: 12/539,232
International Classification: A61K 31/5377 (20060101); A61K 31/497 (20060101); A61K 31/4965 (20060101); A61K 31/4545 (20060101);
